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Background: It is not clear which young children presenting acutely unwell to primary care should be
investigated for urinary tract infection (UTI) and whether or not dipstick testing should be used to inform
antibiotic treatment.
Objectives: To develop algorithms to accurately identify pre-school children in whom urine should be
obtained; assess whether or not dipstick urinalysis provides additional diagnostic information; and model
algorithm cost-effectiveness.
Design: Multicentre, prospective diagnostic cohort study.
Setting and participants: Children < 5 years old presenting to primary care with an acute illness and/or
new urinary symptoms.
Methods: One hundred and seven clinical characteristics (index tests) were recorded from the child’s past
medical history, symptoms, physical examination signs and urine dipstick test. Prior to dipstick results
clinician opinion of UTI likelihood (‘clinical diagnosis’) and urine sampling and treatment intentions
(‘clinical judgement’) were recorded. All index tests were measured blind to the reference standard,
defined as a pure or predominant uropathogen cultured at ≥ 105 colony-forming units (CFU)/ml in a single
research laboratory. Urine was collected by clean catch (preferred) or nappy pad. Index tests were
sequentially evaluated in two groups, stratified by urine collection method: parent-reported symptoms with
clinician-reported signs, and urine dipstick results. Diagnostic accuracy was quantified using area under
receiver operating characteristic curve (AUROC) with 95% confidence interval (CI) and bootstrap-validated
AUROC, and compared with the ‘clinician diagnosis’ AUROC. Decision-analytic models were used to
identify optimal urine sampling strategy compared with ‘clinical judgement’.
Results: A total of 7163 children were recruited, of whom 50% were female and 49% were < 2 years old.
Culture results were available for 5017 (70%); 2740 children provided clean-catch samples, 94% of whom
were ≥ 2 years old, with 2.2% meeting the UTI definition. Among these, ‘clinical diagnosis’ correctly
identified 46.6% of positive cultures, with 94.7% specificity and an AUROC of 0.77 (95% CI 0.71 to 0.83).
Four symptoms, three signs and three dipstick results were independently associated with UTI with an
AUROC (95% CI; bootstrap-validated AUROC) of 0.89 (0.85 to 0.95; validated 0.88) for symptoms and
signs, increasing to 0.93 (0.90 to 0.97; validated 0.90) with dipstick results. Nappy pad samples were
provided from the other 2277 children, of whom 82% were < 2 years old and 1.3% met the UTI definition.
‘Clinical diagnosis’ correctly identified 13.3% positive cultures, with 98.5% specificity and an AUROC of
0.63 (95% CI 0.53 to 0.72). Four symptoms and two dipstick results were independently associated with
UTI, with an AUROC of 0.81 (0.72 to 0.90; validated 0.78) for symptoms, increasing to 0.87 (0.80 to 0.94;
validated 0.82) with the dipstick findings. A high specificity threshold for the clean-catch model was more
accurate and less costly than, and as effective as, clinical judgement. The additional diagnostic utility of
dipstick testing was offset by its costs. The cost-effectiveness of the nappy pad model was not clear-cut.
Conclusions: Clinicians should prioritise the use of clean-catch sampling as symptoms and signs can
cost-effectively improve the identification of UTI in young children where clean catch is possible. Dipstick
testing can improve targeting of antibiotic treatment, but at a higher cost than waiting for a laboratory
result. Future research is needed to distinguish pathogens from contaminants, assess the impact of the
clean-catch algorithm on patient outcomes, and the cost-effectiveness of presumptive versus dipstick
versus laboratory-guided antibiotic treatment.
Funding: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xv
List of figures xxi
List of boxes xxv
Glossary xxvii
List of abbreviations xxix
Plain English summary xxxi
Scientific summary xxxiii
Chapter 1 Introduction 1
Prevalence of urinary tract infection 1
Importance of diagnosis 2
Asymptomatic bacteriuria 2
Longer-term adverse consequences 3
Missed diagnosis 3
Frequency of paediatric urine sampling in primary care 4
Methods of urine sampling in primary care 4
Which children should have their urine sampled? 5
Existing evidence for the diagnostic value of symptoms and signs 5
Other risk factors 6
Summary of symptoms and signs 6
Dipstick tests 7
Microbiological diagnosis of urinary tract infection in the laboratory 7
Bacteriuria threshold 7
Culture techniques and uropathogenic organisms 8
Contamination 8
Economic considerations 9
Summary of DUTY study design 9
Summary of the research brief 9
Summary of the justification for the DUTY study design 9
Aim of the DUTY study 10
Research objectives 10
Changes to the original funding proposal 10
Planned change to age inclusion criterion 10
Planned change to research objective 5 10
Unanticipated changes to the validation process and reference standard 11
Other changes from the detailed project description 11
Chapter 2 Overall study methods 13
Summary of study design 13
Ethics and research and development approvals 14
Parental contributions to the study 14
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
ix
Site recruitment 15
Recruitment period and locations 15
Selection of primary care sites 15
Site recruitment approach 15
The role of the local research networks 15
Recruitment models 16
Study staff 16
Site and staff training 16
(Local) NHS laboratory recruitment 17
Service support costs 17
Participant selection 18
Eligibility criteria 18
Widening participation 18
Participant recruitment 19
Registration and informed consent 20
Non-registration 20
Urine sample collection 20
Rationale for urine collection methods 20
Maximising urine retrieval rates 21
Urine dipstick methods 21
Dispatching urines to the laboratories 22
Study thank you vouchers 22
Data collection 22
Clinical case report form 22
Patient follow-up 24
Telephone follow-up at day 14 24
Three-month notes review process 25
Day-14 and 3-month selection 25
Withdrawal and loss to follow-up 25
Discrepant laboratory results and patient safety 25
Serious adverse events 26
Processing of urine samples by a ‘typical’ local NHS laboratory 26
Specimen collection 26
Sample processing 26
Urine microscopy 27
Urine culture 27
Bacterial identification 27
Susceptibility testing 28
Reporting procedure and storage of organisms 28
Quality control 28
Processing of urine samples by the research laboratory 28
Data processing 28
Urine microscopy 29
Urine culture 29
Colony counting 29
Identification of isolates 29
Susceptibility testing 29
Detection of antimicrobial substance in urine 30
Storage of urine and cultured organisms 30
Data entry to website 30
Quality control 30
Returning positive isolates to the research laboratory after the study 30
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
Electronic data entry 30
Data entry in primary care sites 31
Data entry in the NHS and research laboratories 31
Follow-up data entry in research centres 31
Data management 31
Data quality 31
Data cleaning 31
Data storage and retention 32
Statistical methods 32
Research objective algorithm 32
Sample size calculation 32
Determining prevalence rates 33
Economic evaluation 33
Other analyses 33
Preventing and minimising bias 34
Chapter 3 General results 35
Site recruitment 35
Types of primary care site 36
Recruitment models used by primary care sites 36
NHS laboratories 37
Participant recruitment 37
Eligibility assessment 37
Comparison of children recruited to DUTY with those not recruited 37
Recruitment accruals 39
Exclusions 41
Withdrawals 41
Serious adverse events 41
Positive unintended consequences of the DUTY study 42
Urine collection 42
Urine collection methods 42
Microbiological culture results 43
Participant follow-up 44
Proportional selection for follow-up 44
Fourteen-day follow-up 45
Three-month notes review 45
Participant characteristics: descriptive statistics 46
Description of study population 46
Description of presenting symptoms and signs 47
Description of clinical examination findings 54
Study monitoring 61
Chapter 4 Microbiological diagnosis of urinary tract infection by NHS and
research laboratories 63
Introduction 63
Methods 63
Urine collection and sample processing 63
Statistical analysis 63
Results 65
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xi
Discussion 73
Summary of findings 73
Results in context with other studies 73
Clinical and microbiological implications 74
Implications for the DUTY study 74
Chapter 5 Derivation and validation of a clinical algorithm to guide diagnosis
and treatment of urinary tract infection in pre-school children in primary care 75
Introduction 75
Methods 75
Participants 75
Index tests and urine collection 75
Reference standard 75
Statistical analysis 76
Fever of unknown origin 77
Points-based models 77
Added value of dipstick testing 77
Results 78
Participants 78
Clean-catch models 78
Nappy pad models 89
Discussion 101
Summary of findings 101
Strengths and limitations 102
Results in context with other studies 102
Clinical and research implications 103
Conclusions 104
Chapter 6 Health economic analysis and modelling of diagnostic strategies 105
Introduction 105
Methods 105
Overview 105
Model structure 106
Model inputs 115
Assumptions 125
Analytical methods 126
Sensitivity analysis 126
Results 127
Comparison of sampling strategies 127
Medium- and long-term outcomes 131
Comparison of testing and treatment strategies for the clean-catch DUTY5% strategy 136
Comparison of the full DUTY risk score with points-based algorithm 137
Deterministic sensitivity analysis 141
Discussion 142
Summary of findings 142
Strengths and limitations 142
Results in context with other studies 143
Clinical and research implications 143
Conclusions 144
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
Chapter 7 Determinants of urinary contamination 145
Introduction 145
Methods 145
Participants, urine collection and microbiological methods 145
Definition of contamination 146
Statistical analysis 147
Results 147
Microbiological predictors of contamination 149
Clinical predictors of contamination 151
Discussion 153
Summary of main results 153
Comparison with existing literature 153
Clinical implications 154
Chapter 8 Other results 155
Introduction 155
Microbiological results (sensitivities and susceptibilities) 155
Follow-up outcomes 157
Generalisability and potential bias 162
Verification bias 162
Incorporation bias 166
Prevalence in urinary tract infection and its variation 166
Discussion 168
Chapter 9 Discussion 169
Summary of objectives and main results 169
Strengths 171
Weaknesses 171
Design weaknesses 171
Analytic weaknesses 172
Results in the context of research literature 173
Clinical and research implications 173
Acknowledgements 175
References 187
Appendix 1 National Institute for Health Research Health Technology
Assessment brief 199
Appendix 2 Systematic review (update) for the DUTY study: accuracy of
symptoms and signs and dipstick tests for diagnosing UTI in children < 5 years
old in primary care and choice of urine sampling method 201
Appendix 3 DUTY study protocol 217
Appendix 4 Case report forms 233
Appendix 5 Day-14 data collection forms 247
Appendix 6 Three-month follow-up data collection form 265
Appendix 7 Laboratory data entry forms 271
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xiii
Appendix 8 Laboratory methods 277
Appendix 9 Health economic analysis and modelling of diagnostic strategies 281
Appendix 10 STROBE checklist 291
Appendix 11 STARD checklist 293
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
List of tables
TABLE 1 DUTY eligibility criteria 18
TABLE 2 Selection rules used to select children for day-14 and 3-month follow-up 24
TABLE 3 Summary of NHS laboratory methods: microscopy 26
TABLE 4 Summary of NHS laboratory methods: culture 26
TABLE 5 Reporting of significant isolates 27
TABLE 6 Recruitment of primary care sites involved in DUTY across study centres 35
TABLE 7 Recruitment models used by primary care sites involved in DUTY across
study centres 36
TABLE 8 Children screened but not recruited by the four study centres 39
TABLE 9 Comparison of ages and sex of children recruited with those declined
to participate 39
TABLE 10 Frequency of urine sample growth in each of the research and NHS
laboratory result categories 43
TABLE 11 Proportions of cases selected for follow-up in each of the urine sample
result categories and numbers completed 44
TABLE 12 Day-14 follow-up interviews completed for the four study centres 45
TABLE 13 Three-month note reviews completion by study centres 45
TABLE 14 Demographic data (from section 2 of the CRF) for the study
population overall 46
TABLE 15 Comparison of DUTY recruits with national census data 47
TABLE 16 Symptoms and signs 48
TABLE 17 Clinical examination findings for all 7163 recruited participants 55
TABLE 18 Parent-reported medical history for the 7163 recruited participants 57
TABLE 19 Parent-reported medical history of previous urinary, bladder or
renal problems 58
TABLE 20 Clinical observations recorded for recruited participants 59
TABLE 21 Treating clinicians’ working diagnosis 59
TABLE 22 Antibiotic treatment prescribed by clinical diagnosis 60
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xv
TABLE 23 Characteristics of children and urine samples collected via clean catch
or nappy pads, for the 4808 children with both NHS laboratory and research
laboratory results 66
TABLE 24 Extent of agreement between NHS and research laboratory result 68
TABLE 25 Associations of signs, symptoms and urine dipstick tests with separate
NHS and research laboratory results, and ‘agree UTI positive’ 68
TABLE 26 Areas under the ROC curve (95% CI) from sensitivity analyses using
six-variable logistic regression models 72
TABLE 27 Clean-catch samples: children’s characteristics and crude ORs for index
tests associated with UTI 80
TABLE 28 Clean-catch samples: ‘full’ coefficient models based on symptoms and
signs and on symptoms, signs and dipstick results, including results based on MI 82
TABLE 29 Clean-catch diagnostic test characteristics (95% CI) for a range of
cut-points, using both the symptoms and signs model (upper part of table) and
the symptoms, signs and dipstick model (lower part of table) 84
TABLE 30 Parameters to calculate risk score for the clean-catch ‘full’
coefficient-based models 85
TABLE 31 Fever and fever of unknown origin 86
TABLE 32 Clean-catch points-based models using multiple imputation 87
TABLE 33 Clean-catch rule of points-based models using multiple imputation for
under-3-year-olds 88
TABLE 34 Clean-catch diagnostic test characteristics (95% CI) for a range of
cut-points for the points-based model, using both symptoms and signs model
(upper part of table) and symptoms, signs and dipstick (lower part of table) 88
TABLE 35 Outcome for illustrative 1000 children ≥ 2 years presenting unwell to
primary care using ≥ 5 points (sensitivity= 51.7%, specificity= 94.6%) 89
TABLE 36 Clean-catch diagnostic test characteristics (95% CI) for all possible
cut-points of the coefficient-based points-based model, using the symptoms and
signs model 90
TABLE 37 Additional diagnostic value of dipstick testing and also the prevalence
of each combination of symptoms and signs (clean-catch samples) 91
TABLE 38 Nappy pad samples: children’s characteristics and crude ORs for index
tests associated with UTI 93
TABLE 39 Nappy pad samples: models based on symptoms and signs, and on
symptoms, signs and dipstick results, including results based on multiple imputation 95
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
TABLE 40 Parameters to calculate risk score for the nappy pad ‘full’
coefficient-based models 97
TABLE 41 Relationship between fever of unknown origin and UTI in nappy
pad samples 97
TABLE 42 Nappy pad points-based dichotomised models with and without
dipstick test 98
TABLE 43 Nappy pad diagnostic test characteristics (95% CI) for a range of
cut-points using both the symptoms and signs model (upper part of table) and
the symptoms, signs and dipstick model (lower part of table) 99
TABLE 44 Nappy pad diagnostic test characteristics (95% CI) for a range of
cut-points of the points-based model using both the symptoms and signs model
(upper part of the table) and the symptoms, signs and dipstick model (lower part
of the table) 100
TABLE 45 Nappy pad diagnostic test characteristics (95% CI) for a range of
cut-points of the coefficient-based points-based model, using the symptoms and
signs model (upper part of table) 101
TABLE 46 Prevalence of UTI in children presenting to primary care 115
TABLE 47 Risk stratification for CJ and full DUTY risk scores 117
TABLE 48 Risk stratification for DUTY points-based risk scores 118
TABLE 49 Short-term model probabilities 119
TABLE 50 Diagnostic test performance 120
TABLE 51 Short-term Markov model probabilities 120
TABLE 52 Symptom duration, costs and utilities in each treatment pathway
during acute illness 121
TABLE 53 Medium-term Markov model probabilities 122
TABLE 54 Long-term probabilities 122
TABLE 55 Costs (£) 123
TABLE 56 Utilities 124
TABLE 57 Diagnostic pathway 128
TABLE 58 Diagnostic accuracy 129
TABLE 59 Treatment pathway 130
TABLE 60 Short-term costs and benefits 132
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xvii
TABLE 61 Medium- and long-term outcomes 135
TABLE 62 Comparison of testing and treatment strategies for clean-catch
DUTY5% algorithm 136
TABLE 63 Comparison of full and points-based models for clean-catch samples 138
TABLE 64 Sensitivity analysis, short-term parameters 141
TABLE 65 Sensitivity analysis, long-term parameters 141
TABLE 66 Comparing other research definitions of contamination (in date order) 146
TABLE 67 Numbers of contaminated urines by different definition (research
laboratory) 149
TABLE 68 Number of contaminated urines by collection method (clean catch/
nappy pad) 149
TABLE 69 Organisms prevalent in clean-catch contaminated urines compared
with UTI-positive urines 149
TABLE 70 Organisms prevalent in nappy pad contaminated urines compared
with UTI-positive urines 150
TABLE 71 Organisms prevalent in contaminated urines 150
TABLE 72 Numbers of urines from nappy pad and clean-catch collection methods
with ≥ 10 SECs 151
TABLE 73 Predictors of contamination in clean-catch urines 151
TABLE 74 Predictors of contamination in nappy pad urines 152
TABLE 75 Antimicrobial sensitivities for the 94 organisms considered positive for
UTI at the research laboratory 156
TABLE 76 NHS local laboratory antimicrobial sensitivities for the 94 organisms
considered positive for UTI at the research laboratory 158
TABLE 77 Early outcomes index visit and first 2 weeks 159
TABLE 78 Outcomes up to 3 months 163
TABLE 79 Comparison of those with a UTI status with those without a UTI status 164
TABLE 80 Comparison of days unwell prior to consulting for those with a UTI
status with those without a UTI status 166
TABLE 81 Variation in UTI prevalence (clean-catch samples) 167
TABLE 82 Variation in UTI prevalence (nappy pad samples) 168
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xviii
TABLE 83 Inclusion criteria 201
TABLE 84 Diagnostic utility of symptoms, signs and urine dipstick testing for UTI
in children < 5 years 204
TABLE 85 Symptoms and signs and dipstick test results helpful for ruling out UTI
in children < 5 years 209
TABLE 86 Typical results recorded for a calibrated loop method 277
TABLE 87 Dilution of urine 277
TABLE 88 Summary of research laboratory methods 277
TABLE 89 Identification of isolates at the research laboratory 278
TABLE 90 Time for activities (minutes) 286
TABLE 91 Fourteen-day resource use 288
TABLE 92 Fixed and variable costs of infection excluding antibiotic treatment or
imaging scans 289
TABLE 93 Comparison of mean TAPQOL domain scores across GP diagnosis 289
TABLE 94 STROBE statement: checklist of items that should be included in
reports of observational studies 291
TABLE 95 STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003) 293
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xix

List of figures
FIGURE 1 DUTY scheme (see Figure 4 for numbers recruited) 14
FIGURE 2 DUTY study participant flow diagram (the numbers of children recruited
are reported in Figure 4) 19
FIGURE 3 Recruitment of primary care sites 35
FIGURE 4 DUTY study participant flow diagram 38
FIGURE 5 Histograms of the ages of the children recruited and those who
declined to participate 40
FIGURE 6 DUTY recruitment accruals against HTA targets 40
FIGURE 7 Urine collection methods 42
FIGURE 8 Flow of participants in microbiological diagnosis of UTI in young children 65
FIGURE 9 Receiver operating characteristic curves of symptoms, signs and urine
dipstick tests with different definitions of urine culture positivity 70
FIGURE 10 DUTY flow diagram for diagnostic algorithm 79
FIGURE 11 Clean-catch ROC curve for multiple imputation models for symptoms
and signs only (solid line) and symptoms, signs and dipstick (dotted line) 84
FIGURE 12 Nappy pad ROC curve from multiple imputation for symptoms and
signs only (solid line) and symptoms, signs and dipstick (dotted line) 96
FIGURE 13 Sampling, testing and treatment strategies 106
FIGURE 14 Laboratory-based treatment (LT) 107
FIGURE 15 C1, not presumptive not positive 109
FIGURE 16 C2, presumptive not positive 110
FIGURE 17 C3, not presumptive positive 110
FIGURE 18 C4, presumptive positive 111
FIGURE 19 Laboratory- and dipstick-based treatment (DT) 112
FIGURE 20 Presumptive treatment (PT) 113
FIGURE 21 Short-term Markov model 114
FIGURE 22 Clean-catch sampling and testing costs vs. percentage of
laboratory-confirmed UTI 133
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xxi
FIGURE 23 Clean-catch short-term costs vs. average QALDs, comparison of
sampling strategies 133
FIGURE 24 Nappy pad sampling and testing costs vs. percentage of
laboratory-confirmed UTI 134
FIGURE 25 Nappy pad short-term costs vs. average QALDS, comparison of
sampling strategies 134
FIGURE 26 Clean-catch short-term costs vs. average QALDs, comparison of
treatment and testing strategies 137
FIGURE 27 Clean-catch sampling and testing costs vs. post-laboratory test
sensitivity, comparison of full and points-based models 140
FIGURE 28 Clean-catch short-term costs vs. average QALDs, comparison of full
and points-based models 140
FIGURE 29 Effect of clinical suspicion of UTI on the number of days until
symptoms improved among children with UTI 148
FIGURE 30 Participant flow in contamination chapter (research laboratory) 148
FIGURE 31 Effect of clinical suspicion of UTI on the number of days until
symptoms resolved among children with UTI 161
FIGURE 32 Effect of clinical suspicion of UTI on the number of days until
symptoms improved among children with contaminated urine 161
FIGURE 33 Effect of clinical suspicion of UTI on the number of days until
symptoms resolved among children with contaminated urine 162
FIGURE 34 Flow of studies through the review 202
FIGURE 35 Summary ROC plot showing estimates of sensitivity and specificity from
studies assessing dipstick positive for both nitrite and LE together with summary
ROC curve, summary estimate and 95% confidence and prediction regions 211
FIGURE 36 Summary ROC plot showing estimates of sensitivity and specificity from
studies assessing dipstick positive for either nitrite and LE together with summary
ROC curve, summary estimate and 95% confidence and prediction regions 211
FIGURE 37 Medium-term model 281
FIGURE 38 Medium-term model, no VUR 282
FIGURE 39 Medium-term model, untreated VUR 283
FIGURE 40 Medium-term model, treated VUR 284
FIGURE 41 Long-term model 285
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
FIGURE 42 Comparison of observed and modelled (using a Weibull model:
shape= 1.497, scale= 0.091) symptom resolution rates for patients with UTI
treated immediately with antibiotics (n= 38) 285
FIGURE 43 Comparison of observed and modelled (using a Weibull model:
shape= 1.246, scale= 0.099) symptom resolution rates for patients without UTI
(n= 733) 285
FIGURE 44 Symptom resolution in a selection of treatment states 286
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xxiii

List of boxes
BOX 1 Final DUTY Clean-Catch Urine Criteria 92
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
xxv

Glossary
Local laboratory The NHS laboratory local to, and used by, the primary care site at which the child
was recruited.
Primary care sites Any primary care site (general practices, walk-in centres, children’s emergency
departments, out-of-hours general practitioner co-operatives or polyclinics) at which children
were recruited.
Research centre One of the four partner organisations (at the universities of Bristol, Cardiff, London and
Southampton) at which the principal investigators were based.
Research laboratory The term used to describe the Specialist Antimicrobial Chemotherapy Unit
laboratory, Cardiff.
Responsible clinician A medical doctor or nurse practitioner whom the child was consulting for the
illness when he/she presented to primary care.
Urinary tract infection The term (abbreviated to UTI) used by clinicians to refer to an illness caused by an
infection of the urinary tract. In this report we sometimes use the term to refer to ‘laboratory positivity’,
that is the culture of a significant quantity of a uropathogen in the laboratory.
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Plain English summary
The DUTY (Diagnosis of Urinary Tract infection in Young children) study was designed to improve theway in which doctors and nurses find out when a young child has a urine infection so that they can
start effective treatment earlier.
A total of 7163 children under 5 years old, who were visiting their general practitioner (GP) or a similar
NHS service, joined the study. All were unwell or had urine symptoms. We collected details about the
child’s illness and their general health, and a urine sample. We preferred the urine sample to be collected
by a ‘clean catch’ (straight from the child into a urine container), but where this was not possible we used
a ‘nappy pad’ (a clean towel put into the child’s nappy after cleaning their bottom). Once we had the
urine, we did a simple test (urine dipstick) at the GP practice. After that, it was sent to a research
laboratory to see if there was an infection.
We looked to see if any parent-reported symptoms or doctor-/nurse-reported examination findings or the
dipstick test results made a urine infection more likely. We found that they did, especially when children
were able to provide a ‘clean-catch’ sample. These urine infections were more likely when their parents
said that children:
l had pain/crying when they passed urine
l had smelly urine
l had had a previous urine infection and
l did not have a severe cough.
Urine infections were also more likely:
l when the doctor/nurse thought that the child was more unwell, and
l when the dipstick test was positive.
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Scientific summary
Background
It is not clear which young children with acute illness presenting to primary care should be investigated
for urinary tract infection (UTI) and whether or not dipstick testing should be used to inform
antibiotic treatment.
Objectives
The Diagnosis of Urinary Tract infection in Young children (DUTY) study objectives were to (1) develop
algorithms, based on symptoms and signs to accurately identify children in whom a urine sample should
be obtained; (2) assess whether or not dipstick urinalysis provides additional diagnostic information;
(3) model algorithm cost-effectiveness; and (4) compare contamination rates between the clean-catch and
‘Newcastle’ nappy pad sampling methods.
Design
The DUTY study was a multicentre, prospective diagnostic cohort study that included: a comparison of
reliability and accuracy between NHS laboratories and a single research laboratory to establish the
optimum reference standard; the derivation and validation of algorithms to identify children warranting
urine collection and establish the added value of urine dipstick testing for antibiotic treatment decisions;
a health economic evaluation of validated algorithms; and a comparison of urinary contamination rates
from clean-catch and nappy pad samples.
Setting
NHS ‘first-point-of-contact’ primary care sites, including 225 general practitioner (GP) surgeries,
four children’s emergency departments (CEDs) and four walk-in centres across England and Wales.
Participants
Children < 5 years of age and presenting with any acute (up to 28 days) illness and/or new urinary
symptoms. Children were excluded if they were not constitutionally unwell; if they were known to have a
neurogenic or surgically reconstructed bladder; if they were using a permanent or intermittent urinary
catheter; if the main presenting problem was trauma; or if antibiotics had been taken in the previous
7 days. Clinicians were asked to recruit consecutive eligible children and, where this was not possible, to
collect non-recruited children’s age and sex.
Index tests and urine collection methods
Following consent, and blind to the reference standard, index tests (symptoms, signs and dipstick results)
were recorded on a case report form. Symptoms included the child’s medical history and parent-reported
symptoms (graded as absent, mild, moderate or severe, when at their worst during the illness). Clinically
qualified NHS staff (GPs, nurse practitioners and emergency department doctors/nurses) performed and
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recorded examination findings, which included ‘clinicians’ global impression of the child’s illness severity’
and full respiratory and abdominal assessments. In total, 107 symptoms and signs were recorded and,
preceding urine dipstick testing, clinicians recorded their opinion of UTI likelihood (‘clinical diagnosis’), and
their urine sampling and UTI treatment intentions (‘clinical judgement’). Urine was collected by ‘clean
catch’ (preferred) or nappy pad.
Methods to compare culture results from NHS and
research laboratories
Microbiology reports from the NHS and research laboratories were classified based on extent and purity
of growth and whether or not the species grown was a uropathogen (defined as a member of the
Enterobacteriaceae group). For NHS laboratories, pure/predominant growths of uropathogens at
≥ 105 colony-forming units (CFU) per ml were considered positive and research laboratory samples
were considered positive if ≥ 105 CFU/ml of a single uropathogen (‘pure growth’) or ≥ 105 CFU/ml of a
uropathogen with ≥ 3 log10 difference between the growth of this and the next species (‘predominant
growth’) was present. This analysis included only those children with index test and both NHS and research
laboratory results available. Agreement between laboratories was assessed using kappa statistics, with
analyses additionally stratified by urine collection method (clean catch or nappy pad) and by age (0 to < 2,
2 to < 3 and 3 to < 5 years). Laboratory accuracy was investigated by comparing the strength of
association between NHS and research laboratory UTI positivity and a small number of symptoms, signs
and dipstick test results selected because they had previously been reported in the literature to be clearly
related to UTI, albeit largely in emergency care settings. Those with the strongest associations and
thought suitable for all ages and collection methods were urinary symptoms (pain/crying when passing
urine, passing urine more often, changes in urine appearance); temperature ≥ 39 °C; and nitrite- or
leucocyte-positive results from urine dipstick tests. We used logistic regression models to quantify
associations of selected variables with laboratory UTI positivity and we plotted receiver operating
characteristic (ROC) curves and used the area under ROC curve (AUROC) to quantify diagnostic accuracy.
Algorithm development methods
We sequentially evaluated selected index tests in two groups: parent-reported symptoms and
clinician-reported signs (from the physical examination); and urine dipstick results. First, we selected those
variables with either trend or heterogeneity univariable p-value < 0.01 for either collection method or when
all samples were analysed together. Second, we derived models from among all the selected symptoms
and signs, separately for nappy pad and clean-catch samples, using backwards stepwise selection and an
exclusion criterion of heterogeneity p-value > 0.1. Third, we used backwards stepwise selection with the
same exclusion p-value for models in which dipstick results were added to the previously selected symptoms
and signs, to give models including symptoms, signs and dipstick results. For each model, we quantified
diagnostic accuracy as the AUROC and compared this with the ‘clinician-diagnosis’ AUROC. We internally
validated the models using the bootstrap procedure. As these coefficient-based models require relatively
complex computation to estimate UTI probabilities, we also developed points-based models, the results of
which are presented in the main report.
Health economic methods
We developed decision-analytic models using decision trees and Markov models to identify the optimal
urine sampling strategy. We developed a ‘clean-catch’ model and a ‘nappy pad’ model to reflect the
different symptoms and signs predictive of UTI in older and younger pre-school children and the different
diagnostic accuracy of the two urine collection methods. The models synthesised data from the DUTY
study and the wider literature to estimate the lifetime costs and health outcomes. We compared six urine
sampling risk stratification strategies: three derived from the DUTY risk score reflecting high specificity
(DUTY5%), intermediate (DUTY10%) and high sensitivity (DUTY20%) thresholds, one based on ‘clinical
judgement’ and two boundary strategies (sample none, sample all). The model comprised three parts:
short term (diagnosis and acute illness; up to 21 days), medium term (recurrent UTI; up to 3 years) and
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long term (long-term sequelae; lifetime). Costs were estimated from a NHS perspective and included
diagnostic costs and short- and long-term treatment costs. Health outcomes were expressed using
quality-adjusted life-years (QALYs) and quality-adjusted life-days (QALDs). Net benefit statistics were used
to compare the cost-effectiveness of urine sampling and testing strategies.
Contamination comparison methods
We selected a research laboratory contamination definition for its specificity (and previously termed
‘frankly contaminated’), that is > 2 organisms all grown at ≥ 105 CFU/ml. Univariable associations with
contamination were estimated using logistic regression, grouped by clinical and dipstick variables and
stratified by urine collection method. We selected variables with p-values < 0.01 for multivariable modelling.
Results: general
Between April 2010 and April 2012, 516 clinicians from 233 primary care sites screened 14,724 children
for eligibility. Of these, 4390 were ineligible; 1276 declined participation; 1684 could not be recruited;
196 were subsequently excluded; and 15 withdrew. This left a recruited sample of 7163 children, of whom
50% were female; 49% were < 2 years old; 82% were white; and 26% had parents who reported
education to degree level. A total of 6390 (89%) children provided a urine sample, 6241 (87%) by clean
catch or nappy pad. Culture results were available from the NHS, research and both laboratories,
respectively, for 5945 (83%), 5017 (70%) and 4828 (67%).
Results: comparison of NHS and research laboratory reliability and accuracy
This was conducted in the 4808 children with culture results from both laboratories originating from clean-catch
or nappy pad samples and index test data. NHS laboratories reported UTI positivity in 6.6% (< 3 years) and
3.2% (≥ 3 years). The research laboratory reported positivity in 1.8% and 1.9% for the same age groups.
Overall agreement [95% confidence interval (CI)] between the NHS and research laboratories was moderate
(kappa= 0.36; 95% CI 0.29 to 0.43). Agreement was better for clean-catch samples (0.54; 95% CI 0.45 to
0.63) than for nappy pads (0.20; 95% CI 0.12 to 0.28). For clean-catch samples, agreement was similar in
children aged ≥ 3 years (0.55; 95% CI 0.43 to 0.67) and < 3 years (0.52; 95% CI 0.37 to 0.67), which was
better than for nappy pad samples in children aged < 3 years (0.20; 95% CI 0.12 to 0.28). Similar patterns were
seen when comparisons were further stratified into age groups < 2 and ≥ 2 to < 3 years, suggesting that the
lower reliability was attributable to nappy pad samples rather than the child’s age. The AUROC (95% CI) for the
six pre-specified symptoms, signs and dipstick test findings in clean-catch samples for the research and NHS
laboratories were 0.86 (95% CI 0.79 to 0.92) and 0.75 (95% CI 0.69 to 0.80), respectively. The corresponding
AUROCs for nappy pad samples were 0.79 (95% CI 0.70 to 0.88) and 0.65 (95% CI 0.61 to 0.70). As a result,
we used the research laboratory culture result for the algorithm development reference standard and stratified
algorithm development and health economic analyses by urine collection method.
Results: clean-catch diagnostic algorithm
Of the 2740 children providing clean-catch urines, 2.2% met the laboratory definition of UTI, 94%
were aged ≥ 2 years and 54% were female. ‘Clinical diagnosis’ correctly identified 46.6% of the
culture-positive children, with 94.7% specificity and an AUROC 0.77 (95% CI 0.71 to 0.83). Four
symptoms (pain/crying while passing urine, smelly urine, history of UTI and absence of severe cough)
and three signs (clinician-reported global impression of illness severity, abdominal tenderness and the
absence of acute ear abnormality) were independently associated with UTI. The AUROC (95% CI;
bootstrap-validated AUROC) for the symptoms and signs model was 0.89 (95% CI 0.85 to 0.95; validated
0.88), increasing to 0.93 (95% CI 0.90 to 0.97; validated 0.90) with leucocytes, nitrites and blood on
dipstick testing.
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Results: nappy pad diagnostic algorithm
Of the 2277 children providing nappy pad samples, 1.3% met the laboratory definition of UTI, of whom 82%
were < 2 years old and 48% were female. ‘Clinical diagnosis’ correctly identified 13.3% of the culture-positive
children, with 98.5% specificity and AUROC 0.63 (95% CI 0.53 to 0.72). Four symptoms (parent-reported
smelly urine, darker urine, female sex and the absence of a nappy rash) and two dipstick results (leucocytes and
nitrites) were independently associated with UTI. The AUROC (95% CI; bootstrap-validated AUROC) for the
symptom model was 0.81 (95% CI 0.72 to 0.90, validated 0.78), increasing to 0.87 (95% CI 0.80 to 0.94,
validated 0.82) with the dipstick findings.
Results: health economic analyses (clean-catch samples)
In clean-catch samples, the ‘DUTY5%’ (high specificity) threshold urine sampling strategy resulted in fewer
urine samples being collected than risk stratification based on clinical judgement (4.8% vs. 9.2%), and
slightly higher sensitivity (58.6% vs. 56.7%) and specificity (96.1% vs. 91.4%). The high specificity
threshold of the clean-catch model was both cheaper and no less effective than clinical judgement in
terms of QALDs in the short term and QALYs in the long term. The absolute difference in short-term net
benefits among the three DUTY risk score thresholds evaluated was very small (ranging from £1088 in
‘DUTY20%’ to £1090 for ‘DUTY5%’). The relatively low cost of urine sampling and an antibiotic
prescription, the high rate of serendipitous antibiotic prescriptions, and the low prevalence of UTI within
the DUTY population all contributed to the narrow range of estimated net benefits. Our results slightly
favoured conservative (i.e. high specificity) urine sampling strategies, particularly for GPs concerned about
the societal impact of bacterial resistance to antibiotics.
A greater percentage of children would be treated with immediate appropriate antibiotics according to
urinary bacterial susceptibility (presumptive treatment 45.2%; dipstick testing 41.8%; laboratory testing
31.2%) and fewer would have delayed antibiotics (presumptive treatment 0.9%; dipstick testing 4.5%;
laboratory testing 16.6%) if treatment was presumptive or dipstick-test guided. However, average
sampling, testing and treatment costs were higher for the presumptive treatment and dipstick testing
strategies (£1.18) than for the laboratory testing strategy (£1.10). Short-term net benefits were similar
across all three testing and treatment strategies.
Results: health economic analyses (nappy pad samples)
In younger children, if urine was collected using a nappy pad, the distinction in cost-effectiveness between
the DUTY risk score and clinical judgement was not clear-cut. This is due to the lower diagnostic value of
the DUTY risk score in younger children, the higher contamination rates necessitating repeat urine
sampling and the lower accuracy of NHS laboratory results in urine collected using nappy pads raising the
possibility that a correct clinical diagnosis is overturned by an incorrect laboratory test result.
Using dipstick tests to determine treatment in children at intermediate risk of UTI slightly increased
initial sampling, testing and treatment costs compared with a laboratory test-based treatment strategy
(£1.18 vs. £1.10 per patient); however, it increased the proportion of children with UTI treated
immediately with antibiotics (41.8% vs. 31.2%). There was no difference in short-term net benefits
between dipstick- (£1090) and laboratory test- (£1090) based treatment strategies.
Results: comparison of contamination rates
‘Frankly contaminated’ urine was found in 1.8% and 12.2% of clean-catch and nappy pad samples,
respectively, giving a risk ratio (95% CI) of 6.66 (95% CI 4.95 to 8.96; p< 0.001). Contamination and UTI
was reported more often by the NHS than by research laboratories, especially for nappy pad samples.
Probability of contamination was not increased by increasing the time taken for samples to arrive at
laboratories or the presence of a nappy rash, but was increased by being female, home sampling, and
increased frequency of nappy use.
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Conclusions
Agreement of microbiological UTI diagnosis in routine NHS laboratories and a research laboratory was
lower than expected and worse for nappy pads than for clean-catch samples. Accuracy was lower for NHS
laboratory than research laboratories and for nappy pad than for clean-catch samples. Algorithms provided
better diagnostic accuracy than ‘clinical diagnosis’ in identifying the children in whom urine collection was
warranted and diagnostic accuracy was greater for clean-catch than nappy pad samples. Diagnosis and
treatment based on a clean-catch coefficient model was more cost-effective than clinical judgement and
although dipstick testing provided additional diagnostic utility, its benefit was offset by dipstick test costs.
Implications for health care
Primary care clinicians should prioritise the use of clean-catch sampling wherever possible. Parent-reported
symptoms and clinical examination signs can be efficiently used to identify children who warrant
clean-catch urine sampling. Dipstick testing has additional diagnostic value in deciding which children
should receive antibiotic treatment, albeit at a higher cost than awaiting the laboratory result. NHS
laboratories may wish to adopt the processing and reporting methods used by the research laboratory for
paediatric urine samples and update national procedures accordingly.
Future research
Further research is needed to distinguish pathogens from contaminants when multiple urinary bacteria are
found in significant concentrations. The impact of using the DUTY clean-catch coefficient algorithm on
clinical behaviour and patient outcome in routine clinical practice, and the cost-effectiveness of presumptive
versus dipstick versus laboratory-guided antibiotic treatment, should be assessed in randomised trials.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Acute illness in young children is one of the most common reasons for consulting health careworldwide, and urinary tract infection (UTI) is an important cause of serious bacterial illness in
children.1 The National Institute for Health and Care Excellence (NICE) published a guideline on UTI
in children in 2007.2 This guideline emphasised the importance of prompt, microbiologically confirmed
diagnosis and treatment of children, particularly in primary care where there is evidence that UTIs are
missed. It also recommended a large prospective study to provide the diagnostic evidence needed to help
primary care clinicians improve their recognition of children with UTI.2
The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme issued
a commissioning brief (see Appendix 1) for such a study in 2008. Our four-centre consortium, led by the
universities of Bristol and Cardiff, proposed the Diagnosis of Urinary Tract infection in Young children
(DUTY) study with the aim of deriving and validating an algorithm for the diagnosis of UTI in children
< 5 years old presenting to primary care with any acute (and largely undifferentiated) illness. We proposed
a two-step algorithm, reflecting the two-step clinical process in the diagnosis of UTI: first to use symptoms
and signs to help clinicians efficiently identify which young children should have their urine tested; and
second to determine the added value of dipstick testing for determining which children warrant immediate
antibiotic treatment.
We were particularly well placed to understand the challenges of conducting this study, with all the
complexities of urine collection from acutely unwell children in the context of busy, UK primary care
centres, as the Cardiff group, led by Dr Kathryn O’Brien, had been conducting a smaller study of similar
design called ‘EURICA’ (The Epidemiology of URinary tract Infection in Children presenting with Acute
illness in primary care) to establish the prevalence of UTI in pre-school children.
In this introductory chapter, we summarise the background leading to this study and describe the aims and
objectives of the DUTY study.
Prevalence of urinary tract infection
It is important to know how often UTI is the cause of acute illness in children presenting in primary care in
the UK as this will inform urine sampling strategies and influence levels of clinical suspicion among general
practitioners (GPs).
There are wide variations in the reported rates of UTI in children depending on setting, inclusion criteria
and microbiological laboratory test criteria.3 Most studies report the rate of UTI as determined from
laboratory samples which have been requested by clinicians who suspect UTI to be present. We cannot rely
on urine sampling based on clinician suspicion to determine an accurate prevalence of UTI, as children
with non-specific symptoms will be excluded from urine sampling.
Shaikh et al. published a review of the prevalence of UTI in children in 2008.4 They included 14 studies of
children < 2 years old and found a pooled prevalence of 7.0% [95% confidence interval (CI) 5.5% to
8.4%]. Urine was collected using suprapubic aspiration (SPA), catheters or clean catch in the majority of
studies. None used nappy pads and studies were excluded if > 25% of subjects with UTI had urine
collected using bags. The review found a high degree of heterogeneity and a range in prevalence from
3.3% to 13.8%. The review included studies which had not systematically sampled urine from children,
and two of the largest studies had included urine samples requested on the basis of clinician suspicion.5,6
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A more recent review (2012),7 of 21 studies, which included only studies where urine was systematically
sampled (urine sampled from consecutive children from the study population rather than urine sampled
according to clinician suspicion of UTI), found similar pooled prevalences to Shaikh et al. for UTI [7% for
children < 3 months old (5.9% including only studies with more stringent UTI definitions); 8% for children
up to 5 years old]. There was significant heterogeneity between studies. Furthermore, almost all of the
studies were from the USA and included populations with very different ethnic makeups and levels of
circumcision than the UK, both of which factors have been associated with UTI.3,8 Most studies were from
paediatric emergency departments and all excluded children without a fever (where fever was usually
defined as > 38 °C). Therefore, these findings may not be generalisable to UK primary care. The EURICA
study, conducted in UK general practice (n= 1003), with systematic urine sampling, found that 5.9% of
children < 5 years presenting with an acute undifferentiated illness had UTI.9
Importance of diagnosis
The accurate and timely diagnosis of UTI is important because appropriate treatment may alleviate
short-term suffering and help to prevent longer-term adverse consequences such as renal scarring,
impaired renal growth, recurrent pyelonephritis, impaired glomerular filtration, hypertension, end-stage
renal disease (ESRD) and pre-eclampsia.10,11 Some recommendations advise prompt antibiotic treatment for
symptoms suggestive of UTI in young children to prevent renal scarring.2
That said, some childhood UTI may be self-limiting. Although there are no randomised placebo controlled
trials of UTI in children, there is evidence in adults, and some indirect evidence in children, that some UTIs
are self-limiting.1,12,13 However, it is not clear which children have a self-limiting UTI, and, when they
recover clinically, if they are still at risk of renal scarring and long-term complications. We do know that in
half of adult women, bacteriuria persists following a symptomatic UTI if this is left untreated, even if their
clinical symptoms have improved,14 and an experimental study in pigs found that renal scarring could occur
even after symptomatic recovery.15 In contrast to the guidelines for other self-limiting infections, those for
UTI in children advocate its prompt microbiological diagnosis and treatment due to the association with
long-term complications.2
Asymptomatic bacteriuria
Asymptomatic bacteriuria is the growth of significant bacteria [≥ 105 colony-forming units (CFU) per ml on
culture of urine] in a patient with no symptoms. Although the population of interest for the DUTY study
are acutely ill, and therefore not asymptomatic, it is possible that some of the children identified as having
UTI due to a positive culture result could have asymptomatic bacteriuria with another coincidental illness.
It is impossible to distinguish this case from a child with UTI because the presenting symptoms of UTI are
often thought to be non-specific.
The significance and treatment of asymptomatic bacteriuria in children remains controversial. Guidelines
recommend that asymptomatic bacteriuria should not be treated in children.2 However, this advice was
based on a review of four studies, none of which included children < 4 years old.2,16–19 A recent Cochrane
review concluded that there were insufficient data to form reliable conclusions about the harms and
benefits of treating covert bacteriuria in children.20 A review in 1990 concluded that neonates and
preschool children with asymptomatic bacteriuria should be treated.21 We found only one study which
followed up infants with asymptomatic bacteriuria for 6 years. None of the nine girls and 27 boys had
renal damage on follow-up urography, although some developed pyelonephritis.22 Numbers were small
and some of the infants had received antibiotics for respiratory tract infections.
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Several studies (most from the 1970s) have reported the prevalence of asymptomatic bacteriuria in
children.23–31 Rates range from 0% to 1.8% for children < 5 years old, depending on sex and age.7 NICE
points out that children found to have asymptomatic bacteriuria on screening will include ‘those with no
discernible history of UTI, some with a previous history of UTI, and some who have had symptomatic
UTIs but have not been diagnosed’.2 The authors of a Cochrane review of interventions for covert
bacteriuria in children comment that some children identified with asymptomatic bacteriuria subsequently
become symptomatic.20
We considered these issues for the design of the DUTY study and concluded that we should only
recruit children with constitutional or urinary symptoms associated with their acute illness, such that all
children found to have significant bacteriuria with a uropathogenic organism would be considered to
have a UTI.
Longer-term adverse consequences
There is evidence that UTI can lead to renal scarring.2,32,33 A systematic review of the risk of renal scarring
following first childhood UTI included 33 studies with a total of 4891 children.33 The authors found that
57% had evidence of acute pyelonephritis (defect on early scans; based on 29 studies) and 18% had
evidence of renal scarring (persistent defect on follow-up scans; based on 14 studies but this dropped to
15% when only the nine most recent studies were considered). However, there was significant
heterogeneity between studies and children with UTI were not necessarily identified systematically.
Although this systematic review represents the best available evidence, the finding that renal scarring
occurs in 15–18% of children with UTI seems very high and may not be generalisable to a primary care
population of children with UTI, if they had been identified through systematic urine sampling.
The risk of renal scarring following UTI seems to be greater in younger children, and renal scarring is
uncommon over the age of 4 years.2,32,34,35 It was previously thought that vesicoureteral reflux (VUR) had to be
present for renal scarring to occur, but it is now accepted that renal scarring can occur, without VUR.2,33,36,37
It is thought that renal scarring can be prevented if UTI is treated promptly with antibiotics,2 and there is
some evidence that a delay in the treatment of acute UTI is more likely to result in renal scarring.38–44
Renal scarring has been associated with long-term complications including renal failure [end-stage renal
failure (ESRF)], hypertension and pre-eclampsia.2,45–47 These are serious, chronic conditions responsible for
significant morbidity and costs to the NHS. However, the evidence is weak and bias and/or confounding
could be responsible for the observed associations.47 A recent paper estimated the risk of ESRF following
childhood UTI to be 0.1% but the authors suggest that this could be an underestimate.46 The NICE
guideline concludes that ‘there are no appropriate studies that accurately estimate the risks of long-term
complications as a result of childhood UTI’, highlighting the need for a long-term cohort study.2
Missed diagnosis
It is thought that many cases of UTI are currently being missed in primary care.2 One UK-based randomised
controlled trial (RCT), in which the intervention was a nurse-led clinic to facilitate urine collection and
diagnosis, found a usual-care-arm diagnosis rate half that of the intervention group.48 This study suggested
that even more UTIs are missed in children < 1 year old and in children without specific urinary symptoms
(up to 75%).48
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Frequency of paediatric urine sampling in primary care
The main barrier to diagnosing UTI is failure to request or obtain a urine sample. GPs may not request a
urine sample if they do not suspect UTI, perhaps owing to non-specific symptoms or signs, or perhaps
because they do not believe that UTI is sufficiently prevalent or likely in that child. Even if a urine sample is
requested, it may not be obtained due to the practical difficulties of obtaining a urine sample from a
young child.49
An estimate of how often GPs obtain urine samples from acutely ill children consulting can be calculated
from several studies published prior to the NICE guidelines.2 Jadresic found that two urine samples per
100 registered children (< 2 years old) per year were sent to laboratories by GPs.50 We know that children
< 5 years old consult on average six times per year and that 87% of consultations are for acute illness.51–53
This equates to urine being sampled in 0.4% of illness consultations in children < 2 years old. Another
study in Wales gave a similar estimate, of 0.6% of illness consultations involving a urine sample.54
The publication of the NICE guideline in 2007 may have raised the level of suspicion of UTI and urine
sampling from acutely ill children. We estimated current levels of urine sampling from consultations with
acutely ill children in Wales from Public Health Wales data. In 2012, 12,689 urine samples were received
by microbiology laboratories from general practices in Wales for children < 5 years old (Dr Robin Howe,
Consultant Microbiologist, Public Health Wales, Cardiff, 11 June 2013, personal communication). We do
not know how many children were registered with practices in 2012, but from the Office for National
Statistics (ONS) 2011 census there were 178,000 children < 5 years old living in Wales in 2011.55 Assuming
that all children were registered with practices; that numbers for 2012 were similar to 2011; that urine
sampling reflected normal practice (some practices were participating in the DUTY study); that children
consulted six times per year; and that 87% of consultations were for acute illness gives an estimate of
urine sampled in 1.4% of acute illness consultations in children < 5 years old in Wales in 2012.
Unless GPs can target urine sampling extremely accurately, it is unlikely that such low levels of urine
sampling will allow detection of the majority of UTIs.
Methods of urine sampling in primary care
There are five main methods of obtaining urine samples from children: SPA, catheter insertion, clean catch,
nappy pad and bag collection. Owing to concerns about their invasive nature and the restrictions of time
and space in the UK primary care setting, SPA and catheters are not recommended for use in UK primary
care.2 NICE suggest that samples should be collected using a method suitable for the age of the infant or
child.2 ‘Clean-catch’ samples are preferred, but urine collection pads are suggested if this is not possible.
Our HTA systematic review published in 2006 reviewed methods of urine sampling and included four
studies in children < 5 years.56 We have updated this systematic review for the DUTY study (see
Appendix 2).
We found a further two primary studies, giving a total of six studies, that assessed urine sampling
methods.57–62 Two studies compared culture of urine bag specimens with culture of SPA samples.57,59
One reported a sensitivity of 100% and the other of 50%; both studies found specificity to be around
90%. Two studies compared culture results from urine samples obtained by bag specimens with those
obtained by catheter.58,61 The appropriateness of a catheter specimen as the reference standard is
questionable, meaning that these results are of limited value. One study compared culture of a nappy pad
specimen with culture of SPA samples. This study reported a sensitivity of 100% and specificity of 94%,
suggesting excellent agreement between the two sampling methods.60
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A recently published study assessed a device known as the ‘U-test’, which is a nappy pad incorporating a
urine dipstick.62 The accuracy results are, therefore, a combination of the nappy pad and the dipstick but
show good accuracy with a sensitivity of 100% and specificity of 79%. However, these were compared
with a reference standard consisting of a variety of urine collection methods (clean catch, bag, catheter or
SPA) and the study had results available for only 25 participants.
The NICE guidelines found ‘insufficient data to draw conclusions about urine collection bags and urine
collection pads’ but advised that either is acceptable for UK primary care.2 There have been only two
studies published since these guidelines and these do not provide sufficiently strong data to change these
conclusions, although the limited data suggest that pad specimens may be a more accurate method of
urine collection than bag specimens. Furthermore, the pad sampling method has been shown to be more
acceptable to parents than the bag method due to the problems of the bag adhesive irritating the child’s
skin.63 We prioritised clean-catch urine sampling where this was possible, and the use of nappy pad
sampling where it was not, for the DUTY study.
Which children should have their urine sampled?
When faced with an acutely ill child, the clinician has several decisions to make to diagnose possible UTI:
1. Should a urine sample be obtained from the child?
2. If so, should the urine sample be tested with a dipstick?
3. Should the urine sample be sent to the laboratory for culture?
4. Should antibiotics be prescribed before the culture result is available?
5. Should antibiotics be prescribed once the culture result is available?
Identifying which pre-school children should be sampled in primary care is challenging, particularly in those
< 2 years, because most are pre-verbal, symptoms and signs are usually non-specific, and obtaining
uncontaminated samples is difficult.2,49,64 NICE suggests that clinicians should test for UTI in children
< 5 years with unexplained fever, vomiting, lethargy, irritability, poor feeding, abdominal pain, offensive urine,
haematuria, frequency or dysuria.2 However, they acknowledge a lack of evidence to support the
diagnostic utility of these symptoms and signs, and uncertainty regarding the role of dipstick testing.64
Existing evidence for the diagnostic value of symptoms
and signs
We reviewed the evidence for the predictive values of clinical symptoms and signs for UTI in children
(see updated systematic review in Appendix 2). We identified five primary studies (Craig et al.,1 Gorelick
and Shaw,65 Gorelick et al.,66 Gauthier et al.67 and O’Brien et al.9) (n= 17,793) and one systematic review
(eight primary studies)3 in children aged < 5 years old (n= 7892) that assessed clinical symptoms and signs.
These were conducted mainly in hospital emergency departments; only one was conducted in general
practice.9 No individual or any combination of symptom(s) or sign(s) were sufficient to rule in a diagnosis of
UTI, although some post-test probabilities (e.g. 25% for increased capillary refill time, no fluid intake and
suprapubic tenderness) appear high enough to mandate urine testing and empirical treatment while
awaiting culture confirmation.
The largest study, which included almost 16,000 children aged < 5 years presenting to the emergency
department,1 derived a clinical prediction rule based on a combination of 27 symptoms and signs. The
model was found to have an area under the receiver operating characteristic curve (AUROC) of 0.80
(95% CI 0.78 to 0.82). However, UTI was not identified through systematic urine sampling in this study,
with urine cultures obtained in only 21% of children, calling into doubt the representativeness of this
model to diagnose UTI.
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The most representative primary care study to date (based in UK general practices with systematic urine
sampling) also considered the predictive value of presenting symptoms and signs.9 This study found
younger age, urinary frequency and dysuria to be associated with UTI and found no association with fever
or the presence of an alternative site of infection. However, the study was powered to determine UTI
prevalence, not diagnostic accuracy, and this led to wide CIs around the diagnostic utility estimates.
Other risk factors
Age and sex
Previous studies have suggested that UTI is more common among males up until 3 to 6 months old.
For children older than 12 months, UTI is more prevalent in females.4,43
In our updated systematic review, we found that age < 3 months was a risk factor for UTI, irrespective of
sex [likelihood ratio (LR) 3.9; 95% CI 3.2 to 4.8].68 The same study found a decreased likelihood of UTI in
children aged > 3 years (LR 0.47; 95% CI 0.37 to 0.61). This study also found that being female increased
the likelihood of UTI (LR 1.3; 95% CI 1.1 to 1.3) (see Appendix 2).
Circumcision status
Our review found consistent evidence that circumcision protected against UTI. The systematic review
included in our review included six studies in boys aged < 24 months that assessed the association of
circumcision and UTI, and reported a pooled LR of 0.33 (95% CI 0.18 to 0.63), suggesting that the
likelihood of a UTI was lower in circumcised boys.56 An additional study in boys aged 0–36 months
supported this finding, although the CI was wide (LR 0.07; 95% CI 0.00 to 1.16).67 It is worth recognising
that many of the studies concerning UTI in children have been conducted in countries with much higher
levels of circumcision than the UK.7,69–71 The UK rate of circumcision is approximately 3%, compared with
80% in the USA.72
Ethnicity
The systematic review included in our review included six studies that evaluated ethnicity in children aged
< 24 months and found that non-black race increased the likelihood of UTI (LR 1.4, 95% CI 1.1 to 1.8;
systematic review of six studies)56 (see Appendix 2).
Past history of urinary tract infection
In our updated systematic review, we found that a prior history of UTI increased the risk of UTI, with a LR
of 2.9 (95% CI 1.2 to 7.1) in children < 24 months old and a LR of 2.3 (95% CI 0.3 to 17.4) in children
< 12 months old (see Appendix 2).
Summary of symptoms and signs
In our review we found that none of the risk factors, individually or in combination, was sufficient to
rule in a diagnosis of UTI. Some combinations of symptoms, signs and proposed clinical prediction rules
did reduce the probability of UTI below 2% and may be considered low enough to rule out UTI (see
Appendix 2, Table 84). However, the studies on which these findings are based did not necessarily
systematically sample urine, and were based on populations with a different ethnic mix and rate of
circumcision from the UK and, therefore, may not be generalisable to UK general practice.
In the absence of accurate predictive symptoms and signs, a broad urine sampling strategy in children is
advocated by NICE.2 Others have also advocated urine ‘screening’ in some groups of children, for example
in all febrile infants or broader urine sampling strategies in ill children.70,73,74
A survey of 200 paediatricians in 1983 concerning the management of febrile infants found that all of the
respondents felt that a UTI prevalence of 5% would warrant urine sampling in all; more than 80% felt
that a prevalence of more than 3% would warrant urine sampling in all, and about half felt that a
prevalence of between 1% and 3% would warrant sampling urine from all febrile children.74
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A recent retrospective study concluded that urine analysis should be added to the NICE ‘traffic light’
system for the detection of serious illness in febrile children < 5 years old.73 This would require a large
increase in urine sampling from acutely ill children.
Dipstick tests
Once a urine sample has been obtained, the clinician has the option of testing the urine sample with a
urinary dipstick. The HTA-funded systematic review in 200656 found that urinary dipsticks were similar to
the overall conclusions based on the updated review, that is that dipstick positive for both leucocyte
esterase (LE) and nitrite is useful for ruling in a UTI and negative for both LE and nitrite is useful for ruling
out a UTI.56 NICE recommend only using dipsticks for diagnosis in children ≥ 3 years. They recommend that
a urine sample should also be sent for culture in most cases (unless both LE and nitrite are negative on
dipstick).2 For children 3 years or older, and occasionally in younger children, NICE advise using a dipstick
to help to target empirical antibiotics while waiting for urinary culture results.2
We have updated the 2006 systematic review for the DUTY study, which assessed the accuracy of dipstick
testing for UTI in children (see Appendix 2). We found data from six primary studies57–62 (including those
included in the HTA review) which assessed dipstick testing for LE and nitrite in children aged < 5 years.
There was substantial heterogeneity across studies. Negative LRs were too heterogeneous to permit
conclusions regarding the utility of LE or nitrite negative for ruling out a diagnosis of UTI, ranging from
< 0.01 to 0.88 with a pooled estimate of 0.46 (95% CI 0.18 to 1.13). Positive LRs ranged from 6 to 108
with a pooled estimate of 22.8 (95% CI 11.1 to 46.5) suggesting that a dipstick positive for both LE and
nitrite may be useful for ruling in a UTI. Positive LRs for the combination of LE or nitrite positive were also
extremely heterogeneous, ranging from 1.8 to 73 with a pooled estimate of 10.5 (95% CI 3.4 to 32.2),
making it difficult to draw conclusions regarding the utility of this combination in ruling in a diagnosis of
UTI. Negative LRs ranged from 0.16 to 0.32 with a pooled estimate of 0.22 (95% CI 0.16 to 0.30),
suggesting that a dipstick negative for both nitrite and LE may be useful in ruling out a diagnosis of UTI.
Overall, the data were too heterogeneous to draw firm conclusions regarding the accuracy of dipstick
testing; however, the data suggest that a dipstick positive for both nitrite and LE may be useful for
ruling in a diagnosis of UTI, while a dipstick negative for both nitrite and LE may be useful for ruling out
a UTI. The NICE guidelines stated that ‘further investigation of LE and nitrite dipstick tests alone and in
combination, stratified by age and method of urine collection, is required to determine their accuracy
in diagnosing UTI.’2
Microbiological diagnosis of urinary tract infection in
the laboratory
Bacteriuria threshold
Laboratory diagnosis of UTI is based on colony counts following culture, which reflect the concentration
of organisms in urine and hence the likelihood that the bacteria grown arise from a UTI rather than
contamination. The standard threshold for diagnosing UTI from culture of ≥ 105 CFU/ml was established
by Kass over 50 years ago.75 This was based on studies of adult women with acute pyelonephritis and
asymptomatic women. Some have questioned if this threshold is appropriate for children,76,77 with most
suggesting a lower threshold76–79 but one advocating an increase.80 UTI is typically thought to be caused by
a single organism present in a high concentration, usually ≥ 105 CFU/ml.81 However, laboratory guidelines
differ regarding the urine sampling method, nature and extent of bacterial growth required to confirm
UTI.82,83 For a clean-catch specimen in children, > 103 CFU/ml of a single species ‘may be diagnostic
of UTI’; and a pure growth of between 104–105 CFU/ml is ‘indicative of UTI’.82 Although usually a pure or
predominant growth is required for the diagnosis of UTI, the growth of two organisms, each with a
growth of ≥ 104 CFU/ml, would also be considered as positive by these guidelines.82 NICE guidelines do
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not provide a definitive threshold for diagnosing UTI on culture but provide advice about the level of
bacterial growth in relation to symptoms and signs.2 Although NHS laboratories in the UK follow the UK
Standards for Microbiological Investigation for the examination of urine, application of the method varies
between laboratories.
Some secondary care studies have required two consecutive urine samples with significant bacteriuria to
diagnose UTI.84,85 It has been suggested that obtaining two samples from children in primary care would
reduce the risk of false-positive results;80 however, it is unlikely that this would prove successful in primary
care given the challenges and current low levels of urine sampling. It is also unclear if two samples would
improve validity as there may be a greater number of false-negative results with this technique. Current
guidelines advocate one sample.2
Chapter 4 reports the DUTY study analyses used to determine the reference standard and bacteriuria
threshold to be used for the development of the DUTY study diagnostic algorithm.
Culture techniques and uropathogenic organisms
Standard techniques for culturing urine vary but usually rely on either cystine-lactose-electrolyte-deficient
(CLED) agar or, more recently, chromogenic agar.83 No single medium is likely to support the growth of
(and detection of) all possibly significant organisms; however, most organisms commonly associated with UTI
are supported. Organisms less commonly associated with UTI may not grow at all or may grow at an
insufficient rate to be detected, for example Haemophilus influenzae, Streptococcus pneumoniae and the
coagulase-negative staphylococci.86 There is no definitive list of uropathogenic organisms and the distinction
between uropathogenic and non-uropathogenic is not always clear.82 Staphylococaus saprophyticus is
commonly associated with UTI in females and growth is supported on the normal media used. Most studies
report that most UTI is caused by Escherichia coli, both in adult and paediatric populations.14
Enterobacteriaceae are usually considered to be uropathogens.30,34–36,82,87 Non-enterobacteriaceae such as
enterococci (Lancefield Streptococcus group B), coagulase-negative staphylococci, Staphylococcus aureus,
S. saprophyticus and pseudomonads are also considered to be potentially significant isolates.88 Colonies are
counted following culture (for ‘between 18–24 hours’). However, reporting varies from laboratory to
laboratory and often depends on the clinical information given on the clinical request form.
Contamination
It is recognised that difficulty in specimen collection and the interpretation of specimens potentially
contaminated prior to culture, from skin, faeces and other sources may contribute to the misdiagnosis of
UTI.89–98 Overdiagnosing UTI can lead to unnecessary investigations and treatment, which entail risks of
complications and psychological stress to the child and family. Discriminating between contamination with
faecal organisms and potential UTI pathogens in the laboratory is difficult as the most common faecal
organism and the most common pathogen causing UTI is E. coli, and high colony counts may be found in
children without UTI.
Contamination rates in collection methods vary, as indeed do the definitions of contamination. Contamination
rates range from 0% in clean catch to 48% of bag urines.98 In a retrospective observational cohort study,
contamination in clean catch, catheter specimen of urine and bag was 1%, 12% and 26%, respectively.98
Definitions of contamination vary from single organism growth < 105 CFU/ml OR ≥ 2 organisms to
≥ 2 organisms present at ≥ 105 CFU/ml of urine.89,91
In a US study, no institutional factors such as access to refrigeration were found to be associated with
either low or high contamination rates.99 Gender and diarrhoeal symptoms also had no association
with higher contamination rates in children.100 Perineal cleansing in female adults had no association with
contamination rates, while urine contamination rates were higher in midstream urine collected from
toilet-trained children when obtained without perineal/genital cleaning.89,94 One of the only factors affecting
contamination rates which has been published is changing nappy pads every 30 minutes.91
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Although contamination is generally considered to increase the probability of false-positive results, there is
some suggestion that contaminated samples or samples with mixed growth may hide a true UTI, that is
lead to false-negative results.101,102
Economic considerations
Urinary tract infection is the fourth most common reason for prescribing antibiotics, accounting for
approximately 8% of all antibacterial prescriptions.103 While the unit costs of laboratory testing and
antibiotic prescribing are relatively low,56 the economic implications of new clinical algorithms for urine
sampling and testing may be substantial owing to (1) the large numbers of children who present with
non-specific symptoms which might be caused by UTI; (2) the cost of subsequent diagnostic tests used to
further evaluate children with recurrent/atypical UTI;2 (3) the substantial costs and impact on quality of life
of a missed diagnosis that leads to rare but serious complications of UTI; and (4) the wider, long-term
population impact of diagnostic algorithms on antibiotic prescribing and bacterial resistance.104
The few economic evaluations of the diagnosis of UTI in young children have primarily aimed to identify
the most cost-effective test or series of tests for diagnosing UTI, rather than address the important issue of
exactly which children should be selected for urine sampling and testing in the first place.2,5,6 There is
limited economic evidence on which children should have a urine sample taken, by what sampling
method, and which urinalysis tests should be used to guide initial treatment. Guidance is especially needed
for children < 3 years of age for whom current NICE clinical guidelines are not based on evidence of
cost-effectiveness.3
Summary of DUTY study design
Summary of the research brief
The background given to the NIHR HTA research brief for improving the recognition of UTI in children in
primary care (see Appendix 1) was summarised indicating the nature of the problem, that young children
with UTI may present with non-specific symptoms such as poor feeding, vomiting, irritability, jaundice
(in newborns) or fever alone, suggesting that a broader approach to testing may be appropriate. The
research question that the commissioning brief proposed should be answered was: ‘Which clinical features
of potential infection are useful in making a preliminary diagnosis of UTI in children < 2 years of age and
indicate the need for a urine specimen to be taken?’
Summary of the justification for the DUTY study design
DUTY was a diagnostic cohort study, set up to systematically sample urine from acutely unwell children,
with constitutional and/or urinary symptoms, in UK primary care in order to determine the diagnostic value
of symptoms and signs for UTI. We proposed to develop and validate an algorithm in two steps: first, to
use symptoms and signs to help clinicians to efficiently identify which young children should have their
urine tested; and second, to determine the added value of dipstick testing. We included a health economic
evaluation to determine the cost-effectiveness of the clinical algorithm compared with existing practice.
We recognised that the age at which children can verbalise their symptoms and achieve bladder control
varies between children and that no single age < 5 years would adequately reflect this. We also knew
that collecting urine samples from children under the age of 2 years would be challenging and that
information from older pre-school children might still be valuable for younger pre-school children.
We therefore proposed a study that recruited children up to but not including the age of 5 years.
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Aim of the DUTY study
The aim of the DUTY study was to derive and validate an algorithm to improve the recognition of UTI in
children < 5 years of age presenting to primary care with an acute illness. It was envisaged that the
algorithm would be constructed to address two questions: (1) which children are at sufficient risk to
warrant urine sampling; and (2) to determine the added value of point-of-care urine dipstick testing.
The findings from these two stages would be combined to produce the overall algorithm.
Research objectives
The DUTY study’s ‘Detailed Project Description’ (the final protocol submitted with the final funding
application) contained the following five research objectives:
1. To develop an algorithm that accurately identifies children presenting in primary care with an acute
illness in whom a urine sample should be obtained, based on socio-demographic factors, medical
history, symptoms and signs (see Chapter 5).
2. To assess whether dipstick urinalysis for nitrite, LE, protein, blood and glucose gives additional
diagnostic information to objective (1) in the identification (ID) of urine samples that should be sent to
the laboratory (see Chapter 5).
3. To model the cost-effectiveness (cost per correct diagnosis of UTI, cost per symptomatic day avoided
and lifetime cost per quality-adjusted life-year (QALY), including potential long-term complications of
UTI) from NHS and societal perspectives of one or more diagnostic algorithm guided strategies
(see Chapter 6).
4. To compare contamination rates for nappy pad versus clean-catch urine sampling methods
(see Chapter 7).
5. To explore the significance of two categories of positive urine culture (laboratory diagnosed UTI vs.
asymptomatic bacteriuria/contamination) by (a) comparing the number of NHS contacts at 3 months in
children with positive urine culture stratified at presentation by the responsible clinician’s assessment of
possible UTI versus plausible alternative diagnosis, and (b) investigating for persisting bacteriuria in a
second urine sample.
Changes to the original funding proposal
Planned change to age inclusion criterion
In response to reviewers’ comments (suggesting eligibility to < 4 years) to our detailed project description, and
in communication with the HTA, we decided to increase eligibility to < 5 years. This was a pragmatic decision
informed by early findings from the EURICA study (a similar study being conducted by the Cardiff members
of the DUTY group) that showed higher recruitment, urine return rates and UTI prevalence in the ≥ 4 and
< 5 years group and a judgement by the DUTY investigators that children ≥ 4 and < 5 years were often
similar, with regard to development of language and bladder training skills, to children aged ≥ 3 and < 4 years.
Planned change to research objective 5
The original funding proposal submitted to the HTA on 12 February 2009 contained five research
objectives. The outcomes of the first four objectives are reported in this publication but the fifth was
changed prior to publication of the final protocol105 (see Appendix 3). This was because the study eligibility
criteria meant all children were unwell (or had urinary symptoms) thus making it difficult to determine
asymptomatic bacteriuria as no children were asymptomatic. We therefore removed this as an objective
and, instead, have undertaken exploratory analysis on the children who had positive or contaminated
urine, investigating the impact of their clinician’s working diagnosis on symptom duration and number of
NHS contacts at 43 months. These latter findings are reported in Chapter 7. We also decided that taking
a second urine sample in this population would have been too large a logistic undertaking and that
persistent bacteriuria was not the focus of the study.
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Unanticipated changes to the validation process and reference standard
Our original intention had been to derive and externally validate the diagnostic algorithm, using an
approximate 66/33 data split for derivation/validation and to analyse the clean-catch and nappy pad
samples together. However, analyses reported in Chapter 4 suggested that the urine collection method
was having a greater than anticipated effect on laboratory culture results. Therefore, and in consultation
with a number of international experts, we decided to stratify algorithm development by the clean-catch
and nappy pad collection method (approximately a 50/50 division of data) and to use bootstrapping to
validate the algorithms. This decision was made for two reasons. First, the smaller than anticipated
numbers of outcome events in the stratified analyses meant that analyses restricted to a development
sample would have been underpowered and estimated coefficients imprecise. Second, our statistical advice
was that the properties of a random split into development and validation samples could be mimicked by
the bootstrap procedure that we adopted, and statistical overoptimism quantified using calibration slopes.
As it would better reflect day-to-day clinical practice, we originally intended to use ≥ 105 CFU/ml of a
known uropathogen from the NHS laboratories as our reference standard. However, as the analyses
presented in Chapter 4 show, there was greater than expected disagreement between local and research
laboratories, with evidence that the research laboratory was both more reliable and more accurate than
NHS laboratories. We therefore decided to use the research laboratory result as the reference standard.
Other changes from the detailed project description
Sample size
The original plan was to recruit 6000 children by end of April 2012. As this target was met early and the
prevalence of UTI was lower than expected, we obtained ethical approval to continue recruiting until
April 2012 even though this exceeded the original projected study requirement.
Investigation of UTI prevalence
In our protocol paper (see Appendix 3), we said that we would investigate factors influencing UTI
prevalence. These results are reported in Chapter 7.
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Chapter 2 Overall study methods
Summary of study design
DUTY was a 3-year multicentre, prospective diagnostic cohort study which aimed to recruit at least
6000 children aged before their fifth birthday, being assessed in primary care for an acute undifferentiated
illness. Children were invited to participate when they presented to primary care acutely unwell (with
non-traumatic aetiology) of ≤ 28 days’ duration. Urine samples were obtained from as many eligible,
consented children as possible, and data were collected on medical history and presenting symptoms and
signs. Urine samples were dipstick tested in primary care and sent for standard microbiological analysis,
microscopy and culture at the primary care site’s usual local NHS microbiology laboratory, from here on
referred to as the ‘local laboratory’.
In addition, and where sufficient urine volumes were available, a fraction of the urine sample was
decanted and sent for parallel microbiological analysis at the study’s designated research laboratory in
Cardiff [the Specialist Antimicrobial Chemotherapy Unit (SACU), Public Health Wales Microbiology Cardiff,
University Hospital Wales], from here on referred to as the ‘research laboratory’. All children with culture
positive urines and a random sample of children with urine culture results in other, non-positive categories
were followed up by telephone to record symptom duration and health-care resource use at 14 days from
recruitment, and through review of the child’s primary care medical notes at 3 months.
The primary outcome was a validated diagnostic algorithm using a reference standard derived from
research laboratory results (see Chapter 4) of ≥ 105 CFU/ml of a single uropathogen (‘pure growth’) or
≥ 105 CFU/ml of a uropathogen with ≥ 3 log10 (1000-fold) difference between the growth of this and the
next species (‘predominant growth’). We defined uropathogens as members of the Enterobacteriaceae
group. We used logistic regression to identify the clinical factors (i.e. demographic, medical history,
presenting symptoms and signs and urine dipstick analysis results) most strongly associated with a positive
urine culture result to create a rule for use in clinical practice. An economic evaluation was conducted to
compare the cost-effectiveness of the candidate prediction rules from the perspectives of families and
the NHS.
The study was sponsored by the University of Bristol and run jointly by Bristol and Cardiff University in
collaboration with centres at Southampton University and King’s College London. The study is summarised
in Figure 1.
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Ethics and research and development approvals
Ethical approval for this multicentre study was given by a National Health Service (NHS) research ethics
committee. The initial approval was granted by the National Research Ethics Service Southmead Research
Ethics Committee on 9 December 2010, reference #09/H0102/64. NHS research and development (R&D)
approval was also gained where the research was undertaken.
Parental contributions to the study
The study protocol, study documentation and procedures benefited significantly from feedback from
parent groups and from continued engagement with parents both as formal advisors and as study
participants. During study start-up, the parent members of the NIHR South West Medicines for Children
Research Network were supplemented by additional parents, volunteering to serve on the Study Steering
Committee and/or review and comment on study documents. This feedback informed, for example, our
staffing structure (recruiting staff’s competence in working with children was considered absolutely
essential) and methods for raising local awareness generally about what was considered a worthwhile and
important study.
Once the study was under way, all questionnaires, processes and information (all formats) were reviewed
and refined according to ongoing parental feedback about participation in the study.
Culture > 105 CFU/ml
from NHS laboratory or research laboratory
14-day follow-up by telephone
(for all)
14-day follow-up by telephone
(selected following proportional selection rules)
3-month notes review
(for all)
3-month notes review
(for those selected as above)
Culture < 105 CFU/ml
from NHS laboratory or research laboratory
Set up study in organisations providing first point of care for acutely unwell children
Recruit children under 5 years of age presenting with constitutional symptoms or
UTI and/or urinary symptoms
Collect data on presenting symptoms and signs and past medical history
Obtain urine sample
Urine sample tested with dipstick, result given to clinician and entered on
case report form
Urine sample divided and sent to local NHS laboratory through routine collection and
to central research laboratory by overnight post
Urine results
FIGURE 1 DUTY scheme (see Figure 4 for numbers recruited).
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Site recruitment
Recruitment period and locations
The study was open to participant recruitment from 7 April 2010 until 30 April 2012. Recruitment was
implemented from four research centres at the universities of Bristol, Cardiff, Southampton and King’s
College London. Each centre recruited children from primary care, defined as any NHS facility providing
first-point-of-contact, face-to-face advice for parents of unwell children.
Selection of primary care sites
The majority of UK acute paediatric care is provided by GPs in primary care practices. To ensure we
recruited to target, we estimated that we required between 80 and 100 primary care sites per centre, with
each centre needing to contribute around 1500 children to achieve the study sample of 6000.
General practitioner practices were supplemented by NHS walk-in centres (WICs) and children’s emergency
departments (CEDs). WICs manage large numbers of young children with acute, undifferentiated illnesses.
For example, the South Bristol WIC estimated 2500 contacts for acute, non-traumatic, illnesses in children
< 5 years old annually. Parents also use CEDs as a first point of contact for large numbers of acutely unwell
children, particularly outside normal working hours. For example, > 5% of all attendances at UK CEDs are
due to fever,106 which represents approximately 1400 children annually in each of Bristol, Cardiff and
Southampton, and more in London. The majority of these are < 5 years old.
Site recruitment approach
In England and Wales, practice recruitment was supported by research staff from the primary care research
network (PCRN) and the National Institute for Social Care and Health Research – Clinical Research Centre
(NISCHR-CRC) Network.
General practitioner practices were invited to take part in the study either by letter or via a PCRN
newsletter. Interested practices were contacted initially by e-mail to provide further information about the
study and were followed up by telephone or face-to-face visit with the practice manager or lead research
GP to discuss the study in more detail.
Working with the local research networks in both Wales and England provided the study team with the
knowledge of which practices had experience of recruiting to studies within primary care and also
highlighted practices to approach. The role of the local research networks is described below.
The role of the local research networks
Local research network support, primarily the PCRN and comprehensive local research networks (CLRNs) in
England and, in Wales, NISCHR-CRC, was a decisive factor in enabling this study to recruit ahead of target.
Collaboration with the local research networks provided the following benefits.
Advocacy and advice for general practitioner practice recruitment
Each study centre worked closely with local research networks to identify and recruit primary care sites to
the study. This included attending research meetings, contributing to research network newsletters and
bulletins, and working with the networks to approach appropriate sites to elicit expressions of interest.
Strategic advice for recruitment across the UK
Local research networks suggested the extension of recruitment to new areas of England. For example,
PCRN South West supported the extension of DUTY study recruitment into the Peninsula area (Devon and
Cornwall) to develop local research capacity and increase access to primary care portfolio studies, as well
as boosting DUTY recruitment. In addition, the proactive support for the study provided by the Cumbria
and Lancashire CLRN was a further significant boost to recruitment figures while enhancing the
generalisability of the study findings by including more patients from rural rather than urban areas.
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Support with gaining research and development approvals
For some local research network areas (e.g. Western, and the London networks) R&D approvals for
recruitment in primary care (with the exception of CEDs in acute trusts) were granted at the level of the
primary care trust (PCT). However, for some areas (e.g. Wales, Cornwall, Cumbria and Lancashire)
site-specific approvals were required at the level of each GP practice. In these situations the local research
network provided administrative time to support the completion of specific approvals for each of the
numerous sites participating in the study.
Provision of research nurse resource
The DUTY study benefited from significant additional community research nurse (RN) capacity funded
by the CLRNs, PCRNs and NISCHR-CRC. Dedicated sessions of nurse time were provided to support local
primary care sites that did not have sufficient recruitment capacity in-house. Clinical staff recruiting
to DUTY within the three active CEDs (the Bristol Children’s Hospital, the Evelina Children’s Hospital and
Southampton Paediatric Accident & Emergency) were employed by the acute trusts and funded through
the research networks or similar organisations.
Provision of training for recruiting staff
Local research networks not only provided facilities for DUTY researchers to train primary care-based
recruiting staff, but offered ongoing training in good clinical practice and paediatric consent to clinicians
and researchers involved in all aspects of the study.
Recruitment models
Primary care sites were offered two models of recruitment. The first was known as option 1, in which the
majority of the recruitment procedures were undertaken by a RN or clinical studies officer (CSO) external to
the primary care site, and funded by the DUTY study or the local PCRN, CLRN or NISCHR-CRC, to work
with and recruit for the primary care site’s clinical team.
In option 2, recruitment was undertaken entirely ‘in-house’ by the primary care site’s practice team.
The acute environment of CED and WIC recruitment meant that, for these settings, the option 1 model was
the only viable model.
Study staff
The study grant provided full-time equivalent DUTY RN posts across all four study centres, which were
supplemented by additional research staff (RN/CSOs) provided by local PCRNs and CLRNs (in England) and
by NISCHR-CRC (in Wales).
Dedicated RNs/CSOs were available to provide external support for option 1 primary care sites, and to
support autonomously recruiting option 2 sites through the provision of expert training, mentoring and
problem-solving.
Site and staff training
The DUTY study team from each centre would meet with individual sites to explain the study and identify
their working requirements and match this to the appropriate model of recruitment in order to meet both
the study’s needs and those of each individual primary care site. The geographical area of the site was also
taken into consideration. Rural practices were encouraged to adopt the option 2 approach, as it was
impractical to use DUTY recruiters (RNs/CSOs).
OVERALL STUDY METHODS
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DUTY recruiters were provided with study-specific training including paediatric informed consent, data
confidentiality, data collection [using paper-based and electronic case report forms (CRFs)], collection of
urine samples and safety reporting. Staff were encouraged to access PCRN or NISCHR-CRC’s informed
consent and good clinical practice training days.
Sites were also offered practice-based training adjusted to meet their needs in order to tailor recruitment
methods to the individual site. Reception staff were advised on how to introduce DUTY to parents of
potential participants. Practice staff were trained on the method of processing the urine sample to send to
local NHS and research laboratories and clinicians were provided guidance on informed paediatric consent.
All staff involved with the study were provided training on data collection and CRF completion.
(Local) NHS laboratory recruitment
The participation of any primary care site in recruitment to the study depended on the support and
participation of the local NHS microbiology laboratory to which the site routinely sent urine samples. In
each area of recruitment, the local NHS laboratory was approached and service-level agreements put in
place prior to involvement in the study. Key staff were provided with a study manual, essential documents
and database instructions.
Training of staff was not required as they were only executing their normal routine procedures that were
covered within the standard operating procedure (SOP) for their own laboratory. Laboratories were
reimbursed with service support costs at a rate locally determined per sample processed.
Service support costs
Service support costs were provided by the local CLRNs for each centre in England and NISCHR-CRC in
Wales. They were provided on a ‘per-patient’ basis for primary care sites and on a ‘per-sample’ basis for
NHS microbiology laboratories.
For option 1 practices, which were supported by DUTY recruiters, the ‘per-patient’ reimbursement
excluded activities undertaken by the DUTY recruiter (e.g. consent, CRF completion, urine sample
management and online data entry). For option 2 practices, where all aspects of recruitment were
undertaken by site staff, all recruitment activities were reimbursed. Payments were made only for children
recruited with valid informed consent and without significant deviation from the study protocol.
To emphasise the importance of obtaining the urine sample in order to achieve the study’s primary
outcome, service support reimbursements were linked to sites’ urine sample retrieval rates. Reimbursements
of 100% were dependent on sites having a local laboratory urine sample retrieval rate of at least 90%,
and a research sample dispatch rate of at least 85%. Practices that did not meet both of these thresholds
were reimbursed only for those children in whom a urine sample was obtained.
For NHS microbiology laboratories, service support costs were reimbursed for all urine samples processed
by the laboratory. The laboratory service support costs were based on a Department of Health-agreed cost
for standard microscopy and culture, plus a component of administrative time for entering the urine
culture results onto the DUTY study web-based database.
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Participant selection
Eligibility criteria
The study inclusion criteria were designed to be as broad as possible. Children were eligible if they were
aged before their fifth birthday and presented to primary care with a new acute illness episode of
≤ 28 days’ duration.
This illness needed to be associated with (1) at least one ‘constitutional’ symptom or sign identified by
NICE2 as a potential marker for UTI – that is, fever, vomiting, lethargy/malaise, irritability, poor feeding and
failure to thrive; and/or (2) at least one urinary symptom identified by NICE2 as a potential marker of
UTI – that is, abdominal pain, jaundice (children < 3 months only), haematuria, offensive urine, cloudy urine,
loin pain, frequency, apparent pain on passing urine and changes to continence.
Therefore, children consulting with other apparently obvious causes for their symptoms such as otitis
media or bronchiolitis, as well as those with a history of previous UTI and known abnormalities of the
urinary tract, learning difficulties, or reconsulting for an existing illness, were all included, as long as none
of the exclusion criteria applied. Where possible, data were included for children recruited and immediately
referred from primary care to secondary care. The eligibility criteria are summarised in Table 1. The same
inclusion and exclusion criteria also made up the CRF section 1: screening form (see Appendix 4).
Widening participation
The study included parents who spoke non-English languages. Parent information sheets and consent
forms were translated into other languages as required by participating GP practices (e.g. Welsh, Polish
and Brazilian Portuguese). For languages less commonly spoken in the UK, particularly for those in which
oral translation was more useful than written translation (e.g. Somali), translational services were accessed.
TABLE 1 DUTY eligibility criteria
Children only included if ALL criteria were met Children were excluded if ANY criterion is met
Aged before their fifth birthday Aged ≥ 5 years
Presenting at a participating NHS primary care site Parents are unable or unwilling to assist with the study
Presenting with an acute (≤ 28 days) illness as the
main reason for the parent to have requested an
appointment
Illness longer than 28 days’ duration
Presenting with trauma as a predominant concern
Presenting with at least one ‘constitutional’
symptom or sign identified by NICE2 as a potential
marker for UTI – i.e. fever, vomiting,
lethargy/malaise, irritability, poor feeding and
failure to thrive and/or at least one urinary
symptom identified by NICE2 as a potential marker
of UTI – i.e. abdominal pain, jaundice (children
< 3 months only), haematuria, offensive urine,
cloudy urine, loin tenderness, frequency, apparent
pain on passing urine and changes to continence
No urinary or constitutional symptoms as defined by NICE2 and listed
in the left hand column
Known neurogenic (e.g. spina bifida) or surgically reconstructed
bladder or urinary permanent or intermittent catheterisation
(for whom different bacterial concentration cut points are used)
Taking any antibiotics in the last 7 days
Taking immunosuppressant medication (e.g. antirejection drugs, oral
or intramuscular steroids or chemotherapy)
Already recruited into the DUTY study
Involved in current research or have recently (within 28 days) been
involved in any research prior to recruitment
There will be no recruitment to the study after the last NHS
laboratory transport of the day has departed from that primary care
site on Fridays
For recruitment at A&E settings only: Children will not be eligible
if their presentation at A&E is a direct result of GP referral (as they
were then not acting as a first point of primary care contact)
A&E, accident and emergency.
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Where possible, interpreters employed by recruiting primary care sites were used to support patient-clinician
communications. When these services were not available, translational services were provided via
Language Line (www.languageline.co.uk). In primary care sites in urban areas, the clinical care team
often included a translator whose services were used when available.
Participant recruitment
The study recruitment process is summarised in Figure 2.
The term ‘parent’ is used to refer to the person with legal responsibility for the child, but it also
encompasses other carers (e.g. foster carers and legal guardians).
Parents of children < 5 years of age who have approached the primary care site and
requested an appointment are identified by reception staff or nurse and given information
about the study and asked to indicate if they would like to see
the RN/CSO before they see the clinician
Parent and child see RN/CSO who answers
questions about the study, assesses eligibility,
takes consent, collects basic information and
explains to parents how to get a urine sample
14-day follow-up
(for all those ≥ 105 CFU/ml and a sample ≤ 105 CFU/ml using the proportional selection rules)
A second voucher is posted to the parent from the study centre after completion of the
follow-up questionnaire   
Parent and child see clinician who
answers questions about the study,
assesses eligibility and records diagnostic
and examination information
Parent and child see RN/CSO who
takes consent, collects basic information
and explains to parents how to get a
urine sample
Parent and child see clinician who records
diagnostic and examination information
Urine sample provided to RN/CSO (either during visit or done at home and returned to the surgery)
Urine sample tested with dipstick by RN/CSO, result passed to clinician and recorded on CRF/website
Parent receives voucher from RN/CSO as a ‘thank you’ token
Management according to local clinical practice
3-month medical notes review
(for all those with ≥ 105 CFU/ml and a sample ≤ 105 CFU/ml using the proportional selection rules)
FIGURE 2 DUTY study participant flow diagram (the numbers of children recruited are reported in Figure 4).
Dashed line indicates that the parents can choose to participate either before or after the child sees the
doctor/nurse.
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Registration and informed consent
All recruiting primary care sites displayed posters detailing the study in waiting areas. Parents and children
were invited into the study in a number of ways:
1. Where possible, the study was mentioned to the parents of children < 5 years old by reception staff
when they telephoned for an appointment or during telephone triage. In this instance, the parent was
invited to come to the surgery 15 minutes early to receive further information from the RN/CSO.
2. Where the study was not raised at the time of making the appointment, parents of children already
booked in were telephoned and advised about the study and invited to attend a little earlier.
3. If contact prior to attendance at the site was not possible, the parent was approached on arrival, given
study information sheets and asked if they were happy to discuss participation with the RN/CSO.
4. Once the parent indicated that they were happy to discuss the study, the RN/CSO explained the study,
answered any questions, ensuring that they fully understood the implications of participation, and
checked the child’s eligibility.
Where possible, the RN/CSO recruited the participant while they were waiting to see the GP, in order that
the participant was not delayed. However, if the participant’s appointment was at risk of being delayed, or
it was more convenient for them, the RN/CSO offered to see them after their appointment or visit the
parent and child later the same day at their home.
If the parent agreed for their child to participate, written informed consent was obtained from the parent.
If the parent was not interested in hearing more about the study, no further approach was made.
In addition to the child being seen by the RN/CSO, they were seen by the child’s responsible clinician who
managed the child according to their normal practice. The study CRF was then completed for all consented
children by the RN/CSO and with clinical examination, diagnosis and management sections completed by
the treating clinician (see Appendix 4).
Non-registration
Sites were asked to complete a screening log of all children whose parents were approached by the
recruiting clinician and invited to participate in the study. Details were recorded such as their eligibility,
whether consent was given or declined, and reason for declining to participate.
Urine sample collection
The collection of the urine sample was commenced as soon as possible and often while the RN/CSO
completed the study CRF, with every effort made to obtain the urine sample while the child was at the
recruiting site.
Rationale for urine collection methods
Suprapubic aspiration and ‘in-out’ catheterisation carry the lowest risk of contamination56 but are invasive and
unacceptable to parents, and so are uncommon in UK primary care. They were, therefore, not appropriate
or feasible for widespread use in the DUTY study. The risk of contamination is low with clean-voided
midstream urine or ‘clean-catch’ samples compared with SPA samples.2 However, obtaining clean-catch
samples can be difficult for children in nappies, and parents find nappy pads or urine bags preferable.63 Many
parents prefer pads to bags as the bags have an adhesive strip that attaches to, and can irritate, the child’s
skin. These may be suitable alternatives to SPA,2 but there are few data comparing ‘clean-catch’ with nappy
pad samples. Thus, the preferred primary care method is the ‘clean catch’, and NICE recommend pad or bag
when ‘clean catch’ is not possible.2 Therefore, we followed the NICE recommendation for collecting urines,
with clean catch being preferred to pads, and pads being preferred to bag.
OVERALL STUDY METHODS
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Clean catch
The preferred method of ‘clean catch’ was used for children who were toilet trained or for whom the
parent was happy to attempt collection. For the toilet-trained child, a small sterile bowl was used which
could fit in a potty or which the parent could hold under the child while sitting on the toilet. For the child
still in nappies, the parent first cleaned the nappy area, and then sat with the child on their knee with the
bowl placed under the perineal area to collect the urine.
Nappy pad
As per NICE guidelines,2 ‘Newcastle nappy pads’ were used for children still in nappies whose parents did
not think clean catch would be successful. First, the parent cleaned the nappy area using water or wipes
(the wipes being supplied by the study). A nappy pad was inserted inside a clean nappy, and the nappy
refastened. The nappy pad was removed as soon as the child urinated in order to reduce the risk of
contamination. The perineum was recleaned and a fresh pad inserted every 30 minutes until micturition or
immediately if the pad became contaminated with faeces. Once the child had urinated, and wearing
disposable gloves, the RN/CSO removed the pad and urine was extracted into a sterile container as per the
manufacturer’s instructions.
Bag urine collection
The child was cleaned in the nappy area by the parent using water or wipes. This was followed by careful
drying with sterile towels to ensure that the bag stuck. The RN/CSO applied the bag in such a way to cover
the child’s genitals. A nappy was then placed over the bag and checked after 30 minutes for urine.
The urine was then decanted into a sterile container as per individual manufacturer’s instructions.
Collection of urine at home
If it was not possible to obtain a sample prior to the child leaving the primary care site, the parent was
given the necessary equipment and advice on obtaining a urine sample at home. The parent was advised
to store the sample in the fridge and return it to their primary care site as soon as possible, ideally within
24 hours. The RN/CSO telephoned parents the next day to remind them to return the sample. Where
feasible, the RN/CSO offered to collect the urine sample from the child’s home.
Maximising urine retrieval rates
Obtaining urine samples can be challenging, which is one of the reasons why urine samples are not
currently routinely collected in primary care at a rate sufficient to avoid missed diagnoses. As a suboptimal
rate of return of samples to the surgery by parents would have diminished power and increased risk of
bias, a number of strategies were implemented to maximise retrieval rates. In addition to the role of the
RN/CSO in following up parents whose child was not able to provide a sample during the recruitment visit,
the data recorded in the study database were used to monitor the retrieval of urine specimens, allowing
the research team to identify children for whom urine samples had not been provided, and therefore
followed up with the recruiter. Additionally, primary care sites’ urine sample return rates were linked to the
level of reimbursement via service support costs.
Urine dipstick methods
The RN/CSO tested the urine sample with a urine dipstick (Siemens Multistix® 8 SG, Siemens Healthcare
Diagnostics, Surrey, UK) provided by the study. The dipstick point-of-care test used tested for presence of
blood, protein, glucose, ketones, nitrite and LE, and measured pH and specific gravity. A dipstick was
placed in the urine as instructed, and results were interpreted according to the manufacturer’s instructions.
Urine collection information was collected in section 5 of the CRF (see Appendix 4). The time, the urine
collection method and the dipstick test results (using the study-supplied Siemens Multistix® 8 SG) were also
recorded in this section.
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Dispatching urines to the laboratories
All urine samples, if sufficient quantity of urine was available, were divided into two fractions at the
recruiting sites. The priority fraction was sent to the local NHS laboratory for routine diagnostic processing,
and the second ‘research’ fraction to a research laboratory – the SACU, Public Health Wales Microbiology
Laboratory, Cardiff – for more in-depth analysis. As only small volumes of urine (minimum 1ml) were
required for each laboratory, it was thought possible that most urine samples would be split into the
two fractions.
The NHS ‘clinical’ fraction was placed in the urine specimen container stipulated by the site’s local NHS
laboratory and labelled with the child’s unique DUTY study ID number on DUTY specific labels as provided
in patient recruitment packs. Similar DUTY labels were adhered to specific DUTY microbiology requisition
form and the sample sent to the local NHS laboratory using the site’s normal method of transport. Any
samples returned to the site and not collected within 4 hours were refrigerated on site and processed
within 36 hours. Clinicians received and acted on reports from their local laboratory as per usual clinical
care. Research laboratory urine results were not routinely fed back to clinicians; this occurred only if a
discrepancy was identified between local and research laboratory results.
The remaining portion of urine was decanted into a sterile container (Monovette®, Sarstedt AG & Co.,
Nümbrecht, Germany) containing boric acid. This was labelled with the child’s study ID number and sent
by first-class Royal Mail using Post Office-approved Safeboxes™ to the research laboratory.
The urine sampling method, time of sample, time of dipstick test, results of dipstick and quantity of urine
were recorded in section 5 of the CRF (see Appendix 4).
Study thank you vouchers
All parents received a £5 high street voucher from the RN/CSO as a ‘thank you’ token for their time in
taking part in this first part of the study. A second £5 voucher was sent to those who were proportionally
selected for follow-up at 14 days.
Data collection
The DUTY data collection process was complex and the CRF sections were developed with input from the
study management group, which included primary care clinicians, consultant nephrologists, health
economists, methodologists and statisticians.
To minimise human error, optimise the quality of data entry, and enable effective data collection from
multiple sites across England and Wales, we developed a secure, web-based electronic data collection
platform. Although this was our preferred data collection mechanism, it was supplemented by a parallel
paper-based data collection system for clinicians not wishing to use web-based systems and to cover
the event of internet failure. Unique study ID numbers were sequentially generated and used on
pre-printed consent forms, paper CRFs, urine sample labels and microbiology requisition forms (for local
NHS and research laboratories).
Clinical case report form
The purpose of the CRF was to capture children’s medical histories, examination findings and any known
risk factors for UTI. It balanced the need to include as many of the known and potential features
associated with UTI with the maximisation of speed and simplicity of completion.
OVERALL STUDY METHODS
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DUTY index tests
Where available, the selection of index tests (the parent-reported symptoms, clinical signs and dipstick test
results) was based on existing evidence. For example, at the time the CRF was developed, ethnicity,66
circumcision107 and a history of VUR108 were known to be associated with UTI in children. Moreover,
the NICE clinical guideline2 on the diagnosis, treatment and long-term management of UTI in children had
not long been published, and symptoms and signs were selected from these where evidence of diagnostic
utility was available. Furthermore, DUTY was fortunate to be able to build on the experience of the
EURICA study,109 and many of the EURICA symptoms and signs were considered for collection in DUTY.
Rationale for measuring symptom severity
We decided to measure not only the presence/absence of symptoms, but also their severity. We postulated
that the presence of mild symptoms might not be as diagnostically important as severe symptoms.
Therefore, parents were asked to rate all 30 symptoms as no problem/slight problem/moderate problem/
severe problem, as well as giving a global rating of illness severity from ‘0’ to ‘10’.
Case report form summary
The CRF comprised five sections that facilitated data entry by different personnel so as to minimise the
burden to busy health-care professionals meeting the demands of day-to-day clinical practice:
1. Eligibility screening and consent (to be completed by recruiting clinician within the recruitment interview
with the parent).
2. Registration: background socioeconomic data included date of consultation, name, address, postcode,
contact number/s, ethnicity, date of birth and sex. We also asked about the parent’s highest
educational attainment level and their financial well-being to ascertain the financial burden on families,
as postcode mapping may not address this at a household level.
3. Presenting symptoms and medical history included child’s presenting symptoms, ongoing health
problems (such as asthma or heart disease), antenatal history (gestation at birth and the presence of
urinary tract abnormalities on antenatal ultrasound), circumcision, previous UTI, and a sibling or parental
history of UTI or other urinary tract diseases.
Medication history included recent and long-term use of medications (for chronic diseases). We were
also interested in medicines that could predispose to UTI and these included the use of laxatives
(as a proxy marker for constipation), salbutamol (which could relax bladder smooth muscle) and
inhaled steroids (potential immune-suppressant). Toileting and hygiene behaviour was also included,
as under- and overwashing and prolonged use of nappies/pull-ups have been postulated as risk factors
for UTI.2
4. Clinical examination and findings were measured using routine clinical method and included global
clinician assessment of illness severity, the child’s vital signs and assessments of the child’s hydration,
consciousness level, throat, ears, chest and abdomen.
Clinician working diagnosis and management included the clinician’s working diagnosis with an
accompanying assessment of diagnostic certainty before and after seeing the dipstick urinalysis result.
Section 4 of the CRF also asked clinicians to report their subsequent management including the use of
antibiotics and referral for secondary care assessment, and whether or not they would have requested a
urine sample had the child not been entered into the DUTY study.
5. Urine collection and processing: urine sampling method (clean catch or nappy pad) and urinalysis results
with date, time of testing, with a prompt to inform the responsible clinician of the dipstick result and
confirmation that the sample had been sent to the local NHS and research laboratories. As one of
the DUTY study aims was to assess the added diagnostic value of dipstick urinalysis (over and above the
symptoms and signs), dipstick results were included in the CRF as an index test.
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Patient follow-up
DUTY participants were proportionally selected for a follow-up interview at day 14 and medical notes
review at 3 months post recruitment. The process by which children were selected and followed up is
described below.
Telephone follow-up at day 14
At 14 days from the recruitment interview, study centre staff contacted parents of all children selected for
follow-up according to the proportional selection rules (described in Table 2) to record symptom duration
and health-care resource use during the 14-day period after recruitment. In older children (> 9 months),
the interview also included a parent-completed questionnaire measuring child health-related quality of life
(see Appendix 5). Owing to the young age of the participants, standard methods [e.g. European Quality of
Life-5 Dimensions (EQ-5D)] for measuring health utilities were thought to be invalid. Instead, we used the
TNO-AZL (Netherlands Organisation for Applied Scientific Research Academic Medical Centre) Preschool
children Quality of Life (TAPQOL) questionnaire, completed at 14 days, to describe the health profiles of
children with and without UTI.110 TAPQOL measures parents’ perceptions of health across 12 domains
(e.g. sleep, social functioning) and has been shown to be a reliable instrument for both infants and
toddlers.111 No mapping from TAPQOL responses to utility values exists, hence we used a proxy value from
a condition (rotavirus) thought to have a similar health-related quality of life impact to UTI. The TAPQOL
responses allowed us to validate this choice and make robust comparisons between the health-related
quality of life of children with and without UTI.
A booklet version was posted to the parent when telephone contact failed. Details of data collected in the
DUTY questionnaire are described below.
1. Symptom duration: we asked if children responded to treatment < 48 hours as NICE has identified
failure to respond within 48 hours as a marker of ‘atypical UTI’ and recommends dimercaptosuccinic
acid (DMSA) scan and micturating cystourethrogram (MCUG) in such children.
2. Primary care resource use: practice-based contacts in hours, out-of-hours contacts and
community-based contacts (e.g. WIC, NHS Direct or health visitor) and associated expenses for the
child’s family (fares or mileage, car parking).
3. Hospital resource use [visits to accident and emergency (A&E), attendance at hospital clinics, overnight
stays in hospital, use of ambulance services, hospital tests] and associated expenses for the child’s family.
4. Consumption of prescribed and over-the-counter medicines.
5. Other out-of-pocket expenses impinging on the child’s family, for example time off work, loss of
earnings, additional childcare costs.
6. Quality of life (TAPQOL or TNO-AZL Preschool children Quality of Life, after Fekkes et al.110). The parent
was asked to rate the child’s quality of life against specific measures of child health including
symptoms, sleeping, feeding, behaviour and well-being. The TAPQOL questionnaire is designed for
children aged 9 months to 6 years. However, a subset of questions on social, mobility and
communications skills are used only in children aged > 18 months.
TABLE 2 Selection rules used to select children for day-14 and 3-month follow-up
Category
Culture growth
category Definition Laboratory
Proportion
sampled, %
1 ≥ 105 CFU/ml Pure or predominant species BOTH NHS laboratory and
research laboratory
100 (all)
2 > 103 and < 105 CFU/ml Pure or predominant species Research laboratory 20
3 ≥ 105 CFU/ml Two or more species BOTH NHS laboratory and
research laboratory
20
4 < 103 CFU/ml and
‘no growth’
BOTH NHS laboratory and
research laboratory
10
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Three-month notes review process
The 3-month notes review (see Appendix 6) collected the following data: (1) number and type of
consultations (not including routine immunisations, screening checks or NHS Direct contacts); (2) results of
any further urine samples; (3) secondary care utilisation [including A&E, hospital clinics, outpatient
attendances, admissions and investigations/tests (e.g. ultrasound, MCUG or DMSA scans)]; and (4) the
dates, types and doses of any prescribed medications.
The majority of these reviews were completed by the study centre RNs and administrators; however, where
recruiting sites were geographically remote from the study centre, the assistance of RNs employed by the
PCRNs, NISCHR-CRC and practice staff in completing these reviews was sought.
Day-14 and 3-month selection
Selection of DUTY participants to complete the follow-up interview at day 14 and notes was carried out
proportionally according to the growth result of the urine sample provided. All children with a pure
predominant positive culture (as defined by the NHS or research laboratory at ≥ 105 CFU/ml) and a
representative number of children with other growth results were selected as described in Table 2.
An automatic algorithm within the database was created in order for those children to be selected
from growth results posted to the database from the day of recruitment until 28 days post recruitment.
Results for any child posted after that time would be deemed too late for them to be selected for a
follow-up interview.
Withdrawal and loss to follow-up
In the majority of cases the only active participation of children was at the initial consultation; therefore,
withdrawal from the study was anticipated to be infrequent. For those parents who did wish to withdraw
their child from the study, they were asked whether they wished to (1) withdraw completely such that
none of the child’s data were used; (2) withdraw from all further study activities, but allow all data
collected so far to be used; or (3) withdraw from day-14 telephone follow-up but consent to review of
patient medical notes at 3 months.
Attrition in those selected for follow-up as a result of the challenges of making contact with busy parents
was expected to be a greater threat to follow-up rates than withdrawal by parents. Attrition was
minimised by making several attempts to contact parents by telephone. However, if unsuccessful, a postal
questionnaire was sent to parents with a stamped addressed envelope. If a telephone interview was not
achieved and the postal questionnaire not returned within 2 weeks of sending, the participant was
considered lost to the 14-day follow-up, but was still included in the 3-month notes review.
Discrepant laboratory results and patient safety
All NHS local laboratory results were reported back to clinicians in the same way as for routine care.
In order to optimise patient safety the study team informed children’s responsible clinicians regarding
patients where the NHS local laboratory result was not positive (i.e. contaminated, no growth or not
processed) but the research laboratory result indicated clinically significant urine culture positivity.
A process was set up by which they were identified and important discrepancies reported to the child’s
responsible clinician using a purpose-designed letter. While this result was unlikely to drive immediate
patient management (as it could be up to a week after the consultation), it was felt that it would be useful
for clinicians in cases where the illness was ongoing or recurring.
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Serious adverse events
We did not expect to see any related serious adverse events (SAEs) happening as a result of this research,
as the study involved only a non-invasive urine test which is often part of the routine clinical care of
patients. However, we did anticipate a relatively high number of unrelated and expected SAEs as a
consequence of hospital admissions of acutely unwell children, especially (though not exclusively) for
children presenting to recruiting CED sites.
Processing of urine samples by a ‘typical’ local NHS laboratory
All local NHS laboratories were ‘Clinical Practice Accredited’ and NHS laboratory SOPs were used to
process DUTY urine samples. All local NHS laboratory SOPs were based on the Public Health England
guideline for the investigation of urine.82 A summary of these processes is given in Tables 3 and 4.
Specimen collection
Specimens were collected in sterile containers (some with boric acid, depending on local NHS laboratory
procedures) and, where possible, filled to the line indicated on the tube. All samples were sent to the
laboratory as soon as possible after collection, but refrigerated if transport to the laboratory was delayed
for more than 4 hours. Specimens in boric acid were refrigerated for no longer than 48 hours.
Sample processing
On arrival at the laboratory, all DUTY urines and requisition forms were processed as routine specimens
using standard laboratory procedures. The patient ID information provided by the requesting primary care
site was entered onto the Laboratory Information Management Systems (LIMS). In addition, laboratories
were asked to record unique DUTY patient ID, date of birth, date and time of sample collection, sample
receipt, and urine processing in laboratory on the DUTY web-based database.
TABLE 3 Summary of NHS laboratory methods: microscopy
Microscopy Manual Automated Dipstix
Number of laboratories using method 16 8 2a
a One laboratory uses Dipstix as well as manual microscopy.
Automated microscopy was performed by the research laboratory.
TABLE 4 Summary of NHS laboratory methods: culture
Culture method Paper foot Calibrated loop Multipoint
Number of laboratories using method 4 19 2
Culture media CLED Chromogenic media Both
Number of laboratories using media 7 14 4
Calibrated loop culture volume 1µl 2 µl 5 µl 10 µl
Number of laboratories using volumea 11 5 1b 1
Number of laboratories using volumea 11 5 1b 1
Plate area used 1/4 1/3 1/2 Whole
Number of laboratories using plate area 13 2 3 1
a Two laboratories use a 3-µl volume for culture.
b One laboratory uses a 5-µl calibrated loop on certain urines, but normally uses multipoint method.
Based on Public Health England’s guideline.82
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Samples were not processed if (1) there was too little sample volume (< 0.5ml); (2) a boric acid container
was under- or overfilled; (3) the sample was leaking; (4) the data on the form and sample did not match;
or (5) if the container was unlabelled.
Urine microscopy
Microscopy was performed on all specimens by either manual or automated methods. Manual methods
vary by laboratory but are based upon the methods set out in Health Protection Agency (HPA) guideline
for the ‘Investigation of urine’.83 Validated automated urine analysers were used in some laboratories, in
accordance with manufacturers’ instructions.
Numbers of white blood cells (WBCs), red blood cells (RBCs), squamous epithelial cells and bacteria were
recorded according to local ranges (e.g. WBC: < 10; 10–30; > 30–100; or > 100). The ranges varied by
laboratory and were based around the method used.
The presence of other organisms (e.g. Trichomonas, Schistosoma or Amoeba), casts [stating type and
quantity (scanty, moderate or numerous)], crystals and yeasts was also recorded.
Urine culture
Urine culture was performed using local techniques as described in Table 4. Standard media, usually UTI
chromogenic and CLED media, were inoculated, typically using 1 µl to 2 µl, and plates incubated at 35 °C
to 37 °C for 16 to 24 hours or according to local SOPs. Further specialised plates for detection of yeasts,
for example, were added if required. Plates were read after incubation by a qualified BioMedical Scientist
and results recorded.
Bacterial identification
The semiquantitative calibrated loop method of culture is only sensitive for screening down to 103 CFU/ml
if a 5-µl or 10-µl loop is used (e.g. 5 or 10 colonies), or 104 CFU/ml if a 1-µl or 2-µl loop is used (e.g. 10 or
20 colonies).
Bacterial ID of significant isolates was performed according to local SOPs but reported according
to Table 5.
TABLE 5 Reporting of significant isolates
Bacterial ID Level of reporting
Anaerobes ‘Anaerobes’ level
β-Haemolytic streptococci Lancefield group level
Enterobacteriaceae (except Salmonella species) ‘Coliform’ level
Enterococcus Genus level
Pseudomonads ‘Pseudomonads’ level
S. saprophyticus Species level
Other coagulase-negative staphylococci ‘Coagulase-negative’ level
S. aureus Species level
S. Typhi/Paratyphi Species level
Yeasts ‘Yeasts’ level
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Susceptibility testing
Susceptibility testing was performed by a variety of standard methods including disc testing and breakpoint
testing. Susceptibility testing was performed on all significant isolates using local SOPs based upon
susceptibility testing guidelines [for e.g. British Society for Antimicrobial Chemotherapy (BSAC) standardise
disc susceptibility testing method (version 11)].112
Disc susceptibility testing can be performed either from isolates recovered from urine or direct from urine.
Briefly, a standard inoculum was plated onto susceptibility testing media and antimicrobial discs applied.
Plates were incubated for 18 to 20 hours in air at 35 °C to 37 °C. Zone sizes were read by a qualified
BioMedical Scientist and interpreted using BSAC or other guidelines such as the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) and Clinical & Laboratory Standards Institute (CLSI).
The breakpoint method utilises agar plates containing antimicrobials at concentrations around the
breakpoint. Significant isolates were emulsified in sterile saline then spot inoculated onto the plates.
Typical antimicrobials tested were firstline antimicrobials: amoxycillin/ampicillin, nitrofurantoin,
trimethoprim, ciprofloxacin, co-amoxiclav, cefpodoxime and cephalexin. Cefpodoxime-resistant coliforms
were tested for production of extended spectrum beta-lactamase (ESBL) enzymes in some
local laboratories.
Growth on the plates by either method indicates susceptibility/resistance to the antimicrobials tested.
Reporting procedure and storage of organisms
NHS laboratories reported results as per local SOP to the requesting clinician and were required to
transcribe the results onto the DUTY web-based database within 1 week in order to allow for patient
sampling for follow-up. This was also the trigger to activate laboratory payment (see Appendix 8 for details
of laboratory CRF).
Isolates from pure or predominant culture at ≥ 103 CFU/ml were stored on cryogenic beads at –20 °C
or –70 °C.
Quality control
All stock reagents, media, antimicrobials and equipment were monitored for quality assurance at locally
specified times. Quality assurance records were completed for lot numbers and expiry dates. All
laboratories perform internal quality control and participate in internal quality assurance and external
quality assurance schemes.
Processing of urine samples by the research laboratory
The research laboratory had experience in supporting other primary care UTI studies and supported the
EURICA study.109
Data processing
Urines were sent overnight by Royal Mail SafeBoxes™ by the participating sites. Monovette containers
containing boric acid were used to stabilise bacterial counts.
On arrival in the laboratory all DUTY urines and forms were checked for matching identifiers. The following
data from each sample were recorded: centre ID, patient ID, date of birth, date and time of sample
collection, sample receipt and urine processing in laboratory on the DUTY web-based database. If samples
were received out of hours then urines were stored at 4 °C until processed and the date received recorded.
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Samples were not processed if (1) there was too little sample volume (< 0.5ml); (2) the sample was
leaking; (3) the sample was received in a non-sterile container; (4) the data on the form and sample did
not match; or (5) the container was unlabelled.
Before processing, each Monovette was weighed using a fine-scale balance and the total weight recorded.
Urine microscopy
Urine microscopy was performed on all urine samples with sufficient volume. If 1 to 2ml only were
received then culture only was performed. Microscopy was performed using the iQ200SPRINT analyser
(Beckman Coulter Ltd, High Wycombe, UK). Samples that exceed the pre-set thresholds for a given
category were manually reviewed by the BioMedical Scientist.
Microscopy results including WBC counts, RBC counts, bacteria counts, squamous epithelial cell counts,
presence of yeasts and presence of casts were recorded.
Urine culture
Urines were diluted prior to spiral plating in accordance with standard dilution factors and 50 µl of urine
dilution was inoculated onto UTI chromogenic agar and Columbia Blood Agar (CBA) and allowed to dry.
Spiral plating was repeated for other dilutions. The stylus was washed between urine samples using 5%
hypochlorite (× 1) then sterile water (× 2). Agar plates were incubated at 35 °C to 37 °C for 18 to 24 hours
in aerobic conditions. If yeasts were seen on microscopy, these were also spiral plated onto two Sabouraud
agar plates and incubated at 35 °C to 37 °C and 30 °C for 5 days.
Colony counting
Total colony counts were performed for all sample CBA plates following the spiral plater manufacturers’
instructions. Colonies were counted in sectors of a grid which overlays the agar plate and the number of
colonies in each sector translated into CFUs per ml using the manufacturers’ tables and counts were
recorded. Species-specific counts were performed on all isolates present at > 103 CFU/ml in pure or
predominant growth cultures on the UTI chromogenic agar.
Identification of isolates
A preliminary identity of all counted isolates was ascribed using the UTI chromogenic agar. Significant
isolates were identified further by basic microbiological tests (e.g. colony morphology, biochemical tests
such as indole for E. coli). Potentially significant isolates were considered to be Enterobacteriaceae
(E. coli, Klebsiella spp., Citrobacter spp., Enterobacter spp., Serratia spp., Proteus spp., Morganella spp.)
(see Appendix 8).
For samples with mixed ≥ 3 organisms with colony counts of 103 CFU/ml and/or no significant isolates,
the ID was performed by UTI chromogenic agar alone.
Susceptibility testing
Antimicrobial susceptibility was determined for all pure or predominant significant organisms according to
BSAC disc susceptibility testing guidelines. Isolates were cultured onto CBA plates for single colonies and
inspected for purity. A few colonies were suspended in 3ml sterile water to turbidity 0.5 McFarland and
inoculated onto Iso-Sensitest Agar (Oxoid Thermofisher, Basingstoke, UK). The surface was allowed to dry
for a few minutes and then the antimicrobial discs applied and plates were aerobically incubated for 18 to
20 hours at 35 °C to 37 °C.
Antimicrobials tested for Gram-positive isolates were trimethoprim, nitrofurantoin, amoxicillin, cefoxitin,
vancomycin and novobiocin.
Antimicrobials tested for Gram-negative isolates were trimethoprim, nitrofurantoin, amoxicillin,
co-amoxiclav, cephalexin, ciprofloxacin and cefpodoxime.
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All antimicrobials except vancomycin were purchased from Sigma-Aldrich Ltd, Poole, Dorset, UK. Disc zone
sizes were recorded and interpreted using BSAC guidelines.
Detection of antimicrobial substance in urine
All urines were tested for the presence of any antibacterial substance in the urine. A 0.5 McFarland
solution of Bacillus subtilis (NCTC 10400) was inoculated onto an Iso-Sensitest Agar plate. After
5–10 minutes’ drying time, 10 µl of urine was spotted onto the plate, and the plate incubated for
18 to 24 hours’ aerobic incubation at 35 °C to 37 °C. This detects any antimicrobial substances that are
in the urine.
Storage of urine and cultured organisms
For samples exhibiting either pure or predominant culture at > 103 CFU/ml, each isolate was stored on
cryogenic beads at –70 °C. For samples exhibiting mixed ≥ 3 organisms at 103 CFU/ml, a sweep of the
growth was saved on cryogenic beads at –70 °C. Any significant isolates were stored on cryogenic beads
at –70 °C. Samples with no growth or growth < 103 CFU/ml were not stored.
Two aliquots of all urine samples were stored in cryogenic vials at –70 °C, one containing 5% sterile
glycerol for bacterial preservation.
Data entry to website
All data recorded were transcribed to the DUTY web-based database on a weekly basis (see Appendix 8
for details of laboratory CRF). Lists of those patients considered to have a positive UTI result based on
research laboratory data were collated and reported to the study centres.
Quality control
All stock reagents, media, antimicrobials and equipment were monitored for quality assurance at locally
specified times. Quality assurance records were completed for lot numbers and expiry dates. See Appendix 8
for research laboratory quality control methods.
Returning positive isolates to the research laboratory after the study
After closure of recruitment for the DUTY study, all isolates retained by the local NHS laboratories
were transported to the research laboratory for long-term storage. All isolates were labelled
pseudo-anonymously with the study patient ID only. The transfer was made using an Amies charcoal
transport swab (Technical Service Consultants Ltd, Heywood, UK) and using Hayes DX couriers
(www.dxdelivery.com) (Royal Mail was used as an alternative). Hayes DX ensured that specimen delivery
services were fully compliant and International Air Transport Association-approved to meet the current HPA
legislation requiring that infectious samples have to be moved in accordance with strict guidelines.
Electronic data entry
The DUTY electronic database and DUTY website were hosted on the electronic PCRN (ePCRN) Citrix
servers at the South London and Maudsley (SLaM) NHS Foundation Trust. The Citrix environment provided
a secure connection for the users via the client software which was required to be installed on each
computer. The secure web-based system was developed by King’s College London, using industry best
practice and in collaboration with the NHS Research Capability Programme and the PCRN, to provide
research tools to enhance recruitment to NIHR portfolio studies in primary care.
The electronic CRF, 14-day follow-up, 3-month notes review, local laboratory and research laboratory
input, web-based data collection pages entirely mirrored their paper-based counterparts. They were
created in ASP.net (a dynamic web application framework; www.asp.net) on top of a dedicated Structured
Query Language (SQL) data management server, with data variables forced to comply with entry and
validation rules defined in the data element definitions. The SQL data management server incorporated
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auditing, back-up and recovery facilities. The study workflow and algorithms were enforced using the
same methods, and a visual algorithm on the web pages guided users. The web-based system was piloted
for ease of use prior to data entry going live. The data were backed up nightly off-site. The patient
identifiable data on the server were encrypted before storage on the database. For added security the
encryption/decryption functions were not part of the database but were implemented using linked
functions whose code was in a different location from the database on the server. Once logged on to the
Citrix environment, users connected to the DUTY website using a separate account. Accounts were linked
to roles with different privileges for accessing sections of the website and different privileges for viewing/
editing patient data. Data were exported as comma-separated values (CSV) files from the export section of
the DUTY website.
Data entry in primary care sites
The web-based database system was presented as the preferred method of data collection, and DUTY
recruiting staff were encouraged and supported to enter CRF data onto the database directly or, if using
paper-based CRFs during the recruitment interviews, to retrospectively enter the data in a timely manner
(consent and registration within 24 hours, and full eCRF data within 5 working days).
Data entry in the NHS and research laboratories
All laboratory data generated from microscopy and culture for each urine sample received from the NHS
local laboratory and research laboratory were entered into the DUTY web-based database. Local NHS and
research laboratories staff were only able to access the microbiology data collection pages to log the
samples on receipt and enter the results within 1 week of data being available.
Follow-up data entry in research centres
Follow-up data collected at day 14 and 3 months from telephone interviews, postal questionnaires and
patient records were entered either directly at time of collection, or retrospectively from paper CRFs, onto
the web-based follow-up data collection forms by research staff at each centre.
Data management
Data quality
Sites where concerns regarding the possibility of protocol deviations and/or data entry issues not being
concordant with electronic data recorded were subject to a data quality audit. The audit questions to be
addressed were developed after discussion with both the sponsor and University Hospitals Bristol NHS
Foundation Trust. Audits were followed by updated training and agreed reaudits. Following the reaudit of
one particular site, by the University Hospital NHS Bristol R&D team on behalf of the sponsor, a study-wide
audit was initiated with a random selection of participating primary care sites.
Data cleaning
Where data between paper CRFs and web-based database conflicted, the value on the paper CRF was
deemed the true value (making the assumption that the database value was the result of a keying error),
unless the paper CRF had already been appropriately annotated with a correction.
All missing data that could not be resolved, for example where no paper record was available,
were recorded.
Some ‘self-evident correction’ rules were developed for areas where it was evident that a data entry
mis-key had occurred. Self-evident corrections did not involve any changes to actual data or result values;
they were used only for process-orientated variables such as dates.
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Other cleaning issues were considered, as shown below in order of importance:
1. duplicate patients/NHS numbers
2. missing urine samples and illogical microbiology data
3. time periods – overlong and negative times (e.g. date of birth and date of recruitment)
4. overall missing data – large numbers of missing data for individual recruits
5. outliers – for example in examination findings (temperature, pulse rate, etc.)
6. relationship of consenter to child – to confirm that consent was given by the parent.
All CRF data queries were provided to each centre for verification either against the paper CRFs or by
contacting the recruiting site for clarification.
In order to maximise the urine sample laboratory data, all entries on the CRF/database indicating that a
urine sample had been obtained, but the laboratory had not entered the results, were followed up directly
with the laboratories.
An inbuilt SQL quality control facility provided a full audit of all amendments made and was available as a
CSV download. All amendments made to the database were also manually audited and recorded separately.
Data storage and retention
All data will be archived until the youngest participant reaches the age of 21 years, in line with each
centre’s governance framework regulations for clinical research. The archive will consist of the protocol
and all of the amendments, patient information sheets, CRFs and the follow-up data, and analysis records.
Additionally, all of the legally required documentation relating to ethical approval, sponsorship and
indemnity will be archived.
Statistical methods
Research objective algorithm
The overall objective of the study was to derive and validate a clinical algorithm for the diagnosis of UTI,
in children aged before their fifth birthday presenting to primary care with an acute illness. The algorithm
was constructed in two stages: ID of children at risk (in whom a urine sample should be obtained) and
determination of the added value of point-of-care urine dipstick testing. The determination of when
to obtain a urine sample was based on sociodemographic factors, medical history, symptoms and signs.
The purpose of the dipstick analysis was to assess whether dipstick urinalysis for nitrite, LE, protein, blood
and glucose gives additional diagnostic information to assist in the ID of children who should receive
immediate antibiotic treatment and urine samples that should be sent to the laboratory. The findings were
combined to produce an overall algorithm.
Sample size calculation
Our sample size calculation was targeted at our main objective, namely the development of the clinical
algorithm. We assumed a candidate predictor with 10% prevalence and UTI prevalence of 2%. With 80%
power and a two-sided alpha of 5%, 3000 urine sample results are required to detect an odds ratio (OR)
of 2.4, while 3100 results give a 95% CI with width 10% for an algorithm with 80% sensitivity. We
originally proposed to recruit 4000 children with a target of recovering urines from at least 77.5% for
algorithm derivation and a further 2000 children for external validation. However, we did not originally
anticipate the need to stratify analyses by urine collection method. We therefore decided to use all
available results to derive the models, with internal bootstrap validation instead of external validation as
originally planned.
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Determining prevalence rates
We calculated the prevalence in all samples and also by the collection method using methods appropriate
for small proportions.113 We also looked at the degree of variation in prevalence stratified by collection
method. First, we considered the degree of variation in prevalence between practices using a two-level
random-effect logistic regression model with practice/site as a random effect and no fixed effects. Second,
we used a LR test between this multilevel model and logistic regression to show if there was any
evidence of clustering, using a conservative p-value threshold of 0.1. Finally, using the chosen model type,
multilevel logistic or logistic regression, we then added a number of variables to the model: area, type of
recruitment site, age, sex and an Index of Multiple Deprivation (IMD) deprivation score for each child.
We then assessed the effect these variables had on prevalence by listing the crude and adjusted ORs
(with 95% CIs) for each of these variables.
Economic evaluation
We developed decision-analytic models using decision trees and Markov models to identify the optimal
urine sampling strategy for acutely unwell children under the age of 5 presenting to primary care. As
diagnostic accuracy depended on the urine collection method, we developed a ‘clean-catch’ model and a
‘nappy pad’ model. The models, which synthesise data from the DUTY study and the wider literature,
estimate the lifetime costs and health outcomes for six urine sampling strategies including three derived
from the DUTY risk score. A lifetime horizon is important to capture the rare but serious complications of
UTI that may occur later in life.
In secondary analyses, we extended the models to compare three testing and treatment strategies to
explore the role of dipstick testing in guiding laboratory testing and antibiotic prescriptions. Costs were
estimated from a NHS perspective and included diagnostic, short-term treatment and long-term
complication costs. Health outcomes were expressed using QALYs and quality-adjusted life-days (QALDs).
The model was made up of three parts: short term (diagnosis and acute illness; 21 days), medium term
(recurrent UTI; 3 years) and long term (long-term sequelae; lifetime).
A full description of the methods used in this analysis is given in Chapter 6.
Other analyses
We planned to use methods appropriate for small proportions113 to estimate the prevalence (with 95% CI)
of culture positive urines in acutely unwell children under 5 years. This was undertaken on all children
with cultured urines. The degree of variation in prevalence between practices and geographical areas was
explored. This analysis was also explored by looking at difference by recruitment site type (general practice,
WICs, out-of-hours providers and CEDs).
Recruited children for whom urine samples were obtained were compared with those for whom no urine
sample was obtained in terms of clinical presentation and demographics.
We compared the probability of contamination in samples that were retrieved via a ‘clean-catch’ method
with those using nappy pads and investigated the factors associated with contamination. We examined
the impact of the time between obtaining the urine, transportation (including day of the week) and
laboratory analysis on the rates of positive and contaminated urine samples (e.g. exploring if delayed
samples such as those taken after daily laboratory collection have an impact on contamination rates) using
recommended methods.114
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
33
Preventing and minimising bias
The following design and analytic strategies were employed to minimise bias:
1. Selection bias: where possible we recruited consecutive children; we asked sites to keep a screening log
of patients who were approached but did not take part in the study and the reasons for this.
2. Index test technology: all tests (symptoms, signs, nappy pads, dipstick tests) were carried out blind to
the reference standard using standardised equipment and protocols (the blinding was easily achieved as
the report on the urine sample took a minimum of 2 days to be processed).
3. Incorporation bias: the reference standard consisted of culture alone and did not incorporate any of the
index tests.
4. Review bias: observers assessing the index tests differed from and were blind to the reference standard
(and vice versa).
5. Verification bias: as many children as possible had a urine sample to assess the reference standard.
Children in whom it was not possible to obtain a sample were excluded from the analysis.
We compared the characteristics of children with and without urine culture results.
6. Disease progression bias: we measured the time between clinical assessment and obtaining the
urine samples.
7. Treatment paradox: for most children, it was anticipated that antibiotic treatment would be started
after the urine sample had been obtained, but to assess the degree to which this was the case,
we tested for the presence of urinary antimicrobial substances.
8. Handling of missing values and withdrawals: these parameters were measured and modal and multiple
imputations used in the analyses.
9. Appropriateness of the reference standard: research laboratory samples were processed by two staff
members using a single, standardised procedure. We used a microbiological definition of UTI of
≥ 105 CFU/ml of a single uropathogen (‘pure growth’) or ≥ 105 CFU/ml of a uropathogen with
≥ 3 log10 (1000-fold) difference between the growth of this and the next species (‘predominant growth’).
We defined uropathogens as members of the Enterobacteriaceae group.
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Chapter 3 General results
This chapter presents the general results of the DUTY study, providing descriptive statistics regardingrecruiting sites and participating laboratories, CRF data and the proportion of participants who were
followed up. Recruitment accruals across the four study centres and a comparison of the recruited
participants with those who declined to participate are also presented.
Site recruitment
A breakdown of the number of sites approached, those expressing an interest, those that agreed to
participate and those actively recruiting for each of the four study centres are presented in Figure 3
and Table 6.
234 (79.6%) sites who actively recruited to DUTY
55 PCTs/LHBs
1559 primary care sites approacheda
496 (31.8%) sites expressed an interest in DUTY
326 (65.7%) sites agreed to participate in DUTY
294 (90.2%) sites trained in DUTY study
170 (34.3%) sites declined
after expression of interest
60 (20.4%) sites trained did
not actively recruit to DUTY
32 (9.8%) sites agreeing to
participate were not trained
in study procedures
99 (42.3%)
option 1
recruitment
123 (52.6%)
option 2
recruitment
12 (5.1%)
option 1 and 2
mixed
1063 (68.2%) sites did not
take part 
FIGURE 3 Recruitment of primary care sites. a, Incomplete data set: owing to involvement of PCRNs it is not
possible to determine the total number of primary care sites approached.
TABLE 6 Recruitment of primary care sites involved in DUTY across study centres
Recruitment of primary care sites Bristol, n Cardiff, n London, n Southampton, n Total, n (%)b
PCTs/LHBs involved 20 6 11 18 55 (N/A)
Primary care sites approacheda 139 465 90 865 1559 (N/A)
Sites expressing an interest in DUTY 139 113 47 197 496 (31.8)
Sites agreeing to participate in DUTY 112 51 44 119 326 (20.9)
Sites trained in study procedures 112 49 42 91 294 (18.9)
Sites that actively recruited to DUTY 96 44 36 58 234 (15.0)
LHB, local health board; N/A, not applicable.
a Incomplete data set as full records of primary care sites approached not kept by PCRNs.
b Percentage of primary care sites approached.
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A total of 55 PCTs in England and local health boards (LHBs) in Wales were involved in setting up
recruitment sites for the DUTY study. This figure was correct at the commencement of the study; however,
some of the PCTs have since reconfigured. We are aware of 1467 sites that were approached about
participating in the DUTY study; however, this is an underestimation as it was not possible to determine
the actual number of primary care sites that were approached about the DUTY study in the areas covered
by the some of the PCRNs involved.
A total of 496 sites expressed an interest in the study and 326 (65.7%) agreed to participate. Of these,
294 (90.2%) sites were trained in the DUTY study processes. However, there were 32 sites (9.8%) that
agreed to participate but did not progress any further; this was due to reasons such as difficulties faced by
DUTY RNs in setting up meetings at the practice to go through the DUTY training.
Of the 294 sites that were trained, 79.6% of these actively recruited at least one participant to the study.
Sites were monitored by their local centre and efforts were made to support practices to increase the
recruitment potential of slow recruiting sites.
Table 6 shows that 96 (41.0%) of the total 234 sites actively recruiting were co-ordinated by the Bristol
centre, and 58 (24.8%) were co-ordinated from the Southampton centre. The Cardiff centre co-ordinated
44 sites (18.9%) and the London centre co-ordinated 35 sites (15.0%).
Types of primary care site
The majority of primary care sites were GP surgeries (n= 226, 96.6%), with four WICs and four CEDs.
The Cardiff centre was the only centre to recruit exclusively from GP surgeries (n= 44). The final
recruitment figures were 6797 (94.9%) in GP surgeries, 284 (4.0%) in CEDs and 82 (1.1%) in WICs.
Three WICs were co-ordinated by the Bristol centre and one by Southampton. The Bristol centre also
co-ordinated two CEDs, and London and Southampton each co-ordinated one CED site.
Recruitment models used by primary care sites
The two models of recruitment (option 1 and option 2) offered to primary care sites are described in
Chapter 2. Owing to the practicalities of recruiting in busy clinical environments, the WICs and CEDs
employed only the option 2 recruitment model. Table 7 shows the distribution of recruitment methods
by centre.
Over half of the primary care sites (n= 124) employed an option 2 recruitment model, while 99 (42.5%)
employed an option 1 model. There were 12 (5.1%) sites that used a mixed recruitment model, where
both the site staff and the DUTY RN/CSOs would recruit at the site.
TABLE 7 Recruitment models used by primary care sites involved in DUTY across study centres
Recruitment model used by primary
care sites Bristol, n Cardiff, n London, n Southampton, n Total, N (%)
Option 1 recruitment model 41 27 17 14 99 (42.3)
Option 2 recruitment model 48 14 17 44 124 (52.6)
Mixed-options recruitment models 7 3 2 0 12 (5.1)
Total primary care sites 96 44 36 58 234
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NHS laboratories
All the local NHS laboratories related to the sites in the Bristol centre agreed to participate, process the
urine samples and then enter the results on the DUTY study online database. In the Cardiff centre, all local
NHS laboratories approached agreed to take part, but one laboratory did not enter results on the DUTY
database. Two NHS laboratories in the London centre (South West London area) were approached but
declined to participate. In the Southampton centre, two laboratories declined to participate in the study;
therefore, related primary care sites were not included. Out of the 28 laboratories that had agreed to
participate, 24 entered results of the DUTY samples processed onto the DUTY database. The urine sample
results from the local NHS laboratories that did not use the DUTY database were retrieved via the reports
sent to the GP surgery and were entered onto the database retrospectively by the centre study managers.
Participant recruitment
The flow of participants through the DUTY study is shown in Figure 4. This includes the number of children
and their families approached and assessed for eligibility, the number recruited to the study, urine sample
retrieval rates, urinalysis and the number of participants followed up at 14 days via interview and at 3 months
via note reviews. Reporting is in accordance with the STROBE checklist for reporting observational studies.115
Eligibility assessment
A total of 14,724 children were assessed for eligibility across the four study centres according to
completed screening logs. However, this figure is an underestimation of the total number of children
assessed, as not all sites completed screening logs and some were incomplete.
Of the 234 primary care sites taking part, 198 (85%) completed and returned at least one screening log to
the study centres. These show that 7350 children were screened but not recruited (see Figure 4), as they
declined (1276) or were not eligible (4390), or for other reasons (1684) including that they left the primary
care site prior to invitation (811), they did not give consent (214) or there was a language barrier (112) and
an appropriate translator was not available at the time of recruitment. Table 8 shows the distribution of
these children by centre.
Comparison of children recruited to DUTY with those not recruited
From the screening log information, which recorded the sex and date of birth of the children visiting the
primary care sites, we were able to compare the age and sex of the children who were recruited to DUTY
(n= 7163) with that of the children whose parents declined to participate (n= 1276) (Table 9).
Comparing the proportion of males in the two samples with a two-sample proportion test shows strong
evidence that the proportion of males is higher in the declined sample, with a mean difference of 5.2%
(95% CI 2.2% to 8.2%; p< 0.001). The mean age in the declined sample was 24.06 months and in the
recruited sample it was 26.88 months. Comparing the mean age in the two samples with an independent
sample t-test also shows strong evidence that the mean age is higher in the recruited sample, with a mean
difference of 2.04 months (95% CI 1.08 to 3 months; p< 0.001).
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Urine collection
(n = 6390, 89% of 7163)
Enrolled
(n = 7374)
Assessed for eligibilitya
(n = 14,724)
Recruited
(n = 7163)
• Bristol, n = 2947 (41%)
• Cardiff, n = 1768 (25%)
• London, n = 1435 (20%)
• Southampton, n = 1013 (14%)
• Excluded,c n = 196
• Withdrawals, n = 15
No urine collected
(n = 773, 11% of 7163)
• Ineligible, n = 4390
• Declined, n = 1276
• Other reasons,b n = 1684
Sent to research laboratory
(n = 5264, 82% of 6390)
Sent to NHS laboratories
(n = 6337, 99% of 6390)
Processed by both laboratories
(n = 4910)
Box B
Box A
Cultured by research
lab only
(n = 197)
Research laboratory cultured
(n = 5107, 97.6% of 5231)
NHS laboratory cultured
(n = 6079, 97.4% of 6242)
• Not cultured, n = 162
• Missing data, n = 1
Not received
(n = 95)
Not received
(n = 33)
Not cultured
(n = 124)
Urinalysis
Selected for
proportional
follow-up
(n = 1553) Unable to locate notes
(n = 11)
3-month review
(n = 1542, 99% of 1553)
Sample not sent
(n = 53)
14-day interview
(n = 918, 72% of 1276d)
Uncontactable
(n = 635)
FIGURE 4 DUTY study participant flow diagram. a, Incomplete data set: number approached represents data
received from screening logs; b, other reasons include left prior to invitation, no consent or there was a language
barrier; c, includes n= 44 retrospectively ineligible due to GP referral (protocol amendment 6), n= 55 data quality
issues and n= 97 cases removed during data cleaning; and d, omits 277 cases not selected by DUTY database
(see Participant follow-up, Proportional selection for follow-up). Box A used in Chapters 3, 6 and 8. Box B used in
Chapters 4, 5 and 7.
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Differences in sex and age are not particularly large and the small p-value and narrow 95% CIs are due to
the large sample size. Figure 5 shows that the distribution of age in the two samples is similar, with both
skewed towards the younger age.
Recruitment accruals
A total of 7374 children were enrolled into the study (50.1% of those assessed for eligibility); of these 196
were excluded and 15 were withdrawals (see Exclusions and Withdrawals, below).
Of the 7163 total recruited children, 6797 (94.9%) were recruited in GP surgeries, 284 (4.0%) in CEDs
and 82 (1.1%) in WICs. The Bristol centre recruited 2947 (41.1%), the Cardiff centre recruited 1768
(24.7%), the London centre recruited 1435 (20.0%) and the Southampton centre recruited 1013 (14.1%)
participants to the study during the recruitment period.
When comparing the total number of children recruited to the DUTY study with the original recruitment
targets set by the HTA for study viability assessment, it can be seen that that the study consistently
exceeded its projected study target (Figure 6). The sample size requirement (6000) was reached in
January 2012, when we sought approval (protocol amendment 9) to continue recruiting until the end of
the scheduled period (30 April 2012) in order to maximise the statistical power of the sample and provide
more precise estimates of association of index tests with UTI in the final algorithm, and to take account of
missing data.
TABLE 8 Children screened but not recruited by the four study centres
Reasons for
non-recruitment Bristol, n (%) Cardiff, n (%) London, n (%) Southampton, n (%) Total, N (%)
Declined 265 (20.8) 420 (32.9) 379 (29.7) 212 (16.6) 1276 (17.4)
Not eligible 1236 (28.2) 1294 (29.5) 1276 (29.1) 584 (13.3) 4390 (59.7)
Other (including missing) 455 (27.0) 706 (41.9) 339 (20.1) 184 (10.9) 1684 (22.9)
Total 1956 (26.6) 2420 (32.9) 1994 (27.1) 980 (13.3) 7350 (100)
TABLE 9 Comparison of ages and sex of children recruited with those declined to participate
Variable Category Declined, n (%) Recruited, n (%)
Age of child < 6 months 166 (13.2) 651 (9.1)
6 to < 12 months 178 (14.2) 1141 (15.9)
1 to < 2 years 353 (28.1) 1681 (23.5)
2 to < 3 years 216 (17.2) 1347 (18.8)
3 to < 4 years 194 (15.4) 1333 (18.6)
4 years plus 151 (12.0) 1010 (14.1)
Missing 18a 0
Total 1258 7163
Sex Male 691 (54.4) 3526 (49.2)
Female 579 (45.6) 3637 (50.8)
Missing 6 0
a Twelve missing dates of birth and six ages of zero or lower.
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FIGURE 5 Histograms of the ages of the children recruited and those who declined to participate. Histogram of
age for (a) recruits and (b) decliners.
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Exclusions
A total of 196 children were retrospectively excluded, including 44 children who were retrospectively
ineligible because they had been recruited in a CED after being referred by their GP. These participants
had not been recruited on their first point of contact in primary care, and were likely to be selected as
more unwell. The study protocol was subsequently amended (protocol amendment 6) to ensure that only
children consulting the CED for the first time, without prior GP or other primary care contact, were
included. An additional 55 children were excluded from a site co-ordinated by the London centre due to
poor data quality issues. This site received intensive training and recruited a further 10 participants;
however, the data quality was still poor, and therefore the site was closed to further recruitment. During
data cleaning a further 97 children were also found retrospectively to be ineligible owing to absence of
urinary and/or constitutional symptoms, previous (duplicate) recruitment or invalid consent, or because
someone other than the parent had (inappropriately) consented.
Withdrawals
There were 20 withdrawals during the course of the study, of which nine consented to use the data
already collected. However, in four cases data were inadvertently removed from the database instead of
retaining data collected up to the point of withdrawal. Therefore, all data were withdrawn for 15 children,
whereas five withdrawals were made with the retention of data already collected. The most common
reason for withdrawal was the parent changing his or her mind about the child participating in the study.
Serious adverse events
Serious adverse events were categorised as ‘related’ if additional information was available for the
responsible clinician as a result of the child being in the DUTY study, or if the admission to hospital was
delayed or altered as a result of the child being recruited to the study. For example, if a urine sample
would not have routinely been collected had the child not been recruited, but the urine sample results had
provided information that changed the way the GP would have normally diagnosed or treated the child,
the SAE would have been categorised as related. Conversely, SAEs were categorised as ‘unrelated’ if a
hospital admission was not affected by study participation.
Serious adverse events were also reported as ‘expected’ or ‘unexpected’, with classification of ‘expected’
used if hospitalisation was consistent with the study population of acutely unwell children presenting to
primary care, and ‘unexpected’ if the SAE deviated from what would be expected in that population.
The co-chief investigators reviewed all SAEs to reach consensus on these classifications.
A total of 79 of 7163 (1.1%) children from the entire study were reported as being hospitalised, that is
having a SAE, three of whom were admitted for UTI. In Bristol there were 36 (1.2%) of the 2947 children
recruited (45.6% of all SAEs), from the Cardiff centre 19 of 1768 (1.1%, 24.1% of all), from London
centre 17 of 1435 (1.2%, 21.5% of all), and from Southampton centre 4 of 1013 (0.4%, 5.1% of all).
The majority of these were expected.
Three (3.7%) SAEs were classified as being related to taking part in DUTY as a result of dipstick test
results. Two were diagnosed by the responsible clinician as having UTI. One child was referred for an
ultrasound scan that showed bilateral nephrocalcification and was subsequently referred to a paediatrician.
The second was admitted to hospital for intravenous antibiotics for treatment of the UTI and the third child
was admitted for a respiratory infection and a possible diagnosis of diabetes.
One adverse event was reported, where the parent of a child recruited to DUTY concluded that the nappy
pad inserted into the child’s nappy had caused a nappy rash. The nappy pad was removed, and though a
urine sample was retrieved it was dipstick tested only and not sent to the laboratories.
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Positive unintended consequences of the DUTY study
One child was diagnosed with type I diabetes as a direct consequence of taking part in the DUTY study.
This was as a result of the dipstick showing high glucose levels in combination with their medical history.
Type I diabetes can be missed as the symptoms may often be missed in primary care.
Urine collection
Figure 4 shows that urine samples were collected from 6390 (89%) children, sent to the NHS (priority)
laboratory in 6337 (99%) and the research laboratory in 5264 (82%) of cases. A small proportion of
samples were obtained (n= 53, 0.8%) but not sent to either laboratory; these were dipstick tested at the
primary care site only.
Of the urine samples recorded as being sent to NHS laboratories, 95 (2%) were not received, 162 (2.5%)
were not cultured and the results from one urine sample were missing. Of the samples sent to the
research laboratory, 33 (1%) were not received and 124 (2%) were not cultured, mainly due to too little
volume of urine for the laboratory to process, or because samples had leaked in transit. Therefore, of the
6390 urine samples collected from DUTY participants, results were available for 6079 (95%) from NHS
laboratories and 5107 (80%) results from the research laboratory. Of these, 4910 (76.8%) were available
from both laboratories.
Urine collection methods
Of the 6390 urine samples collected, 3721 (58.2%) were collected in the surgery and 2632 (41.2%) were
collected in the child’s home and returned to the surgery or collected by the RN/CSOs. In 37 cases, no data
were recorded on where the sample was collected.
Figure 7 shows the method of urine collection, which included the DUTY-preferred method of clean catch
which accounts for just under half (47.5%) of the samples collected (n= 3036), while 50.2% were
collected using our alternative method of Newcastle nappy pads (n= 3205). A small proportion of samples
were collected by urine bag (n= 100, 1.6%), with a further 49 cases where the method of collection was
not recorded (0.8%).
Urine collection
(n = 6390, 89.2% of 7163)
Clean catch
(n = 3036,
47.5% of 6390)
Nappy pad
(n = 3205,
50.2% of 6390)
Bag
(n = 100,
1.6% of 6390)
Collection method missing
(n = 49, 0.8% of 6390)
FIGURE 7 Urine collection methods.
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Microbiological culture results
The results presented in this section represent those data entered by the local NHS laboratories and the
research laboratory onto the DUTY online database (see Appendix 7).
Table 10 shows the urine culture results as reported by the research laboratory. The prevalence for the
pure/predominant growth at ≥ 105 CFU/ml was 3.2%, lower than the local NHS laboratories, which
reported 7.8% of samples with ≥ 105 CFU/ml pure/predominant growth.
Other differences between the research and local NHS laboratory categories of bacterial growth include
higher rates of growth in the local NHS than research laboratories of ≥ 105 CFU/ml – mixed growth
(> 2 species) at 15.6% versus 6.4%; much lower rates of growth in the local NHS than research
laboratories of 103 to 105 CFU/ml – mixed growth (two species) at 1.5% versus 14.5%; lower rates of
growth in the local NHS than research laboratories of 103 to 105 CFU/ml – mixed growth (> 2 species) at
7.4% versus 18.8%; and much higher rates of reported ‘no growth’ in the local NHS than research
laboratories at 31.7% versus 8.6%.
TABLE 10 Frequency of urine sample growth in each of the research and NHS laboratory result categories
Result categories
Research
laboratory, n
Research
laboratory, %
NHS
laboratory, n
NHS
laboratory, %
≥ 105 to CFU/ml: pure/predominant 169 3.2 488 7.8
≥ 105 CFU/ml: mixed growth (two species) 185 3.5 72 1.2
≥ 105 CFU/ml: mixed growth (> 2 species) 337 6.4 976 15.6
103 to 105CFU/ml: pure/predominant 361 6.9 199 3.2
103 to 105 CFU/ml: mixed growth
(two species)
757 14.5 91 1.5
103 to 105 CFU/ml: mixed growth (> 2 species) 982 18.8 460 7.4
< 103 CFU/ml: pure/predominant 56 1.1 15 0.2
< 103 CFU/ml: mixed growth (two species) 78 1.5 15 0.2
< 103 CFU/ml: mixed growth (> 2 species) 48 0.9 69 1.1
No growth 452 8.6 1978 31.7
No significant growth 1682 32.2 1716 27.5
Unable to process urine 124 2.4 73 1.2
Culture not performed N/A 89 1.4
Missing data N/A 1 0.0
Total 5231 100 6242 100
N/A, not applicable.
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Participant follow-up
This section presents data on the number of children who were selected for follow-up at 14 days via
interview and 3 months via a primary care medical notes review at their GP surgery. The proportional
representation of follow-up cases, based on the urine culture result categories used by the database
algorithm to select participants for follow-up, is also described.
Proportional selection for follow-up
The algorithm for proportional selection of participants for follow-up was set up to ensure that children
with a positive culture as defined by the NHS laboratory or research laboratory at ≥ 105 CFU/ml were
followed up (see Chapter 2, Patient follow-up, Day-14 and 3-month selection). For a short period, the
algorithm was not working as intended, in that if the results from the laboratories had different levels of
growth, the lower category was chosen, meaning that the higher (≥ 105 CFU/ml) result category was
under-represented. This error was detected too late to follow up 277 children at 14 days, but 3-month
notes review data were collected for these children.
Table 11 shows the proportion of participants that were selected and the number of 14-day interviews
that were completed for each of the result categories (omitting the 277 urine samples that failed to be
selected by the algorithm). Of the 13 urine sample result categories, nine were near the target proportion
set, or on, or above it. There were 6390 children for whom a urine sample had been taken; 6314 had
results entered into the DUTY database during the course of the study and 1276 (20%) children were
successfully selected for follow-up.
TABLE 11 Proportions of cases selected for follow-up in each of the urine sample result categories and
numbers completed
Highest result category from either
laboratory
Data in result
category, n
Target for
selection, %
Selected for
interview, n (%)
Interview
completed, n (%)
105 CFU/ml: pure/predominant 855 100 579 (67.7) 413 (71.3)
≥ 105 CFU/ml: mixed growth (two species) 132 20 42 (31.8) 30 (71.4)
≥ 105 CFU/ml: mixed growth (> 2 species) 866 20 132 (15.2) 89 (67.4)
103 to 105 CFU/ml: pure/predominant 1040 20 192 (18.5) 149 (77.6)
103 to 105 CFU/ml: mixed growth
(two species)
283 10 28 (9.9) 19 (67.9)
103 to 105 CFU/ml: mixed growth
(> 2 species)
508 10 41 (8.1) 26 (63.4)
< 103 CFU/ml: pure/predominant 59 10 10 (16.9) 4 (40.0)
< 103 CFU/ml: mixed growth (two species) 34 10 5 (14.7) 2 (40.0)
< 103 CFU/ml: mixed growth (> 2 species) 37 10 4 (10.8) 3 (75.0)
No growth 1626 10 176 (10.8) 125 (71.0)
Culture not performed 40 10 1 (2.5) 0 (0.0)
Unable to process urine 74 10 2 (2.7) 2 (100.0)
No significant growth 760 10 64 (8.4) 56 (87.5)
Total with urine sample 6314 1276 (20.2) 918 (71.9)
Omits 277 samples missed for selection at 14-day follow-up by the algorithm.
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All of the pure/predominant samples of ≥ 105 CFU/ml should have been selected by the algorithm for
follow-up; however, only 579 were actually selected, giving a selection rate of 67.7%. There were
413 interviews completed, giving a completion rate of 71.3% for this category.
Fourteen-day follow-up
There were 1276 participants who were selected for 14-day interviews, for whom 918 (71.9%) were
successfully completed. Table 12 shows the completion rates across the four study centres.
Of the 1276 participants successfully selected for follow-up, interviews could not be completed for 358
(28.1%). The majority of cases (n= 164, 45.8%) were missed because the parent could not be contacted,
while in 129 cases (30.6%) no reason was recorded, and a further 13 interviews (3.6%) were not
completed for other reasons (e.g. parent refused to complete the interview or the participant
was withdrawn).
The majority of the 14-day follow-ups were completed by telephone interview. However, postal
questionnaires were sent if, after three or four attempts at contacting the parents by telephone were
made, no successful contact resulted. Postal questionnaires were implemented from September 2011
onwards. In total, 69 14-day follow-ups (7.5%) were completed by postal questionnaire. We can only
estimate the response rate of the postal questionnaires, as only three of the centres recorded the number
of postal questionnaires sent out. With the information we do have from those centres, the collective
response rate for the whole of the study was 45.9%. The Cardiff centre had a response rate of 44.2%
(19 out of 43 questionnaires returned), London had a response rate of 31.3% (10 out of 32 questionnaires
returned) and Southampton had a 100% response rate (10 out of 10 questionnaires returned). The Bristol
centre had 32 questionnaires returned. Fifty-two postal questionnaires were not returned (14.5%).
Three-month notes review
Of the 1553 children selected for follow-up, 3-month note reviews were completed for 1542 (99.3%)
(Table 13). Only 11 3-month note reviews were not completed, the main reason being that the child had
left the surgery. In the London centre, reviews could not be completed in instances where the child was
recruited outside their usual GP practice (e.g. WIC or CED) and no PCT R&D approval was in place for
the recruited GP practice.
TABLE 12 Day 14 follow-up interviews completed for the four study centres
14-day follow-up Bristol, n (%) Cardiff, n (%) London, n (%) Southampton, n (%) Total, N (%)
Selected 541 (42.4) 353 (27.6) 199 (15.6) 184 (14.4) 1276
Completed 419 (77.4) 243 (68.8) 125 (63.8) 131 (71.2) 918 (71.9)
Not completed 122 (22.6) 110 (31.2) 74 (36.2) 53 (28.8) 358 (28.1)
TABLE 13 Three-month note reviews completion by study centres
Three-month note
reviews Bristol, n Cardiff, n London, n Southampton, n Total, N (%)
Selected 673 388 255 237 1553 (100.0)
Completed 672 384 249 237 1542 (99.3)
Not completed 1 4 6 0 11 (0.7)
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Participant characteristics: descriptive statistics
This section describes the characteristics of participants as recorded on sections 2 to 5 of the CRF
(see Appendix 4). Descriptive statistics have been presented for the overall sample.
Description of study population
Table 14 shows the demographic characteristics of the 7163 recruited children. Approximately half of the
children were aged < 2 years with equal numbers of boys and girls (49.2% and 50.8%, respectively).
TABLE 14 Demographic data (from section 2 of the CRF) for the study population overall
Characteristics n (%)
Age
Less than 6 months 650 (9.1)
6 months to less than 12 months 1140 (15.9)
1 year to less than 2 years 1682 (23.5)
2 years to less than 3 years 1348 (18.8)
3 years to less than 4 years 1333 (18.6)
4 years and over 1010 (14.1)
Gender
Male 3526 (49.2)
Female 3637 (50.8)
Ethnicity groupings
White 5895 (82.3)
Mixed 371 (5.2)
Asian 301 (4.2)
Black 471 (6.6)
Other 36 (0.5)
Missing 89 (1.2)
Highest parental level of qualification
Degree (or equivalent) 1829 (25.5)
Diploma (or equivalent) 971 (13.6)
‘A’ level 742 (10.4)
GCSE/’O’ level 1710 (23.9)
Other 0 (0)
None 400 (5.6)
Missing 1511 (21.1)
Cost of living
Find it a strain to get by week to week 381 (5.3)
Have to be careful about money 2894 (40.4)
Able to manage without much difficulty 1806 (25.2)
Quite comfortably off 614 (8.6)
Missing 1468 (20.5)
GCSE, General Certificate of Secondary Education.
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The sample was predominantly white (82.3%), with one-quarter of the parents educated to degree level
or equivalent, and nearly another quarter educated to GCSE level or equivalent. The financial status of
parents was also assessed by asking a question regarding the cost of living, where 40.4% reported they
had to be careful about money, and almost one-quarter said that they were able to manage without
much difficulty.
The comparison of DUTY recruits with the national census data for age, sex and ethnicity can be seen in
Table 15. This shows that the children recruited to DUTY were broadly similar in age to the national
profile, bearing in mind that children recruited to DUTY were presenting unwell to primary care.
Description of presenting symptoms and signs
Table 16 demonstrates the frequencies of the symptoms and signs categories (see Appendix 4, section 3 of
the case report form) for all 7163 children who were recruited to the DUTY study. The children had been
unwell for a median of 4 days (including the day of recruitment) before consulting at the primary care
site with their acute illness. In 5261 (73%) children, it was the first time parents had consulted their doctor or
nurse with the illness episode. The most prevalent sign and symptom was that the ‘child was not themselves’,
with this being reported as a moderate/severe problem in 4682 (65.4%) participants. The second most
prevalent sign/symptom was confusion/disorientation, which was reported as a moderate/severe problem in
4628 (64.6%) participants. Fever at any time during the illness was a moderate/severe problem in 3803
(53.1%) participants. Other most prevalent presenting symptoms and signs, reported as a moderate/severe
problem, included cough (n= 3771, 52.6%), blocked or runny nose (n= 3695, 51.6%), refused feeds/eating
less than normal (n= 3670, 51.2%), and fever at any time during the past 24 hours (n= 3057, 42.7%).
TABLE 15 Comparison of DUTY recruits with national census data
Characteristics From Census 2011, n (%) From DUTY, n (%)
Agea
Less than 1 year 711,529 (20.3) 1790 (25.0)
1 year to less than 2 years 704,155 (20.1) 1682 (23.5)
2 years to less than 3 years 698,777 (20.0) 1348 (18.8)
3 years to less than 4 years 699,399 (20.0) 1333 (18.6)
4 years to less than 5 years 682,890 (19.5) 1010 (14.1)
Genderb
Male 27,573,376 (49.2) 3526 (49.2)
Female 28,502,536 (50.8) 3637 (50.8)
Ethnicity groupingsb
White 48,209,395 (86.0) 5895 (82.3)
Mixed 1,224,400 (2.2) 371 (5.2)
Asian 4,213,531 (7.5) 301 (4.2)
Black 1,864,890 (3.3) 471 (6.6)
Other 563,696 (1.0) 36 (0.5)
Missing 0 (0.0) 89 (1.2)
a Census 2011: those aged under 5 years old in England and Wales.
b Census 2011: all England and Wales.
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TABLE 16 Symptoms and signs
Symptoms and signs n Median IQR
How many days (including today has your child been unwell)? 7163 4.0 2.0–7.0
n (%)
Compared with yesterday, is your child the same, better or worse?
Same 2799 (39.1)
Better 1445 (20.2)
Worse 2902 (40.5)
Missing 17 (0.2)
Please rate your overall impression of your child’s current illness when it is at its worst
0 47 (0.7)
1 187 (2.6)
2 339 (4.7)
3 684 (9.5)
4 941 (13.1)
5 1326 (18.5)
6 1250 (17.5)
7 1277 (17.8)
8 760 (10.6)
9 216 (3.0)
10 121 (1.7)
Missing 15 (0.2)
Child not themselves
No problem 580 (8.1)
Slight problem 1885 (26.3)
Moderate problem 3250 (45.4)
Severe problem 1432 (20.0)
Missing 16 (0.2)
Confused or disorientated
No problem 1138 (15.9)
Slight problem 1381 (19.3)
Moderate problem 2458 (34.3)
Severe problem 2170 (30.3)
Missing 16 (0.2)
Disturbed sleep
No problem 5952 (83.1)
Slight problem 709 (9.9)
Moderate problem 388 (5.4)
Severe problem 98 (1.4)
Missing 16 (0.2)
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TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Fever at any time during this illness
No problem 1802 (25.2)
Slight problem 1542 (21.5)
Moderate problem 2346 (32.8)
Severe problem 1457 (20.3)
Missing 16 (0.2)
Fever now or in the past 24 hours
No problem 2796 (39.0)
Slight problem 1294 (18.1)
Moderate problem 1925 (26.9)
Severe problem 1132 (15.8)
Missing 16 (0.2)
Chills or shivering
No problem 5149 (71.9)
Slight problem 909 (12.7)
Moderate problem 811 (11.3)
Severe problem 278 (3.9)
Missing 16 (0.2)
New generalised rash with this illness
No problem 5777 (80.7)
Slight problem 678 (9.5)
Moderate problem 486 (6.8)
Severe problem 206 (2.9)
Missing 16 (0.2)
Nappy rash or similar
No problem 5912 (82.5)
Slight problem 707 (9.9)
Moderate problem 372 (5.2)
Severe problem 156 (2.2)
Missing 0 (0.0)
Muscle aches or pain all over
No problem 2389 (33.4)
Slight problem 540 (7.5)
Moderate problem 429 (6.0)
Severe problem 91 (1.3)
Missing 3714 (51.8)
continued
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TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Headaches
No problem 2351 (32.8)
Slight problem 494 (6.9)
Moderate problem 419 (5.8)
Severe problem 89 (1.2)
Missing 3810 (53.2)
Refused feeds/eating less than normal
No problem 1584 (22.1)
Slight problem 1893 (26.4)
Moderate problem 2429 (33.9)
Severe problem 1241 (17.3)
Missing 16 (0.2)
Poor weight gain or weight loss
No problem 4242 (59.2)
Slight problem 514 (7.2)
Moderate problem 247 (3.4)
Severe problem 71 (1.0)
Missing 2089 (29.2)
Vomiting
No problem 4467 (62.4)
Slight problem 1300 (18.1)
Moderate problem 903 (12.6)
Severe problem 477 (6.7)
Missing 16 (0.2)
Diarrhoea (at any time)
No problem 5074 (70.8)
Slight problem 1058 (14.8)
Moderate problem 663 (9.3)
Severe problem 352 (4.9)
Missing 16 (0.2)
Diarrhoea (in the past 24 hours)
No problem 5700 (79.6)
Slight problem 697 (9.7)
Moderate problem 474 (6.6)
Severe problem 276 (3.9)
Missing 16 (0.2)
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TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Constipation in the last week
No problem 5824 (81.3)
Slight problem 764 (10.7)
Moderate problem 419 (5.8)
Severe problem 140 (2.0)
Missing 16 (0.2)
Abdominal pain/tummy ache/pulling up legs
No problem 4703 (65.7)
Slight problem 1165 (16.3)
Moderate problem 964 (13.5)
Severe problem 315 (4.4)
Missing 16 (0.2)
Passing urine more often
No problem 4149 (57.9)
Slight problem 487 (6.8)
Moderate problem 464 (6.5)
Severe problem 158 (2.2)
Missing 1905 (26.6)
Any changes in urine appearance
No problem 4502 (62.9)
Slight problem 1027 (14.3)
Moderate problem 609 (8.5)
Severe problem 140 (2.0)
Missing 885 (12.4)
Pain/crying when passing urine
No problem 4780 (66.7)
Slight problem 294 (4.1)
Moderate problem 190 (2.7)
Severe problem 94 (1.3)
Missing 1805 (25.2)
Day or bed wetting when previously dry
No problem 2054 (28.7)
Slight problem 238 (3.3)
Moderate problem 161 (2.2)
Severe problem 82 (1.1)
Missing 320 (4.5)
Wears nappies day and night 4308 (60.1)
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TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Blocked or runny nose
No problem 1621 (22.6)
Slight problem 1831 (25.6)
Moderate problem 2434 (34.0)
Severe problem 1261 (17.6)
Missing 16 (0.2)
Cough
No problem 1846 (25.8)
Slight problem 1530 (21.4)
Moderate problem 2222 (31.0)
Severe problem 1549 (21.6)
Missing 16 (0.2)
Wheeze
No problem 4406 (61.5)
Slight problem 1250 (17.5)
Moderate problem 1058 (14.8)
Severe problem 433 (6.0)
Missing 16 (0.2)
Short of breath, difficulty breathing or grunting
No problem 5061 (70.7)
Slight problem 1082 (15.1)
Moderate problem 710 (9.9)
Severe problem 294 (4.1)
Missing 16 (0.2)
Chest pains
No problem 3386 (47.3)
Slight problem 142 (2.0)
Moderate problem 77 (1.1)
Severe problem 24 (0.3)
Missing 3534 (49.3)
Earache or holding ear(s)
No problem 3717 (51.9)
Slight problem 1003 (14.0)
Moderate problem 760 (10.6)
Severe problem 436 (6.1)
Missing 1247 (17.4)
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TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Sore throat
No problem 2557 (35.7)
Slight problem 973 (13.6)
Moderate problem 896 (12.5)
Severe problem 355 (5.0)
Missing 2382 (33.3)
More unwell than with similar previous illnesses
No problem 4246 (59.3)
Slight problem 1104 (15.4)
Moderate problem 1357 (18.9)
Severe problem 440 (6.1)
Missing 16 (0.2)
Darker urine?
No 6299 (87.9)
Yes 764 (10.7)
Missing 100 (1.4)
Cloudy urine?
No 6890 (96.2)
Yes 173 (2.4)
Missing 100 (1.4)
Smelly urine?
No 5952 (83.1)
Yes 1111 (15.5)
Missing 100 (1.4)
Bloody urine?
No 7039 (98.3)
Yes 24 (0.3)
Missing 100 (1.4)
Other urine appearance problems?
No 6980 (97.4)
Yes 83 (1.2)
Missing 100 (1.4)
Any other symptoms?
No 6117 (85.4)
Yes 1030 (14.4)
Missing 16 (0.2)
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Description of clinical examination findings
Clinical examinations were performed by either a doctor or a nurse, and the reported findings recorded on
the CRF (see Appendix 4, section 4 of the case report form) for all recruited patients are presented in
Table 17.
For the 7163 children recruited, the responsible clinician’s global impression score was recorded as between
0 and 4 in over 90% of cases. Hydration and consciousness level were reported as normal in 94.6% and
96.8% of cases, respectively. From a general examination, 68.0% of cases were recorded as normal.
Normal findings were recorded by the responsible clinician on examination of the throat, ear, chest and
abdomen in 60.5%, 63.0%, 79.6% and 81.2% for recruited children, respectively (see Table 17).
TABLE 16 Symptoms and signs (continued )
Symptoms and signs n Median IQR
Does the child have an eye problem?
No 6894 (96.2)
Yes 253 (3.5)
Missing 16 (0.2)
Does the child have decreased urinary frequency or lower urine volume?
No 7082 (98.9)
Yes 65 (0.9)
Missing 16 (0.2)
Not counting today, approximately how many times has your child previously consulted a doctor or nurse for this episode
of illness?
0 5261 (73.4)
1 1157 (16.2)
2 361 (5.0)
3 169 (2.4)
4 78 (1.1)
5 48 (0.7)
6 15 (0.2)
7 14 (0.2)
8 16 (0.2)
9 2 (0.0)
10 13 (0.2)
10+ 9 (0.1)
Missing 20 (0.3)
Does your child have any ongoing health problems?
No 5883 (82.1)
Yes 1261 (17.6)
Missing 19 (0.3)
IQR, interquartile range.
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TABLE 17 Clinical examination findings for all 7163 recruited participants
Clinical examination n (%)
Please give your global impression of the child on a scale of 0–10a
0 604 (8.4)
1 1825 (25.5)
2 1966 (27.4)
3 1417 (19.8)
4 675 (9.4)
5 284 (4.0)
6 192 (2.7)
7 101 (1.4)
8 35 (0.5)
9 8 (0.1)
10 2 (0.0)
Hydration
Not examined 21 (0.3)
Normal 6776 (94.6)
Some dehydration 308 (4.3)
Severe dehydration 1 (0.0)
Missing 57 (0.8)
Consciousness level
Not examined 11 (0.2)
Normal 6933 (96.8)
Drowsy 87 (1.2)
Irritable 74 (1.0)
Missing 58 (0.8)
General examination
Not examined 22 (0.3)
Normal 4871 (68.0)
Abnormal 2213 (30.9)
Missing 57 (0.8)
Throat examination
Not examined 1065 (14.9)
Normal 4334 (60.5)
Abnormal 1707 (23.8)
Missing 57 (0.8)
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For the 2213 (30.9%) cases with an abnormal general examination the following findings were recorded:
pallor (27.8%); flushed (35.1%); jaundice (0.4%); lymphadenopathy (15.6%); distressed (11.5%); rash
(7.6%); and other (17.3%). For the 1707 cases with an abnormal throat examination the following
findings were recorded: red or inflamed (84.7%); swollen (17.3%); quinsy (10.0%); lymph nodes (1.1%);
tonsillitis (1.55); mouth ulcer (1.2%); oral thrush (1.1%); and other (4.2%). For the 1751 with an abnormal
ear examination an acute abnormality was recorded in 1576 cases (90.0%) and a chronic abnormality in
4.7%. The main findings recorded were pink (43.9%); red or bulging (42.6%); fluid (1.8%); acute
perforation (0.1%); chronic perforation (2.2%); glue ear (0.6%); grommets (0.3%); otitis externa (1.3%);
otorhoea (2.2%); otitis media (3.2%); wax (6.45); and other (3.0%). For the 919 cases with an abnormal
chest examination the following findings were recorded: bronchial breathing with distribution (7.95);
wheeze (44.5%); crackles (57.8%); recession (8.1%); grunting (1.5%); nasal flaring (0.5%); transmitted
sounds with distribution (2.6%); and other (4.4%). For the 179 cases with an abnormal abdomen
examination the following findings were recorded: mass or organomegaly (3.4%); loin tenderness (5.6%);
suprapubic tenderness (22.9%); other abdominal tenderness (25.7%); genital inflammation or nappy rash
(10.1%); and other (33.0%). These data are not included in the report, but are available from the authors
on request. Chapter 5 provides a description of the inclusion of symptoms and signs in the prediction rule
statistical analysis (see Methods, Statistical analysis) and the results of the rule (see Results, Clean-catch
models and Nappy pad models).
Medical history
For almost 75% of children, the pregnancy was reported as full term, with over 65% being breastfed for a
period of time. In 89 cases, parents reported that they had been told that the child’s kidney, bladder or
urinary system was abnormal after a pregnancy ultrasound test. A small proportion of boys were reported
as having been circumcised (3.5%) (Table 18).
TABLE 17 Clinical examination findings for all 7163 recruited participants (continued )
Clinical examination n (%)
Ear examination
Not examined 843 (11.8)
Normal 4512 (63.0)
Abnormal 1751 (24.4)
Missing 57 (0.8)
Chest examination
Not examined 483 (6.7)
Normal 5704 (79.6)
Abnormal 919 (12.8)
Missing 57 (0.8)
Abdomen examination
Not examined 1108 (15.5)
Normal 5819 (81.2)
Abnormal 179 (2.5)
Missing 57 (0.8)
a 0= completely well, 10= extremely unwell.
GENERAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
TABLE 18 Parent-reported medical history for the 7163 recruited participants
Medical history n (%)
What length was your pregnancy?
Early (37 weeks or less) 733 (10.2)
Full term 5260 (73.4)
Late 1121 (15.6)
Missing 49 (0.7)
Was your child breastfed?
No 2191 (30.6)
Less than 3 months 1896 (26.5)
More than 3 months 2995 (41.8)
Missing 81 (1.1)
Has your child been circumcised?
No 3199 (44.7)
Yes 253 (3.5)
Missing 74 (1.0)
Female – N/A 3637 (50.8)
Were you ever told that your child’s kidney, bladder or urinary system was abnormal in any way after a pregnancy
ultrasound test?
No 7053 (98.5)
Yes 89 (1.2)
Missing 21 (0.3)
Is your child taking any medications?
No 3349 (46.8)
Yes 3799 (53.0)
Missing 15 (0.2)
Does your child use nappies?
No 1783 (24.9)
Day 23 (0.3)
Night 1028 (14.4)
Day and night 4308 (60.1)
Missing 21 (0.3)
Age of child N Median (IQR)
How many nappies has your child used in the last 24 hours? 0 1787 6.0 (5.0–8.0)
1 1678 6.0 (5.0–7.0)
2 1340 3.0 (1.0–5.0)
3 1331 0.0 (0.0–1.0)
4 1006 0.0 (0.0–0.0)
Number of baths/showers in a week?
7114 6.0 (4.0–7.0)
IQR, interquartile range.
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For the 3799 cases reported as currently taking medication, paracetamol and ibuprofen were the most
commonly reported (76.5% and 31.0%, respectively), and the following were reported for the remainder
of cases: laxatives (4.2%); steroid inhaler (4.4%); beta2 agonist inhaler (8.6%); antihistamines (1.9%);
cough medicine (4.7%); and other (11.4%).
Parents reported that 4308 (60.1%) children wore nappies both day and night, with a further 1028
(14.4%) wearing nappies in the night only. One-quarter of the DUTY recruits were reported as not using
nappies at all.
Table 19 shows the reported number of cases with a history of any congenital abnormalities of the kidney
and urinary tract (CAKUT) diseases, UTI infections, bladder or renal problems in the child or direct family
members. The most prevalent reported item was history of UTI infection, both in the child (4.3%) and in
the family (14.1%), with maternal history of UTI infection representing the highest proportion of
mother-, father- or sibling-reported infection.
For the children in whom clinical observations could be recorded, the mean or median recordings are
presented in Table 20. 13.6% (or 14.3% of those with a measurement) had an extreme temperature of
≥ 38 °C and 3.6% (or 5.4% of those with a measurement) had an extreme oxygen saturation of < 94%.
Clinical diagnoses and antibiotic treatment
Most clinicians did not have a working diagnosis of UTI prior to knowledge of the dipstick result. Table 21
indicates the number and proportions of different diagnoses made.
Table 22 shows that a total of 2246 patients were treated with antibiotics (31.3%), and, of these, 86.7%
were issued with an immediate prescription. Amoxicillin was the most common antibiotic prescribed by
clinicians, accounting for 49.4% of scripts issued (n= 1109), followed by trimethoprim at 11.4% (n= 256)
and penicillin at 9.9% (n= 222) (see Table 22). When these antibiotics are split up by the diagnoses for
which they were prescribed, amoxicillin is generally the most frequent antibiotic. However, when tonsillitis
was diagnosed, penicillin was the most commonly prescribed antibiotic, and when UTI, gastroenteritis or a
viral illness were diagnosed, trimethoprim was the most frequently prescribed antibiotic.
TABLE 19 Parent-reported medical history of previous urinary, bladder or renal problems
Medical history n yes (%)
Does the child have a history of any CAKUT diseases? 45 (0.6)
Does the mother, father or sibling have a history of any CAKUT diseases? 120 (1.7)
Does the child have a history of any urinary, bladder or renal infections? 310 (4.3)
Does the mother, father or sibling have a history of any urinary, bladder or renal infections? 1008 (14.1)
Does the child have a history of non-CAKUT bladder problems including enuresis/dysfunctional voiding
problems?
2 (0.0)
Does the mother, father or sibling have a history of non-CAKUT bladder problems including
enuresis/dysfunctional voiding problems?
58 (0.8)
Does the child have a history of any non-CAKUT renal problem? 13 (0.2)
Does the mother, father or sibling have a history of any non-CAKUT renal problem? 173 (2.4)
Does the child have a history of any other renal/urinary problem? 11 (0.2)
Does the mother, father or sibling have a history of any other renal/urinary problem? 25 (0.4)
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TABLE 20 Clinical observations recorded for recruited participants
Clinical observations (continuous) n Mean SD
Temperature (°C) 6833 37.05 0.869
Pulse rate (beats per minute) 5610 119.6 20.51
Oxygen saturation (%) 4778 98.0 96.0, 98.0
Respiratory rate (rpm) 5732 28.0 24.0, 32.0
Clinical observations (categorised) n (%)
Capillary refill time (seconds)
< 2 5320 (74.3)
2 to 5 913 (12.7)
> 5 13 (0.2)
Missing 917 (12.8)
Temperature (°C)
< 38 5859 (81.8)
≥ 38 974 (13.6)
Missing 330 (4.6)
Oxygen saturation (%)
< 94 260 (3.6)
≥ 94 4518 (63.1)
Missing 2385 (33.3)
TABLE 21 Treating clinicians’ working diagnosis
What is your working diagnosis? n (%)
No UTI 6673 (93.2)
UTI 361 (5.0)
UTI + another diagnosis 67 (0.9)
Missing 62 (0.9)
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Study monitoring
This section describes the monitoring procedures employed in the DUTY study to identify
protocol deviations.
Data quality issues were identified in one primary care site, in relation to incomplete CRFs, source data,
paper CRF and database data entries. As a result of an internal audit of the site, all data for recruits
from that site were removed, and the site was retrained. A further audit was completed after further
recruitment had taken place. Similar issues were found in terms of poor data quality, and as such this site
was closed to recruitment.
As a result, a whole study-wide audit was undertaken. This involved a sample of 16 study sites selected
from all four centres that were audited to (1) ensure that the study was being conducted to protocol
standards; (2) identify any protocol deviations; and (3) assess data quality. The sites were selected where at
least 20 children had been recruited into the study. For each site, 10 records were randomly selected and
audited by either a research manager or an experienced RN.
The audit points included evidence of good clinical practice training; consent being taken accurately
(as evidenced by the correct completion of the consent form); the completeness of the CRF (either electronic
or paper and the accurate transcription from paper to electronic where both had been completed); evidence
of medical attendance in the child’s medical notes; and any other areas of concern that had the potential
to significantly affect either the data quality or the safety of the child.
Errors were divided into those regarded as (1) minor, such as not changing the day/date, when entering
information electronically, by 1 day after recruitment (the database defaulted to the day it was being
used), and (2) significant, such as where one form had the urine collection recorded as ‘clean catch’ on
paper and ‘nappy pad’ on the database or the database recorded the presence of a symptom, such as
diarrhoea, where this did not appear on the paper CRF. Significant errors had the potential to adversely
affect data quality or the recognition of contamination in a urine sample.
Overall, we found good concordance between medical notes and entry onto the CRF, and also between
paper CRFs and the online database. Minor errors accounted for 5.2% and major errors for 0.2% of the
data examined. In conclusion, minor errors were typically in the form of miskeying dates, as described
above, and under-reporting eligibility, and only two significant errors were found in the review. In the data
cleaning these typographical errors were able to be corrected.
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Chapter 4 Microbiological diagnosis of urinary
tract infection by NHS and research laboratories
Introduction
Laboratory diagnosis is based on colony counts following culture, which reflect the concentration of
organisms in urine and hence the likelihood that the bacteria grown arise from a UTI rather than
contamination. UTI is typically caused by a single organism that is present in a high concentration, usually
≥ 105 CFU/ml.81 However, laboratory guidelines differ regarding the nature and extent of bacterial growth
required to confirm UTI.82,83 NICE guidelines do not provide a definitive threshold for diagnosing UTI on
culture but provide advice about the level of bacterial growth in relation to symptoms and signs.2 Based on
paediatric data, others have since proposed higher thresholds, for example ≥ 106 CFU/ml.80 It is not surprising,
then, that laboratory guidelines differ regarding the nature and extent of bacterial growth required to confirm
UTI according to the patient’s age, symptoms and urine collection method.82,83 Although NHS laboratories in
the UK follow the UK Standards for Microbiological Investigation for examination of urine, application of the
method varies between laboratories.
For this reason, and when sufficient urine was available, we sent a fraction of the urine to a single research
laboratory where it was to be processed by a small number of technicians and according to a SOP.
Although we wanted the algorithm results to be generalisable to current NHS practice, we did not know
whether the NHS or research laboratory was providing the more reliable and accurate results.
Therefore, the aim of this chapter is to report the comparison of reliability and accuracy of UTI laboratory
diagnosis between routine NHS laboratories and a single research laboratory. We investigated associations
of pre-specified symptoms and signs related to UTI, and urine dipstick test results identified from the
literature, with different laboratory definitions of urine culture positivity.
Methods
Urine collection and sample processing
Urine samples were obtained by clean catch, where possible, for children who were toilet trained or for
whom the parent was happy to attempt such collection. A full description of the urine collection methods
is given in Chapter 2.
NHS laboratories processed urine samples using their local SOPs and recorded data according to local
reporting procedures, including, where possible, quantifying bacterial growth (as < 103; 103 to < 105;
or ≥ 105 CFU/ml), purity of growth (pure/predominant; mixed growth two species; mixed growth
> 2 species), organism speciation for up to two species, and microscopy for white and red cells. The
research laboratory quantified absolute colony counts (range 101–1010 CFU/ml) for all organisms
present and established species ID for organisms present at ≥ 103 CFU/ml.
Statistical analysis
Results reported by the NHS and research laboratories were initially classified based on extent and
purity of growth and whether or not the species grown was a uropathogen, defined as a member of
the Enterobacteriaceae group. For NHS laboratory results, samples for which the laboratory reported
pure/predominant growth of a uropathogen at ≥ 105 CFU/ml were considered UTI positive. For research
laboratory results, samples were considered UTI positive if there was growth of ≥ 105 CFU/ml of a single
uropathogen (‘pure growth’) or growth of ≥ 105 CFU/ml of a uropathogen with ≥ 3 log10 difference
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between the growth of this and the next species (‘predominant growth’). Agreement between laboratories
was assessed using kappa statistics, with analyses additionally stratified by urine collection method
(clean catch or nappy pad) and by age (0 to < 2, 2 to < 3 and 3 to < 5 years).
Analyses were restricted to samples with a result from both the NHS and research laboratories. Samples
classified as UTI positive by both NHS and research laboratories results were denoted ‘Agree UTI positive
(step 1)’. Where there was disagreement between the NHS and research laboratories, we considered
whether or not the combined evidence was consistent with a UTI. When the result classified as negative in
one of the laboratories met either of the two conditions (1) growth of ≥ 105 CFU/ml of a uropathogen with
lesser growth of at most one other species, or (2) pure/predominant growth of 103 to 105 CFU/ml of a
uropathogen, samples were denoted ‘Agree UTI positive (step 2)’.
A priori (before examining their associations with different definitions of microbiological positivity from
different laboratories), we selected a small number of variables (symptoms, signs and dipstick test results)
reported in the literature to be clearly related to presence of a UTI.116 Those thought suitable for all ages
and collection methods were urinary symptoms (pain/crying when passing urine, passing urine more often,
changes in urine appearance); temperature ≥ 39 °C, and nitrite- or leucocyte-positive results from urine
dipstick tests. Additional symptoms and signs thought to be relevant mainly for older children were
daytime or bed wetting when previously dry, and a history of UTI. Most parent-reported symptoms were
recorded using categories ‘no’, ‘slight’, ‘moderate’ or ‘severe problem’; we decided a priori (based only on
inspection of symptom frequencies) to dichotomise these into ‘no or slight problem’ and ‘moderate or
severe problem’. Responses of ‘not known’ were coded with ‘no or slight problem’. A small number of
samples for which there were missing data on most or all urine symptoms (five samples), or for which
urine dipstick tests were not available (12 samples), or there was missing information on prior infection
(three samples) were excluded. Missing data on temperature (204 children) were coded as < 39 °C.
The remaining, sporadic missing values (on five children) were coded as ‘no or slight problem’.
We used separate logistic regression models to quantify associations of the selected variables with UTI
positivity in the NHS and research laboratories, and for the different outcomes ‘agree UTI’, ‘disagree
(NHS positive, research negative)’ and ‘disagree (NHS negative, research positive)’, all compared with ‘agree
UTI negative’. We plotted receiver operating characteristic (ROC) curves and AUROCs to quantify diagnostic
utility. The maximum value of the AUROC is 1 (perfect prediction) while a value of 0.5 corresponds to no
association with any predictor. The symptoms ‘day or bed wetting when previously dry’ and ‘history of UTI’
were recorded in too few of the children who provided nappy pad samples to permit their associations with
microbiology results to be examined. For these children, therefore, we examined associations of the
remaining six signs, symptoms and dipstick results with microbiology results. For children who provided a
clean-catch sample, we fitted two sets of logistic regression models, one including all eight symptoms and
dipstick results (the ‘eight variable model’) and the other, for comparability, including the same six
symptoms and results as for children providing nappy pad samples (the ‘six variable model’).
In sensitivity analyses we (1) stratified by age (< 3 and ≥ 3 years); (2) allowed for ‘not known’ categories
in the questionnaire responses for variables for which such responses occurred sufficiently frequently;
(3) stratified according to whether samples were coded as ‘agree UTI positive’ at step 1 or step 2;
(4) stratified by whether the sample was collected at the surgery or at home; (5) stratified by time between
recruitment and laboratory sample receipt (< 24 hours and ≥ 24 hours); (6) stratified NHS laboratory results
according to extent of pure/predominant growth (≥ 105, ≥ 103 to < 105 CFU/ml); (7) stratified research
laboratory results according to extent of pure/predominant growth (≥ 107; ≥ 106 to < 107; ≥ 105 to < 106;
≥ 104 to < 105; and ≥ 103 to < 104 CFU/ml); (8) stratified NHS and research laboratory results according to
whether the WBC count was < 30 or ≥ 30/mm3; (9) stratified research laboratory results according
to whether growth was pure or predominant, and (10) as the research laboratory received only the urine
available after the priority fraction was placed in the NHS collection sample, we stratified by research
laboratory urine volume (using the cut-point of median urine Monovette weight for clean-catch and nappy
pad samples). All analyses were carried out using Stata version 12 (StataCorp LP, College Station, TX, USA).
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Results
Of the 7163 children included in the study, 6241 provided a urine sample using the clean-catch or nappy
pad collection methods, for whom 5945 and 5071 culture results were available from the NHS and
research laboratories, respectively. A total of 4828 children had results from both laboratories, of whom
4808 had information available on candidate predictors. [The starting point for the number of urine results
in this chapter was determined by the use of the individuals with cultured specimens in both laboratories
(see box B in Figure 4).] The detail of the urine samples in this chapter is shown in Figure 8. Most children
(4543, 94.5%) were recruited from GP surgeries (Table 23).
There were approximately equal numbers of boys and girls. Of 2884 children aged < 3 years, urine
samples for 758 (26.3%) were collected using clean catch. By contrast, 1861 (96.7%) of 1924 children
aged 3–5 years provided a clean-catch sample. Among children aged < 3 years, samples were obtained in
the surgery in 1470 cases (51.0%), compared with 1477 (76.8%) among children aged 3–5 years. Parents
reported the following symptoms as a moderate or severe problem: pain or crying when passing urine in
217 (4.5%) children; passing urine more often in 484 (10.1%); day or bed wetting when previously dry in
209 (4.3%); and a change in urine appearance in 523 (10.9%). The symptoms that were most commonly
reported as ‘not known’ among children aged < 3 years were pain or crying when passing urine (980,
34.0%) and passing urine more often (1038, 40.0%). A history of UTI was reported in 221 (4.6%)
children, 140 of whom were aged ≥ 3 years. Only 185 (3.8%) children had a temperature ≥ 39 °C.
Dipstick urine results were positive for nitrites in 416 (8.7%) and for leucocytes in 670 (13.9%) children.
Both nitrite (12.9% compared with 2.2%) and leucocyte (16.0% compared with 10.8%) positivity were
more common in children aged < 3 years than in children aged ≥ 3 years. Monovette weights (grams)
were available for all but 22 of the research laboratory urine samples. Median weight was 16.23 g
(IQR 13.67–17.03 g) for clean-catch samples, and 11.08 g (IQR 9.53–13.26 g) for nappy pad samples.
Urine samples processed
by both laboratories
(n = 4910)a
Collection method
(n = 4828, 98% of 4910)
Information available on
candidate predictors
(n = 4808, 99% of 4828)
Excluded
(n = 20)
Children with missing data on 
most or all urine symptoms, 
or for which urine dipstick 
tests were not available, 
or there was no information 
on prior infection
• Missing collection method, n = 13
• Bag collection method, n = 69
• Clean catch, n = 2630
• Nappy pad, n = 2198
Excluded
(n = 82)
FIGURE 8 Flow of participants in microbiological diagnosis of UTI in young children. a, See Figure 4 for how this
number was reached.
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TABLE 23 Characteristics of children and urine samples collected via clean catch or nappy pads, for the
4808 children with both NHS laboratory and research laboratory results
Variable Category
Age, n (%)
< 3 years 3–5 years
Gender Male 1439 (49.9) 919 (47.8)
Female 1445 (50.1) 1005 (52.2)
Age (years) 0 to < 1 1016 (35.2) 0
1 to < 2 942 (32.7) 0
2 to < 3 926 (32.1) 0
3 to < 4 0 1099 (57.1)
4 to < 5 0 825 (42.9)
Ethnicity White 2429 (84.2) 1575 (81.9)
Non-white 431 (14.9) 328 (17.1)
Not known 24 (0.8) 21 (1.1)
Recruitment site GP surgery 2716 (94.2) 1827 (95.0)
Emergency department 128 (4.4) 66 (3.4)
WIC 40 (1.4) 31 (1.6)
Sample method Clean catch 758 (26.3) 1861 (96.7)
Nappy pad 2126 (73.7) 63 (3.3)
Location of sample collection Surgery 1470 (51.0) 1477 (76.8)
Home 1414 (49.0) 447 (23.2)
Time between recruitment and laboratory sample receipt NHS < 24 hours 2045 (70.9) 1432 (74.4)
NHS ≥ 24 hours 839 (29.1) 492 (25.6)
RL < 24 hours 816 (28.3) 608 (31.6)
RL ≥ 24 hours 2068 (71.7) 1316 (68.4)
Pain/crying when passing urine No or slight problem 1812 (62.8) 1734 (90.1)
Moderate or severe problem 92 (3.2) 125 (6.5)
Not known 980 (34.0) 65 (3.4)
Passing urine more often No or slight problem 1618 (56.1) 1604 (83.4)
Moderate or severe problem 228 (7.9) 256 (13.3)
Not known 1038 (40.0) 64 (3.3)
Changes in urine appearance No or slight problem 2206 (76.5) 1539 (80.0)
Moderate or severe problem 297 (10.3) 226 (11.8)
Not known 381 (13.2) 159 (8.3)
Day or bed wetting when previously dry No or slight problem 364 (12.6) 1551 (80.6)
Moderate or severe problem 45 (1.6) 164 (8.5)
Wears nappies day and night 2377 (82.4) 70 (3.6)
Not known 98 (3.4) 139 (7.2)
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A total of 251 (5.2%) and 88 (1.8%) samples were classified as positive according to the NHS and
research laboratory result, respectively. The causative organism distributions were similar between
laboratories: in the NHS, E. coli 71.7%, unidentified coliforms 19.5%, other coliforms 2.8%, Proteus spp.
6.0%; and in the research laboratory, E. coli 84.1%, other coliform (Klebsiella spp., Enterobacter spp.,
Serratia spp., Citrobacter spp., Morganella spp.) 10.2%, Proteus spp. 5.7%. NHS laboratory positivity was
more common (6.6%) in children aged < 3 years than in those aged 3–5 years (3.2%). By contrast, rates
of research laboratory positivity were similar in these age groups (1.8% and 1.9%, respectively). Only 64
(1.3%) samples were positive in both laboratories and coded as ‘agree UTI positive (step 1)’. In 187 (3.9%)
the NHS laboratory result was positive but the research laboratory result negative, while in 24 (0.5%) the
research laboratory result was positive but the NHS laboratory result negative (Table 24).
Overall agreement between the NHS and research laboratories was moderate (kappa= 0.36; 95% CI 0.29
to 0.43; see Table 24). Agreement was better for clean-catch samples (0.54; 95% CI 0.45 to 0.63) than
for nappy pads (0.20; 95% CI 0.12 to 0.28). For children aged ≥ 3 years, too few nappy pad samples were
available to allow assessment of reliability. For clean-catch samples, reliability was similar in children aged
≥ 3 years (0.55; 95% CI 0.43 to 0.67) and < 3 years (0.52; 95% CI 0.37 to 0.67), which was better than
for nappy pad samples in children aged < 3 years (0.20; 95% CI 0.12 to 0.28). Similar patterns were seen
when comparisons were further stratified into age groups < 2 and ≥ 2 to < 3 years. It thus appeared that
lower reliability was attributable to nappy pad samples rather than to child’s age.
There was little evidence that passing urine more often or day/bed wetting when previously dry were
associated with UTI positivity (Table 25). Associations of pain or crying when passing urine, and dipstick
nitrite and leucocyte positivity, were markedly stronger in clean-catch than nappy pad samples and with
research laboratory than with NHS laboratory positivity. The association with temperature ≥ 39 °C
appeared stronger in clean-catch than nappy pad samples, though CIs were wide. Associations with
change in urine appearance and history of prior UTI did not differ markedly between NHS and research
laboratory results.
TABLE 23 Characteristics of children and urine samples collected via clean catch or nappy pads, for the
4808 children with both NHS laboratory and research laboratory results (continued )
Variable Category
Age, n (%)
< 3 years 3–5 years
History of UTI No 2699 (93.6) 1708 (88.8)
Yes 81 (2.8) 140 (7.3)
Not known 104 (3.6) 76 (4.0)
Temperature < 39 °C 2780 (96.4) 1843 (95.8)
≥ 39 °C 104 (3.6) 81 (4.2)
Urine dipstick nitrite Negative 2511 (87.1) 1881 (97.8)
Positive 373 (12.9) 43 (2.2)
Urine dipstick leucocytes Negative/trace 2423 (84.0) 1715 (89.1)
Positive 461 (16.0) 209 (10.8)
NHS laboratory result Negative 2695 (93.5) 1862 (96.8)
Positive 189 (6.6) 62 (3.2)
RL result Negative 2833 (98.2) 1887 (98.1)
Positive 51 (1.8) 37 (1.9)
RL, research laboratory.
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TABLE 24 Extent of agreement between NHS and research laboratory result
Age group and
sample collection
method n
NHS –ve,
RL –ve
NHS –ve,
RL +ve
NHS +ve,
RL –ve
NHS +ve, RL +ve
(agree UTI step 1) Kappa (95% CI)
Both collection
methods
4808 4533 24 187 64 0.36 (0.29 to 0.43)
Clean catch 2619 2501 14 59 45 0.54 (0.45 to 0.63)
Nappy pad 2189 2032 10 128 19 0.20 (0.12 to 0.28)
≥ 3 years 1924 1852 10 35 27 0.53 (0.41 to 0.65)
Clean catch 1861 1792 10 32 27 0.55 (0.43 to 0.67)
Nappy pad 63 60 0 3 0 N/A (N/A)
< 3 years 2884 2681 14 152 37 0.29 (0.21 to 0.36)
Clean catch 758 709 4 27 18 0.52 (0.37 to 0.67)
Nappy pad 2126 1972 10 125 19 0.20 (0.12 to 0.28)
< 2 years 1958 1809 7 121 21 0.23 (0.15 to 0.31)
Clean catch 173 155 0 12 6 0.47 (0.23 to 0.72)
Nappy pad 1785 1654 7 109 15 0.19 (0.10 to 0.27)
≥ 2 and < 3 years 926 872 7 31 16 0.44 (0.29 to 0.59)
Clean catch 585 554 4 15 12 0.54 (0.36 to 0.72)
Nappy pad 341 318 3 16 4 0.27 (0.05 to 0.50)
–ve, negative; +ve, positive; N/A, not applicable; RL, research laboratory.
N/A: cannot compute kappa statistic because no samples were classified as positive by the research laboratory.
TABLE 25 Associations of signs, symptoms and urine dipstick tests with separate NHS and research laboratory
results, and ‘agree UTI positive’
Signs, symptoms and
dipstick results by
laboratory
Clean catch
(eight-variable model)
Clean catch
(six-variable model)
Nappy pad
(six-variable model)
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
NHS laboratory
Pain/crying passing urine 2.8 (1.6 to 5.1) < 0.001 2.9 (1.6 to 5.1) < 0.001 1.1 (0.4 to 3.1) 0.838
Passing urine more often 0.6 (0.3 to 1.1) 0.089 0.6 (0.3 to 1.1) 0.073 0.7 (0.3 to 1.5) 0.370
Change in urine
appearance
2.9 (1.8 to 4.9) < 0.001 3.0 (1.8 to 4.9) < 0.001 2.1 (1.3 to 3.5) 0.005
Day/bed wetting,
previously dry
1.0 (0.5 to 2.1) 0.961 N/A N/A
History of UTI 1.7 (0.9 to 3.3) 0.129 N/A N/A
Temperature ≥ 39 °C 1.8 (0.8 to 3.9) 0.129 1.7 (0.8 to 3.8) 0.157 0.7 (0.2 to 2.2) 0.526
Dipstick: nitrite +ve 7.3 (3.9 to 13.6) < 0.001 7.6 (4.1 to 14.1) < 0.001 2.0 (1.4 to 2.9) 0.001
Dipstick: leucocyte +ve 3.1 (1.9 to 5.0) < 0.001 3.1 (1.9 to 5.1) < 0.001 3.1 (2.1 to 4.4) < 0.001
n observations (n +ve) 2619 (104) 2619 (104) 2189 (147)
AUROC (95% CI) 0.75 (0.70 to 0.81) 0.75 (0.69 to 0.80) 0.65 (0.61 to 0.70)
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For both clean-catch and nappy pad samples, values of the AUROC were consistently lower for NHS than
research laboratory positivity (see Table 25 and Figure 9). For clean-catch samples (eight-variable model)
the AUROC was 0.75 (95% CI 0.70 to 0.81) for NHS laboratory positivity and 0.87 (0.80 to 0.93) for
research laboratory positivity. Values of the AUROC were similar in the six-variable models. Values of the
AUROC were lower in nappy pad than clean-catch samples: 0.65 (95% CI 0.61 to 0.70) for NHS
laboratory positivity and 0.79 (95% CI 0.70 to 0.88) for research laboratory positivity.
Of the 211 samples that were coded as positive in one laboratory only, 38 (10 from clean-catch samples
and 28 from nappy pad samples) were coded as ‘agree UTI positive (step 2)’ when the NHS and research
laboratory results were considered together. Thus, a total of 102 (2.1%) samples were considered as
‘agree UTI’ on the basis of both the NHS and research laboratory results. Strong associations of pain/crying
TABLE 25 Associations of signs, symptoms and urine dipstick tests with separate NHS and research laboratory
results, and ‘agree UTI positive’ (continued )
Signs, symptoms and
dipstick results by
laboratory
Clean catch
(eight-variable model)
Clean catch
(six-variable model)
Nappy pad
(six-variable model)
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Research laboratory
Pain/crying passing urine 5.9 (3.0 to 11.7) < 0.001 6.0 (3.0 to 11.8) < 0.001 1.4 (0.3 to 7.0) 0.716
Passing urine more often 0.7 (0.3 to 1.6) 0.457 0.8 (0.4 to 1.7) 0.543 1.2 (0.3 to 4.4) 0.839
Change in urine
appearance
2.8 (1.4 to 5.6) 0.004 3.1 (1.6 to 6.1) 0.001 3.1 (1.2 to 7.9) 0.019
Day/bed wetting,
previously dry
1.6 (0.7 to 3.7) 0.299 N/A N/A
History of UTI 2.7 (1.2 to 6.3) 0.017 N/A N/A
Temperature ≥ 39 °C 2.0 (0.7 to 5.9) 0.223 1.7 (0.6 to 5.1) 0.333 1.1 (0.1 to 8.8) 0.930
Dipstick: nitrite +ve 10.7 (5.1 to 22.3) < 0.001 11.2 (5.4 to 23.1) < 0.001 5.2 (2.4 to 11.3) < 0.001
Dipstick: leucocyte +ve 5.2 (2.8 to 9.8) < 0.001 5.3 (2.8 to 10.0) < 0.001 4.1 (1.9 to 8.9) < 0.001
n observations (n +ve) 2619 (59) 2619 (59) 2189 (29)
AUROC (95% CI) 0.87 (0.80 to 0.93) 0.86 (0.79 to 0.92) 0.79 (0.70, 0.88)
‘Agree UTI positive’ (steps 1 and 2 combined)
Pain/crying passing urine 6.0 (2.9 to 12.5) < 0.001 6.1 (3.0 to 12.7) < 0.001 1.0 (0.2 to 4.9) 0.993
Passing urine more often 0.5 (0.2 to 1.2) 0.121 0.6 (0.2 to 1.3) 0.160 0.4 (0.1 to 2.0) 0.279
Change in urine
appearance
3.7 (1.8 to 7.6) < 0.001 4.1 (2.0 to 8.3) < 0.001 3.5 (1.6 to 7.6) 0.001
Day/bed wetting,
previously dry
1.7 (0.7 to 4.3) 0.258 N/A N/A
History of UTI 2.1 (0.9 to 5.2) 0.103 N/A N/A
Temperature ≥ 39 °C 2.0 (0.6 to 6.2) 0.245 1.8 (0.6 to 5.5) 0.339 0.6 (0.1 to 5.1) 0.674
Dipstick: nitrite +ve 17.1 (8.0 to 36.6) < 0.001 18.0 (8.5 to 38.4) < 0.001 3.2 (1.7 to 5.9) < 0.001
Dipstick: leucocyte +ve 4.6 (2.3 to 8.9) < 0.001 4.7 (2.4 to 9.1) < 0.001 4.1 (2.2 to 7.5) < 0.001
n observations (n +ve) 2556 (55) 2556 (55) 2079 (47)
AUROC (95% CI) 0.87 (0.81 to 0.94) 0.88 (0.82 to 0.94) 0.74 (0.67 to 0.81)
–ve, negative; +ve, positive; N/A, not applicable.
N/A: variable was not considered for the six-variable model.
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FIGURE 9 Receiver operating characteristic curves of symptoms, signs and urine dipstick tests with different
definitions of urine culture positivity. CC, clean catch; NP, nappy pad.
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passing urine and nitrite and leucocyte dipstick positivity with an overall ‘agree UTI’ microbiology result in
clean-catch samples were lower or absent in nappy-pad samples (see Table 25). For the six-variable model,
the AUROC was higher in clean-catch (0.88; 95% CI 0.82 to 0.94) than nappy pad samples (0.74; 95% CI
0.67 to 0.81) (see Table 25 and Figure 9).
Values of the AUROC were much lower for samples classified as ‘disagree (NHS positive, research
negative)’ (six-variable model 0.62; 95% CI 0.54 to 0.69 for clean-catch and 0.62, 95% CI 0.57 to 0.68
for nappy pad samples). Only a small number (11 clean catch, 7 nappy pad) of samples were classified as
‘disagree (NHS negative, research positive)’ and values of the AUROC were also lower for these than
for samples classified as ‘agree UTI’. Values of the AUROC in sensitivity analyses conducted using the
six-variable model are shown in Table 26.
Results for clean-catch samples using the eight-variable model and six-variable model were similar, and are
available from the authors on request. For clean-catch samples, the values of the AUROC were similar for
children aged < 3 and 3 to < 5 years, for both NHS laboratory and research laboratory positivity. Allowing
for ‘not known’ responses for children aged < 3 years made little difference to the AUROC, for either NHS
or research laboratory positivity. The AUROC was markedly higher for samples that were positive in both
NHS and research laboratories than in those coded as ‘agree UTI’ after considering both results, for both
clean-catch and nappy pad samples. For the research laboratory, but not for NHS laboratories, values of
the AUROC were higher for samples collected in surgery than those collected at home. Values of the
AUROC were similar in samples received by both laboratories within 24 hours and samples received after
24 hours except for nappy pad samples in the research laboratory, where the diagnostic accuracy
appeared higher for samples received within 24 hours. For both NHS and research laboratory positivity, the
AUROC increased with increasing threshold of pure/predominant growth count. For research laboratory
positivity, values of the AUROC were markedly lower for pure/predominant growth < 105 CFU/ml. Values
of the AUROC were markedly higher in samples with WBC count ≥ 30/mm3, except for research laboratory
positivity in nappy pad samples. There was little evidence that values of the AUROC were higher for
research laboratory positivity with pure than with predominant growth. There was little difference in
AUROCs when stratifying by research laboratory urine volume (Monovette weight) in clean-catch and
nappy pad samples.
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
71
TABLE 26 Areas under the ROC curve (95% CI) from sensitivity analyses using six-variable logistic regression models
Characteristics of stratified analysis
Clean catch Nappy pad
n observed
(n positive) AUROC (95% CI)
n observed
(n positive) AUROC (95% CI)
NHS positive age < 3 years 758 (45) 0.75 (0.67 to 0.84) 2126 (144) 0.66 (0.61 to 0.71)
NHS positive age 3 to < 5 years 1861 (59) 0.74 (0.67 to 0.81) 63 (3) Too few
NHS positive age < 3 years, with ‘not known’a 758 (45) 0.76 (0.68 to 0.85) 2126 (144) 0.66 (0.61 to 0.71)
RL positive age < 3 years 758 (22) 0.88 (0.80 to 0.97) 2126 (29) 0.79 (0.70 to 0.88)
RL positive age 3 to < 5 years 1861 (37) 0.85 (0.77 to 0.94) 63 (0) Too few
RL positive age < 3 years, with ‘not known’a 758 (22) 0.89 (0.81 to 0.98) 2126 (29) 0.81 (0.72 to 0.89)
‘Agree UTI’ age < 3 years 730 (21) 0.91 (0.83 to 0.98) 2017 (45) 0.75 (0.68 to 0.83)
‘Agree UTI’ age 3 to < 5 years 1826 (34) 0.87 (0.79 to 0.95) 62 (2) Too few
‘Agree UTI’ age < 3 years, with ‘not known’a 730 (21) 0.93 (0.89 to 0.98) 2017 (45) 0.76 (0.68 to 0.84)
‘Agree UTI positive (step 1)’ 2546 (45) 0.92 (0.87 to 0.97) 2051 (19) 0.85 (0.76 to 0.94)
‘Agree UTI positive (step 2)’ 2511 (10) 0.76 (0.60 to 0.91)b 2060 (28) 0.66 (0.55 to 0.76)
NHS surgery sample 2012 (84) 0.73 (0.67 to 0.80) 935 (64) 0.66 (0.58 to 0.73)
NHS home sample 607 (20) 0.81 (0.71 to 0.92) 1254 (83) 0.66 (0.59 to 0.72)
RL surgery sample 2012 (47) 0.90 (0.84 to 0.96) 935 (12) 0.84 (0.73 to 0.95)b
RL home sample 607 (12) 0.73 (0.55 to 0.90)b 1254 (17) 0.76 (0.64 to 0.89)b
NHS sample receipt < 24 hours 1959 (76) 0.76 (0.69 to 0.82) 1518 (108) 0.67 (0.31 to 0.72)
NHS sample receipt ≥ 24 hours 660 (28) 0.73 (0.64 to 0.83) 671 (39) 0.62 (0.53 to 0.70)b
RL sample receipt < 24 hours 794 (15) 0.89 (0.77 to 1.00) 630 (7) 0.94 (0.87 to 1.00)b
RL sample receipt ≥ 24 hours 1825 (44) 0.84 (0.76 to 0.92) 1559 (22) 0.75 (0.64 to 0.86)b
NHS p/pc ≥ 105 2619 (104) 0.75 (0.69 to 0.80) 2189 (147) 0.65 (0.61 to 0.70)
NHS p/pc ≥ 103 to < 105 2515 (47) 0.58 (0.51 to 0.66)b 2042 (40) 0.57 (0.48 to 0.65)b
RL p/pc ≥ 107 2593 (33) 0.89 (0.81 to 0.97) 2166 (6) 0.74 (0.60 to 0.89)b
RL p/pc ≥ 106 to < 107 2573 (13) 0.84 (0.70 to 0.98) 2166 (6) 0.96 (0.92 to 1.00)b
RL p/pc ≥ 105 to < 106 2573 (13) 0.79 (0.64 to 0.94) 2169 (9) 0.81 (0.68 to 0.94)b
RL p/pc ≥ 104 to < 105 2560 (24) 0.59 (0.51 to 0.68)b 2160 (61) 0.59 (0.54 to 0.64)b
RL p/pc ≥ 103 to < 104 2560 (110) 0.57 (0.52 to 0.62) 2160 (93) 0.61 (0.56 to 0.66)
NHS positive and WBC ≥ 30/mm3 2572 (57) 0.85 (0.79 to 0.91) 2068 (26) 0.74 (0.62 to 0.86)
NHS positive and WBC < 30/mm3 2562 (47) 0.63 (0.55 to 0.71) 2163 (121) 0.64 (0.59 to 0.69)
RL positive and WBC ≥ 30/mm3 2599 (39) 0.97 (0.93 to 1.00) 2164 (4) 0.79 (0.48 to 1.00)b
RL positive and WBC < 30/mm3 2580 (20) 0.67 (0.54 to 0.81)b 2185 (25) 0.80 (0.71 to 0.89)b
RL pure growth ≥ 105 2604 (44) 0.84 (0.76 to 0.92) 2172 (12) 0.83 (0.72 to 0.94)b
RL predominant growth ≥ 105 2575 (15) 0.92 (0.84 to 1.00) 2177 (17) 0.76 (0.64 to 0.89)b
RL urine weight < mediand 1306 (30) 0.90 (0.82 to 0.97)b 1092 (9) 0.77 (0.59 to 0.94)b
RL urine weight ≥ mediand 1303 (27) 0.83 (0.72 to 0.93) 1085 (19) 0.81 (0.70 to 0.91)
RL, research laboratory.
a Including ‘not known’ responses for ‘pain/crying when passing urine’ and ‘passing urine more often’.
b Not all variables included because of perfect prediction.
c Pure/predominant growth.
d The median Monovette weights cut-point was 16.23 g for clean-catch samples and 11.08 g for nappy pad samples.
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Discussion
Summary of findings
Based on a large, unselected cohort of children presenting to primary care in England and Wales with
acute illness, the reliability of microbiological diagnosis of UTI in routine NHS laboratories and a research
laboratory was lower than expected and worse for urine samples collected using nappy pads than for
clean-catch samples. Associations of microbiological positivity with pre-specified symptoms, signs and urine
dipstick test results were lower for NHS laboratories than the research laboratory, and for nappy pad
samples than clean-catch samples. Urines giving a ‘positive’ result in a NHS laboratory but not in the
research laboratory had only modest associations with the preselected symptoms, signs and dipstick test
results. These findings did not appear to be attributable to the younger age of the children providing
nappy pad samples. Discrimination improved with increasing bacteriuria concentration and with the
presence of WBCs in the urine sample (pyuria). Results of urine microbiology should, therefore, not be
regarded as dichotomous result, but rather as a continuous phenomenon to be interpreted in the clinical
context, with UTI possible even when bacterial concentrations are between 103 and 104 CFU/ml, and
becoming increasingly probable with higher concentrations of pure or predominant bacterial growth in the
presence of pyuria.
Results in context with other studies
To our knowledge, this is the largest and most generalisable primary care-based study comparing the
diagnostic performance of NHS laboratories with a research laboratory, and using nappy pad and
clean-catch collection methods. However, the number of UTI positive samples was relatively small,
especially for clean-catch samples in younger children and for the research laboratory. We do not know
which samples were sent to NHS laboratories in containers with boric acid: all samples were sent via the
routine mechanisms for that laboratory. All research laboratory samples were sent in containers with boric
acid by Royal Mail post, introducing longer delays (which were not associated with UTI status) before
processing than with NHS laboratories. In current UK primary care, nappy pad and bag samples are often
the only feasible methods for obtaining urine samples from young children: there is usually insufficient
space or staffing for parents and children to wait to provide clean-catch specimens. Moreover, most
primary care clinicians (other than those with specialist paediatric or emergency department training) are
not trained in SPA or catheter techniques, and neither of these are acceptable to parents. Nappy pads
have been shown to be acceptable to parents63 and endorsed by NICE.2
In the early development of microbiology, laboratory diagnosis of UTIs required isolation of the same
organism from repeated urine samples. It was recognised in the 1940s that high urine bacterial counts
were related to UTI, and subsequently proposed that a single sample with a high count could support a
laboratory diagnosis of UTI and allow early treatment.117 Early proposed thresholds to define positivity
were derived from detailed investigation of fresh urine samples and ranged from ≥ 103 CFU/ml118 to
≥ 3 × 103 CFU/ml119 and ≥ 105 CFU/ml.120 Recently, it was suggested that a threshold of ≥ 106 CFU/ml
would be more appropriate.80 Current laboratory guidelines differ with respect to recommended
thresholds. The UK Standards for Microbiological Investigations do not have specific paediatric guidance
and suggest a threshold of a ‘single organism ≥ 104 CFU/ml indicating UTI’, but other thresholds are also
discussed.82 European paediatric guidelines suggest a threshold of ≥ 104 CFU/ml if symptoms are present
and ≥ 105 CFU/ml if no symptoms are present for midstream specimens, and lower thresholds for
specimens collected by bladder catheterisation or SPA.83 US guidance suggests that clinicians require both
urinalysis evidence of infection and a threshold of ≥ 5 × 104 CFU/ml.121
Microbiological examination of urine requires quantification of bacteria and the ability to differentiate
mixed from pure growths. The pour-plate method proved too labour-intensive given the large numbers
of urine samples submitted to routine microbiology laboratories in the UK:82 in 2012, 663,355 samples
(12,689 from children aged < 5 years) were submitted in Wales alone, equating to some 12.1 million
samples annually (250,000 from children aged < 5 years) in England and Wales. More rapid methods using
calibrated loops, filter paper strips or multipoint methods to deliver a standard inoculum were developed
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in response to the need for rapid throughput.122–124 All were validated against viable counts performed by
pour plates or the method of Miles and Misra.125 The Standards for Microbiological Investigation followed
by most UK laboratories provide options for urine culture using these methods to inoculate CLED or
chromogenic agar, but they have not previously been calibrated against clinical symptoms. Difficulties in
defining mixed growths and achieving accurate bacterial counts may be due to the small volumes of urine
inoculated onto small areas of agar.80,122 Spiral plating, which was used by the research laboratory in this
study and involves a much larger inoculum (50 µl) over an entire 9-cm agar plate, is a more accurate
method of quantifying bacterial counts and allows easy differentiation of mixed cultures.126 Enhanced
diagnostic performance might also be achieved through improvements in procedures for sample collection
and transport.
NHS laboratory UTI positivity was consistently less strongly associated with urinary symptoms and dipstick
results than research laboratory UTI positivity. A substantial number of UTI positive NHS laboratory samples
[128 (5.8%) nappy pad and 59 (2.3%) clean catch] were negative in the research laboratory, and
associations of the NHS laboratory positive results with symptoms, signs and dipstick results were modest.
These findings suggest that the diagnostic performance of current routine NHS laboratory testing is
suboptimal and may lead to overtreatment and unnecessary investigations.
Clinical and microbiological implications
Even for samples processed in the research laboratory, the diagnostic utility of microbiology based on
nappy pad samples was less than for clean-catch samples. The prevalence of UTI positivity diagnosed in the
research laboratory was lower for nappy pad (1.3%) than for clean-catch (2.3%) samples, suggesting that
UTIs are missed in nappy pad samples because of contamination. Therefore, primary care clinicians should
try to obtain clean-catch samples in even very young children in whom they suspect a UTI,127 for example
by providing time and space to support urine collection. If an algorithm based on parent-reported
symptoms can provide earlier ID of the children at greatest risk of UTI, then parents could be advised to
obtain a urine sample prior to attending primary care.
In adult medicine, results from urine microbiology can be interpreted in the clinical context of the patient’s
presentation. However, in young children the significant difficulties in obtaining uncontaminated samples,
together with the non-specific nature of the presenting symptoms, mean that there is greater reliance on
the laboratory result. More detailed routine microbiological examination of paediatric urine samples would
have resource implications that could better be justified if urines were selected for testing through an
algorithm that increased the prior probability of positivity. Our results suggest that NHS laboratories should
distinguish primary care paediatric (age < 5 years) samples from adult samples and consider reporting
these in more detail, and that national procedures should be correspondingly updated.
Adoption of the more accurate but labour-intensive research laboratory methods would not be appropriate
to use for all urines processed in NHS laboratories but, in many laboratories, extra or augmented methods
are used for ‘special urines’, usually received in small numbers, to enhance reporting. It seems reasonable
that research laboratory methods be implemented in NHS laboratories for the processing of paediatric
urines if associated with enhanced diagnostic performance.
Implications for the DUTY study
For the purposes of the DUTY study, samples will be considered UTI positive (called ‘the reference
standard’ in Chapter 5) if there is growth in the research laboratory of ≥ 105 CFU/ml of a single
uropathogen (‘pure growth’) or growth of ≥ 105 CFU/ml of a uropathogen with ≥ 3 log10 difference
between the growth of this and the next species (‘predominant growth’).
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Chapter 5 Derivation and validation of a clinical
algorithm to guide diagnosis and treatment of urinary
tract infection in pre-school children in primary care
Introduction
The main aim of the DUTY study was to derive and validate a two-step algorithm for the diagnosis of UTI
in children under 5 years presenting to primary care with acute illnesses. The first step was to identify the
children in whom urine sampling is warranted and the second to establish if dipstick testing provides
additional value in identifying children warranting antibiotic treatment. There are three stages in the
development of such algorithms: derivation, validation, and assessment of impact on clinical behaviour and
patient outcome.128 In this chapter, we report the first two of these stages against STARD criteria.129
Methods
Participants
The methods of recruitment are described in detail in Chapter 2 and our study protocol
(see Appendix 3).106
Index tests and urine collection
All participating NHS staff received training in study procedures and only clinically qualified staff
(GPs, nurse practitioners or emergency department doctors/nurses) performed and recorded clinical
examination findings. Following consent, index tests (symptoms, signs or dipstick results) were recorded on a
CRF (see Appendix 4) using a paper- or a web-based data collection system, with the latter requiring a unique
log-in account for each staff member. Symptoms included the child’s medical history and parent-reported
symptoms (graded as absent, mild, moderate or severe when at their worst during the illness). Signs, from a
full clinical examination, included ‘clinicians’ global impression of the child’s illness severity’, rated on a scale of
0 (child displaying no constitutional upset) to 10 (child displaying life-threatening signs requiring immediate
hospitalisation) and ‘abdominal tenderness’ (any of suprapubic, loin or other abdominal tenderness). In total,
107 symptoms and signs were recorded and, preceding urine dipstick testing, clinicians recorded their
working diagnosis, including a rating of the likelihood of UTI (‘clinical diagnosis’) as ‘UTI fairly to very certain’,
‘no UTI fairly certain or uncertain’ or ‘no UTI certain to very certain’.
Our preferred urine collection method was ‘clean catch’. NICE-recommended ‘Newcastle nappy pads’2
were used for children still using nappies and those for whom the parent/guardian did not think clean
catch would be successful. Urine collection bags were used in a few instances, but data from these
samples were excluded from the present study. At the primary care site, urine samples were dipstick tested
(using Siemens Multistix 8 SG) for blood, protein, glucose, ketones, nitrite, LE, pH and specific gravity
(eight dipstick index tests). For full details of urine collection methods, see Chapter 2, Urine sample
collection, and our protocol paper (see Appendix 3).106 All 107 index tests and the clinicians’ working
diagnosis were measured blind to the reference standard.
Reference standard
Research laboratory samples were processed by two staff members using a single, standardised procedure.
We used a microbiological definition of UTI of ≥ 105 CFU/ml of a single uropathogen (‘pure growth’) or
≥ 105 CFU/ml of a uropathogen with ≥ 3 log10 (1000-fold) difference between the growth of this and
the next species (‘predominant growth’) (see Chapter 4). We defined uropathogens as members of the
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
75
Enterobacteriaceae family. Aside from knowing children’s dates of birth (used as part of the urine ID
process), research laboratory staff were blind to children’s index test characteristics. We compared the
characteristics of children for whom research laboratory culture results were and were not available.
Statistical analysis
We examined the frequency of symptom and sign categories, blind to their associations with urine culture
results, and merged the least frequent categories prior to analyses. We used logistic regression to estimate
associations of index tests with urine culture positivity. We fitted separate models for clean-catch and
nappy pad samples because of the markedly different age distributions of children providing samples using
these methods and concerns about contamination reducing the sensitivity of urine culture in nappy pad
samples. The p-values were derived using LR tests. For ordinal variables, both heterogeneity and trend
p-values were derived. Continuous variables were divided into quintiles and trend p-values were derived
using the median within categories. We examined plots of the log-odds of culture positivity against the
median within quintiles for evidence of non-linearity.
We used two methods for dealing with missing data, including the response ‘don’t know’ to questions
about the presence of symptoms such as pain or crying when passing urine. In both univariable and
multivariable analyses, missing data were coded as the modal value, usually absence of the symptom.
We repeated multivariable analyses using the chained equations approach to multiple imputation:
estimates and Wald p-values130 based on 50 imputed data sets derived using Rubin’s rules.131
We sequentially evaluated selected index tests in two groups: parent-reported symptoms and
clinician-reported signs, and urine dipstick results. This reflects the clinical process, where symptoms and
signs are used to identify children from whom urine should be collected and dipstick testing may
additionally help clinicians to decide which children should be treated. First, we selected those variables
with either trend or heterogeneity univariable p-value < 0.01 for either collection method or when all
samples were analysed together. Second, we derived models from among all of the selected symptoms
and signs, separately for nappy pad and clean-catch samples, using backwards stepwise selection and an
exclusion criterion of heterogeneity p-value > 0.1. Third, we used backwards stepwise selection with the
same exclusion p-value for models in which dipstick results were added to the previously selected
symptoms and signs, to give models including symptoms, signs and dipstick results. We investigated the
effect of using more liberal p-value thresholds of 0.1 and 0.2 at each stage, and found no important
differences in the final models (results available from the authors on request).
For each model, we quantified diagnostic accuracy as the AUROC (also known as the c-statistic). We also
estimated AUROC values for ‘clinician diagnoses’ of UTI. To formally test the additional value of dipsticks
we calculated the difference in AUROC, along with 95% CI and p-value, between the symptoms and signs
model and the symptom, sign and dipstick model. We internally validated the models, calculating the
AUROC and calibration slope, using the bootstrap procedure described by Steyerberg.132 The calibration
slope is a shrinkage factor that compares predicted with observed probabilities, where 1 is perfect
calibration and 0 reflects no agreement between predicted and observed probabilities. Multiplying the
estimated coefficients (log-odds ratios) in a predictive model by the calibration slope would correct the
estimated positive predictive values for statistical overoptimism due to the model fitting. For each model,
we selected cut-points corresponding to a range of values for sensitivity, and then calculated the
corresponding specificity, negative and positive predictive values, and the proportion of children classified
positive. This was completed using the linear predictors that were combined using Rubin’s rules.131 CIs
were calculated for these parameters by transforming to the log-odds sale, and then using the standard
error formula for log-odds, and then transforming back to a proportion. As log-odds are undefined for
a proportion of 0 or 1, we were unable to calculate CIs when these parameters were equal to either
0% or 100%.
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We also investigated the robustness of our clean-catch models in younger children by fitting the clean-catch
models to those with clean-catch samples who were under 3 years of age. Finally, to investigate the
robustness of our nappy pad models, we fitted the nappy pad models to those with clean-catch samples
who were under 3 years of age.
Fever of unknown origin
In order to investigate if ‘fever of unknown origin’ was associated with UTI, we identified children with
fever and no symptoms or signs suggestive of an alternative source. We did three analyses using the three
fever variables – two parent-reported (‘fever now or in the past 24 hours’ and ‘fever at any time during
this illness’) and one from the physical examination (temperature of ≥ 38 °C) – for children without any of
the following symptoms and signs: new generalised rash; vomiting; diarrhoea (any time and last 24 hours);
blocked/runny nose; cough; wheeze; shortness of breath; chest pains; earache; sore throat; oxygen
saturations < 94%; any throat abnormality; any ear abnormality; and any chest abnormality. The categories
‘slight’, ‘moderate’ and ‘severe problem’ for the parent-reported fever variables were merged owing to
the small number of UTI positives within these categories. We conducted two analyses for each of the
clean-catch and nappy pad samples: one used a complete case approach and the other assumed
‘modal/normal’ imputation for each of the 14 variables above.
Points-based models
As the above models are relatively complex and would need a computer or calculator to estimate risk
scores, we also generated points-based models where the risk of UTI could be more easily calculated.
To do this, we first dichotomised all variables in our original models, including dipsticks. To make the
resulting rule as user-friendly as possible, we dichotomised all variables at the ‘present/absent’ threshold.
We removed clinical examination variables, as these variables contributed the least to the models
and would take a disproportionate amount of time to collect in relation to their value. After deriving
these dichotomised variable models using the multiple imputed data, we calculated a corresponding
points-based model. Using methods similar to previous studies,133,134 points were calculated for each
variable by dividing that coefficient’s variable by the smallest coefficient in the model and then rounding to
the nearest integer. We quantified the diagnostic accuracy of the resulting points-based models using the
AUROC, and compared these with the ‘full models’. To formally test the additional value of dipsticks,
we calculated the difference in AUROC, along with its 95% CI and p-value, between the symptoms and
signs model and the symptoms, signs and dipstick model. This comparison was estimated for both the
coefficient and the integer points-based models. The points-based models cannot be validated using
bootstrapping as this method relies on the coefficients being estimable in different (bootstrap) samples
and, in the ‘points-model’, these are fixed. However, to assess possible optimism of the points-based
models, we internally validated the dichotomised models without the points’ scores. For the points-based
models, we selected cut-points corresponding to a range of integer risk scores, and then calculated the
corresponding sensitivity, specificity, negative and positive predictive values, and the proportion of
children classified positive. This was completed with the points risk scores that were combined using
Rubin’s rules.131
Additionally, for the points-based models we selected cut-points corresponding to the complete range of
risk scores for each possible combination of symptoms and signs, and then calculated the corresponding
sensitivity, specificity, negative and positive predictive values, and the proportion of children
classified positive.
Added value of dipstick testing
In addition to looking at the difference in the AUROC between the models with and without the dipstick
test results, we fitted multinomial logit models for the association of the selected symptoms and signs with
the dipstick test results included in the symptoms, signs and dipstick model. We then quantified the
additional value of dipstick testing in diagnosis of UTI using a three-step simulation approach based on
the points-based models. The steps were (1) sample coefficient values from the multivariate normal
distribution of the multinomial logit parameter estimates; (2) based on the sampled coefficients, randomly
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generate a set of dipstick results; and (3) compute the probability of UTI based on the symptoms, signs
and dipstick points-based model. For each combination of symptoms and signs we generated 10,000
samples and calculated the probability of UTI, with and without the dipstick results, and the change in
probability of UTI after accounting for the dipstick results. One of the dipstick combinations was dropped
as it was observed in only 3 out of 2740 individuals and led to numerical instabilities. We grouped the
distribution of these probabilities and changes in probabilities according to whether or not primary care
clinicians considered it reasonable to recommend urine sampling based on symptoms and signs and the
cost-effectiveness analyses; results were weighted according to the relative frequencies of different
combinations of symptoms and signs within the groups.
Results
Participants
The recruitment of participants is described in Chapter 3. In summary, 14,724 children were screened for
eligibility, of whom 4390 were immediately ineligible, 1276 declined, 1684 could not be recruited for
other reasons, 196 were subsequently excluded and 15 withdrew (see Figure 4). Urine was collected using
clean-catch or nappy pad methods from 6241 (87%) children and sent to the NHS (priority) laboratory in
6192 (86%) and the research laboratory in 5170 (72%); these figures and where they flow from can be
seen in Figure 10. Reference standard results were available from the research laboratory (our final analytic
sample) in 5017 (70%), of which 2740 (55%) were collected via clean catch and 2277 (45%) via nappy
pad (see Figures 4 and 10). The number in Figure 10 in the box ‘urine sent to research laboratory’ does not
include those urines collected by bag or those for which we did not know the collection method.
Comparing recruited children with (n= 5017) and without (n= 2146) a research laboratory culture result,
we found that children with a culture result were older (59% vs. 33% were ≥ 2 years); more likely to have
a mild illness (83% vs. 80% clinician global impression < 3); more likely to report pain/crying on passing
urine (12% vs. 8%); more likely to report darker urine (14% vs. 7%); more likely to have UTI suspected
clinically (7% vs. 4%); less likely to report nappy rash (16% vs. 20%); and less likely to be nitrite positive
(9% vs. 14%). However, they were similar in terms of sex (female 51% vs. 50%); ethnicity (non-white
17% vs. 18%); parental highest qualification (diploma or degree 49% vs. 50%); deprivation (21% vs.
21% for most deprived quintile score); parental impression of overall illness severity (19% vs. 15% < 3);
days unwell prior to recruitment (both median 4 days); and the prevalence of all the other symptoms,
signs and dipstick index tests found to be independently associated with UTI. Further details of these
comparisons are given in Chapter 3.
The most common non-UTI clinical diagnoses in the clean-catch and nappy pad groups, respectively,
were ‘upper respiratory tract infection’ (28% and 35%), ‘viral illness’ (15% and 18%) and otitis media
(10% and 9%). Gastroenteritis was thought to be present in 3.6% and 5.7%, respectively. Antimicrobial
substances, which can arise from the use of both systemic antibiotics and locally applied cleaning agents,
were found in 4.5% and 6.6% of clean-catch and nappy pad samples, respectively, and for both collection
methods samples were more likely to be present in children with than without UTI (Table 27, and see
Table 38). A total of 79 children were reported hospitalised, none as a result of study participation. We are
not aware of any adverse events resulting from the measurement of index or reference tests.
Clean-catch models
Table 27 shows that 2.2% of the 2740 children providing clean-catch samples met the criteria for a
microbiological diagnosis of UTI, and that 94% were aged ≥ 2 years, 54% were female, and 96% of
samples were provided within 24 hours of index test measurement. Clinicians correctly identified 47% of
the 60 UTIs. Missing data or ‘not known’ responses were generally infrequent other than in the youngest
children (nappy pad samples), in whom symptoms, such as pain/crying on passing urine, cannot be
determined (see Tables 27 and 38).
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Assessed for eligibility
(n = 14,724)
Enrolled
(n = 7374)
Recruited
(n = 7163)
• Excluded,b n = 196
• Withdrew, n = 15
Urine collected using clean catch or
nappy pad
(n = 6241, 87% of 7163)
Reference standard result available
(n = 5017, 70% of 7163)
Urine sent to research laboratory
(n = 5170, 72% of 7163)
• Declined, n = 1276
• Ineligible, n = 4390
• Other reasons,a n = 1684
Nappy pad
(n = 2277, 45% of 5017)
• No sample, n = 773
• Bag urine sample, n = 100
• Method missing, n = 49
Clean catch
(n = 2740, 55% of 5017)
UTI
(n = 30, 1.3% of 2277)
UTI
(n = 60, 2.2% of 2740)
Urine received at research laboratory
(n = 5137, 72% of 7163)
• Insufficient urine for
   either laboratory, n = 49
• Sent to NHS (priority)
   laboratory only, n = 1022
• Not cultured, n = 120
   (urine leaked, incorrect
   container or sample
   volume too small)
• Not received at research
   laboratory, n = 33
FIGURE 10 DUTY flow diagram for diagnostic algorithm. a, Includes left prior to invitation (n= 811), no consent
(n= 214), language barrier (n= 112); and b, excluded as retrospectively ineligible/duplicate recruitment/invalid
consent (n= 141) and poor data quality (n= 55).
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TABLE 27 Clean-catch samples: children’s characteristics and crude ORs for index tests associated with UTI
Demographics and index testsa n (%)b UTI positive (%)c Crude OR (95% CI)
Gender
Male 1267 (46.2) 13 (1.0) 1 (ref.)
Female 1473 (53.8) 47 (3.2) 3.18 (1.71 to 5.90)
Age of child
< 6 months 34 (1.2) 1 (2.9) 1.13 (0.15 to 8.77)
6 to < 12 months 54 (2.0) 3 (5.6) 2.19 (0.62 to 7.77)
1 to < 2 years 91 (3.3) 2 (2.2) 0.84 (0.19 to 3.70)
2 to < 3 years 612 (22.3) 16 (2.6) 1 (ref.)
3 to < 4 years 1073 (39.2) 21 (2.0) 0.74 (0.39 to 1.44)
4 years plus 876 (32.0) 17 (1.9) 0.74 (0.37 to 1.47)
Clinician diagnosis prior to dipstick
Not UTI certain/very certain 1149 (41.9) 6 (0.5) 0.28 (0.12 to 0.69)
Not UTI fairly certain/uncertain 1417 (51.7) 26 (1.8) 1 (ref.)
UTI fairly to very certain 168 (6.1) 28 (16.7) 10.75 (6.13 to 18.8)
Missing 6 (0.2) 0 (0.0)
Pain/crying when passing urinea
No problem 2234 (81.5) 22 (1.0) 1 (ref.)
Slight problem 182 (6.6) 6 (3.3) 2.97 (1.21 to 7.29)
Moderate problem 128 (4.7) 12 (9.4) 9.01 (4.45 to 18.2)
Severe problem 51 (1.9) 15 (29.4) 36.30 (17.81 to 74.0)
Missing/not known 145 (5.3) 5 (3.4)
Smelly urinea
No problem 2108 (76.9) 20 (0.9) 1 (ref.)
Slight problem 174 (6.4) 10 (5.7) 5.87 (2.76 to 12.5)
Moderate problem 179 (6.5) 16 (8.9) 9.46 (4.93 to 18.2)
Severe problem 51 (1.9) 10 (19.6) 23.5 (10.6 to 52.3)
Missing/not known 228 (8.3) 4 (1.8)
Cough
No problem 773 (28.2) 24 (3.1) 1 (ref.)
Slight problem 556 (20.3) 16 (2.9) 0.93 (0.48 to 1.76)
Moderate problem 829 (30.3) 17 (2.1) 0.66 (0.35 to 1.23)
Severe problem 579 (21.1) 3 (0.5) 0.16 (0.05 to 0.54)
Missing/not known 3 (0.1) 0 (0.0)
History of UTIa
No 2449 (89.4) 43 (1.8) 1 (ref.)
Yes 177 (6.5) 12 (6.8) 3.81 (1.99 to 7.31)
Missing/not known 114 (4.2) 5 (4.4)
Clinician global impression of illness severity (0–10)a
0–1 989 (36.1) 14 (1.4) 1 (ref.)
2 739 (27.0) 14 (1.9) 1.35 (0.64 to 2.85)
3 531 (19.4) 14 (2.6) 1.89 (0.89 to 4.00)
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‘Full’ coefficient-based models
Tables 27 and 28, respectively, show the crude and adjusted ORs for the index tests (marked with footnote
marker d in Table 28) selected for the clean-catch model, for children predominantly ≥ 2 and < 5 years.
Table 28 shows that parent-reported pain/crying while passing urine, smelly urine, history of UTI, and
absence of severe cough were independently associated with UTI and, for the first two of these, evidence
of increasing strength of association for increasing severity of symptoms with UTI. Clinician-reported
global impression of illness severity, abdominal tenderness on examination and the absence of acute ear
abnormality on examination were independently associated with UTI, again with the former showing a
TABLE 27 Clean-catch samples: children’s characteristics and crude ORs for index tests associated
with UTI (continued )
Demographics and index testsa n (%)b UTI positive (%)c Crude OR (95% CI)
4–5 363 (13.2) 12 (3.3) 2.39 (1.09 to 5.21)
≥ 6 115 (4.2) 6 (5.2) 3.85 (1.45 to 10.21)
Missing 3 (0.1) 0 (0.0)
Abdominal exam: any abdominal paina
No 2237 (81.6) 46 (2.1) 1 (ref.)
Yes 63 (2.3) 8 (12.7) 7.34 (3.33 to 16.19)
Missing 440 (16.1) 6 (1.4)
Ear exam: any acute abnormalitya
No 1783 (65.1) 50 (2.8) 1 (ref.)
Yes 635 (23.2) 4 (0.6) 0.23 (0.08 to 0.64)
Missing 322 (11.8) 6 (1.9)
Dipstick: leucocytesa
Negative 2272 (82.9) 17 (0.7) 1 (ref.)
Trace 154 (5.6) 6 (3.9) 5.40 (2.10 to 13.9)
+ 110 (4.0) 2 (1.8) 2.47 (0.56 to 10.8)
++ 148 (5.4) 19 (12.8) 19.61 (9.95 to 38.6)
+++ 48 (1.8) 16 (33.3) 66.6 (30.9 to 143.3)
Missing 8 (0.3) 0 (0.0)
Dipstick: nitritesa
Negative 2658 (97.0) 35 (1.3) 1 (ref.)
Positive 74 (2.7) 25 (33.8) 38.4 (21.4 to 68.9)
Missing 8 (0.3) 0 (0.0)
Dipstick: blooda
Negative 2297 (83.8) 29 (1.3) 1 (ref.)
Non-haem 246 (9.0) 8 (3.3) 2.64 (1.19 to 5.84)
Haem trace 50 (1.8) 6 (12.0) 10.70 (4.23 to 27.08)
Haem + 67 (2.4) 4 (6.0) 4.98 (1.70 to 14.60)
Haem ++ or +++ 72 (2.6) 13 (18.1) 17.29 (8.56 to 34.94)
Missing 8 (0.3) 0 (0.0)
Ref., reference.
a Index tests independently associated with UTI in multivariable models. Missing values were assigned to the
modal category.
b All children column gives the percentage of observations within that category.
c ‘UTI positive’ column gives the percentage of positives relative to the number of observations within that category.
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TABLE 28 Clean-catch samples: ‘full’ coefficient models based on symptoms and signs and on symptoms, signs and
dipstick results, including results based on MI
Index tests
Symptoms and signs model Symptoms, signs and dipstick model
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Pain/crying when passing urine
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight problem 1.68 (0.64 to 4.41) 1.87 (0.70 to 4.99) 1.01 (0.30 to 3.45) 1.19 (0.34 to 4.11)
Moderate problem 5.81 (2.58 to 13.10) 6.06 (2.60 to 14.12) 3.26 (1.19 to 8.92) 3.55 (1.25 to 10.04)
Severe problem 21.69 (9.19 to 51.23) 23.79 (9.91 to 57.10) 15.23 (5.17 to 44.89) 16.55 (5.46 to 50.11)
Smelly urine
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight problem 5.08 (2.23 to 11.60) 5.30 (2.24 to 12.55) 3.70 (1.35 to 10.11) 3.99 (1.39 to 11.42)
Moderate problem 6.43 (3.07 to 13.46) 6.56 (2.99 to 14.37) 5.55 (2.33 to 13.23) 5.83 (2.30 to 14.77)
Severe problem 11.85 (4.60 to 30.57) 12.09 (4.58 to 31.90) 5.51 (1.64 to 18.46) 6.00 (1.72 to 20.90)
History of UTI
No 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 3.16 (1.46 to 6.83) 3.07 (1.40 to 6.72) 2.86 (1.15 to 7.11) 2.80 (1.13 to 6.96)
Cough
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight problem 1.33 (0.63 to 2.82) 1.37 (0.64 to 2.93) 1.33 (0.53 to 3.32) 1.37 (0.54 to 3.46)
Moderate problem 1.36 (0.65 to 2.86) 1.45 (0.68 to 3.10) 2.23 (0.94 to 5.29) 2.35 (0.98 to 5.64)
Severe problem 0.23 (0.06 to 0.92) 0.24 (0.06 to 0.97) 0.29 (0.05 to 1.60) 0.29 (0.05 to 1.64)
Clinician global impression of illness severity (0–10)
0–1 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
2 2.19 (0.94 to 5.14) 2.19 (0.92 to 5.17) 2.50 (0.92 to 6.77) 2.49 (0.90 to 6.87)
3 3.09 (1.32 to 7.23) 3.16 (1.32 to 7.55) 3.22 (1.19 to 8.74) 3.19 (1.15 to 8.85)
4–5 4.35 (1.73 to 10.92) 4.73 (1.86 to 12.04) 3.68 (1.22 to 11.12) 4.12 (1.34 to 12.62)
≥ 6 9.23 (2.91 to 29.28) 9.71 (2.98 to 31.61) 8.27 (2.04 to 33.57) 9.11 (2.18 to 37.97)
Abdominal exam: any abdominal pain
No 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 2.76 (1.04 to 7.34) 2.52 (0.95 to 6.72) 1.42 (0.34 to 6.01) 1.22 (0.29 to 5.19)
Ear exam: any acute abnormality
No 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Yes 0.25 (0.08 to 0.81) 0.22 (0.07 to 0.71) 0.40 (0.12 to 1.27) 0.34 (0.10 to 1.10)
Dipstick: leucocytes
Negative 1 (ref.) 1 (ref.)
Trace 2.04 (0.63 to 6.60) 1.99 (0.61 to 6.56)
+ 0.66 (0.11 to 3.94) 0.61 (0.10 to 3.92)
++ 7.38 (3.04 to 17.92) 7.24 (2.94 to 17.81)
+++ 16.78 (5.47 to 51.44) 16.62 (5.20 to 53.13)
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gradation of association with increasing illness severity. Leucocytes, nitrites and blood on dipstick testing
were strongly and independently associated with UTI. The increase in the AUROC while using the
symptoms, signs and dipstick model was around 0.06 for both the modal and the multiple imputation, and
the low p-value means that there is very strong evidence that the dipsticks increase the AUROC when
added to the symptoms and signs model. The validated multiple imputation AUROC for the symptoms and
signs model (0.876) demonstrated very good diagnostic accuracy (see Table 28). Adding dipstick findings
increased the validated AUROC to 0.903. For comparison, the AUROC for ‘clinician diagnosis’ was 0.774
(0.714 to 0.833). Figure 11 shows the multiple imputed ROC curves for the models with and without
dipstick urinalysis. Model calibration slopes were 0.832 (> 0.8 indicates a model with good calibration).
The upper section of Table 29 shows the diagnostic test characteristics corresponding to various choices
of cut-point for positivity using the coefficient-based symptoms and signs model, which could be used to
identify the children in whom urine collection is warranted. The risk scores for these cut-points can be
calculated using the parameters in Table 30. For a sensitivity of 60%, 70% or 80%, respective urine
sampling of approximately 5%, 7% or 13% of unwell children aged ≥ 2 years presenting to primary care
would be required. At these cut-points, urine samples would be positive for UTI in 27%, 23% and 13% of
children, with corresponding specificities of 96.3%, 94.6% and 88.3%. The lower section of Table 29
shows the diagnostic test characteristics for the model based on the symptoms, signs and dipstick test
results. If a decision to treat presumptively with antibiotics was made using the 80% sensitivity cut-point,
this model would improve the specificity from 88% to 94% and would reduce the overall number of
children treated from 13% to 8%, compared with the symptoms and signs only model.
TABLE 28 Clean-catch samples: ‘full’ coefficient models based on symptoms and signs and on symptoms, signs and
dipstick results, including results based on MI (continued )
Index tests
Symptoms and signs model Symptoms, signs and dipstick model
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Dipstick: nitrites
Negative 1 (ref.) 1 (ref.)
Positive 7.33 (3.09 to 17.40) 7.54 (3.12 to 18.23)
Dipstick: blood
Negative 1 (ref.) 1 (ref.)
Non-haem 0.86 (0.29 to 2.54) 0.86 (0.29 to 2.60)
Haem trace 5.54 (1.43 to 21.53) 5.42 (1.34 to 21.93)
Haem + 3.22 (0.85 to 12.23) 3.51 (0.90 to 13.63)
Haem ++ or +++ 1.90 (0.59 to 6.11) 1.94 (0.58 to 6.47)
AUROC (95% CI) 0.892 (0.84 to 0.94) 0.899 (0.85 to 0.95) 0.926 (0.89 to 0.96) 0.933 (0.90 to 0.97)
Validated AUROCb 0.871 0.876 0.904 0.903
Δ ROCc (95% CI) 0.034 (0.01 to 0.06) 0.034 (0.01 to 0.06)
Δ ROCc p-value 0.007 0.009
MI, multiple imputation; ref., reference.
a Missing values coded to modal category.
b Internal validation using the bootstrap procedure.
c The difference in ROC between symptoms and signs model and symptoms, signs and dipstick model.
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FIGURE 11 Clean-catch ROC curve for multiple imputation models for symptoms and signs only (solid line) and
symptoms, signs and dipstick (dotted line).
TABLE 29 Clean-catch diagnostic test characteristics (95% CI) for a range of cut-points, using both the symptoms
and signs model (upper part of table) and the symptoms, signs and dipstick model (lower part of table)
Risk score (≥) Sensitivity, % Specificity, % PPV, % NPV, % Children positive, %
Symptoms and signs model
–0.195 20.0 (11.7 to 32.0) 99.8 (99.5 to 99.9) 66.7 (42.9 to 84.2) 98.2 (97.7 to 98.7) 0.7 (0.4 to 1.0)
–0.87 30.0 (19.8 to 42.7) 99.5 (99.1 to 99.7) 56.3 (39.0 to 72.1) 98.4 (97.9 to 98.9) 1.2 (0.8 to 1.6)
–1.698 40.0 (28.5 to 52.8) 98.2 (97.6 to 98.6) 32.9 (23.1 to 44.4) 98.7 (98.1 to 99.0) 2.7 (2.1 to 3.3)
–1.98 50.0 (37.6 to 62.4) 97.5 (96.9 to 98.1) 31.3 (22.8 to 41.2) 98.9 (98.4 to 99.2) 3.5 (2.9 to 4.3)
–2.34 60.0 (47.2 to 71.5) 96.3 (95.5 to 97.0) 26.7 (19.9 to 34.7) 99.1 (98.6 to 99.4) 4.9 (4.2 to 5.8)
–2.75 70.0 (57.3 to 80.2) 94.6 (93.7 to 95.4) 22.6 (17.1 to 29.1) 99.3 (98.9 to 99.6) 6.8 (5.9 to 7.8)
–3.515 80.0 (68.0 to 88.3) 88.3 (87.0 to 89.4) 13.3 (10.1 to 17.2) 99.5 (99.1 to 99.7) 13.2 (12.0 to 14.5)
–3.884 85.0 (73.6 to 92.0) 83.9 (82.4 to 85.2) 10.6 (8.1 to 13.6) 99.6 (99.2 to 99.8) 17.6 (16.2 to 19.1)
–4.86 93.3 (83.5 to 97.5) 61.0 (59.1 to 62.8) 5.1 (3.9 to 6.6) 99.8 (99.4 to 99.9) 40.2 (38.4 to 42.0)
–5.7 96.7 (87.6 to 99.2) 37.8 (35.9 to 39.6) 3.4 (2.6 to 4.3) 99.8 (99.2 to 100.0) 63.0 (61.2 to 64.8)
–6.664 100 15.7 (14.4 to 17.1) 2.6 (2.0 to 3.3) 100 84.6 (83.2 to 85.9)
Symptoms, signs and dipstick model
1.43 20.0 (11.7 to 32.0) 99.9 (99.7 to 100.0) 85.7 (57.3 to 96.4) 98.2 (97.7 to 98.7) 0.5 (0.3 to 0.9)
0.321 40.0 (28.5 to 52.8) 99.9 (99.7 to 100.0) 88.9 (70.7 to 96.4) 98.7 (98.2 to 99.0) 1.0 (0.7 to 1.4)
–1.15 60.0 (47.2 to 71.5) 99.3 (98.8 to 99.5) 64.3 (51.0 to 75.7) 99.1 (98.7 to 99.4) 2.0 (1.6 to 2.6)
–3.275 80.0 (68.0 to 88.3) 93.8 (92.9 to 94.7) 22.5 (17.4 to 28.6) 99.5 (99.2 to 99.7) 7.8 (6.8 to 8.8)
–3.98 83.3 (71.7 to 90.8) 88.3 (87.0 to 89.5) 13.8 (10.6 to 17.7) 99.6 (99.2 to 99.8) 13.2 (12.0 to 14.6)
–5.237 96.7 (87.6 to 99.2) 66.3 (64.5 to 68.1) 6.0 (4.7 to 7.7) 99.9 (99.6 to 100.0) 35.0 (33.3 to 36.8)
–5.825 98.3 (89.1 to 99.8) 53.1 (51.2 to 54.9) 4.5 (3.5 to 5.7) 99.9 (99.5 to 100.0) 48.1 (46.2 to 49.9)
–6.69 100 29.5 (27.8 to 31.2) 3.1 (2.4 to 3.9) 100 71.2 (69.4 to 72.8)
NPV, negative predictive value; PPV, positive predictive value.
Results based on models using multiple imputation to deal with missing values.
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TABLE 30 Parameters to calculate risk score for the clean-catch ‘full’ coefficient-based models
Variables
Coefficients
Symptoms and signs model Symptoms, signs and dipstick model
Intercept –6.0152 –7.0011
Pain/crying when passing urine
No problem 0 0
Slight problem 0.6263 0.1734
Moderate problem 1.8009 1.2658
Severe problem 3.1693 2.8062
Smelly urine
No problem 0 0
Slight problem 1.6683 1.3838
Moderate problem 1.8805 1.7631
Severe problem 2.4923 1.7924
History of UTI
No 0 0
Yes 1.1227 1.0299
Cough
No problem 0 0
Slight problem 0.3156 0.3118
Moderate problem 0.3736 0.8541
Severe problem –1.4324 –1.2293
Clinician global impression of illness severity (0–10)a
0–1 0 0
2 0.7818 0.9103
3 1.1509 1.1613
4–5 1.5543 1.4148
≥ 6 2.2732 2.2090
Abdominal exam: any abdominal pain
No 0 0
Yes 0.9244 0.1987
Ear exam: any acute abnormality
No 0 0
Yes –1.5122 –1.0919
Dipstick: leucocytes
Negative 0
Trace 0.6904
+ –0.4912
++ 1.9791
+++ 2.8103
continued
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Clean-catch samples were available for 88, 91 and 612 children aged < 12, 12–23 and 24–35 months,
with UTI diagnosed in 4, 2 and 16 of these children, respectively. We acknowledge that the small number
of UTIs may have led to results from multiple imputation analyses being unstable and estimated AUROC
values being overoptimistic.
Fever and fever of unknown origin (clean-catch samples)
Table 31 shows that neither of the parent-reported fever variables met our clean-catch multivariable model
inclusion criteria on univariable analysis, that is they were not associated with UTI. None of the children
with a temperature of ≥ 38 °C and no other localising symptoms or signs providing a clean-catch sample
had a UTI.
Points-based models
Table 32 shows the ORs (95% CI) and AUROC (95% CI) for the dichotomised points-based models with
and without the dipstick tests and, for comparison, the AUROC for the respective full models. It shows the
relative (integer) contribution of symptoms, signs and dipstick to UTI and that the assigned points do
change with the addition of the dipstick tests. The table also shows that for symptoms and signs model,
the AUROC marginally falls from the full validated symptoms and signs model 0.867 to the dichotomised
coefficient-based points-based model-validated AUROC of 0.849 to the (non-bootstrapped) AUROC of
0.856 for the points-based model. The AUROC for the dichotomised symptoms, signs and dipstick points
models remain highly discriminatory at 0.900 and little different from the full symptoms, signs and dipstick
TABLE 30 Parameters to calculate risk score for the clean-catch ‘full’ coefficient-based models (continued )
Variables
Coefficients
Symptoms and signs model Symptoms, signs and dipstick model
Dipstick: nitrites
Negative 0
Positive 2.0204
Dipstick: blood
Negative 0
Non-haem –0.1465
Haem trace 1.6902
Haem + 1.2556
Haem ++ or +++ 0.6638
a 0= completely well, 10= extremely unwell.
TABLE 31 Fever and fever of unknown origin
Symptom Category
Complete cases Modal imputation
OR (95% CI) p-value OR (95% CI) p-value
Fever now or in past 24 hours:
unknown origin
No 1 (ref.) 0.464 1 (ref.) 0.876
Yes 2.36 (0.31 to 18.24) 1.18 (0.16 to 8.72)
Fever at any time during this illness:
unknown origin
No 1 (ref.) 0.163 1 (ref.) 0.484
Yes 3.42 (0.77 to 15.12) 1.74 (0.41 to 7.32)
Ref., reference.
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validated model AUROC of 0.903. The difference in AUROC for both the points- and coefficient-based
models was just over 0.04 and the low p-values show that there is very strong evidence that the dipsticks
do increase the AUROC when added to the symptoms and signs model. The calibration slopes of 0.95
indicate a very well-calibrated clean-catch points-based model.
The clean-catch model in under-3-year-olds (Table 33) is parametrically similar to the clean-catch model in
all children (see Table 32), as the ORs have overlapping CIs. In general the ORs are slightly higher within
the under-3-year-olds, except for pain/crying passing urine presence and absence of severe cough, which
are slightly lower. Given this evidence, we conclude that our model is applicable to all children under 5
with clean-catch samples.
Table 34 shows the diagnostic test characteristics [sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV)] and the proportion rule positive for different cut-points for the
points-based models for symptoms and signs, and symptoms, signs and dipstick results (based on
models using multiple imputation to deal with missing values). The cost-effectiveness analyses presented
in Chapter 6 suggest that the optimal threshold to sample urine would be the 51.7% sensitivity
(high specificity) threshold (shaded in green in Table 34). The cost-effectiveness analyses could not discern
the optimal antibiotic treatment strategy. Table 35 gives an illustrative example for 1000 children. It shows the
number of samples that would have to be collected and how many would have UTI present if a clinician used
the points-based model.
TABLE 32 Clean-catch points-based models using multiple imputation
Dichotomised
variables
Symptoms and signs model Symptoms, signs and dipstick model
Adjusted OR (95% CI) Points Adjusted OR (95% CI) Points
Pain/crying
passing urine
presence
5.46 (3.06 to 9.75) 2 3.27 (1.70 to 6.30) 2
Smelly urine
presence
6.83 (3.75 to 12.44) 2 5.20 (2.70 to 9.99) 2
UTI history 2.72 (1.33 to 5.55) 1 2.17 (0.94 to 5.02) 1
Absence of
severe cough
4.66 (1.37 to 15.92) 2 3.13 (0.88 to 11.08) 2
Severe illness
presencea
4.57 (1.77 to 11.79) 2 4.51 (1.61 to 12.66) 2
Dipstick:
leucocytes
positive
4.36 (2.22 to 8.56) 2
Dipstick: nitrites
positive
8.07 (3.90 to 16.70) 3
Dipstick: blood
positive
2.13 (1.12 to 4.05) 1
AUROC 0.860 (0.810 to 0.910) 0.856 (0.808 to 0.903) 0.902 (0.8 to 0.950) 0.900 (0.853 to 0.948)
Validated AUROC 0.849 0.892
Δ ROC curveb
(95% CI)
0.042 (0.01 to 0.07) 0.045 (0.02 to 0.07)
Δ ROC curveb
p-value
0.004 0.003
Calibration slope 0.947 0.942
a A score of ≥ 6 on the global impression scale.
b The difference in ROC curve between the symptoms and signs model and the symptoms, signs and dipstick model.
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TABLE 33 Clean-catch rule of points-based models using multiple imputation for under-3-year-olds
Dichotomised variables
Symptoms and signs model,
adjusted OR (95% CI)
Symptoms, signs and dipstick
model, adjusted OR (95% CI)
Pain/crying passing urine presence 4.27 (1.54 to 11.85) 2.32 (0.58 to 9.38)
Smelly urine presence 13.36 (3.92 to 45.48) 23.13 (4.60 to 116.46)
UTI history 3.76 (1.05 to 13.41) 2.61 (0.35 to 19.72)
Absence of severe cough 2.23 (0.44 to 11.31) 2.00 (0.28 to 14.42)
Severe illness presencea 8.42 (1.87 to 37.82) 18.17 (2.90 to 113.76)
Dipstick: leucocytes positive 13.63 (3.43 to 54.18)
Dipstick: nitrites positive 8.20 (2.15 to 31.28)
Dipstick: blood positive 3.32 (1.03 to 10.72)
a A score of ≥ 6 on the global impression scale.
TABLE 34 Clean-catch diagnostic test characteristics (95% CI) for a range of cut-points for the points-based model,
using both symptoms and signs model (upper part of table) and symptoms, signs and dipstick model (lower part
of table)
Cut point (≥) Sensitivity, % Specificity, % PPV, % NPV, % Children positive, %
Symptoms and signs model
7 8.3 (3.5 to 18.5) 99.7 (99.4 to 99.8) 35.7 (15.7 to 62.4) 98.0 (97.4 to 98.4) 0.5 (0.3 to 0.9)
6 43.3 (31.5 to 56.0) 96.4 (95.6 to 97.0) 21.1 (14.8 to 29.2) 98.7 (98.2 to 99.1) 4.5 (3.8 to 5.3)
5 51.7 (39.2 to 63.9) 94.6 (93.7 to 95.4) 17.7 (12.7 to 24.1) 98.9 (98.4 to 99.2) 6.4 (5.5 to 7.4)
4 80.0 (68.0 to 88.3) 78.1 (76.5 to 79.6) 7.6 (5.7 to 9.9) 99.4 (99.0 to 99.7) 23.2 (21.6 to 24.8)
3 85.0 (73.6 to 92.0) 74.4 (72.7 to 76.0) 6.9 (5.3 to 9.0) 99.6 (99.1 to 99.8) 26.9 (25.3 to 28.6)
2 98.3 (89.1 to 99.8) 16.9 (15.5 to 18.4) 2.6 (2.0 to 3.3) 99.8 (98.5 to 100.0) 83.4 (82.0 to 84.8)
1 100 15.9 (14.5 to 17.3) 2.6 (2.0 to 3.3) 100 84.5 (83.1 to 85.8)
Symptoms, signs and dipstick model
13 5.0 (1.6 to 14.4) 100 100 97.9 (97.3 to 98.4) 0.1 (0.0 to 0.3)
12 18.3 (10.5 to 30.2) 99.9 (99.7 to 100.0) 78.6 (50.6 to 92.9) 98.2 (97.6 to 98.6) 0.5 (0.3 to 0.9)
11 26.7 (17.0 to 39.2) 99.8 (99.6 to 99.9) 76.2 (54.0 to 89.7) 98.4 (97.8 to 98.8) 0.8 (0.5 to 1.2)
10 33.3 (22.6 to 46.1) 99.6 (99.3 to 99.8) 66.7 (48.4 to 81.0) 98.5 (98.0 to 98.9) 1.1 (0.8 to 1.6)
9 48.3 (36.1 to 60.8) 99.0 (98.5 to 99.3) 51.8 (38.9 to 64.5) 98.8 (98.4 to 99.2) 2.0 (1.6 to 2.6)
8 50.0 (37.6 to 62.4) 98.1 (97.5 to 98.5) 36.6 (26.9 to 47.5) 98.9 (98.4 to 99.2) 3.0 (2.4 to 3.7)
7 66.7 (53.9 to 77.4) 95.4 (94.6 to 96.2) 24.7 (18.7 to 31.9) 99.2 (98.8 to 99.5) 5.9 (5.1 to 6.9)
6 78.3 (66.2 to 87.0) 90.7 (89.5 to 91.8) 15.9 (12.1 to 20.5) 99.5 (99.1 to 99.7) 10.8 (9.7 to 12.0)
5 81.7 (69.8 to 89.5) 85.0 (83.6 to 86.3) 10.9 (8.3 to 14.1) 99.5 (99.1 to 99.7) 16.4 (15.1 to 17.9)
4 86.7 (75.5 to 93.2) 68.9 (67.1 to 70.6) 5.9 (4.5 to 7.6) 99.6 (99.1 to 99.8) 32.3 (30.6 to 34.1)
3 91.7 (81.5 to 96.5) 59.1 (57.3 to 61.0) 4.8 (3.7 to 6.2) 99.7 (99.2 to 99.9) 42.0 (40.1 to 43.8)
2 100 15.1 (13.8 to 16.5) 2.6 (2.0 to 3.3) 100 85.3 (83.9 to 86.5)
1 100 13.4 (12.1 to 14.7) 2.5 (2.0 to 3.2) 100 86.9 (85.6 to 88.1)
Shaded cells are the thresholds at which urine could be cost-effectively sampled (upper table).
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Added value of dipstick testing
Table 36 shows the diagnostic test characteristics (sensitivity, specificity, PPV and NPV) and the proportion
rule positive for different cut-points for the coefficient-based points-based models for any combination of
symptoms and signs.
Table 37 shows, for each symptom and sign combination, the probability of UTI (in this case, the modelled
PPV), the points total, the number of UTIs and total observations, and the absolute change in probability
using the dipstick model from our simulations. It shows that there is a clear trend towards an increased
change (both increasing and decreasing) in the UTI probability with added dipstick as the probability of
UTI post symptoms and signs increases. We then grouped the data into those symptoms and signs
combinations where we have or have not thought that urine sampling would be reasonable. The change
in probability for those in whom we would not suggest sampling (group 2) is very slight and clustered
around zero so dipstick testing would add very little diagnostic value. However, for those in whom we
would suggest urine sampling (group 1), there is a clinically important change in probability and dipstick
testing is worthwhile in the ID of those with and without a UTI.
Box 1 shows how the points-based model could be presented to practising clinicians and includes practical
guidance regarding when to obtain a urine sample. Data from Chapter 6 show it is not clear which of the
following antibiotic treatment strategies is most cost-effective: immediate presumptive treatment of all
sampled children, immediate dipstick guided treatment or treatment delayed until receipt of laboratory result.
Nappy pad models
Table 38 shows that 1.3% of children providing nappy pad samples met the criteria for a microbiological
diagnosis of UTI, of whom 82% were < 2 years and 48% were female, and that 92% of samples were
provided within 24 hours of index test measurement. Clinicians correctly identified 13% of the 30 UTIs.
‘Full’ coefficient-based model
Table 39 shows adjusted ORs for the index tests (footnote marker d in Table 38) selected for the nappy
pad model, for children predominantly < 2 years. Parent-reported smelly urine, darker urine, female sex
and the absence of a nappy rash were independently associated with UTI; for the first two of these there
was evidence of graded associations. No clinical examination findings were independently associated
with UTI in this age group. The presence of leucocytes and nitrites from dipstick urine testing were
independently associated with UTI, though more modestly than in clean-catch samples. The increase in
AUROC between the symptoms and signs model and the symptoms, signs and dipstick model was about
0.065 in the multiple imputation analysis. However, with a p-value of 0.035 there was only slight evidence
to suggest an increase in the AUROC when adding the dipsticks to the symptoms and signs model. The
symptoms and signs model had reasonable diagnostic accuracy (validated AUROC for the multiple imputed
model was 0.778) and diagnostic accuracy increased (validated AUROC 0.821) with addition of dipstick
findings. For comparison, the AUROC for ‘clinician diagnosis’ was 0.626 (95% CI 0.532 to 0.719).
TABLE 35 Outcome for illustrative 1000 children ≥ 2 years presenting unwell to primary care using ≥ 5 points
(sensitivity= 51.7%, specificity= 94.6%)
DUTY model UTI present UTI absent Total
Points based: collect urine 11 53 64
Points based: do not collect urine 11 926 936
Total 22 978 1000
Number of contaminated samples (data from Chapter 7; see Table 68).
≥ 105 CFU/ml ≥ 3 organisms (1.8% of 64)= 1.
≥ 105 CFU/ml ≥ 2 organisms (2.9% of 64)= 2.
≥ 104 CFU/ml ≥ 3 organisms (6.4% of 64)= 4.
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TABLE 36 Clean-catch diagnostic test characteristics (95% CI) for all possible cut-points of the coefficient-based
points-based model, using the symptoms and signs model
Combination Sensitivity, % Specificity, % PPV,a % NPV,b % Children positive, %
+,+,+,+,+ 0 100 100 97.8 (97.2 to 98.3) 0
+,+,+,+,– 0 100 100 97.8 (97.2 to 98.3) 0
+,+,+,–,+ 8.3 (3.5 to 18.5) 99.7 (99.5 to 99.9) 41.7 (18.5 to 69.2) 98.0 (97.4 to 98.4) 0.4 (0.2 to 0.8)
+,+,–,+,+ 8.3 (3.5 to 18.5) 99.7 (99.4 to 99.9) 38.5 (17.0 to 65.6) 98.0 (97.4 to 98.4) 0.5 (0.3 to 0.8)
+,–,+,+,+ 8.3 (3.5 to 18.5) 99.7 (99.4 to 99.9) 38.5 (17.0 to 65.6) 98.0 (97.4 to 98.4) 0.5 (0.3 to 0.8)
–,+,+,+,+ 11.7 (5.7 to 22.5) 99.7 (99.4 to 99.8) 43.8 (22.5 to 67.6) 98.1 (97.5 to 98.5) 0.6 (0.4 to 1.0)
+,+,+,–,– 41.7 (29.9 to 54.4) 96.8 (96.1 to 97.4) 22.5 (15.7 to 31.2) 98.7 (98.2 to 99.0) 4.1 (3.4 to 4.9)
+,+,–,+,– 41.7 (29.9 to 54.4) 96.8 (96.1 to 97.4) 22.5 (15.7 to 31.2) 98.7 (98.2 to 99.0) 4.1 (3.4 to 4.9)
+,–,+,+,– 41.7 (29.9 to 54.4) 96.6 (95.8 to 97.2) 21.4 (14.9 to 29.7) 98.7 (98.1 to 99.0) 4.3 (3.6 to 5.1)
–,+,+,+,– 43.3 (31.5 to 56.0) 96.3 (95.6 to 97.0) 21.0 (14.7 to 29.0) 98.7 (98.2 to 99.1) 4.5 (3.8 to 5.4)
+,+,–,–,+ 43.3 (31.5 to 56.0) 96.2 (95.4 to 96.8) 20.2 (14.1 to 28.0) 98.7 (98.2 to 99.1) 4.7 (4.0 to 5.6)
+,–,+,–,+ 48.3 (36.1 to 60.8) 95.5 (94.6 to 96.2) 19.3 (13.8 to 26.4) 98.8 (98.3 to 99.2) 5.5 (4.7 to 6.4)
+,–,–,+,+ 48.3 (36.1 to 60.8) 95.4 (94.6 to 96.2) 19.2 (13.7 to 26.3) 98.8 (98.3 to 99.2) 5.5 (4.7 to 6.4)
–,+,+,–,+ 51.7 (39.2 to 63.9) 94.8 (93.9 to 95.6) 18.2 (13.1 to 24.8) 98.9 (98.4 to 99.2) 6.2 (5.4 to 7.2)
–,+,–,+,+ 51.7 (39.2 to 63.9) 94.8 (93.9 to 95.6) 18.2 (13.1 to 24.8) 98.9 (98.4 to 99.2) 6.2 (5.4 to 7.2)
–,–,+,+,+ 53.3 (40.8 to 65.5) 94.4 (93.5 to 95.2) 17.7 (12.8 to 23.9) 98.9 (98.4 to 99.2) 6.6 (5.7 to 7.6)
+,+,–,–,– 53.3 (40.8 to 65.5) 93.5 (92.5 to 94.4) 15.6 (11.3 to 21.2) 98.9 (98.4 to 99.2) 7.5 (6.6 to 8.5)
+,–,+,–,– 65.0 (52.2 to 75.9) 87.0 (85.6 to 88.2) 10.1 (7.4 to 13.5) 99.1 (98.6 to 99.4) 14.2 (12.9 to 15.5)
+,–,–,+,– 65.0 (52.2 to 75.9) 86.8 (85.5 to 88.0) 9.9 (7.3 to 13.3) 99.1 (98.6 to 99.4) 14.3 (13.1 to 15.7)
–,+,+,–,– 76.7 (64.4 to 85.7) 80.2 (78.7 to 81.7) 8.0 (6.0 to 10.5) 99.4 (98.9 to 99.6) 21.0 (19.5 to 22.6)
–,+,–,+,– 76.7 (64.4 to 85.7) 80.1 (78.6 to 81.6) 8.0 (6.0 to 10.5) 99.4 (98.9 to 99.6) 21.1 (19.6 to 22.7)
–,–,+,+,– 81.7 (69.8 to 89.5) 77.8 (76.2 to 79.3) 7.6 (5.8 to 9.9) 99.5 (99.1 to 99.7) 23.5 (22.0 to 25.1)
+,–,–,–,+ 81.7 (69.8 to 89.5) 77.6 (76.0 to 79.1) 7.5 (5.7 to 9.8) 99.5 (99.1 to 99.7) 23.7 (22.2 to 25.4)
–,+,–,–,+ 81.7 (69.8 to 89.5) 77.2 (75.6 to 78.8) 7.4 (5.7 to 9.7) 99.5 (99.0 to 99.7) 24.1 (22.5 to 25.7)
–,–,+,–,+ 85.0 (73.6 to 92.0) 74.5 (72.8 to 76.1) 6.9 (5.3 to 9.0) 99.6 (99.1 to 99.8) 26.8 (25.2 to 28.5)
–,–,–,+,+ 85.0 (73.6 to 92.0) 74.4 (72.7 to 76.0) 6.9 (5.3 to 9.0) 99.6 (99.1 to 99.8) 26.9 (25.3 to 28.6)
+,–,–,–,– 88.3 (77.5 to 94.3) 70.0 (68.3 to 71.7) 6.2 (4.8 to 8.0) 99.6 (99.2 to 99.8) 31.2 (29.5 to 33.0)
–,+,–,–,– 88.3 (77.5 to 94.3) 67.3 (65.5 to 69.1) 5.7 (4.4 to 7.4) 99.6 (99.2 to 99.8) 33.9 (32.2 to 35.7)
–,–,+,–,– 96.7 (87.6 to 99.2) 17.3 (15.9 to 18.8) 2.6 (2.0 to 3.3) 99.6 (98.3 to 99.9) 83.0 (81.5 to 84.4)
–,–,–,+,– 98.3 (89.1 to 99.8) 16.9 (15.5 to 18.3) 2.6 (2.0 to 3.3) 99.8 (98.5 to 100.0) 83.5 (82.0 to 84.8)
–,–,–,–,+ 100 15.9 (14.6 to 17.3) 2.6 (2.0 to 3.3) 100 84.5 (83.0 to 85.8)
–,–,–,–,– 100 0 2.2 (1.7 to 2.8) 100 100
a Positive predictive value.
b Negative predictive value.
If a test was present it is marked as +; if it was negative it is marked –. The first descriptor is for smelly urine, the second
for if pain passing urine is present, the third if severe cough is absent, the fourth if there is severe illness, and the fifth if
there is history of UTI.
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TABLE 37 Additional diagnostic value of dipstick testing and also the prevalence of each combination of symptoms
and signs (clean-catch samples)
Signs and
symptomsa Modelled PPVb Points total UTI/total
Absolute change in probability;
median (2.5th and 97.5 percentiles) Groupingc
+,+,+,+,+ 0.731 9 0/0 0.239 (0.043, 0.433) 1
+,+,+,+,– 0.500 8 0/1 0.336 (0.039, 0.436) 1
+,+,+,–,+ 0.372 7 7/17 0.286 (0.081, 0.503) 1
+,+,–,+,+ 0.368 7 0/1 0.248 (0.004, 0.542) 1
+,–,+,+,+ 0.332 7 0/0 0.217 (0.030, 0.575) 1
–,+,+,+,+ 0.284 7 0/1 0.209 (0.022, 0.575) 1
+,+,+,–,– 0.179 6 19/101 0.138 (0.020, 0.585) 1
+,+,–,+,– 0.176 6 0/0 0.118 (0.038, 0.647) 1
+,–,+,+,– 0.155 6 0/7 0.098 (0.042, 0.523) 1
–,+,+,+,– 0.128 6 1/9 0.091 (0.013, 0.610) 1
+,+,–,–,+ 0.113 5 0/4 0.084 (0.003, 0.579) 1
+,–,+,–,+ 0.098 5 2/23 0.070 (0.014, 0.585) 1
+,–,–,+,+ 0.096 5 0/1 0.056 (0.015, 0.497) 1
–,+,+,–,+ 0.080 5 2/22 0.062 (0.007, 0.495) 1
–,+,–,+,+ 0.078 5 0/0 0.053 (0.024, 0.583) 1
–,–,+,+,+ 0.068 5 0/6 0.043 (0.017, 0.400) 1
+,+,–,–,– 0.045 4 0/6 0.031 (0.012, 0.464) 2
+,–,+,–,– 0.038 4 8/202 0.025 (0.011, 0.280) 2
+,–,–,+,– 0.038 4 0/4 0.019 (0.001, 0.364) 2
–,+,+,–,– 0.031 4 6/198 0.023 (0.004, 0.353) 2
–,+,–,+,– 0.030 4 0/0 0.019 (0.005, 0.267) 2
–,–,+,+,– 0.026 4 3/69 0.015 (0.002, 0.262) 2
+,–,–,–,+ 0.023 3 0/5 0.014 (0.004, 0.056) 2
–,+,–,–,+ 0.018 3 0/4 0.013 (0.006, 0.151) 2
–,–,+,–,+ 0.016 3 3/81 0.010 (0.004, 0.033) 2
–,–,–,+,+ 0.015 3 0/1 0.007 (0.001, 0.054) 2
+,–,–,–,– 0.008 2 2/75 0.004 (0.000, 0.029) 2
–,+,–,–,– 0.007 2 0/21 0.004 (0.001, 0.017) 2
–,–,+,–,– 0.006 2 6/1424 0.003 (0.000, 0.017) 2
–,–,–,+,– 0.006 2 1/14 0.002 (0.002, 0.027) 2
–,–,–,–,+ 0.003 1 0/25 0.002 (0.000, 0.013) 2
–,–,–,–,– 0.001 0 0/418 0.000 (0.000, 0.006) 2
Grouping
Weighted;
median UTI/total
Weighted; median
(2.5th, 97.5th percentiles)
1 0.179 31/193 0.108 (0.013, 0.585)
2 0.006 29/2547 0.003 (0.000, 0.041)
a First plus if smelly urine is present, second plus if pain passing urine is present, third plus if severe cough is absent,
fourth plus if there is severe illness, fifth plus if there is history of UTI.
b Positive predictive value.
c 1= points-based model suggests urine collection cost-effective (≥ 5 points); 2= do not collect urine (< 5 points).
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BOX 1 Final DUTY Clean-Catch Urine Criteria
1. The DUTY Clean-Catch Urine Criteria are for children in whom a clean-catch sample is possible (usually children
≥ 2 years).
2. Use the symptoms and signs in Table A to decide if a clean-catch urine should be collected (≥ 5 points or can be
operationalised as ‘any three of the five’ symptoms and signs has been shown to be cost-effective). Clinicians
concerned about overdiagnosis and treatment can select a higher specificity (at least six points) threshold. Higher
sensitivity thresholds (e.g. ≥ 3 points or ≥ 4 points) would reduce underdiagnosis, but these thresholds have not
been shown to be cost-effective.
3. It is not clear which of the following possible antibiotic treatment strategies is most cost effective: (1) immediate
presumptive treatment of all sampled children; (2) immediate dipstick-guided treatment; or (3) laboratory guided
(delayed) treatment.
4. For children urine sampled at the ≥ 5-point threshold, the probability of UTI will be 18%. Although not
demonstrably cost-effective, dipstick testing can raise or lower this probability (Table B).
5. Consider advising all (urine and non-urine sampled) children’s parents to seek medical advice if their child
gets worse.
6. The DUTY Clean-Catch Urine Criteria are designed to supplement and not replace clinical judgement.
TABLE A Points to select children for urine sampling
Clinical characteristic (present/absent) Pointsa
Symptoms and signs To guide urine collection
Pain/crying passing urine presence 2
Smelly urine presence 2
UTI history 1
Absence of severe cough 2
Severe illness presenceb 2
Collect clean-catch urine if symptoms and signs points
total ≥ 5 or ‘any three of the five’
a Refer to Table 36 (upper) for probability of UTI with any total score.
b Score of ≥ 6 on the clinician global illness severity scale (range 0–10).
TABLE B Points to select children for antibiotic treatment
Clinical characteristic (present/absent) Pointsa
Symptoms, signs and dipstick To guide antibiotic treatment
Pain/crying passing urine presence 2
Smelly urine presence 2
UTI history 1
Absence of severe cough 2
Severe illness presenceb 2
Dipstick: leucocytes positive 2
Dipstick: nitrites positive 3
Dipstick: blood positive 1
a Refer to Table 36 for probability of UTI with total score.
b Score of ≥ 6 on the clinician global illness severity scale (range 0–10).
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TABLE 38 Nappy pad samples: children’s characteristics and crude ORs for index tests associated with UTI
Demographics/index testsa n (%)b UTI (%)c Crude OR (95% CI)d
Total 2277 30 (1.3)
Age of child
< 6 months 369 (16.2) 5 (1.4) 1.72 (0.54 to 5.46)
6 to < 12 months 603 (26.5) 11 (1.8) 2.33 (0.90 to 6.04)
1 to < 2 years 884 (38.8) 7 (0.8) 1 (ref.)
2 to < 3 years 353 (15.5) 7 (2.0) 2.53 (0.88 to 7.28)
3 to < 4 years 58 (2.5) 0 (0.0) N/A
≥ 4 years 10 (0.4) 0 (0.0) N/A
Time from index tests to taking urine sample
Sample before recruitment 120 (5.3) 2 (1.7) 1.33 (0.31 to 5.67)
< 24 hours 1982 (87.0) 25 (1.3) 1 (ref.)
24 hours to < 48 hours 109 (4.8) 3 (2.8) 2.22 (0.66 to 7.45)
48 hours to < 72 hours 18 (0.8) 0 (0.0) N/A
≥ 72 hours 48 (2.1) 0 (0.0) N/A
Clinician diagnosis prior to dipstick
No UTI certain to very certain 1033 (45.4) 8 (0.8) 0.52 (0.22 to 1.19)
Uncertain or no UTI fairly certain 1201 (52.7) 18 (1.5) 1 (ref.)
UTI fairly to very certain 38 (1.7) 4 (10.5) 7.76 (2.49 to 24.18)
Missing 5 (0.2) 0 (0.0)
Gendera
Male 1183 (52.0) 9 (0.8) 1 (ref.)
Female 1094 (48.0) 21 (1.9) 2.55 (1.16 to 5.60)
Smelly urinea
No problem 1518 (66.7) 12 (0.8) 1 (ref.)
Slight problem 206 (9.0) 4 (1.9) 2.20 (0.73 to 6.61)
Moderate problem 138 (6.1) 5 (3.6) 4.18 (1.52 to 11.50)
Severe problem 26 (1.1) 4 (15.4) 20.21 (6.29 to 64.97)
Missing/not known 389 (17.1) 5 (1.3)
Darker urinea
No problem 1764 (77.5) 19 (1.1) 1 (ref.)
Slight problem 83 (3.6) 2 (2.4) 2.19 (0.51 to 9.43)
Moderate or severe problem 41 (1.8) 4 (9.8) 9.59 (3.17 to 29.02)
Missing/not known 389 (17.1) 5 (1.3)
continued
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TABLE 38 Nappy pad samples: children’s characteristics and crude ORs for index tests associated
with UTI (continued )
Demographics/index testsa n (%)b UTI (%)c Crude OR (95% CI)d
Nappy rasha
No problem 1715 (75.3) 29 (1.7) 1 (ref.)
Slight to severe problem 560 (24.6) 1 (0.2) 0.10 (0.01 to 0.77)
Missing 2 (0.1) 0 (0.0)
Dipstick: leucocytesa
Negative 1759 (77.3) 13 (0.7) 1 (ref.)
Trace 125 (5.5) 1 (0.8) 1.09 (0.14 to 8.38)
+ 119 (5.2) 4 (3.4) 4.69 (1.50 to 14.61)
++ 177 (7.8) 4 (2.3) 3.12 (1.01 to 9.66)
+++ 91 (4.0) 8 (8.8) 12.99 (5.24 to 32.20)
Missing 6 (0.3) 0 (0.0)
Dipstick: nitritesa
Negative 1916 (84.1) 13 (0.7) 1 (ref.)
Positive 355 (15.6) 17 (4.8) 7.39 (3.55 to 15.35)
Missing 6 (0.3) 0 (0.0)
N/A, not applicable; ref., reference.
a Index tests independently associated with UTI in multivariable models.
b Total column gives the percentage of observations within that category.
c UTI column gives the percentage of positives relative to the number of observations within that category.
d Index tests associated with UTI.
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TABLE 39 Nappy pad samples: models based on symptoms and signs, and on symptoms, signs and dipstick results,
including results based on multiple imputation
Index tests
Symptoms and signs model Symptoms, signs and dipstick model
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Adjusted OR
(95% CI)a
MI adjusted OR
(95% CI)
Gender
Male 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Female 2.61 (1.16 to 5.83) 2.45 (1.08 to 5.55) 1.71 (0.71 to 4.08) 1.70 (0.70 to 4.11)
Smelly urine
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight problem 1.99 (0.64 to 6.17) 2.47 (0.77 to 7.91) 1.76 (0.54 to 5.78) 2.28 (0.68 to 7.68)
Moderate problem 3.75 (1.21 to 11.65) 5.11 (1.66 to 15.76) 3.26 (0.98 to 10.87) 4.64 (1.39 to 15.53)
Severe problem 17.81 (4.82 to 65.86) 22.04 (6.05 to 80.25) 8.42 (2.03 to 34.88) 12.94 (3.20 to 52.30)
Darker urine
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight problem 2.51 (0.55 to 11.49) 2.50 (0.56 to 11.22) 2.50 (0.51 to 12.30) 2.52 (0.52 to 12.21)
Moderate or severe
problem
3.66 (0.97 to 13.82) 2.98 (0.81 to 10.96) 3.59 (0.90 to 14.42) 3.19 (0.82 to 12.37)
Nappy rash
No problem 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.)
Slight to severe
problem
0.07 (0.01 to 0.55) 0.07 (0.01 to 0.52) 0.08 (0.01 to 0.59) 0.07 (0.01 to 0.56)
Dipstick: leucocytes
Negative 1 (ref.) 1 (ref.)
Trace 0.80 (0.10 to 6.37) 0.74 (0.09 to 6.13)
+ 3.06 (0.88 to 10.68) 3.01 (0.83 to 10.91)
++ 2.13 (0.62 to 7.30) 2.25 (0.65 to 7.84)
+++ 6.23 (2.20 to 17.67) 5.53 (1.90 to 16.10)
Dipstick: nitrites
Negative 1 (ref.) 1 (ref.)
Positive 5.93 (2.72 to 12.93) 6.35 (2.86 to14.12)
ROC (95% CI) 0.769 (0.68 to 0.85) 0.805 (0.72 to 0.89) 0.858 (0.79 to 0.93) 0.870 (0.80 to 0.94)
Validated ROCb 0.744 0.778 0.799 0.821
Δ ROCc (95% CI) 0.089 (0.02 to 0.16) 0.065 (0.00 to 0.13)
Δ ROCc p-value 0.012 0.036
Calibration slopec 0.695 0.749 0.647 0.708
MI, multiple imputation; ref., reference.
a Missing values coded to modal category.
b Internal validation using the bootstrap procedure.
c The difference in ROC between the symptoms and signs model and the symptoms, signs and dipstick model.
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Figure 12 shows the multiple imputed ROC curves for the models with and without dipstick urinalysis.
The calibration slopes being around 0.7 shows that we have a large degree of overoptimism in our nappy
pad models.
The upper section of Table 36 shows the diagnostic test characteristics corresponding to various choices of
cut-point for positivity using the symptoms and signs model, which could be used to identify the children
in whom urine collection is warranted. The risk scores for these cut-points can be calculated using the
parameters in Table 40. For a sensitivity of 50%, 63% or 90%, respective urine sampling of approximately
9%, 20% or 43% of unwell children aged < 2 years presenting to primary care would be required.
At these cut-points, urine samples would be positive for UTI in 8%, 4% and 3% of children, with
corresponding specificities of 92%, 81% and 58%. The lower section of Table 36 shows the diagnostic
test characteristics for the model based on the symptoms, signs and dipstick test results. If a decision to
treat presumptively with antibiotics was made using the (only comparable) 63% sensitivity cut-point, this
model would improve the specificity from 81% to 91% and would reduce the overall number of children
treated from 20% to 10%, compared with the symptoms and signs only model. However, as discussed in
Chapter 6, the cost-effectiveness of this strategy is not clear.
Fever and fever of unknown origin (nappy pad samples)
Table 41 shows that neither of the parent-reported fever variables met our nappy pad multivariable model
inclusion criteria on univariable analysis, that is they were not associated with UTI. None of the children
with a temperature of ≥ 38 °C and no other localising symptoms or signs providing a nappy pad sample
had a UTI.
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FIGURE 12 Nappy pad ROC curve from multiple imputation for symptoms and signs only (solid line) and symptoms,
signs and dipstick (dotted line).
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TABLE 40 Parameters to calculate risk score for the nappy pad ‘full’ coefficient-based models
Index tests
Coefficients
Symptoms and signs model Symptoms, signs and dipstick model
Intercept –5.2709 –6.0041
Gender
Male 0 0
Female 0.8972 0.5293
Smelly urine
No problem 0 0
Slight problem 0.9042 0.8251
Moderate problem 1.6310 1.5343
Severe problem 3.0927 2.5601
Darker urine
No problem 0 0
Slight problem 0.9166 0.9243
Moderate or severe problem 1.0913 1.1598
Nappy rash
No problem 0 0
Slight to severe problem –2.6792 –2.6098
Dipstick: leucocytes
Negative 0
Trace –0.2988
+ 1.1029
++ 0.8105
+++ 1.7095
Dipstick: nitrites
Negative 0
Positive 1.8488
TABLE 41 Relationship between fever of unknown origin and UTI in nappy pad samples
Symptom Category
Complete cases Modal imputation
OR (95% CI) p-value OR (95% CI) p-value
Fever now in or in past 24 hours:
unknown origin
No 1 (ref.) 0.064 1 (ref.) 0.310
Yes 17.6 (1.55 to 199.9) 3.48 (0.45 to 26.72)
Fever at any time during this illness:
unknown origin
No 1 (ref.) 0.092 1 (ref.) 0.339
Yes 12.5 (1.15 to 135.4) 3.19 (0.42 to 24.39)
Ref., reference.
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Points-based models
Table 42 shows the points-based multiple imputation model ORs (95% CIs) using the dichotomised
symptoms, with and without dichotomised dipstick test results, along with their corresponding integer-based
points and the AUROCs for the dichotomised coefficient and points models. These show that, while not
as discriminatory as the clean-catch models, the points-based model AUROCs, remain similar to the
dichotomised coefficient AUROCs and to the full validated model AUROCs with and without the dipstick
tests. It is also noteworthy that the ‘darker urine’ and ‘absence of nappy rash’ points change on the addition
of the dipstick tests to the model, such that clinicians would need to retotal the points in the nappy pad
points-based model in the light of the dipstick results. The difference in AUROC for both the points- and
coefficient-based points-based models was around 0.06, and the low p-values show that there was only
slight evidence that the dipsticks do increase the AUROC when added to the symptoms and signs model. The
calibration slopes being over 0.85 in these points-based models shows that we have good calibration in the
points-based nappy pad models.
Table 43 shows the diagnostic test characteristics (sensitivity, specificity, PPV and NOPV) and the proportion
rule positive for different cut points for the coefficient-based models. Similarly, Table 44 shows the
diagnostic test characteristics (sensitivity, specificity, PPV and NPV) and the proportion rule positive for
different cut-points for the points-based models for symptoms, and symptoms and dipstick results (based
on models using multiple imputation to deal with missing values). This shows that if clinicians were willing
to collect nappy pad samples on 13.4% of younger (< 2 years) preschool children, they would need to use
a cut-point of ≥ 5 with an achieved sensitivity of 53.3%, that is a sensitivity considerably higher than
‘clinician diagnosis’ alone in this age group. However, as we discuss in Chapter 6, the cost-effectiveness of
this strategy is not clear. Table 45 shows the diagnostic test characteristics (sensitivity, specificity, PPV and
NPV) and the proportion rule positive for different cut points for the coefficient-based points-based models
for the symptoms and signs model for any combination of symptoms and signs.
Table 45 shows the diagnostic characteristics of all possible combinations of symptoms and signs for the
dichotomised nappy pad model.
TABLE 42 Nappy pad points-based dichotomised models with and without dipstick test
Dichotomised
variables
Symptoms and signs model Symptoms, signs and dipstick model
Adjusted OR (95% CI) Points Adjusted OR (95% CI) Points
Female 2.48 (1.12 to 5.51) 1 1.88 (0.81 to 4.37) 1
Smelly urine
presence
4.77 (2.14 to 10.61) 2 4.62 (2.02 to 10.53) 2
Darker urine
presence
3.19 (1.20 to 8.49) 1 2.80 (0.99 to 7.95) 2
Absence of nappy
rash
12.74 (1.71 to 94.62) 3 13.96 (1.84 to 105.60) 4
Dipstick: leucocytes
positive
2.89 (1.31 to 6.40) 2
Dipstick: nitrites
positive
6.09 (2.82 to 13.15) 3
AUROC 0.801 (0.716 to 0.885) 0.799 (0.714 to 0.884) 0.860 (0.793 to 0.927) 0.862 (0.795 to 0.927)
Validated AUROC 0.795 0.842
Δ ROCa (95% CI) 0.059 (0.00 to 0.12) 0.062 (0.00 to 0.12)
Δ ROCa p-value 0.019 0.046
Calibration slope 0.887 0.866
a The difference in ROC between the symptoms and signs model and the symptoms, signs and dipstick model.
A CLINICAL ALGORITHM TO GUIDE DIAGNOSIS OF UTI IN PRE-SCHOOL CHILDREN
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
TABLE 43 Nappy pad diagnostic test characteristics (95% CI) for a range of cut-points using both the symptoms
and signs model (upper part of table) and the symptoms, signs and dipstick model (lower part of table)
Risk score (≥) Sensitivity, % Specificity, % PPV, % NPV, % Children positive, %
Symptoms and signs model
–1.64 20.0 (9.3 to 37.9) 99.6 (99.2 to 99.8) 40.0 (19.2 to 65.2) 98.9 (98.4 to 99.3) 0.7 (0.4 to 1.1)
–2.55 30.0 (16.4 to 48.3) 99.0 (98.5 to 99.3) 28.1 (15.3 to 45.8) 99.1 (98.6 to 99.4) 1.4 (1.0 to 2.0)
–2.76 40.0 (24.3 to 58.1) 97.0 (96.2 to 97.6) 15.2 (8.8 to 24.9) 99.2 (98.7 to 99.5) 3.5 (2.8 to 4.3)
–3.46 40.0 (24.3 to 58.1) 95.1 (94.1 to 95.9) 9.8 (5.6 to 16.4) 99.2 (98.7 to 99.5) 5.4 (4.5 to 6.4)
–3.54 50.0 (32.8 to 67.2) 91.9 (90.7 to 93.0) 7.6 (4.6 to 12.2) 99.3 (98.8 to 99.6) 8.7 (7.6 to 9.9)
–3.64 53.3 (35.8 to 70.1) 90.0 (88.7 to 91.2) 6.6 (4.1 to 10.6) 99.3 (98.8 to 99.6) 10.6 (9.4 to 11.9)
–4.36 60.0 (41.9 to 75.7) 83.7 (82.1 to 85.2) 4.7 (3.0 to 7.3) 99.4 (98.9 to 99.6) 16.9 (15.4 to 18.5)
–4.37 63.3 (45.1 to 78.4) 80.6 (79.0 to 82.2) 4.2 (2.7 to 6.5) 99.4 (98.9 to 99.7) 19.9 (18.3 to 21.6)
–4.4 90.0 (73.2 to 96.7) 57.9 (55.8 to 59.9) 2.8 (1.9 to 4.0) 99.8 (99.3 to 99.9) 42.8 (40.8 to 44.8)
–5.3 96.7 (79.8 to 99.5) 24.1 (22.4 to 25.9) 1.7 (1.2 to 2.4) 99.8 (98.7 to 100.0) 76.2 (74.4 to 77.9)
Symptoms, signs and dipstick model
–1 20.0 (9.3 to 37.9) 99.8 (99.5 to 99.9) 54.5 (26.8 to 79.7) 98.9 (98.4 to 99.3) 0.5 (0.3 to 0.9)
–1.6 40.0 (24.3 to 58.1) 99.5 (99.1 to 99.7) 50.0 (31.0 to 69.0) 99.2 (98.7 to 99.5) 1.1 (0.7 to 1.6)
–3.626 63.3 (45.1 to 78.4) 91.0 (89.8 to 92.1) 8.6 (5.6 to 13.1) 99.5 (99.0 to 99.7) 9.7 (8.6 to 11.0)
–4.16 80.0 (62.1 to 90.7) 83.6 (82.0 to 85.1) 6.1 (4.1 to 9.0) 99.7 (99.3 to 99.9) 17.2 (15.7 to 18.8)
–5.48 93.3 (76.9 to 98.3) 50.8 (48.7 to 52.8) 2.5 (1.7 to 3.6) 99.8 (99.3 to 100.0) 49.8 (47.8 to 51.9)
–5.955 96.7 (79.8 to 99.5) 44.5 (42.5 to 46.6) 2.3 (1.6 to 3.3) 99.9 (99.3 to 100.0) 56.0 (53.9 to 58.0)
–6.02 100 22.7 (21.0 to 24.4) 1.7 (1.2 to 2.4) 100 77.6 (75.9 to 79.3)
Results based on models using multiple imputation to deal with missing values.
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TABLE 44 Nappy pad diagnostic test characteristics (95% CI) for a range of cut-points of the points-based model
using both the symptoms and signs model (upper part of the table) and the symptoms, signs and dipstick model
(lower part of the table)
Cut-point (≥) Sensitivity, % Specificity, % PPV, % NPV, % Children positive, %
Symptoms and signs model
7 13.3 (5.1 to 30.6) 99.4 (99.0 to 99.6) 22.2 (8.6 to 46.5) 98.8 (98.3 to 99.2) 0.8 (0.5 to 1.3)
6 43.3 (27.1 to 61.2) 94.0 (92.9 to 94.9) 8.8 (5.2 to 14.5) 99.2 (98.7 to 99.5) 6.5 (5.6 to 7.6)
5 53.3 (35.8 to 70.1) 87.1 (85.7 to 88.5) 5.2 (3.2 to 8.4) 99.3 (98.8 to 99.6) 13.4 (12.1 to 14.9)
4 90.0 (73.2 to 96.7) 57.8 (55.7 to 59.8) 2.8 (1.9 to 4.0) 99.8 (99.3 to 99.9) 42.9 (40.8 to 44.9)
3 96.7 (79.8 to 99.5) 21.2 (19.6 to 23.0) 1.6 (1.1 to 2.3) 99.8 (98.5 to 100.0) 79.0 (77.3 to 80.6)
2 96.7 (79.8 to 99.5) 18.7 (17.2 to 20.4) 1.6 (1.1 to 2.2) 99.8 (98.3 to 100.0) 81.5 (79.8 to 83.0)
1 96.7 (79.8 to 99.5) 9.3 (8.1 to 10.5) 1.4 (1.0 to 2.0) 99.5 (96.7 to 99.9) 90.8 (89.6 to 91.9)
Symptoms, signs and dipstick model
14 6.7 (1.7 to 23.1) 100 (99.7 to 100.0) 66.7 (15.4 to 95.7) 98.8 (98.2 to 99.1) 0.1 (0.0 to 0.4)
13 6.7 (1.7 to 23.1) 100 (99.7 to 100.0) 66.7 (15.4 to 95.7) 98.8 (98.2 to 99.1) 0.1 (0.0 to 0.4)
12 23.3 (11.6 to 41.5) 99.5 (99.1 to 99.7) 38.9 (19.8 to 62.1) 99.0 (98.5 to 99.3) 0.8 (0.5 to 1.3)
11 33.3 (19.0 to 51.6) 98.8 (98.3 to 99.2) 27.0 (15.2 to 43.3) 99.1 (98.6 to 99.4) 1.6 (1.2 to 2.2)
10 40.0 (24.3 to 58.1) 96.0 (95.1 to 96.7) 11.8 (6.8 to 19.6) 99.2 (98.7 to 99.5) 4.5 (3.7 to 5.4)
9 53.3 (35.8 to 70.1) 92.5 (91.3 to 93.5) 8.6 (5.4 to 13.7) 99.3 (98.9 to 99.6) 8.1 (7.1 to 9.3)
8 66.7 (48.4 to 81.0) 88.9 (87.6 to 90.2) 7.4 (4.8 to 11.2) 99.5 (99.1 to 99.7) 11.8 (10.6 to 13.2)
7 80.0 (62.1 to 90.7) 74.9 (73.1 to 76.6) 4.1 (2.8 to 6.0) 99.6 (99.2 to 99.8) 25.8 (24.1 to 27.7)
6 83.3 (65.7 to 92.9) 66.0 (64.1 to 68.0) 3.2 (2.2 to 4.7) 99.7 (99.2 to 99.9) 34.6 (32.7 to 36.6)
5 96.7 (79.8 to 99.5) 47.6 (45.5 to 49.6) 2.4 (1.7 to 3.4) 99.9 (99.3 to 100.0) 53.0 (51.0 to 55.1)
4 100 20.0 (18.4 to 21.7) 1.6 (1.1 to 2.3) 100 80.3 (78.6 to 81.9)
3 100 14.2 (12.8 to 15.7) 1.5 (1.1 to 2.2) 100 86.0 (84.5 to 87.4)
2 100 11.3 (10.1 to 12.7) 1.5 (1.0 to 2.1) 100 88.8 (87.4 to 90.0)
1 100 6.9 (6.0 to 8.1) 1.4 (1.0 to 2.0) 100 93.1 (92.0 to 94.1)
Results based on models using multiple imputation to deal with missing values.
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Discussion
Summary of findings
Based on a large cohort of children in the first 4 years of life presenting with acute illness to primary care,
2.2% and 1.3% of urine samples obtained by clean-catch and nappy pad methods met criteria for a
microbiological diagnosis of UTI in the research laboratory. In children providing clean-catch samples
(predominantly aged ≥ 2 years), four symptoms and three signs were independently associated with a
microbiological diagnosis of UTI, with a combined validated AUROC of 0.876. Diagnostic accuracy
increased to 0.903 with the addition of three dipstick results and the added value of dipstick testing
increased with increasing UTI probability post symptoms and signs. In children providing nappy pad
samples (predominantly aged < 2 years), four symptoms (one in common with clean catch, ‘smelly urine’)
and no signs were associated with a microbiological diagnosis of UTI. Validated AUROCs were more
modest: 0.778 for symptoms and signs, increasing to 0.821 with the addition of two dipstick test results.
Both of the symptom/signs models provide better diagnostic accuracy than ‘clinical diagnosis’ in identifying
the children warranting urine sampling, with the clean-catch model outperforming the nappy pad model
[clean-catch AUROC 0.744 (95% CI 0.714 to 0.833), nappy pad AUROC 0.626 (95% CI 0.532 to 0.719)].
Dipstick testing provides additional diagnostic utility for treatment decisions. Simplification of full
coefficient-based models into dichotomised points-based models resulted in modest reductions in
diagnostic utility (as discussed in Chapter 6, Comparison of testing and treatment strategies for the
clean-catch DUTY5% strategy), but greater immediate clinical accessibility. Also of note is that the
calibration slope and difference between the AUROC and validated AUROC are better in the points-based
models. Neither ‘fever’ nor ‘fever of unknown origin’ was found to be useful for diagnosing UTI.
TABLE 45 Nappy pad diagnostic test characteristics (95% CI) for a range of cut-points of the coefficient-based
points-based model, using the symptoms and signs model (upper part of table)
Combinationa Sensitivity, % Specificity, % PPV, % NPV, % Children positive, %
+,+,+,+ 13.3 (5.1 to 30.6) 99.4 (99.0 to 99.6) 22.2 (8.6 to 46.5) 98.8 (98.3 to 99.2) 0.8 (0.5 to 1.3)
+,+,+,– 23.3 (11.6 to 41.5) 98.8 (98.2 to 99.1) 20.0 (9.8 to 36.4) 99.0 (98.5 to 99.3) 1.5 (1.1 to 2.1)
+,+,–,+ 43.3 (27.1 to 61.2) 94.0 (92.9 to 94.9) 8.8 (5.2 to 14.5) 99.2 (98.7 to 99.5) 6.5 (5.6 to 7.6)
+,–,+,+ 46.7 (29.9 to 64.2) 92.5 (91.4 to 93.5) 7.7 (4.6 to 12.6) 99.2 (98.8 to 99.5) 8.0 (6.9 to 9.2)
+,+,–,– 53.3 (35.8 to 70.1) 86.5 (85.0 to 87.8) 5.0 (3.1 to 8.0) 99.3 (98.8 to 99.6) 14.1 (12.7 to 15.5)
+,–,+,– 63.3 (45.1 to 78.4) 82.4 (80.8 to 83.9) 4.6 (2.9 to 7.1) 99.4 (98.9 to 99.7) 18.2 (16.7 to 19.8)
–,+,+,+ 63.3 (45.1 to 78.4) 81.6 (80.0 to 83.2) 4.4 (2.8 to 6.8) 99.4 (98.9 to 99.7) 19.0 (17.4 to 20.6)
+,–,–,+ 90.0 (73.2 to 96.7) 57.9 (55.8 to 59.9) 2.8 (1.9 to 4.0) 99.8 (99.3 to 99.9) 42.8 (40.8 to 44.8)
–,+,+,– 90.0 (73.2 to 96.7) 52.8 (50.7 to 54.8) 2.5 (1.7 to 3.6) 99.7 (99.2 to 99.9) 47.8 (45.7 to 49.8)
+,–,–,– 96.7 (79.8 to 99.5) 24.2 (22.4 to 26.0) 1.7 (1.2 to 2.4) 99.8 (98.7 to 100.0) 76.1 (74.3 to 77.8)
–,+,–,+ 96.7 (79.8 to 99.5) 21.2 (19.5 to 22.9) 1.6 (1.1 to 2.3) 99.8 (98.5 to 100.0) 79.1 (77.3 to 80.7)
–,–,+,+ 96.7 (79.8 to 99.5) 20.4 (18.8 to 22.1) 1.6 (1.1 to 2.3) 99.8 (98.5 to 100.%) 79.8 (78.1 to 81.4)
–,+,–,– 96.7 (79.8 to 99.5) 18.4 (16.9 to 20.1) 1.6 (1.1 to 2.2) 99.8 (98.3 to 100.%) 81.8 (80.1 to 83.3)
–,–,+,– 96.7 (79.8 to 99.5) 16.7 (15.2 to 18.3) 1.5 (1.1 to 2.2) 99.7 (98.1 to 100.%) 83.4 (81.9 to 84.9)
–,–,–,+ 96.7 (79.8 to 99.5) 9.4 (8.3 to 10.7%) 1.4 (1.0 to 2.0) 99.5 (96.7 to 99.9) 90.7 (89.4 to 91.8)
–,–,–,– 100 0 1.3 (0.9 to 1.9) 100 100
a The first plus represents absence of nappy rash, the second plus presence of smelly urine, the third plus presence of
darker urine and the fourth plus being female.
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Strengths and limitations
To our knowledge, this is the largest primary care diagnostic accuracy study of clinical symptoms, signs and
dipstick tests for diagnosing UTI in young children. Participating children should be representative of those
presenting to primary care: key characteristics were similar for participating children and those who were
invited but declined participation. We achieved high rates of data completeness across a large number of
primary care sites and maintained the blinding of staff to the reference standard. All index tests were
measured according to routine clinical practice using standardised reporting forms and equipment, and
nearly all were completed within 24 hours of urine sample retrieval, minimising the impact of disease
progression bias. Only a small proportion of samples had antimicrobial substances present, and this
was even smaller in those with UTI, suggesting a minimal treatment paradox. Our reference standard was
specific to the commonest uropathogens and did not include any of the index tests. Two members of staff,
blind to all of the index tests except age, performed the microbiological cultures and interpreted results,
using a standardised process in a single laboratory.
The main limitations of our study are the relatively small number of UTI diagnoses and the unanticipated
differences between clean-catch and nappy pad samples in the reliability and accuracy of the laboratory
results. Together, these factors meant that we had insufficient numbers of children with UTI to both derive
and externally validate the algorithms, and limited precision of the diagnostic accuracy estimates, especially
in the nappy pad models. Although bootstrap validation is an accepted technique to use, leading to
reduced AUROC for our models, estimates may be optimistic in relation to values that we would have
achieved with external validation. Despite index tests selection being based on extensive discussion and
literature review, we omitted to investigate infectious contacts as an index test.116,135
Results in context with other studies
Microbiological definitions of UTI, in terms of both the bacterial species and their concentration, vary
between UK,2 European136 and other guidelines, and also according to patients’ age, sex and urine
collection method. Most UTIs are caused by organisms in the Enterobacteriaceae group, with over 90%
being caused by E. coli, Proteus mirabilis, Klebsiella pneumioniae and Enterobacter cloacae.82 Our study
reference standard, therefore, defined uropathogens as members of the Enterobacteriaceae group at the
UK guidelines2,82 threshold of a pure/predominant growth of ≥105 CFU/ml. We used a rigorous criterion
(minimum 3-log difference between the predominant and next most concentrated organism) for defining
predominance. This definition could have reduced estimated prevalence if some UTIs were incorrectly
classified as contamination: the only other UK primary care-based study of which we are aware estimated
prevalence to be 5.9%.9 Collecting an uncontaminated urine specimen is most difficult in the youngest
children, and no study has yet reliably distinguished pathogen from contaminant, especially when they
coexist. Our definition of UTI excluded atypical bacteria causing UTIs, which are also thought to be more
common in younger children.137,138
We are aware of four primary studies1,65–67 of 18,796 children and one systematic review of eight primary
studies3 in children aged < 5 years (7892 children) that assessed the diagnostic value of clinical symptoms
and signs. The only other primary care study found younger age and urinary frequency and dysuria to be
independently associated with UTI.9 Among the remaining studies, largely conducted in emergency
departments, abdominal pain, back pain, dysuria, frequency, and new-onset urinary incontinence increased
the likelihood of a UTI.3 Stridor, audible wheeze, circumcision, temperature < 39 °C with a source,
abnormal chest sounds, chest crackles, age ≤ 3 years, not feeling hot, and breathing difficulty decreased
the likelihood of UTI. The largest study, which included almost 16,000 children aged < 5 years presenting
to the emergency department,1 derived a diagnostic model based on a combination of 27 symptoms and
signs. This model was found to have an AUROC of 0.80 (95% CI 0.78 to 0.82). Data from six primary
studies of dipstick testing in children aged < 5 years70,138–142 suggest that a dipstick positive for both nitrite
and leucocyte may be useful for ruling in a diagnosis of UTI, while dipstick negative for both nitrite and
leucocyte may be useful for ruling it out. However, these data were heterogeneous and should be
interpreted with caution.
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Our clean-catch model includes clinically intuitive items. Previous investigation of malodorous urine has
shown conflicting results,67,139 but our study strongly supports its diagnostic value. We investigated, but did
not find evidence for, a number of non-specific symptoms (including fever, vomiting, lethargy, irritability
and poor feeding) previously found to be diagnostic of UTI116 and recommended for clinical use by NICE.2
It remains possible that such symptoms are of use in the secondary care settings in which studies reporting
their utility were conducted, or in children with a different illness spectrum. We found that the presence
of severe cough and abnormal ear findings on examination (suggestive of alternative diagnoses to UTI)
were associated with a reduced risk of UTI. Such inverse associations are unlikely to reflect biological
mechanisms but to arise because both they and UTI are causes of children attending primary health care.
Such ‘conditioning on a common effect’ induces inverse associations between factors that are independent in
the source population of well and unwell children.140 These associations are, nonetheless, of diagnostic utility.
Our nappy pad model, and to some extent the clean-catch model for children aged 2–3 years, is the first
primary care study to identify parent-reported symptoms that can be used to select preverbal children
warranting urine sampling and presumptive antibiotic treatment. Female sex and parent-reported smelly or
darker urine all appear biologically plausible as contributing to the diagnosis of UTI. However, the reasons
for the apparently substantial reduction in the risk of UTI associated with presence of a nappy rash are not
clear. The inverse association could arise through conditioning on the common effect of primary care
attendance,140 but this is unlikely to produce such a substantial association. Alternative explanations are
that rash may be a risk factor for contamination of urine (though we do not find any evidence of this, as
reported in Chapter 7) and hence mask the presence of a UTI, or that skin products used to treat nappy
rash could render the urine sterile. An increased likelihood of contamination of nappy pad samples might
also explain the more modest associations of symptoms and dipstick test results with UTI than were found
in clean-catch samples. These differences could also arise from differences in illness profiles between older
and younger children.
Given the concerns regarding the vulnerability of children’s kidneys to damage from upper renal tract
infection, it may surprise some clinicians that fever and fever of unknown origin (as a widely perceived
marker of pyelonephritis) were not found to be diagnostic in either of the clean-catch nappy pad algorithms.
NICE reviewed whether or not symptoms and signs could be used to localise UTI (upper or lower) and
concluded that they ‘cannot be used to predict acute pyelonephritic changes on DMSA scanning’ (p. 64).2
The NICE guidance also states that children with bacteriuria and a temperature of 38 °C or no fever but loin
pain or tenderness should be considered to have pyelonephritis (p. 76). However, studies have shown that
both pyelonephritis and renal scarring can occur in the absence of fever33,141 and NICE’s own review
found that symptoms and signs were not predictive. The DUTY study was planned to address the HTA
commissioning brief as closely as possible, which was to identify the clinical features of paediatric UTI in
primary care, without placing any a priori emphasis on a particular symptom (such as fever). We have
clearly demonstrated that, among unwell children presenting to primary care (these are the ones in whom
we do not wish to miss UTI), fever is not diagnostic. This indicates that many UTIs in general practice do
not present with fever, which is a new and important finding. It should not be assumed that, because UTI
has been traditionally linked with fever, especially in hospital settings and in advanced illness, our finding
that fever is not diagnostic of UTI in primary care is wrong.
Clinical and research implications
Parent-reported symptoms and clinical signs can be used to identify preschool children presenting to
primary care in whom urine should be collected, and along with urine dipstick results, who should receive
immediate antibiotic treatment. Dipsticks have been considered unhelpful in young children2 until now.
Diagnostic utility is better for urine collected using clean catch than for urine collected using nappy pads,
but nappy pad samples still provide better diagnostic accuracy than current clinical practice for children
< 2 years, in whom the diagnosis of UTI is most challenging. That said, clinicians should be very cautious
about using the nappy pad collection method in children with a nappy rash, for whom they should try to
collect urine via clean catch. We believe that our results can be applied to other resource-rich nations with
similar ‘first point of contact’ health-service provision, but may not be applicable to the spectra of illness in
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preschool children presenting to primary care in resource-poor settings or those referred to secondary care
following an initial primary care assessment.
In terms of clinical operationalisation, the dichotomised points-based models provide a simplified tool for
clinical use but, as discussed in Chapter 6, at reduced cost-effectiveness compared with the preferred,
coefficient-based model. That said, in the absence of a computer to aid coefficient-based algorithm use,
for older (≥ 2 years) children likely to provide clean-catch samples, we think that it is reasonable to select a
cut-point of ≥ 5 (sensitivity of 51.7%) which would be clinically operationalised as ‘collect urine if any
three of the five symptoms and signs (history or UTI, smelly urine or pain/crying passing urine, absence of
severe cough and severe illness) are present’. At this threshold, urine dipstick testing would be unlikely to
increase the probability of UTI high enough to warrant treatment in children for whom the points-based
model did not recommend urine collection. This would result in urine collection in 6.4% of ‘DUTY eligible’
children aged ≥ 2 years. The cost-effectiveness analyses presented in Chapter 6 suggest that the use of
dipstick testing to guide antibiotic treatment has additional diagnostic value, but at a higher cost than
awaiting the laboratory result.
For younger (< 2 years) children providing nappy pad samples, while selecting a threshold of ≥ 5 points
appears attractive to improve sensitivity, the analyses presented in Chapter 6 suggest that this may not be
cost-effective.
Further research is needed to distinguish pathogens from contaminants when bacteria are found in
significant concentrations in urine and to establish the cost-effectiveness of different sensitivity/specificity
cut-points for the clean-catch and nappy pad models for use in routine clinical practice, using routine
health service laboratories. A RCT is needed to assess impact on clinical behaviour and patient outcome,
the third of the three steps in the development of a clinical algorithm.128
Conclusions
We have found novel symptoms and signs that are useful for identifying preschool children presenting to
primary care who should have urine sampled. Diagnostic utility is better for clean-catch than nappy pad
samples, but both perform better than ‘clinician diagnosis’ alone. Dipstick testing provides additional
diagnostic value for antibiotic treatment. The full model may be operationalised using online/desktop
technology, but a points-based model is available for immediate use. We present a cost-effectiveness
analysis of these strategies in Chapter 6.
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Chapter 6 Health economic analysis and
modelling of diagnostic strategies
Introduction
Urinary tract infection is the fourth most common reason for prescribing antibiotics, accounting for
approximately 8% of all antibacterial prescriptions.103 While the unit costs of laboratory testing and
antibiotic prescribing are relatively low,56 the economic implications of new clinical algorithms for urine
sampling and testing may be substantial owing to (1) the large numbers of children who present with
non-specific symptoms which might be caused by UTI; (2) the cost of subsequent diagnostic tests used to
further evaluate children with recurrent/atypical UTI;2 (3) the substantial costs and impact on quality of life
of a missed diagnosis that leads to rare but serious complications of UTI; and (4) the wider, long-term
population impact of diagnostic algorithms on antibiotic prescribing and bacterial resistance.104
The few economic evaluations of the diagnosis of UTI in young children56,142,143 have primarily aimed to
identify the most cost-effective test or series of tests for diagnosing UTI rather than address the important
issue of which children should be selected for testing in the first place. There is limited evidence on which
children should have a urine sample taken and by what sampling method, and which urinalysis tests
should be used to guide initial treatment. Guidance is especially needed for children < 3 years of age
where current NICE clinical guidelines2 are not based on evidence of cost-effectiveness. In this chapter we
develop decision-analytic models to estimate the costs and outcomes of various diagnostic strategies to
identify children with elevated risk of UTI in whom a urine sample should be collected. The models also
explore the role of dipstick testing in the diagnosis and treatment of UTI in children < 5 years old.
Methods
Overview
We developed decision-analytic models using decision trees and Markov models to identify the optimal
urine sampling strategy for acutely unwell children < 5 years old presenting to primary care. As Chapter 5
showed that the diagnostic accuracy depends on the urine collection method and that NHS laboratory
results do not have perfect diagnostic accuracy, we developed a ‘clean-catch’ model and a ‘nappy pad’
model that account for imperfect NHS laboratory results. The models, which synthesise data from the
DUTY study and the wider literature, estimate the lifetime costs and health outcomes for six urine
sampling strategies, including three derived from the DUTY risk score.
In secondary analyses, we extend the models to compare three testing and treatment strategies to explore
the role of dipstick testing in guiding laboratory testing and antibiotic prescriptions. We also compared
the performance of a simpler points-based DUTY algorithm against the full DUTY algorithm. The DUTY
points-based algorithm attributes an integer score to each sign and symptom predictive of UTI and sums
these to produce a DUTY risk score between 0 and 7.
Costs were estimated from a NHS perspective and included diagnostic costs and short- and long-term treatment
costs. Health outcomes were expressed using QALYs and QALDs. The model is made up of three parts:
short term (diagnosis and acute illness; up to 21 days), medium term (recurrent UTI; up to 3 years) and
long term (long-term sequelae; lifetime).
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Model structure
Short-term decision tree
The short-term decision tree deals with the events before and during the index consultation. At
presentation, a child may have UTI which could develop into a pyelonephritic attack. Children with
pyelonephritis suffer a reduced quality of life during the infection, and the number of pyelonephritic
attacks in childhood is predictive of the probability of progressive renal scarring (PRS), which may lead to
life-limiting long-term complications. Some children may also present with VUR, which increases their
susceptibility to UTI infections, and hence PRS, in future years if it is not diagnosed and treated.
Comparison of sampling strategies
There are six urine sampling strategies, designed to reflect the full variety of clinical behaviour, compared
in the primary analyses (Figure 13). In all strategies, a proportion of children who are very unwell are
referred directly to hospital for testing and treatment (Figure 14). For each strategy, the decision to get a
urine sample is based on whether the child is deemed at ‘very low’, ‘low’ or ‘higher’ risk of UTI. The model
includes two ‘boundary strategies’ for urine sampling. In the first of these (sample all), all children meeting
the DUTY eligibility criteria are judged to be at ‘higher’ risk of UTI and GPs request a urine sample in all. In
the second strategy (sample none), all children meeting the DUTY eligibility criteria are judged to be at
‘very low risk’ of UTI and GPs do not obtain a urine sample. These boundary strategies are not intended to
reflect clinical reality, but provide a reference point against which other intermediate urine sampling
strategies can be compared. The risk stratification for the intermediate sampling strategies is based either
on GPs’ clinical judgement or on the DUTY risk score. We considered three possible DUTY risk score
cut-points reflecting a range from high specificity to high sensitivity and hence there are six diagnostic
strategies compared in the decision model:
1. sample none (‘sample none’)
2. sample based on clinical judgement (‘CJ’)
3. sample based on a high specificity cut-off of the DUTY risk score (‘DUTY5%’)
4. sample based on an intermediate specificity and sensitivity cut-off of the DUTY risk score (‘DUTY10%’)
5. sample based on a high sensitivity cut-off of the DUTY risk score (‘DUTY20%’)
6. sample all (‘sample all’).
No urine sample is requested in children deemed at ‘very low’ risk of UTI (see Figure 14). Urine sampling is
attempted on children deemed at ‘low’ risk of UTI with antibiotic treatment delayed until a laboratory
result is returned (see Figure 14). With a positive laboratory result, a suitable antibiotic is prescribed
depending on the sensitivities of the bacteria. No antibiotics are prescribed if the laboratory test result is
negative. Children at low risk who cannot provide a sample are reviewed in 2 days, and if symptoms have
improved no antibiotic is prescribed; if symptoms do not improve, antibiotics may be given if indicated
based on the working diagnosis. If the sample is contaminated, a repeat is sought. A urine sample is
requested in children considered at ‘higher’ risk of UTI and antibiotics prescribed immediately with the
Sample all
LT
LT
LT
LT
LT
LT
CJ
DUTY5%Children with an
acute illness
DUTY10%
DUTY20%
Sample none
FIGURE 13 Sampling, testing and treatment strategies.
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advice that they should not be taken until the urine sample is obtained (see Figure 14). If no sample is
obtained, symptoms are reviewed within 2 days, and if symptoms have improved the antibiotic is not
started; if symptoms have not improved, the child is referred to hospital. When a sample is provided, the
antibiotics are started immediately and the sample is sent to the laboratory. If the bacteria are found to be
resistant to the prescribed antibiotic the GP will change the antibiotic prescription, and if no infection is
found the GP may ask for the antibiotic to be stopped. If the initial sample is contaminated, a repeat
sample is sought. In all urine sampling strategies a proportion of children with a missed diagnosis of UTI
are serendipitously treated with antibiotics prescribed for another working diagnosis (see Figure 14).
Comparison of dipstick testing and treatment strategies
In secondary analyses we explored the impact of alternative testing and treatment strategies on our
findings. These testing and treatment strategies were developed through discussions with the GPs on the
project team (AH, CB, PL, BD and KO’B) and aim to reflect a range of current practice in primary care
(Figures 15–20). Specifically, we considered two alternatives to the testing and treatment strategy where
treatment of ‘low’ risk children is delayed until the laboratory test result is known (see Figures 15–19). In
the dipstick test and treatment strategy (see Figures 16–20), urine samples obtained in children judged at
‘low’ risk of UTI are tested with a dipstick at the primary care site. Those with a negative dipstick result are
sent to the laboratory with treatment delayed until a result is returned. Those with a positive dipstick result
are prescribed immediate antibiotics and the urine sample sent to the laboratory; if the bacteria are found
to be resistant, the GP will change antibiotic, and if no infection is found the GP may ask for the antibiotic
to be stopped. In the presumptive treatment strategy (see Figures 18, 19 and 21) the GP prescribes
antibiotics immediately for children judged at ‘low’ or ‘higher’ risk of UTI with the advice that they should
not be taken until the urine sample is obtained.
Short-term Markov model
There are four possible Markov health states for children in the 21 days following the initial consultation
(Figure 21). A child can be symptomatic but not have UTI (‘symptomatic not UTI’); a child can be
symptomatic due to UTI and pyelonephritic attack (‘symptomatic UTI+ PA’); a child can be symptomatic
due to UTI alone (‘symptomatic UTI’); and a child can become ‘asymptomatic’.
Each of the four Markov health states has a utility or preference score. Preference scores (anchored at 1 for
perfect health and 0 for a health state as bad as death) are used to value health outcomes (morbidity and
mortality) in one summary measure, the QALY or QALD. The less time a child spends in a symptomatic
health state, the higher their QALDs.
The daily transition probabilities from any symptomatic state to the asymptomatic state depend on the
natural progression of the disease, the accuracy of diagnosis, the timeliness of treatment and the sensitivity
of the bacteria to the antibacterial prescribed. For example, a child correctly diagnosed with UTI and
treated immediately with an appropriate antibiotic will, on average, become asymptomatic more rapidly
than a child with undiagnosed UTI who is not prescribed antibiotics. In total there are nine
treatment pathways:
l not UTI
l immediate treatment [not resistant (NR)]
l immediate treatment [resistant (R)], change antibiotic based on laboratory test result (NR)
l immediate treatment (R)
l immediate treatment (NR), stop treatment based on false-negative laboratory test result
l immediate treatment (R), stop treatment based on false-negative laboratory test result
l delayed treatment (NR)
l delayed treatment (R)
l not treated.
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The post-diagnosis daily costs of NHS treatment depend on both the underlying disease (i.e. UTI or not)
and the treatment (e.g. no antibiotics, delayed antibiotics or immediate antibiotics). Some costs are fixed
and occur at the start of the period, for example the cost of the initial antibiotics prescription. Other costs
occur throughout the 21-day period, for example repeat visits to the GP for ongoing symptoms.
Medium-term model
The medium-term model (see Appendix 9, Figures 37–40) simulates the number of recurrent UTIs and
pyelonephritic attacks a child experiences in the 3 years following the index consultation. All children
enter the medium-term model with no UTIs or one UTI and either zero or one pyelonephritic attacks
(see Appendix 9, Figure 37). The medium-term model then estimates the number of recurrent UTI
infections and GP consultations over a 3-year period following the index consultation. We assume that
only one recurrent UTI or GP consultation may take place in each year. Children who had a UTI as the
index consultation experience an increased probability of recurrent UTI.
We assume that only one recurrent UTI or GP consultation may take place in each year. Children who had
a UTI as the index consultation experience an increased probability of recurrent UTI. Children without UTI
at the index consultation experience a lower probability of a first infection until their first UTI. Children
who do not have a UTI episode may still consult their GP for another reason and be incorrectly tested or
treated for UTI. A higher number of false-positive diagnoses will occur in strategies with lower specificity.
In the medium-term model the diagnosis and acute illness costs and utilities of subsequent GP visits are
identical to the initial GP visit and, therefore, dependent on the urine sampling strategy adopted.
Children with untreated VUR have a higher probability of recurrent UTI. At each consultation a child with
undetected VUR may be referred for imaging, and receive treatment, providing UTI is diagnosed and the
VUR is detected. All patients with a positive ultrasound VUR diagnosis are referred onto a confirmatory,
more invasive and costly MCUG scan before prophylactic antibiotic treatment is commenced. Children
correctly diagnosed with VUR are assumed to be treated with prophylactic antibiotics, according to
NICE guidelines.2
Long-term model
The structure of the long-term model is based on previous work.56 The model provides a link between the
number of pyelonephritic attacks by the end of the medium-term model and infection-related renal
scarring, which could potentially lead to ESRD requiring treatment by dialysis or renal transplant (see
Appendix 9, Figure 41). The long-term model calculates the lifetime cost, quality of life and mortality
consequences of these severe complications.
UTI
+ PA
Asymptomatic
UTI
– PA
Not
UTI
FIGURE 21 Short-term Markov model.
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Model inputs
We used a variety of sources to estimate model parameters and assigned probability distributions to
represent the uncertainty around these point estimates. This enables probabilistic sensitivity analysis (PSA)
to estimate the probability that the DUTY risk scores are more cost-effective than clinical judgement.
Prevalence
A total of 5107 DUTY study samples were cultured in the research laboratory. Of these, 73 collected with
the bag method and 17 collected with an unknown collection method were removed because of the
unsuitability of the collection method. Of the remaining urines, 327 were found to be contaminated by
our primary definition in the research laboratory, leaving 4690 samples with known UTI status. The
prevalence of UTI in the population of children presenting to primary care was based on the research
laboratory test results of the DUTY study (Table 46). Ninety (1.9%) of these 4690 children had a research
laboratory-confirmed UTI, including 60 (2.2%) of 2690 in children with clean-catch collection and
30 (1.5%) of 2000 in children with nappy pad collection. We estimated the prevalence of pyelonephritis
among those with UTI as the proportion of children with laboratory-confirmed UTI and fever (> 38 °C)
recorded.2 Seven children with UTI did not have temperature recorded and so were excluded from this
analysis. Thirteen of the remaining 87 children with UTI had pyelonephritis. In the sensitivity analysis we
increased the prevalence of pyelonephritis among children with UTI up to 57% as has been reported in a
systematic review including secondary care cases.33 The prevalence of VUR among children with UTI is
estimated from a previous meta-analysis of 27 studies.33 Children who do not have UTI at the index
consultation are assumed not to have VUR.
Risk stratification using clinical judgement and the DUTY risk scores
In order to model sampling and treatment based on clinical judgement, we used GP responses to
questions on the DUTY CRF about working diagnosis and planned management. Children are stratified
into three risk categories (‘very low’, ‘low’ and ‘higher’) in the model, and, therefore, the definition of
‘clinical judgement’ is more complex than the definition of ‘clinician diagnosis’ used in Chapter 5, where
diagnostic accuracy is based on a binary categorisation. The proportion of very low-risk children was
identified as those for whom the GP answered ‘no’ to the question ‘If this child was NOT in the DUTY
study would you have requested a urine sample?’ or indicated a working diagnosis of ‘not UTI’. Higher-risk
children were those for whom the GP had a working diagnosis of UTI and answered ‘yes’ to the question
‘Before seeing the dipstick results, are you planning on treating this child with antibiotics for suspected
UTI?’. Finally, low-risk children were those for whom the GP had a working diagnosis of UTI and the GP
answered ‘yes’ to the question ‘If this child was NOT in the DUTY study would you have requested a urine
sample?’. Categorising patients in this way requires complete data on a number of variables from the CRF;
we excluded patients from the analysis if this information was not available or they did not have research
laboratory-confirmed UTI status.
Exploratory analysis demonstrated that the prevalence of research laboratory-confirmed UTI increased
with increasing ‘clinical judgement’ risk strata; 1.1% of patients categorised as very low risk had
laboratory-confirmed UTI compared with 9.4% and 13.2% of those classified as low and higher risk,
TABLE 46 Prevalence of UTI in children presenting to primary care
Parameter Estimate Distribution Source
UTI prevalence 0.019 Beta(91,4601) DUTY
PA (among those with UTI) 0.157 Beta(14,75) DUTY record of fever
VUR (among those with UTI) 0.240 Odds∼LNa (–1.153,0.1132) Shaikh et al.33
PA, pyelonephritic attack.
a Log-normal.
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respectively. Using these methods indicated that around 5% of children meeting the DUTY inclusion
criteria would have had a urine sample requested based on clinical judgement.
We compared the outcomes of the boundary and clinical judgement strategies with those derived from the
DUTY risk score. The diagnostic accuracy of the DUTY risk score depends on the cut-points used to identify
the children who should not be sampled (very low risk), the children who should be sampled and treated
based on the laboratory test result (low risk) and the children who should be sampled and treated
presumptively (higher risk). For each urine collection method we choose three cut-points corresponding to
the selection for urine testing of approximately 5% (DUTY5%), 10% (DUTY10%) or 20% (DUTY20%) of
children. Hence the DUTY5% strategy represents a relatively high specificity strategy where the proportion
of children selected for urine sampling is similar to the clinical judgement sampling strategy. In contrast,
the DUTY20% strategy represents a relatively high sensitivity strategy where the proportion of children
selected for urine sampling is about four times higher than the clinical judgement strategy. For each DUTY
risk score strategy we assumed that the half of those children sampled who had the highest risk scores
would be deemed at higher risk of UTI. For example, in the DUTY5% strategy, children with risk scores in
the highest 2.5 percentiles were classed at higher risk of UTI and treated presumptively, and children with
risk scores between the 25th and 5th percentiles were classed as low risk and treatment was based on the
result of the laboratory test.
The accuracy of the clinical judgement and DUTY risk score stratifications used in the clean-catch and
nappy pad models are shown in Table 47. In clean-catch samples, the DUTY5% urine sampling strategy
outperformed clinical judgement. For example, in the clean-catch subgroup, DUTY5% identified 58.2% of
children who had UTI as being at low to higher risk of UTI and identified 96.2% of children who did not
have UTI as being at very low risk of UTI. In comparison, clinical judgement identified 56.4% of children
who had UTI as being at low to higher risk of UTI and identified 91.4% of children who did not have UTI
as being at very low risk of UTI. In nappy pad samples, clinical judgement only classified 16.7% of children
who had UTI as being at low to higher risk of UTI and identified 97.6% of children who did not have UTI
as being at very low risk of UTI. Sensitivity was higher based on the DUTY5% (40.0%), DUTY10% (53.3%)
and DUTY20% (63.3%) algorithms, but specificity was lower (95.2%, 90.1% and 80.6%, respectively).
Risk stratification using clinical judgement and the DUTY points-based
risk scores
The accuracy of the simpler DUTY points-based algorithm stratifications used in the clean-catch and nappy
pad models is shown in Table 48. We chose cut-points at 3, 4, 5 and 6 on the DUTY points score.
A secondary cut-point was chosen so that approximately half would be deemed at ‘higher’ risk of UTI to
allow direct comparison with the full DUTY risk scores. However, as the points-based risk score had only
eight possible values, a close match was not always possible. The diagnostic accuracy of the points-based
algorithm was slightly lower than the full DUTY risk scores. For example, in clean-catch samples the full
DUTY20% risk scores identified a similar proportion of patients with UTI as at low or higher risk of UTI
(85%) and more people without UTI as at very low risk (80.6% vs. 73.6%) than the points-based DUTY
≥ 3 algorithm.
Short-term model probabilities
The short-term model probabilities are presented in Table 49. A minority of children presenting to primary
care will be referred immediately to hospital before the decision of whether or not to attempt a urine
sample is considered. We identified these ‘very unwell’ children as those for whom the GP answered ‘yes’
to the question ‘Before seeing the dipstick results, would you have referred this child to a paediatrician or
admitted this child to hospital?’. The probabilities of obtaining a sample, having a contaminated sample
and having a uropathogen resistant to antibiotics were based on observations from the DUTY study.
Just over 91% of children in the DUTY study provided a urine sample. The probability of contamination,
stratified by collection method, was based on a NHS laboratory report of heavy mixed growth with a count
> 105 CFU/ml of more than two organisms. In DUTY children with UTI, resistance to both non-UTI
antibiotics (assumed to be amoxicillin) and UTI antibiotics (assumed to be trimethoprim) was based on the
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research laboratory reports of resistance to these antibiotics. We estimated the proportion of children who
would return to primary care before symptom resolution from a cohort study,144 based in UK primary care,
of 222 children presenting with acute respiratory tract infection and cough. We estimated the proportion of
children where an antibiotic was prescribed for another disease (not UTI) by calculating the proportion
of children without UTI in DUTY whose parents reported antibiotic use within 2 days of the initial
consultation in the 14-day follow-up questionnaire.
The probability of a GP stopping antibiotic treatment midway through a prescription following a negative
laboratory test in a presumptively treated child was based on expert opinion from three GPs (AH, CB
and BD). We estimated the proportion referred for further investigation by calculating the proportion
of children in the DUTY cohort with a positive NHS laboratory UTI diagnosis who had a record of an
ultrasound scan within 3 months of the index consultation.
Diagnostic accuracy of dipstick and NHS laboratory test results
The diagnostic accuracy of dipstick tests and NHS laboratory results were both defined against the
reference standard of the research laboratory result in DUTY (Table 50). A positive dipstick test was
defined as a positive result (+, ++ or +++) for either leucocytes or nitrates. Estimates of the diagnostic
accuracy of ultrasound scans are taken from a previous meta-analysis.56 MCUG is the gold-standard test
for VUR diagnosis and hence it is assumed to be 100% sensitive and specific.
Symptom resolution
The daily symptom resolution transition probabilities are based on data from the DUTY 14-day interviews.
We used responses to the question ‘How many days since [name of child] joined the DUTY study (day 0)
was it until [his/her] symptoms improved?’ in the 14-day questionnaire data to calculate symptom duration.
We used the responses from children treated immediately, defined as receiving antibiotics within 2 days of
the index consultation, and children without UTI to parameterise two Weibull survival models. The Weibull
model is a parametric survival model which is used to model time to event data; in this case the event
is symptom resolution. A small proportion of parents of children both with and without UTI reported
symptom recovery times > 14 days and hence we extrapolated our estimates to 21 days, by which time the
vast majority of children were predicted to have become asymptomatic. The estimated symptom resolution
rates from our model were a good fit for the observed rates for both children with treated UTI and those
without UTI (see Appendix 9, Figures 42 and 43).
TABLE 49 Short-term model probabilities
Parameter Estimate Distribution Source
Very unwell – referred directly to hospital 0.037 Beta(263,6840) DUTY
Sample obtained 0.915 Beta(6426,596) DUTY
Contamination DUTY
Clean catch 0.056 Beta(163,2740)
Nappy pad 0.258 Beta(785,2261)
Antibiotic resistance (not UTI Abx) 0.531 Beta(51,45) DUTY
Antibiotic resistance (UTI Abx) 0.281 Beta(27,69) DUTY
Reconsultation before symptom resolution 0.192 Beta(43,181) Hay et al.144
Antibiotics for non-UTI reason 0.267 Beta(209,573) DUTY 14-day
Stop antibiotic given no UTI 0.075 Uniform(0.05,0.10) Expert opinion
Referred for VUR scan 0.077 Beta(26,312) DUTY
Abx, antibiotics.
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As a urine sample was requested in all children participating in DUTY and the vast majority of children with
laboratory-confirmed UTI were treated with antibiotics, we could not directly observe the symptom
resolution rate where antibiotics had not been prescribed. Therefore, we estimated the untreated UTI
symptom resolution rates based on treatment effect sizes in the literature. To our knowledge, no RCTs of
antibiotics for UTI in children exist. We identified a systematic review,145 which included five RCTs
estimating the treatment effect of antibiotics for women with cystitis. In four of these studies the
treatment regimens were thought not to be representative of current UK general practice for treating UTI
(e.g. single-dose amoxicillin 750mg) and hence we used data from a RCT which evaluated the
effectiveness of nitrofurantoin in 78 women aged between 15 and 54 years.146 The study found that in
women with bacteriologically proven UTI, nitrofurantoin was significantly more effective than placebo in
achieving symptomatic relief at 3 days [risk ratio 0.55 (95% CI 0.34 to 0.89)] (Table 51).
We assumed that for children in whom the uropathogens were resistant to the prescribed antibiotic, the
rate of symptom resolution was reduced by 30% based on expert opinion from a panel of GPs and
microbiologists (see Table 51). We assumed that children with UTI who receive antibiotics only once the
NHS laboratory test result is known or who remain untreated because a urine sample cannot be obtained
or is contaminated have treatment delayed for a period of 2 days before antibiotics are taken, at which
point their transition probabilities to the asymptomatic state become identical to those receiving treatment.
We assumed that the treatment benefit from antibiotics persisted for only 7 days and hence all children
TABLE 50 Diagnostic test performance
Parameter
Sensitivity Specificity
SourceEstimate Distribution Estimate Distribution
Dipstick DUTY
Clean catch 0.758 Beta(47,15) 0.840 Beta(2215,423)
Nappy pad 0.781 Beta(25,7) 0.688 Beta(1438,652)
NHS laboratory testa DUTY
Clean catch 0.780 Beta(46,13) 0.976 Beta(2352,58)
Nappy pad 0.769 Beta(20,6) 0.922 Beta(1363,116)
Ultrasound for VUR 0.440 Odds∼LNb (–0.243,0.2352) 0.775 Odds∼LN (1.238,0.2862) Whiting et al.56
MCUG for VUR 1.000 Fixed 1.000 Fixed Assumption
a After removing samples which were found to be contaminated in the NHS laboratory.
b Log-normal.
TABLE 51 Short-term Markov model probabilities
Parameter Estimate Distribution Source
Antibiotic treatment effecta 0.550 RRb∼LNc (–0.599, 0.247) Christiaens et al.146
Effect of resistance on symptom resolution ratesd 0.700 Uniform (0.5, 0.9) Expert opinion
a Risk ratio comparing symptom resolution rates for children not treated with antibiotics with those in children treated
with antibiotics.
b Risk ratio.
c Log-normal.
d Risk ratio comparing symptom resolution rates for uropathogens resistant to antibiotics vs. uropathogens sensitive
to antibiotics.
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with UTI had identical symptom resolution probabilities between days 8 and 21. The average symptom
duration is displayed in Table 52. Symptom resolution rates for a selection of treatment pathways are
displayed in Appendix 9 (see Figure 44).
Medium-term Markov model probabilities
After the initial episode, the medium-term model tracks patients as they consult their GP for new
symptoms, potentially symptoms of UTI, during the following 3 years. We estimated the proportion of
patients who would consult their GP during a 12-month period for symptoms not caused by UTI from a
cohort study of 7727 children (aged ≤ 56 months) attending primary care for acute symptoms.147
The probability of recurrent UTI in patients with a previous history of UTI was estimated from a previous
meta-analysis based on six primary studies.33 Wide variations in incidence rates for UTI in children without a
previous UTI have been reported due to differences in study setting and diagnostic criteria for UTI.148–150
We elected to use data from a study in English general practice,149 which calculated the incidence of UTI
across 18 months in 2789 children up to 14 years old, owing to its use of strict diagnostic criteria and its
UK primary care setting (Table 53).
We estimated the effect of treatment with prophylactic antibiotics on UTI recurrence rates for patients with
VUR using results from a previous meta-analysis.15 This estimate is moderate and open to dispute as it is
largely based on studies with inadequate blinding.15 We assumed that the prevalence of pyelonephritis in
children with recurrent UTI and the probability of being referred for VUR were the same as the index
infection and that the sensitivity of GP diagnosis during recurrent UTI infections was identical to index
infection and, therefore, varied by urine sampling strategy.
Long-term probabilities
The long-term health consequences of UTIs, and specifically the number of pyelonephritic attacks, are
based on natural history evidence.16–19 We used data from a prospective study including 1777 children to
estimate the strength of association between the number of pyelonephritic attacks and the probability of
TABLE 52 Symptom duration, costs and utilities in each treatment pathway during acute illness
TP
Average symptom
duration, days (95% CI)
Average acute illness
cost, £ (95% CI)
Average acute illness
QALDs (95% CI)
TP1: not UTI 6.03 (5.69 to 6.40) 42.61 (32.03 to 53.99) 20.38 (19.79 to 20.97)
TP2: immediate treatment (NR) 4.72 (3.80 to 5.90) 50.24 (32.58 to 69.74) 20.54 (20.02 to 20.98)
TP3: immediate treatment (R), change
antibiotic based on laboratory test
result (NR)
5.06 (4.10 to 6.34) 53.39 (35.31 to 73.40) 20.50 (19.93 to 20.98)
TP4: immediate treatment (R) 5.72 (4.40 to 7.36) 62.51 (40.67 to 88.67) 20.42 (19.73 to 20.97)
TP5: immediate treatment (NR), stop
treatment based on false-negative
laboratory test result
5.63 (4.40 to 7.11) 62.83 (41.03 to 86.76) 20.43 (19.78 to 20.97)
TP6: immediate treatment (R), stop
treatment based on false-negative
laboratory test result
6.07 (4.72 to 7.67) 67.34 (44.26 to 93.17) 20.38 (19.66 to 20.97)
TP7: delayed treatment (NR) 5.22 (4.26 to 6.47) 54.87 (36.24 to 75.44) 20.48 (19.89 to 20.98)
TP8: delayed treatment (R) 5.90 (4.68 to 7.43) 64.24 (42.44 to 89.26) 20.40 (19.71 to 20.97)
TP9: not treated 6.29 (4.66 to 8.08) 69.72 (43.79 to 97.92) 20.35 (19.59 to 20.97)
TP, treatment pathway.
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renal scarring.20 The link between renal scarring and ESRD is based on registry data (Table 54).21 We
assumed that the mean age of ESRD onset following infection-related scarring was 13.67 years,152 with a
range of 7 to 24 years,153 based on the results of two observational studies. We also assumed that half of
children with ESRD would be treated with dialysis, with the remainder treated with renal transplant. Mean
survival times for patients without ESRD, treated with dialysis and treated with transplant are taken from
national statistics, a systematic review of home versus hospital haemodialysis, and renal registry
data, respectively.154–156
Costs
Where appropriate, costs were inflated to 2011 prices using the Unit Costs of Health and Social Care.158
We used a uniform distribution, with the lower bound 50% lower and an upper bound 50% greater than
the estimated mean, to describe parameter uncertainty.
TABLE 53 Medium-term Markov model probabilities
Parameter Estimate Distribution Source
Consult with no UTI 0.69 Beta(21194,9396) Hay et al.147
Consult with UTI given
No UTI history 0.0034
aBeta(10.33,2780.67) Dickinson et al.149
Previous UTI
No VUR/treated VUR 0.08 Odds∼LNb (–2.442,0.2182) Shaikh et al.33
Treatment effect for treated VUR RRc= 0.68 RR∼LN (–0.385,0.2802) Nagler et al.151
a Numerator adjusted to account for 18-month follow-up period.
b Log-normal.
c Relative risk comparing UTI recurrence rates in children with VUR with children without VUR.
TABLE 54 Long-term probabilities
Parameter Estimate Distribution Source
PRS Jodal40
0 PA 0.05 Beta(8,135)
1 PA 0.09 Beta(33,335)
2 PA 0.16 Beta(16,79)
3 PA 0.34 Beta(13,24)
4 PA 0.58 Beta(15,11)
ESRD given PRS 0.05 Alexander et al.157
Mean age of ESRD onset 13.67 Triangle(7,24) Arant,152 Jacobson et al.153
Future treatment
Transplant 0.500
Dialysis 0.500
Mean survival
No ESRD 73.00 Uniform(69.4, 76.7) ONS154
Dialysis 12.25 Uniform(11.6, 12.9) Mowatt et al.155
Transplant 21.60 Uniform(20.5, 22.7) Kaufman156
PA, pyelonephritic attack.
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Cost of the initial urine sample and test
We used time and motion methods, as described in Appendix 9, to evaluate the time taken and resources
used for urine collection. We used results from a report in pathology testing in England159 to estimate the
cost of a laboratory test for UTI (Table 55). We assumed that laboratory urine tests were included in the
least expensive and highest volume basket of pathology tests. Within this basket, prices ranged from £4.04
to £9.43 between the pilot sites in the report; we used the median cost reported across all sites of £6.13.
An additional 45 seconds (£2.33) of GP time is assumed for interpretation of each urine result and
5 minutes (£15.50) for contacting patients in the event of a positive laboratory result after a delayed
prescription, or when a negative laboratory result was returned after a presumptive prescription and the
GP decided to stop the antibiotic treatment.
TABLE 55 Costs (£)
Cost Estimatea Distribution Source
Short-term decision tree
Sample DUTY
No dipstick 6.78 Uniform(3.39,10.17)
Dipstick 7.81 Uniform(3.91,11.72)
Sample attempted but not obtained 1.41 Uniform(0.71,2.12)
Nappy pad collection kit 1.83 Uniform(0.92,2.75) DUTY
Laboratory test 6.13 Uniform(3.07,9.2) Carter Report159
Dipstick 0.38 Uniform(0.19,0.57) DUTY
GP result interpretation cost 2.33 Uniform(1.17,3.5) Expert opinion
GP stop antibiotic 15.50 Uniform(7.75,23.25) Expert opinion
GP start/change antibiotic 15.50 Uniform(7.75,23.25) Expert opinion
UTI antibiotics 2.80 Uniform(1.4,4.2) Prescription cost analysis160
Non-UTI antibiotics 1.24 Uniform(0.62,1.86) Prescription cost analysis160
VUR scan (ultrasound) 50.00 Uniform(25,75) Reference costs161
MCUG 137.06 Uniform(68.53,205.59) Whiting et al.56
Short-term Markov model
UTI DUTY
Fixed cost (2 days) 20.46 Uniform(10.30.69)
Daily cost 13.91 Uniform(6.96,20.87)
Non-UTI DUTY
Fixed cost (2 days) 19.58 Uniform(9.79,29.37)
Daily cost 6.82 Uniform(3.41,10.23)
Medium-term model
Diagnosis DUTY
Acute Illness Table DUTY
Antibiotic prophylaxis 23.80 Uniform(11.9,35.7) Nagler,151 prescription cost analysis160
Long-term model
Dialysis per year 21,655 Uniform(10827.5,32482.5) Baboolal et al.162
Transplantb 19,456 Uniform(9728,29184) Reference costs161
a All costs were included in the model as uniform distributions, with a lower bound 50% lower than the estimated mean
and an upper bound 50% greater than the estimated mean.
b Assuming HRG LA02A: kidney transplant 19 years and over from cadaver heart-beating donor.
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We assumed that children treated with antibiotics for a non-UTI diagnosis received an oral solution of
amoxicillin with dose 125mg/5ml and that children with a UTI diagnosis were treated with an oral
solution of trimethoprim with dose 50mg/5ml. These were, respectively, the most commonly prescribed
antibiotics for non-UTI and UTI diagnoses in the DUTY study. Costs for these antibiotics were estimated
using prescription cost-analysis data.160 Consumable costs (e.g. nappy pads) were estimated using the price
paid in the DUTY study. Imaging costs for ultrasound and MCUG scans were estimated from national
reference costs161 and a previous economic model,56 respectively.
Acute illness and medium-term cost
We used data from a carer-reported resource-use questionnaire, completed by a subsample of 918 parents
at 14 days, to estimate the acute illness cost for children with UTI and other diagnoses. Details of this
analysis are provided in Appendix 9. We estimated a fixed cost due to the initial GP visit and prescription, if
provided, and a variable daily cost reflecting the ongoing costs of further care for children whose
symptoms do not resolve quickly.
The medium-term diagnosis and acute illness costs for repeat GP visits by children with or without UTI
were the same as the index consultation (see Table 52). We used the most common regimen reported in a
systematic review of antibiotic prophylaxis,151 1–2mg per kilo daily, and assumed a child weight of 15 kg
to calculate the annual amount of antibiotics needed during treatment. We assumed that prophylactic
treatment was with an oral suspension of trimethoprim with dose 50mg/5ml (see Table 55).160
Long-term costs
The long-term model requires data on the average number of years spent in a given state (e.g. number of
years spent on dialysis before death) and the costs in each health state. We assumed that patients
experience no increased cost until the onset of ESRD. Some patients will be treated by dialysis with an
ongoing annual cost until death estimated from a UK study based on semistructured interviews with
experts in nephrology management (see Table 55).162 Other patients are treated with a renal transplant
and experience a one-off treatment cost, estimated using the national reference costs, at the time of
procedure and no further costs until death.
Utilities
All utilities used in the model are reported in Table 56. We used a uniform distribution, with a lower
bound 20% lower and an upper bound 20% greater than the estimated mean, to describe
parameter uncertainty.
TABLE 56 Utilities
Utility Estimate Distribution Source
Short- and medium-term models
UTI/no PA 0.943 Uniform(0.75,1.00) Brisson et al.164
UTI/PA 0.711 Uniform(0.57,0.85) Whiting et al.56
Non-UTI 0.943 Uniform(0.75,1.00) Brisson et al.164
Long-term model
No ESRD 1.000 Fixed N/A
Dialysis 0.430 Uniform(0.34,0.52) Churchill et al.163
Transplant 0.840 Uniform(0.67,1.00) Churchill et al.163
N/A, not applicable; PA, pyelonephritic attack.
a All utilities were included in the model as uniform distributions, with a lower bound 20% lower than the estimated
mean and an upper bound 20% greater than the estimated mean.
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Short- and medium-term utilities
We measured health-related quality of life in DUTY using the TAPQOL questionnaire.110 This showed broad
similarity in the quality of life between children in the DUTY study who had working diagnoses of UTI
and other diseases; full details are provided in Appendix 9. We therefore conducted a search of the
Cost-Effectiveness Analysis Registry165 for all studies reporting utility scores for acutely unwell infants. This
search identified studies in a number of diseases, but no estimates for infants with UTI. We elected to use utility
estimates from two studies on rotavirus as it was thought that the symptoms most closely matched those of
UTI. One study, which used the Health Utilities Index (HUI2) questionnaire to elicit utility values from caregivers
of children under the age of 3 presenting with gastroenteritis in Canada with a confirmed rotavirus infection,
reported a utility value of 0.943. Another used response from GP-completed EQ-5D questionnaires and
reported utility values of 0.781 and 0.688 in babies and children, respectively. We used the caregiver-reported
HUI2-derived utility scores in our baseline analysis and, additionally, used the GP EQ-5D-derived utility scores
as a sensitivity analysis to explore the impact of more severe quality of life decrements on our conclusions.
We used utility values for pyelonephritis in adults reported in the literature.166 The average medium-term
acute illness utilities for children with UTI were the same as the index infection (see Table 52).
Long-term utilities
We assumed that patients who do not develop ESRD have a perfect quality of life until death. Patients
with PRS experience no quality of life decrement until the onset of ESRD. Half of patients are treated by
dialysis until death, while the remainder are treated with a renal transplant and experience an increased
quality of life, when compared with those on dialysis, until death. Utility estimates for patients on dialysis
and following renal transplant were estimated from a published time-trade-off exercise of 103 transplant
and 60 hospital haemodialysis patients (see Table 56).163
Assumptions
The structure of the short-, medium- and long-term models and the links between them require a number
of structural assumptions to be made.
Short-term decision tree
l The proportion of children in whom it is not possible to obtain a urine sample and the proportion
where the sample is contaminated are equal across those with and without UTI.
l Following a contaminated sample, a repeat uncontaminated sample will always be obtained on the
second attempt.
l NHS laboratory tests are perfectly accurate at detecting the sensitivity of uropathogens to antibiotics.
Short-term Markov model
l Children for whom antibiotics are administered only when the laboratory test result is known have
delayed treatment. They receive no benefit of treatment for 2 days, until the laboratory results are
known and treatment commences. They receive the full benefit of antibiotic treatment thereafter.
l The small minority of children who are very unwell and referred to hospital are diagnosed correctly and
treated immediately.
Medium-term model
l The probability of detection, cost and utility decrement of a recurrent UTI is the same as the index infection.
l Only one recurrent UTI infection may occur in each year.
l A child consults their GP at most once per year.
l Patients with a positive ultrasound scan for VUR are sent for a confirmatory MCUG, which is 100%
sensitive and specific.
l Once patients have a first UTI, they experience an increased risk of further UTIs in the subsequent years
of the medium-term model.
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Long-term model
l A positive association exists between the number of pyelonephritic attacks and the probability for
renal scarring.
l We did not attempt to model negative externalities of an antibiotic prescription, such as the long-term
impact on bacterial resistance.
Analytical methods
We converted 95% CIs to standard errors using methods detailed in the Cochrane handbook when
parameter standard errors were not reported directly.167 The model was implemented in WinBUGS 1.4.3
(MRC Biostatistic Unit, Cambridge, UK)168 using Markov chain Monte Carlo methods. We took a Bayesian
approach to the analysis, which requires the specification of a prior distribution for each parameter
reflecting uncertainty in the value of the parameter before the data are known. We used diffuse prior
distributions for all parameters, which should not have any significant effect on the parameter estimates,
allowing the observed data to dominate the estimation. We calculated the expected costs and benefits, in
terms of QALYs, for each strategy. The expected costs include the cost of the initial diagnosis, treatment
and long-term complications. Benefits include those in the short term, due to the treatment of initial
infection, and those due to long-term prevention of complications. We ranked all of the strategies
according to their net monetary benefit (NMB), which translates the expected costs and benefits of a
given strategy onto a monetary scale for some value of willingness to pay (WTP) for a QALY. The NMB for
strategy i and a WTP λ is:
NMBi ¼ ½Benefiti  λ−Costi (1)
We calculated NMB at a WTP value of £20,000. On this basis, each urine sampling strategy is ranked in
terms of expected NMB and the optimal strategy is the one with the largest NMB. Outcomes and costs
beyond the first year after presentation were discounted at a rate of 3.5%.169
We conducted a PSA to account for parameter uncertainty. We calculated the probability of each
intervention being cost-effective at a selection of WTP values. We undertook deterministic sensitivity
analysis to evaluate the robustness of conclusions to structural assumptions made within the model.
Sensitivity analysis
Several types of uncertainty exist within our model; we conducted further analysis to assess the impact of
changes in the methodology or parameter estimates on our findings. Parameter uncertainty was explored
through specification of a probability distribution for each of the model parameters. When available, we
used the sampling distribution of the parameter; otherwise, expert opinion was used to identify a range of
plausible values. We assessed the impact of using a discount rate of 1.5% for both costs and outcomes.
We undertook one-way deterministic analysis to assess the generalisability of our results and to identify
how robust our estimates were to large changes in the point estimate of key parameters. We conducted
sensitivity analysis on parameters when they were thought to be particularly influential on our outcomes,
for example the prevalence of UTI, or when no good-quality evidence existed to inform the base-case
parameter estimate, for example the utility of children with UTI. The upper and lower bounds for each
parameter included in the sensitivity analysis were generated through discussion with members of the
project team.
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Results
Comparison of sampling strategies
Diagnostic pathway
In all urine sampling strategies, just over 3% of children who are very unwell are referred directly to
hospital for testing and treatment. In the ‘sample all’ strategy, GPs attempt to obtain a urine sample in
the remaining 96.3%, while in the ‘sample none’ strategy no children are sampled. Using the ‘clinical
judgement’ urine sampling strategy, GPs would attempt to get a sample in 9.2% of older children sampled
with a clean catch, compared with only 2.8% of younger children sampled using a nappy pad (Table 57).
The DUTY5%, DUTY10% and DUTY20% strategies thresholds were selected to sample approximately 5%,
10% and 20% of children, respectively, across both collection methods. When sought, samples were
successfully obtained in 92% of cases in all strategies. Presumptive treatment levels were highest in the
‘sample all’ strategy, where all children in whom a sample was obtained were prescribed immediate
antibiotics. Sixty-two per cent of sampled children in the clean-catch ‘clinical judgement’ strategy were
prescribed immediate antibiotics, while around half of the children in whom samples were obtained were
treated presumptively across all the DUTY strategies and the nappy pad ‘clinical judgement’ strategy.
Diagnostic accuracy
The boundary strategies ‘sample none’ and ‘sample all’ are 100% specific or 100% sensitive, respectively,
in selecting children for urine sampling across both collection methods (Table 58). In the clean-catch
samples, clinical judgement has lower diagnostic accuracy than the DUTY strategies; for example,
DUTY5% has higher sensitivity (58.6% vs. 56.7%) and higher specificity (96.1% vs. 91.4%) than
clinical judgement. DUTY10%, which samples approximately the same proportion of children as clinical
judgement, has similar specificity (91.2% vs. 91.4%) and substantially higher sensitivity (70.7% vs.
56.7%). The DUTY algorithm also outperformed clinical judgement in nappy pad samples; for example,
the DUTY5% strategy offered substantially improved sensitivity (42.7% vs. 21.1%) despite having relatively
similar specificity (95.1% vs. 97.5%) when compared with clinical judgement. The diagnostic accuracy
of both clinical judgement and the DUTY algorithm is substantially lower in nappy pad samples than
clean-catch samples. For example, the clean-catch DUTY5% strategy had much higher sensitivity (58.6%
vs. 42.7%) than the nappy pad DUTY5% strategy despite sampling a similar proportion of children. PPVs
are relatively low, and NPVs are high, across all strategies and both collection methods, primarily due to
the low prevalence of UTI. The sensitivity of each strategy is lower at the post-NHS laboratory result stage
as initially correct decisions to collect a urine sample may be over-ridden by false-negative NHS laboratory
results; however, the ordering of urine sampling strategies, in terms of their sensitivity and specificity,
remains unchanged. The high specificity of the laboratory test results in a significantly increased PPV at the
post-laboratory test stage, although the imperfect sensitivity results in a slightly lower NPV in all strategies.
Treatment pathway
A higher percentage of children with UTI receive appropriate antibiotic treatment in the urine sampling
strategies with higher sensitivity. For example, in the clean-catch DUTY5% strategy, 47.8% of children
receive immediate or delayed treatment with an appropriate antibiotic; the comparable percentage in the
DUTY20% strategy is 60.6% (Table 59). The level of serendipitous treatment was high; despite no urine
samples being conducted in the ‘sample none’ strategy, 15.8% of children with UTI received immediate
non-resistant treatment, and a total of 29.5% received some form of antibiotic treatment for working
diagnoses other than UTI. Conversely, the imperfect sensitivity of the urine sampling strategies, the inability
to obtain samples from some children and the imperfect sensitivity of the laboratory test resulted in 19.0%
of children with UTI not being treated with antibiotics even in the clean-catch DUTY20% strategy. Similar
trends were found in nappy pad samples, although levels of appropriate treatment were lower, across
both the clinical judgement and the DUTY algorithm strategies, owing to a lower accuracy of both the
initial sampling decision and the laboratory test in nappy pad samples.
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Clinical judgement resulted in generally poorer targeting of treatment. For example, the clean-catch
DUTY5% strategy collected fewer urine samples than clinical judgement, but a slightly higher proportion
of children with UTI received non-resistant antibiotics (47.8% vs. 46.4%) and a lower proportion of
children without UTI received UTI antibiotics (1.6% vs. 4.7%). Similarly in nappy pad samples, a much
higher proportion of children received non-resistant antibiotic treatment in DUTY5% than when clinical
judgement was used (38.3% vs. 27.5%), although this was partly offset by a higher proportion of children
without UTI receiving UTI antibiotics (2.7% vs. 1.2%).
When comparing DUTY strategies, a lower percentage of children who did not have UTI were incorrectly
prescribed antibiotics for UTI in the strategies with higher specificity. For example, in the clean-catch
DUTY5% strategy, 1.6% of children who did not have UTI had a false-positive diagnosis and were treated
for UTI with an antibiotic; the comparable figure in the clean-catch DUTY20% strategy was 7.9%.
Short-term costs and benefits
Average sampling, testing and antibiotic costs per patient were highest in strategies that collected urine
samples in more patients (e.g. clean-catch DUTY5% £1.10; clean-catch clinical judgement £1.84;
clean-catch DUTY20% £3.49). In general, short-term costs of treating acute illness were also higher in
strategies that sampled more patients (Table 60).
In clean-catch samples clinical judgement was both more costly and no more effective than the DUTY5%
urine sampling strategy in terms of the proportion of UTIs correctly identified (Figure 22) and QALDs
(Figure 23). In nappy pad samples clinical judgement was less costly than DUTY5% but had a substantially
lower number of UTIs correctly identified (Figure 24) and QALDs (Figure 25). Across both collection
methods, the DUTY20% urine sampling strategy achieved a very marginally higher number of QALDs than
other DUTY strategies; however, the higher use of sampling and antibiotic prescription also resulted in
higher costs.
There were only very small differences between strategies in short-term net benefit, which summarises
the costs and outcomes of each strategy. The relatively low cost of urine sampling and an antibiotic
prescription, the high rate of serendipitous antibiotic prescriptions, and the low prevalence of UTI within
the DUTY population all contributed to the narrow range of estimated net benefits (ranging from £1075
for the ‘sample all’ strategy to £1091 for the ‘sample’ none strategy in the clean-catch samples, and from
£1073 for the ‘sample all’ strategy to £1091 for the ‘sample none’ strategy in the nappy pad samples). The
results of the model slightly favoured conservative (i.e. high specificity, low cost) urine sampling strategies
such as DUTY5%. Furthermore, the PSA indicated that there was a very high probability that the ‘test
none’ strategy was more cost-effective than even the DUTY5% strategy at a WTP of £20,000 per QALY
(see Table 60).
Medium- and long-term outcomes
The magnitude of differences between strategies for all the medium- and long-term outcomes was also
very small for both collection methods (Table 61). Urine sampling strategies with the highest sensitivity
identified and treated VUR in a higher proportion of cases and hence had the lowest rates of UTI
recurrence. However, as the treatment for VUR is only moderately effective and ESRD is rare, the difference
between strategies in ESRD incidence, life expectancy and QALYs is negligible. Lifetime net benefits were
generally marginally higher in urine sampling strategies where fewer children were sampled. Once again,
when considering lifetime net benefits, the model suggested that conservative sampling strategies were
more cost-effective and there was a high probability that the ‘test none’ strategy was the most
cost-effective strategy at a WTP of £20,000 per QALY (see Table 61).
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FIGURE 22 Clean-catch sampling and testing costs vs. percentage of laboratory-confirmed UTI. CJ, clinical
judgement; DUTY5%, highly specific DUTY algorithm; DUTY10%, moderately sensitive and specific DUTY
algorithm; DUTY20%, highly sensitive DUTY algorithm.
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FIGURE 23 Clean-catch short-term costs vs. average QALDs, comparison of sampling strategies. CJ, clinical
judgement; DUTY5%, highly specific DUTY algorithm; DUTY10%, moderately sensitive and specific DUTY
algorithm; DUTY20%, highly sensitive DUTY algorithm.
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FIGURE 24 Nappy pad sampling and testing costs vs. percentage of laboratory-confirmed UTI. CJ, clinical
judgement; DUTY5%, highly specific DUTY algorithm; DUTY10%, moderately sensitive and specific DUTY
algorithm; DUTY20%, highly sensitive DUTY algorithm.
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FIGURE 25 Nappy pad short-term costs vs. average QALDS, comparison of sampling strategies. CJ, clinical
judgement; DUTY5%, highly specific DUTY algorithm; DUTY10%, moderately sensitive and specific DUTY
algorithm; DUTY20%, highly sensitive DUTY algorithm.
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Comparison of testing and treatment strategies for the clean-catch
DUTY5% strategy
In a secondary analysis we compared three alternative urine testing and treatment strategies (laboratory
testing-based treatment; dipstick test-based treatment; and presumptive treatment) to explore the role of
dipstick testing in guiding laboratory testing and antibiotic prescriptions assuming that urine sampling was
based on the DUTY5% strategy. Samples are obtained in 4.35% of children in the DUTY5% strategy; of
these, 2.14% are considered low risk and 2.22% are considered higher risk. In the laboratory testing
strategy, the 2.14% of children considered low risk have their treatment delayed until the laboratory test is
returned. In the dipstick testing strategy, a positive dipstick test result expedites treatment in approximately
26% of these low-risk children, increasing the overall proportion treated immediately with antibiotics form
2.14% to 2.72%. In the presumptive treatment strategy, all low-risk children are treated presumptively
and hence 4.35% receive immediate antibiotics (Table 62 and Figure 26).
A greater percentage of children were treated with immediate non-resistant antibiotics in the strategies
with the highest presumptive treatment rates (laboratory testing 31.2%; dipstick testing 41.8%;
presumptive treatment 45.2%); the laboratory testing strategy has the largest proportion of patients
treated with delayed non-resistant antibiotics (16.6%) due to a larger proportion of children who had their
treatment delayed until the laboratory result was known. More aggressive treatment strategies led to a
higher proportion of children incorrectly treated for UTI (e.g. LT 1.6%; dipstick testing 1.9%; presumptive
treatment 3.4%) (see Table 62).
TABLE 62 Comparison of testing and treatment strategies for clean-catch DUTY5% algorithm
Outcome LT-DUTY5% DT-DUTY5% PT-DUTY5%
Diagnostic pathway
% dipstick sample 0.000 2.217 0.000
% prescribe antibiotics immediately 2.135 2.720 4.352
% wait for laboratory test before antibiotic prescription 2.217 1.631 0.000
Treatment pathway
% UTI, immediate (NR) 31.192 41.804 45.174
% UTI, delayed treatment (NR) 16.617 4.469 0.922
% UTI, other treatment 15.701 19.655 20.857
% UTI, not treated 36.489 34.072 33.047
% not UTI, treated with UTI antibiotics 1.592 1.884 3.416
Short-term costs and benefits
Average cost of sampling, testing (£) 0.668 0.726 0.668
Average cost of sampling, testing, treatment (£) 1.100 1.183 1.187
Short-term average QALDs 20.709 20.709 20.709
Short-term net benefit (£20,000) 1090.44 1090.38 1090.40
INMB, (95% CI)a – –0.05
(–0.07 to –0.04)
–0.04
(–0.05 to –0.03)
DT, dipstick-based treatment; LT, laboratory-based treatment; PT, presumptive treatment.
a Incremental net monetary benefit compared with clinical judgement (bootstrapped 95th percentile CIs).
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Average sampling and testing costs are higher in the DT strategy (£0.73) than in the laboratory testing and
presumptive treatment strategies (£0.67) due to the additional cost of the dipstick test. When including
antibiotic treatment costs, the presumptive treatment strategy (£1.187) was more expensive than both the
dipstick testing (£1.183) and laboratory testing (£1.100) strategies. Strategies with higher levels of
immediate treatment had marginally larger QALDs, but net benefits were very similar across all three
testing and treatment strategies (see Table 62).
Comparison of the full DUTY risk score with points-based algorithm
In a further analysis we compared the outcomes of the full DUTY risk score to the simpler points-based
algorithm. We attempted to choose cut points at 3, 4, 5 and 6 on the DUTY points score. Owing to nature
of the points score, with only a small number of possible values, a secondary cut-point could not always
be chosen to allow close to half of the sample children to be treated presumptively and allow maximum
comparability with the DUTY coefficient model. For example, the proportion of children who were sampled
who were treated with immediate treatment varied from 16% to 65% in the points-based strategies,
compared with between 48% and 49% in the full risk score strategies (Table 63).
The diagnostic accuracy of the points-based algorithms was lower than the full risk score. For example, in
clean-catch samples the full model DUTY5% strategy had similar sampling and testing costs (£0.67 vs.
£0.62) to the points-based DUTY≥ 6 strategy, but much higher post-laboratory test sensitivity (41.9%%
vs. 32.1%) (Figure 27). Despite the loss of accuracy when compared with the full model, the points-based
model still outperformed clinical judgement. For example, the points-based algorithm DUTY≥ 5 strategy
had a similar average number of short-term QALDs to the clinical judgement strategy despite substantially
lower costs (£1.43 vs. £1.84) (Figure 28). Short-term net benefits were similar across all of the full model
and points-based strategies, ranging from £1087 to £1090, but were generally lower in strategies which
sampled more patients.
PT
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FIGURE 26 Clean-catch short-term costs vs. average QALDs, comparison of treatment and testing strategies.
LT, laboratory-based treatment; DT, dipstick-based treatment; PT, presumptive treatment.
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FIGURE 27 Clean-catch sampling and testing costs vs. post-laboratory test sensitivity, comparison of full and
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CJ, clinical judgement; DUTY5%, highly specific DUTY algorithm; DUTY10%, moderately sensitive and specific
DUTY algorithm; DUTY20%, highly sensitive DUTY algorithm; PB, points-based algorithm.
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Deterministic sensitivity analysis
We undertook one-way deterministic analysis to assess the generalisability of our results and to identify
how robust our estimates were to large changes in the point estimate of key parameters (Tables 64
and 65). None of the scenarios tested changed our conclusions that ‘sample none’ or the conservative
DUTY5% sampling strategy were likely to be most cost-effective. Of all short-term scenarios tested (see
Table 64), an assumption that the prevalence of UTI could be as high as 10% had the biggest impact on
the difference in short-term net benefits between the conservative (DUTY5%) urine sampling strategy and
more liberal sampling strategies (e.g. DUTY20%). However, the conservative urine sampling strategies
remained most cost-effective. Similar results were found in sensitivity analyses on nappy pad outcomes.
TABLE 64 Sensitivity analysis, short-term parameters
Parameter Base case
Sensitivity
analysis
Short-term NMB, £
‘Sample
none’ DUTY5% DUTY10% DUTY20%
UTI prevalence 0.019 0.100 1088.96 1088.30 1087.67 1086.20
Pyelonephritis prevalence 0.157 0.570 1090.73 1090.22 1089.53 1087.97
Serendipitous treatment rates 0.267 0.000 1091.67 1091.13 1090.42 1088.83
Diagnostic accuracy of laboratory
culture (sensitivity, specificity)
0.780, 0.978 1.000,1.000 1091.45 1090.88 1090.16 1088.59
Antibiotic treatment effect RRa= 0.550 RR= 0.250 1091.01 1090.61 1089.96 1088.44
Impact of antibiotic resistance on
symptom resolution
RRb= 0.700 RR= 0.550 1091.42 1090.84 1090.13 1088.55
Utility of UTI (UTI, PA)c 0.943,
0.711
0.688,
0.500
1021.61 1021.14 1020.47 1018.93
Resistance rates, non-UTI antibiotics 0.531 0.750 1091.43 1090.86 1090.14 1088.56
Resistance rates, UTI antibiotics 0.281 0.000 1091.45 1090.90 1090.21 1088.65
PA, pyelonephritic attack.
a Risk ratio comparing symptom resolution rates for children not treated with antibiotics with those in children treated
with antibiotics.
b Risk ratio comparing symptom resolution rates for children treated with antibiotics where the uropathogen was resistant
compared with where the uropathogen was sensitive.
c Utility for patients with UTI and pyelonephritis, respectively.
TABLE 65 Sensitivity analysis, long-term parameters
Parameter Base case
Sensitivity
analysis
Short-term NMB, £
‘Sample
none’ DUTY5% DUTY10% DUTY20%
Probability of PRS (0 PA, 1 PA, 2 PA,
3 PA, 4 PA)a
0.05, 0.09,
0.16, 0.34,
0.58
0.10, 0.18,
0.32, 0.68,
1.00
512,740 512,738 512,736 512,731
Cost of ESRD, £ (dialysis, transplant)b 21,655,
19,456
43,310,
38,912
514,594 514,592 514,590 514,585
Discount rate (%) 3.5 1.5 889,820 889,818 889,816 889,811
PA, pyelonephritic attack.
a Probability of PRS given 0–4 pyelonephritic attacks.
b Cost of dialysis (annual) and transplant, respectively.
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Discussion
Summary of findings
The economic analyses described in this chapter evaluated the potential to use the clinical symptoms
and signs predictive of UTI to improve upon current practice in selecting children for urine sampling and
targeting antibacterial therapy. We found that in older children, when a clean-catch urine sample is
feasible, the full DUTY risk score outperformed GPs’ clinical judgement, even taking account of the
reduced reliability and accuracy of NHS laboratories compared with the research laboratory and the need
to repeat contaminated samples. For example, by choosing a high specificity threshold (DUTY5%), GPs
would request a urine sample from fewer children (4.8% vs. 9.2%) with equivalent or higher sensitivity
and specificity, achieving marginally better costs and patient outcomes in the short and long term.
In younger children, if urine was collected using a nappy pad, the distinction in cost-effectiveness between
the DUTY risk score and clinical judgement was not clear-cut. This is a result of the lower diagnostic
value of the DUTY risk score in younger children, noted in Chapter 5, the higher contamination rates
necessitating repeat urine sampling and the lower accuracy of NHS laboratory results in urine collected
using nappy pads, raising the possibility that a correct clinical diagnosis is overturned by an incorrect
laboratory test result.
The choice of a threshold on the DUTY risk score which will optimally identify patients whose risk of UTI
is high enough to justify collecting a urine sample is not straightforward. We explored three possible
thresholds which represented a range of trade-offs between high sensitivity and high specificity. The
results of our decision analysis model slightly favoured conservative (i.e. high specificity) urine sampling
strategies. However, the absolute difference in average short- and long-term net benefits between the
three DUTY thresholds evaluated was very small.
Using a DUTY points-based algorithm in clean-catch samples, which can be calculated simply, achieves
lower short-term costs of testing and treatment and equivalent patient outcomes to clinical judgement.
For example, the incremental net benefit when comparing the DUTY points≥ 5 and clinical judgement
algorithms was £0.42 (95% CI £0.40 to £0.44). However, this simplification came at the expense of lower
diagnostic accuracy than the comparable full DUTY risk score.
The additional diagnostic information provided by dipstick tests has the potential to play a role in the
efficient diagnosis and treatment of children with suspected UTI. We found that, if used in children thought
to be at ‘lower’ risk of UTI to determine whether or not immediate antibacterial therapy should be started,
a dipstick test strategy could increase the proportion of children with UTI treated immediately (41.8% vs.
31.2%) compared with a strategy based on laboratory test results, and decrease the proportion of children
without UTI treated with UTI antibacterials (1.9% vs. 3.4%) compared with a presumptive treatment
strategy. These potential benefits are counterbalanced by the additional costs of the dipstick test.
Strengths and limitations
Our model was based on individual patient data from a large diagnostic cohort study which avoided
many of the potential biases of diagnostic accuracy studies. Our analysis is based on high-quality evidence
about the potential for GPs to use clinical symptoms and signs predictive of UTI to improve upon current
practice in selecting children for urine sampling. However, our estimate of current practice in the
clinical judgement strategy is based on primary care clinicians’ responses to questions about working
diagnoses and hypothetical testing and treatment actions if the child had not been in DUTY. This could
have introduced a type of Hawthorne effect,170 whereby clinicians participating in DUTY had a higher
index of suspicion of UTI or were more careful in reaching their working diagnosis because they were
participating in a research study on UTI. If this were the case, clinical judgement in routine practice might
have lower sensitivity than that which we observed in DUTY. We believe that it is unlikely that any such
effect would alter our finding that the DUTY risk scores in clean-catch samples were a more cost-effective
diagnostic strategy than clinical judgement.
HEALTH ECONOMIC ANALYSIS AND MODELLING OF DIAGNOSTIC STRATEGIES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
142
We did not attempt to quantify the wider societal costs of antimicrobial resistance, beyond the treatment of
childhood UTI. A recent review of the literature concluded that current estimates of the costs of resistance
are likely to be underestimates and that an accurate forecast of costs may not be possible.104 The economic
evidence provided by our study should be viewed in the wider context of increasingly resistant organisms
and fewer new antimicrobial drugs reaching the market. Furthermore, we did not model the impact of
urine sampling strategies on children who do not have UTI. Strategies that promptly and accurately ‘rule
out’ UTI may help children by allowing clinicians to quickly diagnose and treat other illnesses; however,
given the myriad of other illnesses that children may have, this is extremely difficult to quantify.
Our model relies on incomplete and imperfect evidence. For example, the antibiotic treatment effect in the
short-term model is based on a small RCT conducted in adults and the utility scores are based on children
presenting to primary care with other acute conditions. The evidence underlying much of the medium- and
long-term model is based on observational associations which may be subject to bias. In some areas the
evidence is evolving. The Randomised Intervention for Children with Vesicoureteral Reflux (RIVER) study
(ClinicalTrials.gov number NCT00405704), which at the time of writing is yet to publish results, will provide
useful information on the benefits of long-term antibiotic prophylaxis and has the potential to change the
results of our model. We have explored the uncertainty in our model introduced by limited and imperfect
evidence by conducting a range of deterministic and probabilistic sensitivity analyses. These analyses
suggest that our conclusions, favouring conservative (i.e. high specificity) urine sampling strategies, are not
affected by relatively large but plausible changes in parameters such as UTI prevalence and the diagnostic
accuracy of NHS laboratories. Because of the very small differences in predicted average patient outcomes
between strategies, our findings support low-cost, high-specificity strategies across the range of scenarios
tested in sensitivity analyses.
We modelled a limited number of urine sampling, testing and treatment strategies. The large number of
risk score thresholds which could be used to decide which children to sample or treat presumptively and
the multiple permutations of dipstick test results which might be used to expedite treatment or determine
which samples to send to the laboratory produce an almost unlimited number of possible strategies. We
evaluated those which most closely reflected the range of current practice among GPs on the project
team, but these might not be representative of all strategies currently used by GPs, and other strategies
might potentially prove to be more cost-effective.
Results in context with other studies
As far as we are aware, this is the first study to evaluate the cost-effectiveness of prediction rules to
optimise the selection of children with suspected UTI for urine sampling in any primary or secondary care
setting. Previous work has assessed the most cost-effective test or series of tests for diagnosing UTI rather
than evaluating which children should be selected for urine sampling. A NIHR HTA programme systematic
review and economic model evaluating 79 testing and treatment strategies for children with suspected
UTI concluded that the optimal strategy was dependent on the age and sex of the child.56 Presumptive
treatment had the highest probability of being cost-effective at lower willingness-to-pay thresholds. At
higher thresholds, up to £20,000 per QALY, testing and treatment based on positive dipstick nitrites and
LE results became the most probably cost-effective strategy.
Clinical and research implications
For an individual child, who may or may not have UTI, attending primary care with non-specific symptoms,
the expected costs and benefits of all six diagnostic strategies were very similar. This is because the cost of
urine sampling is relatively low and for the vast majority of children, who do not have UTI, outcome is not
dependent on the diagnostic strategy chosen. However, for the NHS’s provision of care to the population of
children visiting primary care throughout their early years, differences in the aggregate costs of the diagnostic
strategies will be important. Equally, for the individual child who does have UTI, the choice of diagnostic
strategy will have a significant impact on outcome. Our findings demonstrate the need for clinicians to base
the decision to collect a urine sample on symptoms and signs known to be predictive of UTI in primary care
rather than on personal judgements or mixed evidence derived from secondary care settings.
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Our results tended to favour low-cost conservative (higher specificity) urine sampling strategies. Indeed, in
both the clean-catch and nappy pad models, the ‘sample none’ strategy yielded the highest expected net
benefit, although the difference between it and the conservative DUTY5% strategy was very small. The
reasons for this are manifold and include the high prevalence of antibiotic prescribing for other illnesses
leading to serendipitous treatment of undiagnosed UTI, the relatively short duration of antibiotic effects in
children with UTI and the rare and uncertain nature of long-term sequelae of untreated UTI. Assuming
that a ‘sample none’ strategy is untenable, then a reasonably conservative strategy for a GP concerned
about the overprescription of antibiotics would be similar to the DUTY5% strategies. For example, a GP
requesting urine samples in children scoring > 5 on the DUTY points-based score or a probability of more
than 0.085 on the DUTY full risk model would sample approximately 4.4% of all children with non-specific
constitutional symptoms and request a sample in > 43% of children who have UTI. A GP more concerned
about missing a diagnosis of UTI could use the more liberal DUTY10% or DUTY20% thresholds.
Where possible, the DUTY risk score should be calculated based on the full model rather than the
points-based model because of the increased diagnostic accuracy. For electronic records where the relevant
symptoms and signs are routinely recorded, this process should be inexpensive and automated. However,
in settings where resources do not permit this, a hand calculation based on the DUTY points-based model
will allow clinicians to more efficiently identify children at highest risk of UTI than through using clinical
judgement alone.
The poorer diagnostic and economic performance of the DUTY risk score in younger children with nappy
pad samples underlines the importance of obtaining a clean-catch sample whenever practical. The initial
inconvenience and time costs of collecting a clean-catch sample in a busy clinical setting is likely to be
more than outweighed by the cost and health implications of contaminated samples, repeated samples
and false-positive laboratory results associated with nappy pad samples.
Future research could further define the role of dipstick testing in diagnosis and treatment strategies for
childhood UTI. We have demonstrated the potential for positive nitrite and leucocyte results to expedite
treatment in children at intermediate risk of UTI. However, the many permutations of dipstick results and
the multiple ways in which it might inform clinical decision-making should be explored further. In
particular, dipstick tests may also be useful in children considered, based on symptoms and signs, to be at
higher risk of UTI. In this group, a negative dipstick test result might be an efficient way to prevent hasty
presumptive treatment in children who do not have UTI. Additional work is needed to also quantify the
benefits of prompt diagnosis of UTI. Studies of parent-reported quality of life and disutility of UTI
symptoms in young children would enable more precise estimations of the short-term benefits of
antibiotics. Long-term epidemiological study designs are also needed to better quantify the strength of
association between childhood UTI and eventual renal disease. However, because some aspects of the
decision problem, such as the societal impact of antibacterial resistance, are essentially intangible, the
choice of diagnostic strategy is likely to remain a balance between evidence and judgement.
Conclusions
For older children, we found that the full DUTY coefficient and the simpler DUTY points-based model were
both marginally more cost-effective than GPs’ clinical judgement in selecting children in whom to collect a
clean-catch sample and test for UTI. Small differences between strategies in cost-effectiveness are important
given the large number of urine samples collected in children. The difference in cost-effectiveness between
the DUTY risk score and clinical judgement for younger children with nappy pad samples was not clear-cut,
underlining the importance of obtaining a clean-catch sample whenever practical. Our findings suggest that
high specificity thresholds, such as DUTY5%, are likely to be more cost-effective, particularly for GPs
concerned about the societal impact of antibacterial resistance.
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Chapter 7 Determinants of urinary contamination
Introduction
Diagnosis of UTI is difficult to make and may be missed in up to 50% of children presenting to primary
care.48,107 Establishing a diagnosis in pre- or early school-aged children is challenging, because a high
proportion are preverbal, there is a lack of specific symptoms, and collection of uncontaminated urine
samples is difficult, particularly in primary care settings where the provision of time and private space for
young children is challenging.64 UK NICE guidelines suggest that samples should be collected using a
method suitable for the age of the infant or child.2 ‘Clean-catch’ samples are preferred, but urine
collection pads (nappy pads) are suggested if this is not possible. In the USA, SPA is the gold standard and
has been used along with urethral catheterisation, but both are invasive and can be painful for infants,
with limited success rate.102,120,146,147 US guidelines recognise ultrasonography increases success but at
increased cost.
Laboratory diagnosis is based on colony counts after culture, using quantity and type of bacteria present
in the urine sample as the main criteria. Culture methods differ between NHS laboratories but all are
derivatives of the UK standards for microbiology investigations (B41),82 which describe criteria for
significant bacteruria for children as ≥ 105 CFU/ml of a single species from a clean-catch specimen,
104–105 CFU/ml single species or ≥105 CFU/ml of any bacteria from a SPA. These guidelines also describe
colony counts of ≤ 104 CFU/ml and ≥105 CFU/ml from bag urines as diagnostically useful for a negative
result and as an indicator of a poor-quality sample, respectively.
It is recognised that difficulty in specimen collection and the interpretation of specimens potentially
contaminated prior to culture, from skin, faeces and other sources, may contribute to the misdiagnosis of
UTI.89 Overdiagnosing UTI can lead to unnecessary investigations and treatment, which entail risks of
complications and psychological stress to the child and his or her family. Discriminating between
contamination with faecal organisms and potential UTI pathogens in the laboratory is difficult, as the most
common faecal organism and the most common pathogen causing UTI is E. coli, and high colony counts
may be found in children without UTI.
Urine samples in the DUTY study were collected by either clean catch or nappy pad, with samples split
between a local NHS laboratory and, for a more detailed examination, a research laboratory. The aim of
this chapter is to compare the prevalence of contamination by urine collection method, based on the
research laboratory result, and to identify the independent factors associated with contamination using the
local laboratory results.
Methods
Participants, urine collection and microbiological methods
These have all been described in detail in previous chapters and our protocol paper.105 For a full description
of the measures taken to minimise contamination of urine specimens, see Chapter 2.
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Definition of contamination
Interpretation of laboratory results from microscopy and culture is not straightforward, with definitions,
collection methods and criteria for contamination and UTI inextricably linked. The HPA in its 2012
guideline82 does not use differing cut levels for the diagnosis of UTI in children, but UTI criteria are
dependent upon all patient information, with different criteria for various patient groups. Generally, UTI is
suspected if culture counts of a pure or predominant growth of organism are ≥ 105 CFU/ml. Any counts
below this with ≥ 2 organisms present may be indicative of contamination. In children, the guidelines
suggest that cultures < 104 CFU/ml from bag urines may be regarded as negative for UTI and that cultures
≥ 105 CFU/ml may be contaminated and should be repeated with a reliable specimen. There is no mention
of any use of nappy pads even though this has been established as a recommended collection method by
NICE.2 Squamous epithelial cells present in the urine are a useful indicator of the degree of contamination,
but no clear cut-off is recommended in the HPA guidelines.
The European Urinalysis Guidelines of 2000136 consider ‘most acute uncomplicated urinary tract infections
result from one bacterial species’ and ‘the isolation of more than one organism from a single specimen of
urine must be interpreted in the light of (potential) contamination’. The European Association of Urology
Guidelines of 2009 regard colony counts of between 103 and 105 CFU/ml as UTI in symptomatic adults and
≥ 105 CFU/ml in asymptomatic adults.83 In children, the UTI cut-off criteria are based on collection method:
any growth from SPA, 103 to 104 CFU/ml from catheter urine, ≥ 104 CFU/ml in children with UTI symptoms
and ≥ 105 CFU/ml without UTI symptoms. Neither mention of contamination nor any mention of nappy
pad as a collection method is made. A variety of different definitions of contamination have been
proposed, differences being in the number of different organisms present and the quantity, derived from
colony counts (Table 66).
For the purposes of this chapter we defined contamination using the research laboratory results, with
a criterion of count ≥ 105 and > 2 organisms, equivalent to Jackson et al.’s94 definition of frankly
contaminated. We also excluded any urines collected via bags (n= 73) and any urines with an unknown
collection method (n= 17), leaving 5017 urines to analyse.
We also considered a number of other definitions of contamination, firstly equivalent to Feasey90 or
Rao et al.91 and secondly equivalent to Bekeris et al.96 or to Jackson et al.93 of probable contamination or
higher. Although we did not carry out extensive analyses using these definitions, we considered their effect
TABLE 66 Comparing other research definitions of contamination (in date order)
Paper authors Contamination definition
Feasey90 > 105 growth and ≥ 2 organisms
Rao et al.91 > 105 growth and ≥ 2 organisms
Alam et al.92 Any growth including < 105 (that is not UTI)
Jackson et al.93 104 to 105 1 or 2 species possible contamination
104 to 105 > 2 species probable contamination
> 105 > 2 species frank contamination
Blake et al.94 Growth of a non-uropathogen
Unlu et al.95 103 to 104 growth and ≥ 2 organisms
Vaillancourt et al.89 Single organism growth < 105 OR ≥ 2 organisms
Bekeris et al.96 > 104 growth and > 2 organisms
Wingerter et al.97 Multiple pathogens OR non-uropathogens OR any growth < 104
Tosif et al.98 ≥ 2 organisms (and a collection method specific growth)
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on the numbers of contaminated urines by collection method. We selected these definitions from Table 66
to most closely reflect what we thought a NHS laboratory would report in practice and also which did not
include too many borderline growths (lower than 104 CFU/ml) that could be a UTI.
Statistical analysis
All analyses used results from the research laboratory to define contamination. We compared
contamination rates by urine collection method. To create a model showing factors associated with
contamination, we selected a priori a number of variables. The variables were grouped in order to reduce
the potential for spurious associations into those associated with laboratory and clinical findings, with
faeces, skin variables and variables from our prediction rule (see Chapter 5). The laboratory and clinical
findings included were dipstick tests results, leucocytes, pH, specific gravity, proteins, ketones, blood,
nitrites, urine collection method, and the urine being smelly, dark or cloudy. In addition, we examined
where the sample was collected, whether the nurse was an in-house or a DUTY nurse, and the time taken
for the sample to reach the laboratory. The faecal variables were diarrhoea in the past 24 hours, the child
taking laxatives and constipation in the last week. The skin variables were sex, circumcision, wearing
nappies, dehydration, number of nappies used in the previous 24 hours, number of showers/baths in a
week and nappy rash. The variables from our prediction rule (see Chapter 5) included were cough, global
impression of child, pain/crying when passing urine, abdominal tenderness on examination, any acute
abnormality on ear examination and history of UTI. We then examined the frequency of variable
categories, blind to their associations with contamination, and merged the least frequent categories prior
to analyses. Univariable associations with contamination were estimated using logistic regression. P-values
were derived from a LR test of adding each single variable. In the case where the variable was ordinal a
single heterogeneity p-value was reported and another for the trend. These univariable associations were
stratified by urine collection method. We selected any variable for our multivariable model if it had a
p-value < 0.01 considering either heterogeneity or trend p-values. These two multivariable models were
then displayed using ORs and their 95% CIs. All analyses were completed using a complete case approach.
We carried out a number of comparisons: the number of contaminated urines in clean catch and nappy
pads; and for the contaminated samples only, the numbers of urines with organisms (coagulase-negative
staphylococci, E. coli, enterococci and staphs) present in clean catch and nappy pads. These comparisons
included the risk difference and risk ratio along with their 95% CIs and a p-value derived from a
chi-squared test.
Finally, we compared the number of squamous epithelial cells (using 10 or more squamous epithelial cells
as a cut-point) in contaminated and uncontaminated samples; and the number of urines with organisms
[E. coli, enterococci and other Enterobacteriaceae (e.g. Proteus)] present in contaminated and UTI-positive
urines. We looked at both the risk difference and risk ratio with their 95% CIs and p-values derived from a
chi-squared test. These analyses were stratified by collection method.
Results
Of the 7163 children in the study as a whole, we received urine from 6390. The local laboratories cultured
6079 samples and the research laboratory 5107 samples, with 4910 urines cultured at both laboratories
(Figure 29). Thirty-three urines were not received at the research laboratory. Of the 5107 research
laboratory results, 5017 were collected using either clean catch or nappy pads with 73 bag urines, and
17 with missing collection method were removed from the analysis due to the unsuitability of the collection
method. This is why the numbers are not the same as in Chapter 5. Similar numbers of urines from each
collection method were included: 55% clean catch and 45% nappy pad. Figure 30 shows the flow of
participants in this chapter which relates only to urines received and processed at the research laboratory.
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FIGURE 29 Effect of clinical suspicion of UTI on the number of days until symptoms improved among children
with UTI.
Sent to research laboratory
(n = 5264, 82.3% of 6390)
Urine collection
(n = 6390, 89.2% of 7163)
Not received, n = 33
Clean catch
(n = 2740, 53.6% of 5107)
Contaminated
(n = 50, 1.8% of 2740)
Nappy pad
(n = 2277, 44.5% of 5107)
Contaminated
(n = 277, 12.2% of 2277)
Research laboratory cultured
(n = 5107, 97.6% of 5231)
Not cultured, n = 124
Not used in
this chapter
• Bag collection,
   n = 73
• Collection
   method
   missing, n = 17
FIGURE 30 Participant flow in contamination chapter (research laboratory).
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Microbiological predictors of contamination
Table 67 shows that both clean-catch and nappy pad samples have increasing prevalence of contamination
as the definition is relaxed according to the criteria outlined in Table 66 (although note that we restricted
this to those definitions that could be reported by a NHS laboratory) and that, for all definitions used,
the nappy pad contamination rate consistently exceeds that seen in the clean-catch samples.
Table 68 shows that there was a 1.8% chance that clean-catch urines were contaminated, compared
with 12.2% in nappy pad urines. The risk was 10% (95% CI 8.9 to 11.8%) greater and the risk of
contamination 6.7 times larger in nappy pad than in clean catch.
The most dominant organisms found in contaminated urines from 10 research laboratories are shown in
Tables 69–71. To verify which organisms were associated with contamination, the prevalence of all
organisms present in the contaminated urines were compared with those present in urines from patients
considered to have a UTI from the same study (see Chapter 4). Tables are divided by collection method of
urine to evaluate any difference between clean catch and nappy pad.
E. coli was present in 85% out of 86.7% of clean-catch/nappy pad urines from patients diagnosed with a
UTI, compared with 76% out of 84.1% in contaminated urines (see Tables 69 and 70). The numbers of
TABLE 67 Numbers of contaminated urines by different definition (research laboratory)
Contamination definition Clean-catch contaminated, n (%) Nappy pad contaminated, n (%)
≥ 105 > 2 organismsa 50 (1.8) 277 (12.2)
≥ 105 ≥ 2 organisms 78 (2.9) 426 (18.7)
≥ 104 > 2 organisms 175 (6.4) 599 (26.3)
Total 2740 2277
a Definition used for subsequent analyses.
TABLE 68 Number of contaminated urines by collection method (clean catch/nappy pad)
Clean catch, n/N (%) Nappy pad, n/N (%) Risk difference (95% CI) Risk ratio (95% CI) p-value
50/2740 (1.8) 277/2277 (12.2) 0.10 (0.08 to 0.11) 6.66 (4.95 to 8.96) < 0.001
TABLE 69 Organisms prevalent in clean-catch contaminated urines compared with UTI-positive urines
Organism
identity
UTI positive,
n/N (%)
Contaminated,
n/N (%) Risk difference (95% CI) Risk ratio (95% CI) p-value
E. coli 51/60 (85.0%) 38/50 (76.0%) –0.090 (–0.239 to 0.059) 0.894 (0.740 to 1.080) 0.232
Enterococcus
species
14/60 (23.3%) 41/50 (82.0%) 0.587 (0.436 to 0.738) 3.514 (2.182 to 5.661) < 0.001
KESa 4/60 (6.7%) 26/50 (52.0%) 0.453 (0.301 to 0.606) 7.800 (2.917 to 20.855) < 0.001
Proteus species 6/60 (10.0%) 7/50 (14.0%) 0.040 (–0.083 to 0.163) 1.400 (0.503 to 3.897) 0.518
a Klebsiella species, Enterobacter species and Serratia species.
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urines with E. coli present were similar for UTI-positive and contaminated samples in both clean-catch and
nappy pad urines (with p-values of 0.232 and 0.715, respectively). Proteus species was also present at
similar levels in clean catch (p-value of 0.518) from patients diagnosed with a UTI and contaminated
urines. However, looking at other Enterobacteriaceae and Enterococcus species showed evidence of a
difference between UTI-positive and contaminated samples in both clean-catch and nappy pad samples,
that is 6.7% of clean-catch and 13.3% of nappy pad urines from patients diagnosed with a UTI contained
one of three other Enterobacteriaceae (Klebsiella, Enterobacter and Serratia species), compared with
52% and 41.1% in contaminated urines, respectively. Enterococci were present in 23.3% of clean-catch
and 53.3% of nappy pad urines from patients diagnosed with a UTI, compared with 82% and 92.1% in
contaminated urines, respectively.
In order to determine if any particular organism was associated with contamination in nappy pad samples,
the most dominant organisms present in the contaminated urines were compared according to
collection method.
Nappy pad urines are 30.8% more likely to be contaminated with coagulase-negative staphylococci than
clean catch (risk difference) or, equivalently, the risk was 1.8 times higher in nappy pad urine. In both
nappy pad and clean-catch urines, contamination caused by E. coli was similar, with a p-value of 0.161.
However, there is some evidence to suggest that enterococci are more likely to be present in contaminated
nappy pad samples, 92.1%, than in contaminated clean-catch samples, 82% (p-value of 0.025) (see
Table 71).
Squamous epithelial cells are routinely used in the laboratory as a guide to contamination. The numbers of
contaminated and all other urines from each collection method to exhibit ≥ 10 squamous epithelial cells
present are shown in Table 72.
In clean-catch urines, the number of urines with ≥ 10 squamous epithelial cells was significantly higher in
contaminated (10%) than in non-contaminated urines (2.7%). However, in nappy pad urines the levels of
squamous epithelial cells were similar for contaminated (10.5%) and non-contaminated (9%) urines.
TABLE 70 Organisms prevalent in nappy pad contaminated urines compared with UTI-positive urines
Organism identity
UTI positive,
n/N (%)
Contaminated,
n/N (%)
Risk difference
(95% CI) Risk ratio (95% CI) p-value
E. coli 26/30 (86.7%) 233/277 (84.1%) –0.026 (–0.155 to 0.104) 0.971 (0.836 to 1.127) 0.715
Enterococcus
species
16/30 (53.3%) 255/277 (92.1%) 0.387 (0.206 to 0.569) 1.726 (1.233 to 2.417) < 0.001
KESa 4/30 (13.3%) 114/277 (41.2%) 0.278 (0.143 to 0.413) 3.087 (1.226 to 7.769) 0.003
a Klebsiella species, Enterobacter species and Serratia species.
TABLE 71 Organisms prevalent in contaminated urines
Organism identity
Clean catch,
n/N (%)
Nappy pad,
n/N (%)
Risk difference
(95% CI) Risk ratio (95% CI) p-value
Coagulase-negative
staphylococci
20/50 (40.0%) 196/277 (70.8%) 0.308 (0.12 to 0.45) 1.769 (1.24 to 2.50) < 0.001
E. coli 38/50 (76.0%) 233/277 (84.1%) 0.081 (–0.04 to 0.20) 1.107 (0.93 to 1.30) 0.161
Enterococcus
species
41/50 (82.0%) 255/277 (92.1%) 0.101 (–0.01 to 0.22) 1.123 (0.98 to 1.28) 0.025
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Clinical predictors of contamination
Univariable associations with contamination were analysed in groups, laboratory and clinical (faecal and
skin) variables, to link potential contamination sources and variables associated with the DUTY algorithm
identified in Chapter 5.
Table 73 shows the variables associated with contamination in clean-catch samples. Other variables
analysed, but not found to be associated, were all other dipstick results, urine colour, odour and opacity,
presence of nurse during collection, urine transport time, laxative use, constipation, presence of diarrhoea,
circumcision, dehydration, number of baths/showers per week, nappy rash (important as this was shown
to be inversely associated with UTI in the nappy pad samples), presence of cough, global impression of
child by clinician, pain/crying on passing urine, abdominal tenderness, ear abnormality and history of UTI.
In clean-catch urines, a positive dipstick test for nitrites, collection of urine at home, sex of child (female)
and a higher number of nappies used in the previous 24 hours were predictors of contamination, the last
exhibiting a consistent gradient.
In nappy pad urines, a positive dipstick test for leucocytes, higher pH, protein and blood, fewer hours
taken in transport and sex (male) were predictors of contamination (Table 74).
TABLE 72 Numbers of urines from nappy pad and clean-catch collection methods with ≥ 10 SECs
Urine collection
method
Contaminated/
non-contaminated
urine
Number of urines
with ≥ 10 SECs,
n/N (%)
Risk difference
(95% CI)
Risk ratio
(95% CI) p-value
Clean catch Contaminated 5/50 (10) 0.073
(–0.010 to 0.156)
3.701
(1.563 to 8.766)
0.002
Non-contaminated 72/2690 (2.7)
Nappy pad Contaminated 29/277 (10.5) 0.011
(–0.028 to 0.050)
1.112
(0.768 to 1.612)
0.575
Non-contaminated 180/2000 (9)
SEC, squamous epithelial cell.
TABLE 73 Predictors of contamination in clean-catch urines
Predictive criterion Category
Number in
contaminated/
all urines, n/N (%) Crude OR (95% CI)a Adjusted OR (95% CI)a
Dipstick: nitrites Negative 44/2658 (1.7) 1 (ref.) 1 (ref.)
Positive 6/74 (8.1) 5.24 (2.16 to 12.72) 3.73 (1.48 to 9.40)
Location of sample collection? Surgery 25/2103 (1.2) 1 (ref.) 1 (ref.)
Home 25/637 (3.9) 3.40 (1.94 to 5.95) 2.88 (1.62 to 5.11)
Gender Male 10/1267 (0.8) 1 (ref.) 1 (ref.)
Female 40/1473 (2.7) 3.51 (1.75 to 7.05) 3.72 (1.83 to 7.56)
How many nappies has
the child used in the past
24 hours?
Missing 10/1552 (0.6) 1 (ref.) 1 (ref.)
1–4 28/963 (2.9) 4.62 (2.23 to 9.55) 4.55 (2.19 to 9.48)
5–9 8/181 (4.4) 7.13 (2.78 to 18.31) 7.06 (2.70 to 18.47)
≥ 10 4/40 (10.0) 17.13 (5.13 to 57.21) 18.11 (5.22 to 62.82)
Ref., reference.
a Crude OR and adjusted OR are from univariable models and a single multivariable model, respectively.
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TABLE 74 Predictors of contamination in nappy pad urines
Variable Category
Number in
contaminated/
all urines, n/N (%) Crude OR (95% CI) Adjusted OR (95% CI)
Dipstick: leucocytes Negative 193/1759 (11.0) 1 (ref.) 1 (ref.)
Trace 17/125 (13.6) 1.28 (0.75 to 2.18) 1.13 (0.65 to 1.97)
+ 15/119 (12.6) 1.17 (0.67 to 2.05) 1.16 (0.64 to 2.10)
++ 36/177 (20.3) 2.07 (1.40 to 3.08) 2.16 (1.38 to 3.38)
+++ 16/91 (17.6) 1.73 (0.99 to 3.03) 1.53 (0.82 to 2.84)
Dipstick: pH 5 60/580 (10.3) 1 (ref.) 0.99 (0.70 to 1.42)
6 87/824 (10.6) 1.02 (0.72,1.45) 1 (ref.)
6.5 53/364 (14.6) 1.48 (0.99 to 2.19) 1.48 (1.02 to 2.16)
7 27/203 (13.3) 1.33 (0.82 to 2.16) 1.20 (0.75 to 1.93)
7.5 21/149 (14.1) 1.42 (0.83 to 2.42) 1.26 (0.75 to 2.13)
8 16/95 (16.8) 1.76 (0.96 to 3.20) 1.59 (0.87 to 2.88)
8.5 13/56 (23.2) 2.62 (1.33 to 5.15) 2.18 (1.10 to 4.31)
Dipstick: protein Negative 180/1649 (10.9) 1 (ref.) 1 (ref.)
Positive 97/622 (15.6) 1.51 (1.16 to 1.97) 1.24 (0.93 to 1.66)
Dipstick: blood Negative 236/2060 (11.5) 1 (ref.) 1 (ref.)
Positive 41/211 (19.4) 1.86 (1.29 to 2.69) 1.44 (0.95 to 2.17)
Dipstick: nitrites Negative 214/1916 (11.2) 1 (ref.) 1 (ref.)
Positive 63/355 (17.7) 1.72 (1.26 to 2.33) 1.55 (1.12 to 2.15)
Hours from urine
sample taken to
arriving at the
research laboratory
< 24 hours 112/652 (17.2) 1 (ref.) 1 (ref.)
24 to < 48 hours 107/816 (13.1) 0.73 (0.55 to 0.97) 0.69 (0.52 to 0.93)
48 to < 72 hours 30/347 (8.6) 0.46 (0.30 to 0.70) 0.43 (0.28 to 0.66)
72 to < 96 hours 18/252 (7.1) 0.37 (0.22 to 0.62) 0.36 (0.21 to 0.61)
≥ 96 hours 10/210 (4.8) 0.24 (0.12 to 0.47) 0.25 (0.13 to 0.48)
Gender Male 166/1183 (14.0) 1 (ref.) 1 (ref.)
Female 111/1094 (10.1) 0.69 (0.54 to 0.89) 0.58 (0.43 to 0.76)
Ref., reference.
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Discussion
Summary of main results
Using a definition selected to reflect ‘frank contamination’, this study showed a 10% greater risk of
contamination when urine was collected using nappy pads than with a clean-catch sample. Depending on
the definition selected, contamination was present in as many as 26% of nappy pad samples, compared
with 6% for clean catch. This corroborates the findings in Chapters 4 and 5 in addition to other reports,
stating that a clean-catch sample is preferred for diagnosing UTI in young children. The two most common
sources of contamination in urine from young children are faeces and skin. E. coli and enterococci are
common faecal organisms and as such would be represented highly in contaminated urines; however,
E. coli is also the most common cause of UTI. In this study, as expected, E. coli was not exclusively
associated with contamination of urine, but E. coli was dominant in urines from patients diagnosed with a
UTI. Enterococci were more prevalent in contaminated urines than UTI positive urines. Contamination of
the urine with both E. coli and enterococci is almost certainly via faeces. In contrast, coagulase-negative
staphylococci, part of normal skin flora, were found to be a dominant contaminant. The data also show no
association between presence of these faecal organisms and nappy pad use, which is corroborated in the
lack of association by univariate analysis of presence of diarrhoea.
Contamination of urine can happen with all collection methods in the young, but nappy pads have been
implicated with increased contamination rates.171 Only coagulase-negative staphylococci showed a
significant association with the nappy pad collection method. Coagulase-negative staphylococci are
considered skin contaminants and the close association with nappy pad reflects the close contact between
nappy pads and skin. The clean-catch samples showed an increasing risk of contamination with use of an
increasing number of nappies per day, but there was no relationship with nappy rash. Relaxing the criteria
for contamination would increase the number of potentially contaminated samples, but we chose to base
our analysis on a conservative definition.
Urinalysis by dipstick test is commonly used in primary care to inform diagnosis of UTI. This study found
that in both clean-catch and nappy pad urines the variables showing association with contaminated urines
are NOT exclusive to contaminated urines. Thus, they are not reliable indicators of when urines are
contaminated. A positive leucocyte test is generally considered to be an indicator of pyuria. Reports have
shown that pyuria can be present in feverish children without UTI172 and so this is probably not a good
predictor of contamination. The pH of urine is dependent upon the patient’s acid–base status, but bacteria
present in the urine can raise pH, as can a recent meal.173 A positive blood dipstick result was associated
with contaminated urines, a finding reported previously.174 Similarly, positive protein dipstick results have
been shown to be caused by bacteriuria and fever in children.173 A positive nitrite dipstick test is used to
detect bacteruria by common pathogens known to cause UTI. In this study, high numbers of squamous
epithelial cells were an indicator of contamination only in clean-catch samples. Squamous epithelial cells
should be ignored if samples are derived from nappy pads.
The study considered if the time taken for the urine sample to reach the laboratory was a factor in
contamination. Probability of contamination was not increased by increased time taken to arrive at the
laboratory, but home sampling was a risk for contamination with clean-catch samples, perhaps reflecting
less controlled collection technique.
Comparison with existing literature
Contamination rates in collection methods vary, as indeed do the definitions of contamination.
Contamination rates have been shown to vary from 0% in clean-catch urine of 23 samples to 48% of bag
urines.98 In a retrospective observational cohort study, contamination in clean catch, catheter specimen of
urine and bag was 1%, 12% and 26%.98 Definitions of contamination vary from single organism growth
< 105 OR ≥ 2 organisms to ≥ 2 organisms present at > 105 CFU/ml of urine.89,91
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In a US study, no institutional factors, such as access to refrigeration, were found to associate with either
low or high contamination rates.99 Similarly, sex and diarrhoeal symptoms have been shown to have no
association with higher contamination rates.100 Perineal cleansing in female adults had no association
with contamination rates, while urine contamination rates were higher in midstream urine collected from
toilet-trained children when obtained without perineal/genital cleaning.89,94 One of the only factors shown
to reduce contamination rates published was changing nappy pads every 30 minutes.91
Clinical implications
To reduce the risk of contamination, urine samples should ideally be clean catch, taken in the GP surgery
and not taken from children where there has been more than usual nappy use within 24 hours of
presenting at surgery. Further, our data suggest that contamination is more likely in clean-catch urines if
the child is female, the sample was taken at home as opposed to the GP surgery and if the child had
increased nappy use 24 hours prior to presenting at the surgery. These factors may be useful in addition to
microbiological criteria in clinical decisions.
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Chapter 8 Other results
Introduction
In this chapter, we describe a number of other results from the DUTY study which have not been covered
in the preceding chapters, including the revisions to objective 5 as detailed in Chapter 1 (see Planned
change to research objective 5). This introduction describes which results we will present and briefly
summarises the methods used to generate these results.
Detailed information (rates and 95% CIs) is presented on the organisms cultured and antibiotic sensitivities
for those individuals with a UTI in both the local and the research laboratories.
As in Chapter 5, we investigated if there are different illness trajectories according to clinical suspicion of
UTI. Children with UTIs and contaminated samples who were or were not suspected of having a UTI by the
clinician were compared for symptom improvement, symptom resolution (at 2 weeks) and numbers of NHS
consultations (at 3 months) using chi-squared tests for categorical data (and, where there were insufficient
data, Fisher’s exact tests), Mann–Whitney U-tests for non-parametric comparisons and log-rank
(Mantel–Cox) tests for survival data.
The main development of the clinical prediction rule was focused on children for whom a result was available
at the research laboratory. In order to consider the generalisability of these results, we compare those with and
without a research laboratory result in more detail than that presented in Chapter 5 (see Results, Participants).
Those without a research laboratory result may have not produced a urine sample, may have only provided
enough urine for a sample to have been sent to the NHS laboratory or may have had a urine sample sent to
the research laboratory which could not be cultured. Those with and without a result are tested for association
with a chi-squared test, and a Mantel–Haenszel test for trend where the chi-squared test is significant.
We also considered if any practice level or demographic factors were associated with UTI prevalence. To do
this, a two-level logistic regression model was fitted to model if patient demographics such as deprivation
(from postcode) were associated with UTI and also to assess the degree to which UTI status was clustered by
practice. This was done separately for samples collected by clean catch and nappy pad and is presented in
addition to the prevalence and 95% CI.175 Finally, this chapter reports the potential for incorporation bias.
Microbiological results (sensitivities and susceptibilities)
Table 75 presents the sensitivities of the research laboratory-cultured Enterobacteriaceae that were
considered to be causing a UTI. Of these isolates, 79 (84.0%; 95% CI 75.3% to 90.1%) were E. coli, of
which 50.6% (95% CI 39.8% to 61.4%) were sensitive to amoxicillin; 89.9% (95% CI 81.3% to 94.8%)
were sensitive to co-amoxiclav [at a 2 : 1 ratio breakpoint (BP) with BP8; 93.6% (95% CI 86.0% to 97.3%)
at BP32], 83.5% (95% CI 75.9% to 90.1%) were sensitive to co-amoxiclav [at a fixed concentration of
2mg/l with BP8; 94.9% (95% CI 87.7% to 98.0%) at BP32], 98.7% (95% CI 93.2% to 99.8%) were
sensitive to cephalexin, 70.9% (95% CI 60.1% to 79.8%) were sensitive to trimethoprim, 100.0%
(95% CI 95.4% to 100.0%) were sensitive to nitrofurantoin and 96.2% (95% CI 89.4% to 98.7%) were
sensitive to ciprofloxacin. The range is that of minimum inhibitory concentration (MIC) values within the
test population, so, for example, for the 79 E. coli tested against amoxicillin, there were one or more
isolates that had a MIC of 0.5mg/l and one or more that had a MIC of > 128mg/l, and all of the other
isolates had MICs in between. It is a standard measure that we report to give an indication of the
population susceptibility that is not determined by the BP or expert rules.
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Table 76 presents the NHS laboratory sensitivities of those same 94 that were considered to be causing a
UTI in the research laboratory. In the NHS laboratory, 55 of these isolates were E. coli, of which 51.5%
(95% CI 35.2% to 67.5%) were sensitive to amoxicillin, 91.1% (95% CI 79.3% to 96.5%) were sensitive
to co-amoxiclav, 100.0% (95% CI 88.3% to 100.0) were sensitive to cephalexin, 88.9% (95% CI 76.5%
to 95.2%) were sensitive to trimethoprim, 96.3% (95% CI 87.5% to 99.0%) were sensitive to
nitrofurantoin and 93.3% (95% CI 82.1% to 97.7%) were sensitive to ciprofloxacin. Local laboratories
only assessed sensitivities to antibiotics within their usual practice and, therefore, this is not a
comprehensive set of results.
Follow-up outcomes
Of the 94 children with a UTI, 57 (60.6%) were suspected as having a UTI by the GP. GPs also suspected
that 38 (10.9%) of the children whose sample was contaminated had a UTI. The definition we used for
contamination here is as described in Chapter 7, that is using the research laboratory results, with a
criterion of count ≥ 105 and > 2 organisms, equivalent to Jackson et al.’s93 definition of frankly
contaminated. In this chapter, all of the different urine collection methods are included, and so the
number differs from that in Chapter 7. A similar proportion of children in all groups, regardless of GP
suspicion of UTI or actual urine culture result (positive or contaminated), had improved by the time of the
2-week interview (92.9% vs. 85.7% and 88.2% vs. 79.2%; Table 77). The median number of days to
improvement was similar in all groups (3 to 4 days).
The group with the highest proportion of children who had fully recovered by the time of the 2-week
interview was children with a contaminated culture result who had been suspected of having a UTI by
clinicians (85.7% vs. 72.3% and 79.4% vs. 75.0%; see Table 77), but there were no statistically significant
differences between groups. Median recovery time was longest (9.5 days) for children who had a UTI that
was not suspected by clinicians. However, there was no statistically significant difference between this
group and those suspected of UTI (p= 0.464).
Of those with UTI, antibiotics were prescribed at the index visit in 73.7% of children in whom clinicians
suspected UTI, compared with 56.8% of those in whom UTI was not suspected (p= 0.09). Trimethoprim
or nitrofurantoin were prescribed at the index visit in 45.6% of children with UTI in whom UTI was
suspected and also in 14.0% during the subsequent 2 weeks. Trimethoprim or nitrofurantoin were
significantly more likely to be prescribed at the index visit if clinicians suspected UTI in both UTI and
contaminated urine culture groups (p< 0.001 and p< 0.001). Children with a contaminated culture result,
in whom clinicians suspected UTI, were also more likely to be prescribed trimethoprim or nitrofurantoin
during the 2 weeks following the index visit (19.2% vs. 1.3%; p< 0.001).
Survival curves are presented (see Figure 29 and Figures 31–33) for the comparisons made in Table 77
regarding symptom improvement and patient recovery. We found no evidence of differences but the
p-values show that these are not significant, although the power for these comparisons is not high.
Children who had a UTI were more likely to have further urine samples in the subsequent 3 months
(19.1%) than children who had contaminated (3.9%) or negative or indeterminate (8.0%) urine
cultures (Table 78).
There was no difference in the proportion of children prescribed antibiotics in the subsequent 3 months
between the three groups (45.7% of those who had UTI, 47.8% of those who had contaminated urine
cultures and 46.7% of those who had negative or indeterminate urine cultures). However, children who
had a UTI were more likely to be prescribed trimethoprim or nitrofurantoin in the subsequent 3 months
(10.6%) than children who had a contaminated urine culture (2.7%) or those who had a negative or
indeterminate urine culture (3.6%).
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
157
TA
B
LE
76
N
H
S
lo
ca
ll
ab
o
ra
to
ry
an
ti
m
ic
ro
b
ia
l
se
n
si
ti
vi
ti
es
fo
r
th
e
94
o
rg
an
is
m
s
co
n
si
d
er
ed
p
o
si
ti
ve
fo
r
U
TI
at
th
e
re
se
ar
ch
la
b
o
ra
to
ry
Sp
ec
ie
s
A
m
o
xi
ci
lli
n
A
m
p
ic
ill
in
C
ep
h
al
ex
in
C
ep
h
p
o
d
o
xi
m
e
C
ep
h
ra
d
in
e
C
ep
h
u
ro
xi
m
e
C
ip
ro
fl
o
xa
ci
n
C
o
-a
m
o
xi
cl
av
G
en
ta
m
ic
in
N
it
ro
fu
ra
n
to
in
Tr
im
et
h
o
p
ri
m
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
Te
st
s
Se
n
si
ti
ve
(%
)
U
nk
no
w
n
co
lif
or
m
(n
=
14
)
7
14
.3
4
25
.0
5
10
0.
0
7
10
0.
0
3
10
0.
0
1
10
0.
0
10
90
.0
12
83
.3
7
10
0.
0
13
92
.3
14
85
.7
E.
co
li
(n
=
55
)
33
51
.5
8
75
.0
29
10
0.
0
28
10
0.
0
12
10
0.
0
12
10
0.
0
45
93
.3
45
91
.1
24
10
0.
0
54
96
.3
55
88
.9
Pr
ot
eu
s
sp
p
(n
=
4)
3
66
.7
0
N
/A
3
10
0.
0
1
10
0.
0
1
10
0.
0
0
N
/A
2
10
0.
0
2
10
0.
0
2
10
0.
0
4
0.
0
4
50
.0
N
/A
,
no
t
ap
pl
ic
ab
le
.
OTHER RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
158
TA
B
LE
77
Ea
rl
y
o
u
tc
o
m
es
in
d
ex
vi
si
t
an
d
fi
rs
t
2
w
ee
ks
G
ro
u
p
U
TI
C
o
n
ta
m
in
at
ed
In
d
et
er
m
in
at
e
an
d
n
eg
at
iv
e
Su
sp
ec
te
d
U
TI
N
o
t
su
sp
ec
te
d
U
TI
p
-v
al
u
e
Su
sp
ec
te
d
U
TI
N
o
t
su
sp
ec
te
d
U
TI
p
-v
al
u
e
n
in
gr
ou
p
57
37
38
31
0
46
65
n
in
gr
ou
p
w
ith
pa
re
nt
-r
ep
or
te
d
te
le
ph
on
e
in
te
rv
ie
w
at
2
w
ee
ks
34
24
14
11
2
61
2
V
ar
ia
b
le
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
D
id
yo
ur
ch
ild
’s
sy
m
pt
om
s
im
pr
ov
e
w
ith
in
th
e
fir
st
2
w
ee
ks
?
(Y
es
)
30
(8
8.
2)
19
(7
9.
2)
0.
46
7a
13
(9
2.
9)
96
(8
5.
7)
0.
69
1a
54
5
(8
9.
1)
D
id
yo
ur
ch
ild
be
co
m
e
en
tir
el
y
w
el
la
nd
ha
d
th
ey
re
tu
rn
ed
to
th
ei
r
no
rm
al
ac
tiv
iti
es
fo
r
tw
o
co
ns
ec
ut
iv
e
da
ys
w
ith
in
th
e
fir
st
2
w
ee
ks
?
(Y
es
)
27
(7
9.
4)
18
(7
5.
0)
0.
69
2
12
(8
5.
7)
81
(7
2.
3)
0.
35
3a
46
1
(7
5.
3)
A
ny
re
co
ns
ul
ta
tio
ns
?
(Y
es
)
11
(3
2.
4)
10
(4
1.
7)
0.
46
7
4
(2
8.
6)
31
(2
7.
7)
1.
00
0a
20
5
(3
3.
5)
V
ar
ia
b
le
M
ed
ia
n
IQ
R
M
ed
ia
n
IQ
R
p
-v
al
u
e
M
ed
ia
n
IQ
R
M
ed
ia
n
IQ
R
p
-v
al
u
e
M
ed
ia
n
IQ
R
H
ow
m
an
y
da
ys
si
nc
e
yo
ur
ch
ild
st
ar
te
d
th
e
st
ud
y
w
as
it
un
til
th
ei
r
sy
m
pt
om
s
im
pr
ov
ed
?
4.
0
5.
0
4.
0
9.
5
0.
28
3c
3.
0
5.
0
4.
0
5.
0
0.
30
4c
4.
0
5.
0
H
ow
m
an
y
da
ys
si
nc
e
yo
ur
ch
ild
st
ar
te
d
th
e
st
ud
y
w
as
it
un
til
th
ey
w
er
e
en
tir
el
y
w
el
la
nd
ha
d
re
tu
rn
ed
to
th
ei
r
no
rm
al
ac
tiv
iti
es
fo
r
2
co
ns
ec
ut
iv
e
da
ys
?
7.
0
10
.0
9.
5
9.
0
0.
46
4c
7.
0
6.
0
7.
0
10
.0
0.
30
3c
8.
0
9.
0 c
on
tin
ue
d
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Hay et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library,
National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
159
TA
B
LE
77
Ea
rl
y
o
u
tc
o
m
es
in
d
ex
vi
si
t
an
d
fi
rs
t
2
w
ee
ks
(c
o
n
ti
n
u
ed
)
G
ro
u
p
U
TI
C
o
n
ta
m
in
at
ed
In
d
et
er
m
in
at
e
an
d
n
eg
at
iv
e
n
in
gr
ou
p
w
ith
no
te
s
re
vi
ew
at
3
m
on
th
s
56
37
p-
va
lu
e
26
22
9
p-
va
lu
e
97
9
V
ar
ia
b
le
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
A
ny
an
tib
io
tic
s
at
th
e
in
de
x
vi
si
t?
(Y
es
)
42
(7
3.
7)
21
(5
6.
8)
0.
08
8
13
(5
0.
0)
10
1
(4
4.
1)
0.
56
7
47
6
(4
8.
6)
A
ny
tr
im
et
ho
pr
im
or
ni
tr
of
ur
an
to
in
at
th
e
In
de
x
vi
si
t?
(Y
es
)
26
(4
5.
6)
2
(5
.4
)
<
0.
00
1
7
(2
6.
9)
3
(1
.3
)
<
0.
00
1a
56
(5
.7
)
A
ny
ur
in
e
te
st
s
in
th
e
fir
st
2
w
ee
ks
af
te
r
th
e
in
de
x
vi
si
t?
(Y
es
)
8
(1
4.
0)
7
(1
8.
9)
0.
52
8
1
(3
.8
)
6
(2
.6
)
0.
53
3a
50
(5
.1
)
A
ny
an
tib
io
tic
s
in
th
e
fir
st
2
w
ee
ks
af
te
r
th
e
in
de
x
vi
si
t?
(Y
es
)
17
(2
9.
8)
15
(4
0.
5)
0.
28
4
7
(2
6.
9)
48
(2
1.
0)
0.
48
4
22
9
(2
3.
4)
A
ny
tim
et
ho
pr
im
or
ni
tr
of
ur
an
to
in
in
th
e
fir
st
2
w
ee
ks
af
te
r
th
e
in
de
x
vi
si
t?
(Y
es
)
8
(1
4.
0)
5
(1
3.
5)
0.
94
3
5
(1
9.
2)
3
(1
.3
)
<
0.
00
1a
47
(4
.8
)
A
ny
se
co
nd
ar
y
ca
re
co
ns
ul
ta
tio
ns
in
th
e
fir
st
2
w
ee
ks
?
(Y
es
)
5
(8
.8
)
3
(8
.1
)
1.
00
0a
1
(3
.8
)
10
(4
.4
)
1.
00
0a
70
(7
.2
)
a
Fi
sh
er
’s
ex
ac
t
te
st
s.
b
M
an
n–
W
hi
tn
ey
U
-t
es
ts
.
c
Lo
g-
ra
nk
(M
an
te
l–
C
ox
)
te
st
s.
OTHER RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
160
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8
How many days did it take for the child to recover?
Pr
o
p
o
rt
io
n
 o
f 
ch
ild
re
n
 w
it
h
 s
ym
p
to
m
s
10 12 14
UTI and suspected UTI
UTI and not suspected UTI
UTI and suspected UTI – censored
UTI and not suspected UTI – censored
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FIGURE 32 Effect of clinical suspicion of UTI on the number of days until symptoms improved among children with
contaminated urine.
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Trimethoprim or nitrofurantoin were significantly more likely to be prescribed in the 3 months following
the index consultation if clinician had suspected UTI in both UTI and contaminated urine culture groups
(p< 0.001 and p< 0.001, respectively).
There was no difference in the median number of reconsultations in the subsequent 3 months between
the groups. Slightly more children (25.5%) who had UTI were seen in secondary care than children with
contaminated (19.2%) and negative or indeterminate (20.8%) urine cultures.
Seven (7.4%) children with UTI and four (1.6%) children with a contaminated urine culture had
urine-related hospital tests (ultrasound scan, DMSA scan or MCUG) in the 3 months following the index
consultation. Children in both groups were more likely to have received these tests if the clinician
had suspected UTI, although the differences were not statistically significant (p= 0.040 and
p= 0.053, respectively).
Generalisability and potential bias
Verification bias
This section supplements data already presented in Chapter 5 (see Results, Participants) and compares the
characteristics of children with and without a culture result from the research laboratory (Tables 79 and 80).
The statistical significance level for the nine tests performed here is set at a Bonferroni corrected
α= 0.05/9= 0.005.
Table 79 shows that as age increases, there is a higher likelihood of having a result (p< 0.001). In
addition, the test for trend gives a p< 0.001 for trend. For clinician impression of illness severity, children
with a result were more likely to have a mild illness as defined by the clinician than those without (82.5%
vs. 79.9% clinician global impression ≤ 3; p= 0.001), although this is a relatively small actual difference.
Clinicians were more likely to suspect UTI in children in whom UTI status was known (6.8% vs. 4.1%;
p< 0.001). Children with results were similar in terms of sex (50.9% vs. 50.4% female), ethnicity (83.7 vs.
82.3% white), parental highest qualification (50.4% vs. 49.2% diploma, degree or equivalent), cost of
living (11.8% vs. 10.4% quite comfortably off), deprivation (21.1% vs. 20.6% most deprived), parental
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FIGURE 33 Effect of clinical suspicion of UTI on the number of days until symptoms resolved among children with
contaminated urine.
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TABLE 79 Comparison of those with a UTI status with those without a UTI status
Criterion
Does the patient have a sample in the research
laboratory from which a UTI result can be ascertained?
p-value
(chi-squared test)No (N= 2056), n (%) Yes (N= 5107), n (%)
Age
< 6 months 238 (11.6) 412 (8.1) < 0.001
6 months to < 12 months 465 (22.6) 675 (13.2)
1 year to < 2 years 676 (32.9) 1006 (19.7)
2 years to < 3 years 359 (17.5) 989 (19.4)
3 years to < 4 years 195 (9.5) 1138 (22.3)
≥ 4 years 123 (6.0) 887 (17.4)
Gender
Male 1019 (49.6) 2507 (49.1) 0.717
Female 1037 (50.4) 2600 (50.9)
Ethnicity groupings
White 1660 (82.3) 4235 (83.7) 0.020
Mixed 110 (5.5) 261 (5.2)
Asian 98 (4.9) 203 (4.0)
Black 146 (7.2) 325 (6.4)
Other 3 (0.1) 33 (0.7)
Highest level of qualification
Degree (or equivalent) 511 (33.3) 1318 (32.0) 0.838
Diploma (or equivalent) 262 (17.1) 709 (17.2)
‘A’ level 202 (13.2) 540 (13.1)
GCSE/’O’ level 458 (29.9) 1252 (30.4)
None 101 (6.6) 299 (7.3)
Cost of living
Find it a strain to get by week
to week
89 (5.7) 292 (7.1) 0.141
Have to be careful about money 793 (50.6) 2101 (50.9)
Able to manage without much
difficulty
501 (32.0) 1305 (31.6)
Quite comfortably off 185 (11.8) 429 (10.4)
Deprivation quintilea
1 359 (17.6) 908 (18.0) 0.869
2 377 (18.5) 962 (19.1)
3 411 (20.2) 981 (19.4)
4 471 (23.1) 1132 (22.4)
5 419 (20.6) 1065 (21.1)
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TABLE 79 Comparison of those with a UTI status with those without a UTI status (continued )
Criterion
Does the patient have a sample in the research
laboratory from which a UTI result can be ascertained?
p-value
(chi-squared test)No (N= 2056), n (%) Yes (N= 5107), n (%)
Please rate your overall impression of your child’s current illness when it is at its worst (parents’ score)
0 7 (0.3) 40 (0.8) 0.069
1 39 (1.9) 148 (2.9)
2 83 (4.1) 256 (5.0)
3 184 (9.0) 500 (9.8)
4 282 (13.8) 659 (12.9)
5 395 (19.3) 931 (18.3)
6 371 (18.1) 879 (17.2)
7 371 (18.1) 906 (17.8)
8 223 (10.9) 537 (10.5)
9 62 (3.0) 154 (3.0)
10 30 (1.5) 91 (1.8)
Please give your global impression of the child on a scale of 0–10 (clinicians’ score)
0 128 (6.4) 476 (9.3) 0.001
1 492 (24.4) 1333 (26.2)
2 553 (27.5) 1413 (27.7)
3 435 (21.6) 982 (19.3)
4 203 (10.1) 472 (9.3)
5 88 (4.4) 196 (3.8)
6 67 (3.3) 125 (2.5)
7 33 (1.6) 68 (1.3)
8 10 (0.5) 25 (0.5)
9 4 (0.2) 4 (0.1)
10 0 (0.0) 2 (0.0)
Clinician’s working diagnosis?
No UTI 1925 (95.8) 4748 (93.2) < 0.001
UTI 63 (3.1) 298 (5.9)
UTI+ another diagnosis 21 (1.0) 46 (0.9)
a For deprivation, quintile 1 is least deprived and quintile 5 is most deprived.
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impression of overall illness severity (18.5% vs. 15.3% score of ≤ 3) and the number of days unwell prior
to recruitment (both have a median of 4.0 days; see Table 80). In summary, for age, clinician impression
and working diagnosis, there were significant associations with whether or not UTI status was known. This
suggests that the chance and gaining a sample which was large enough for splitting to go to the research
lab and be processed was higher for older children, who were not as generally unwell and where UTI
was suspected.
Incorporation bias
Although not important to the development of the algorithm using the research laboratory, in order to
assess how often the sending of clinical information to the local laboratory might be occurring in DUTY, a
sample of 34 clinicians, a mix of GPs and nurses, using a mix of option 1 and 2 recruitment methods, were
asked what, if any, clinical information they provided on the request form to the local NHS laboratory. The
results of this showed that 10 (29.4%) did not provide any information and eight (23.5%) did mention
the possibility of UTI. The extent to which laboratories use such clinical information is also likely to vary,
with the large number of urine samples processed by many NHS laboratories prohibiting use of any clinical
information in many.
Prevalence in urinary tract infection and its variation
We had 5107 children with a known UTI status from the research laboratory, of whom 94 were UTI
positive, giving an overall UTI prevalence of 1.8% (95% CI 1.5% to 2.3%). Of the 2740 samples collected
via clean catch, 60 were positive, giving a prevalence of 2.2% (95% CI 1.7% to 2.8%) and of the 2277
collected via nappy pads, 30 were positive, giving a prevalence of 1.3% (95% CI 0.9% to 1.9%). We also
had 73 samples collected via bags, of which three were positive, and 17 children (one positive) in whom
the collection method was not recorded.
The children were recruited from 229 different sites. This gives an average of 22.3 children per site, varying
between 1 and 337 children per site.
When considering only clean-catch collection method, the children were recruited from 224 different sites;
on average there were 12.2 children per site, with the number varying between 1 and 169. We considered
the degree of variation in UTI prevalence between practices using a two-level random-effect logistic
regression model with practice/site as a random effect and no fixed effects. A LR test between this
multilevel model and logistic regression showed no evidence of clustering (p= 1.000) and hence we
used logistic regression instead of a multilevel model in the analysis, which included recruitment centre,
recruitment site, age, sex and deprivation. Table 81 shows that there was no evidence of variation in
UTI prevalence by recruitment centre or site. Prevalence varied by age (highest prevalence in 6- to
12-month-old children), though numbers were too small to be significant.
TABLE 80 Comparison of days unwell prior to consulting for those with a UTI status with those without a
UTI status
Does the patient have a sample in the research laboratory from which a
UTI result can be ascertained?
p-value
(Mann–Whitney U-test)
No (N= 2056) Yes (N= 5107)
n Median IQR n Median IQR
Days unwell 2047 4.0 5.0 5101 4.0 4.0 0.039
IQR, interquartile range.
OTHER RESULTS
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As seen in Chapter 5 (see Results, Clean-catch models), girls were more likely than boys to have a UTI,
even after adjustment for the other model factors such as deprivation and recruitment centre. On the
whole, children from more deprived areas had higher prevalence of UTI, though this association could
have occurred by chance as there were wide CIs which included no association.
While considering the nappy pad collection method, the children were recruited from 188 different sites;
on average there were 12.1 children per site, with the number varying between 1 and 165 children. We
considered the degree of variation in prevalence between practices using a two-level random-effect logistic
regression model with practice/site as a random effect and no fixed effects. A LR test between this multilevel
model and logistic regression showed little evidence of clustering (p= 0.315), and so we used logistic
regression instead of a multilevel model for the following analyses, which included recruitment centre,
recruitment site, age, sex and deprivation.
Table 82 shows that there was no evidence of variation in UTI prevalence by recruitment centre (though the
Bristol centre rate appears higher than the other centres) and that the number of UTI events was too small to
compare sites. There was less variation by age, reflecting the more narrow age range of children providing
nappy pad samples. Prevalence varied by age (most prevalent in 6- to 12-month-old children), though
numbers were too small to be significant. As seen in Chapter 5 (see Results, Nappy pad models), girls were
more likely than boys to have a UTI, even after adjustment for the other model factors such as deprivation and
TABLE 81 Variation in UTI prevalence (clean-catch samples)
Variable Category UTI–ve/UTI+ve, N/n Prevalence Crude OR (95% CI)
Adjusted OR
(95% CI)a
Centre Bristol 1157/25 2.1% 1 (ref.) 1 (ref.)
Cardiff 593/12 2.0% 0.94 (0.47 to 1.88) 0.90 (0.44 to 1.82)
London 499/13 2.5% 1.21 (0.61 to 2.38) 1.12 (0.53 to 2.37)
Southampton 431/10 2.3% 1.07 (0.51 to 2.25) 1.00 (0.46 to 2.14)
Recruitment site GP surgery 2452/55 2.2% 1 (ref.) 1 (ref.)
ED 190/4 2.1% 0.94 (0.34 to 2.62) 0.60 (0.16 to 2.16)
Walk-in centre 38/1 2.6% 1.17 (0.16 to 8.70) 1.18 (0.15 to 9.43)
Age (months) 0 to < 6 33/1 2.9% 1.51 (0.20 to 11.60) 1.86 (0.21 to 16.9)
≥ 6 to < 12 51/3 5.6% 2.94 (0.85 to 10.17) 3.66 (0.90 to 14.8)
≥ 12 to < 24 89/2 2.2% 1.12 (0.26 to 4.86) 1.41 (0.31 to 6.36)
≥ 24 to < 36 599/16 2.6% 1.33 (0.69 to 2.58) 1.30 (0.67 to 2.52)
≥ 36 to < 48 1049/21 2.0% 1 (ref.) 1 (ref.)
≥ 48 859/17 1.9% 0.99 (0.52 to 1.89) 0.99 (0.52 to 1.89)
Sex Male 1254/13 1.0% 0.31 (0.17 to 0.58) 0.32 (0.17 to 0.60)
Female 1426/47 3.2% 1 (ref.) 1 (ref.)
Deprivation quintileb 1 504/6 1.2% 1 (ref.) 1 (ref.)
2 514/12 2.3% 1.96 (0.73 to 5.26) 2.04 (0.76 to 5.52)
3 517/15 2.8% 2.44 (0.94 to 6.33) 2.37 (0.91 to 6.25)
4 604/18 2.9% 2.50 (0.99 to 6.35) 2.45 (0.93 to 6.46)
5 506/9 1.8% 1.49 (0.53 to 4.23) 1.56 (0.53 to 4.59)
ED, emergency department; ref., reference.
a Ratio adjusted for factors in table only and hence n= 2705 owing to missing deprivation quintiles.
b For deprivation, quintile 1 is least deprived and quintile 5 is most deprived.
recruitment centre. There did not appear to be as much UTI prevalence variation by deprivation as seen in the
clean-catch samples.
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Discussion
The local and research laboratories report marked differences in the proportions of organisms grown at the
various concentration categories. These are likely to represent differences in laboratory processes and
reporting procedures. A range of antimicrobial susceptibilities are observed between the local and research
laboratories, with nitrofurantoin sensitivity appearing to be higher than other commonly used antibiotics in
primary care, such as trimethoprim and amoxicillin. No differences were observed in terms of symptom
improvement or resolution at 2 weeks, or number of NHS consultations at 3 months in children with or
without clinically suspected UTI at the index consultation. Unsurprisingly, clinicians were more likely to use
a UTI-specific antibiotic (trimethoprim or nitrofurantoin) if they suspected that the child had a UTI. UTI
prevalence did not vary by recruitment centre or with deprivation. There were variations by sex (female
more common than male), which are in keeping with the literature.9
The main clinical implication of the results presented in this chapter is that, based on bacterial sensitivities,
clinicians may wish to consider nitrofurantoin as the first-line antibiotic for suspected UTI in young children.
There does seem to be little difference in recovery from this illness episode regardless of accurate diagnosis
TABLE 82 Variation in UTI prevalence (nappy pad samples)
Variable Category UTI–ve/UTI+ve, N/n Prevalence, % Crude OR (95% CI)
Adjusted OR
(95% CI)a
Centre Bristol 1001/20 2.0 1 (ref.) 1 (ref.)
Cardiff 615/5 0.8 0.41 (0.15 to 1.09) 0.44 (0.16 to 1.11)
London 335/3 0.9 0.45 (0.13 to 1.52) 0.44 (0.10 to 1.35)
Southampton 296/2 0.7 0.34 (0.08 to 1.45) 0.32 (0.07 to 1.35)
Recruitment site GP surgery 2206/30 1.3 N/Ab N/Ab
ED 8/0 0 N/A N/A
Walk-in centre 33/0 0 N/A N/A
Age (months) 0 to < 6 364/5 1.4 1.72 (0.54 to 5.46) 2.11 (0.66 to 6.79)
≥ 6 to < 12 592/11 1.8 2.33 (0.90 to 6.04) 2.40 (0.92 to 6.28)
≥ 12 to < 24 877/7 0.8 1 (ref.) 1 (ref.)
≥ 24c 414/7 1.6 2.11 (0.74 to 6.08) 2.03 (0.70 to 5.85)
Gender Male 1174/9 0.8 0.39 (0.18 to 0.86) 0.39 (0.18 to 0.86)
Female 1073/21 1.9 1 (ref.) 1 (ref.)
Deprivation quintiled 1 382/6 1.6 1 (ref.) 1 (ref.)
2 423/4 0.9 0.60 (0.17 to 2.14) 0.65 (0.18 to 2.35)
3 419/11 2.6 1.67 (0.61 to 4.56) 1.92 (0.69 to 5.33)
4 481/5 1.0 0.66 (0.20 to 2.19) 0.81 (0.24 to 2.76)
5 519/4 0.8 0.49 (0.14 to 1.75) 0.62 (0.17 to 2.30)
Missing 23/0 0
ED, emergency department; N/A, not applicable; ref., reference.
a Ratio adjusted for factors in table only and hence n= 2254 owing to missing deprivation quintiles.
b Crude and adjusted ORs could not be calculated for this variable as all the UTI positives are within one category.
c The older age categories were merged (compared with earlier table) owing to there being no UTI positives over the age
of 36 months in nappy pads.
d For deprivation, quintile 1 is least deprived and quintile 5 is most deprived.
of UTI; however, without understanding the potential long-term sequalae of this self-limiting illness in
young children, it is hard to draw firm clinical practice conclusions about this.
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Chapter 9 Discussion
Summary of objectives and main results
The primary aim of the DUTY study was to derive and validate a clinical algorithm for the selection of
children aged < 5 years presenting to primary care with an acute illness of up to 28 days’ duration
who warrant urine sampling. Additional aims were to identify the additional value of a point-of-care
dipstick urine test; model cost-effectiveness of one or more diagnostic algorithm guided strategies;
compare contamination rates for two urine sampling methods; compare the results obtained from
local NHS laboratories with a single research laboratory; and explore the clinical significance of
clinician-suspected UTI.
In total, 7163 children were recruited. Urine samples were obtained from 6390 (89%). Where there was
sufficient urine, samples were split, with 6079 (95%) analysed in a NHS microbiology laboratory and
5107 (80%) analysed in a research laboratory. More than half of the samples analysed by the research
laboratory were obtained by clean catch [n= 2740 (55%)], with 94% of these samples from children aged
≥ 2 years. Samples were obtained by the Newcastle nappy pad method in 2277 (45%), and 82% of these
samples were from children < 2 years.
We showed that the agreement of microbiological diagnosis of UTI in routine NHS laboratories and a
research laboratory was lower than expected and worse for urine samples collected using nappy pads than
for clean-catch samples. Associations of microbiological positivity with prespecified symptoms, signs and
urine dipstick test results were lower for NHS laboratories than the research laboratory and for nappy pad
samples than clean-catch samples. Urines giving a ‘positive’ result in a NHS laboratory but not in the
research laboratory had only modest associations with the preselected symptoms, signs and dipstick test
results. These findings did not appear to be attributable to the younger age of the children providing
nappy pad samples.
We used urine culture results obtained from the research laboratory for our reference standard because
samples were analysed in a single laboratory by a limited number of well-trained individuals using more
detailed urine processing and reporting techniques than routinely available in NHS laboratories, and
because we found that the research laboratory was both more reliable and more accurate than the NHS
laboratories. We defined our reference standard as ≥ 105 CFU/ml of a single uropathogen (‘pure growth’)
or ≥ 105 CFU/ml of a uropathogen with ≥ 3 log10 (1000-fold) difference between the growth of this and
the next species (‘predominant growth’). We defined uropathogens as members of the Enterobacteriaceae
group for the purpose of our analyses.
Although our results suggest the research laboratory was providing more accurate and reliable results than
the NHS laboratories, the reasons for this and the differences in UTI prevalence between research and NHS
laboratories are not clear and could include differences in transport, laboratory methods and laboratory
interpretation. For example, the more rigorous research laboratory methods (including sample processing by
only two laboratory technicians) and UTI definition could have reduced UTI and increased contamination
prevalence. Equally, the NHS laboratories could be classifying contaminated samples as UTI – the clinically
safer policy where doubt exists.
The prevalence of ‘≥ 105 CFU/ml pure/predominant’, ‘≥ 105 CFU/ml > 2 species’ and ‘no growth’ was lower
in the research laboratory than the local NHS laboratories, possibly reflecting the variable use of boric acid
in samples transported to the NHS laboratories. Higher prevalence was seen in all categories with 103 to
105 CFU/ml colony counts, probably due to more accurate bacterial quantification in the research laboratory.
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Of the samples analysed in the research laboratory, 2.2% and 1.3% of urine samples obtained by
clean-catch and nappy pad methods, respectively, met criteria for a microbiological diagnosis of UTI. There
was no evidence of variation in UTI prevalence by recruitment centre or site. Prevalence did vary by age
(most prevalent in 6- to 12-month-old children), but this variation was not statistically significant. Girls
were more likely than boys to have a UTI, even after adjustment for a range of variables. Regarding the
primary objective of developing a diagnostic algorithm to identify the children warranting urine collection,
we used bootstrapping to validate the algorithms, which were developed separately for the clean-catch
and nappy pad samples. Two forms of algorithm were developed for each urine collection method: ‘full’
models, using the adjusted coefficients from index tests with all gradations of severity; and points-based
models, using integer points based on the coefficients from models where index tests were dichotomised
into present or absent. We found that history of UTI, pain/crying on passing urine, smelly urine, absence of
cough, more severe clinician global impression of illness, abdominal tenderness on examination and
normal ear examination were independently associated with UTI in the clean-catch full model. This gave a
validated AUROC of 0.876. UTI in nappy pad samples was positively associated with female sex, smelly
urine, darker urine and absence of nappy rash, giving a full model validated AUROC of 0.778.
Both the clean-catch and nappy pad algorithms performed better than clinicians’ judgement in predicting the
likelihood of a UTI on urine culture. The diagnostic utility increased with the addition of urine dipstick testing
in the clean-catch and, to a lesser degree, in the nappy pad full models, giving validated AUROCs (p-value for
change from symptoms and signs full models) of 0.903 (p= 0.009) and 0.821 (p= 0.036), respectively. In the
clean-catch samples, we were also able to demonstrate that and the added value of dipstick testing increased
with increasing UTI probability post symptoms and signs. We therefore found that parent-reported symptoms
and clinical signs could be useful in identifying the preschool children presenting to primary care who should
have their urine sampled and that dipstick tests provide additional diagnostic information to improve the
targeting of empirical antibiotics. Diagnostic utility was better for clean-catch samples, but nappy pad samples
did provide better diagnostic accuracy than clinical assessment alone for children < 2 years.
With and without the dipstick tests, the diagnostic utility of the points-based models were only marginally
lower than the full models, although the clean-catch points-based models continued to outperform the
nappy pad points-based models.
Our health economic analyses showed that for older children, the symptoms and signs clean-catch (full)
model would result in fewer urine samples, with equivalent or higher sensitivity and specificity and
marginally better costs and patient outcomes than clinical judgement in the short term and long term.
The distinction in cost-effectiveness between clinical judgement and the symptom and sign nappy pad full
model for younger children was not clear-cut, underlining the importance of obtaining a clean-catch
sample whenever practical. Although the points-based symptoms and signs algorithms were found to be
less accurate than the full model algorithm, they had a higher probability of being cost-effective than
clinical judgement alone.
The choice of a threshold on the DUTY risk score which will optimally identify children whose risk of UTI is
high enough to justify collecting a urine sample is not straightforward. We used decision-analytic models
to explore three possible thresholds which represented a range of trade-offs between high sensitivity and
high specificity. The results slightly favoured low-cost, high-specificity urine sampling strategies, particularly
for GPs concerned about the societal impact of antibacterial resistance. The absolute difference in average
short- and long-term net benefits between the three DUTY thresholds evaluated was very small, but likely
to be important for the NHS in aggregate owing to the implications for the volume of urine testing.
The additional diagnostic information provided by dipstick tests has the potential to play a role in the efficient
diagnosis and treatment of children with suspected UTI, which should be explored in further research.
In children with intermediate risk of UTI dipstick results may help differentiate those where immediate
antibacterial therapy is indicated from those at lower risk where laboratory confirmation of UTI is needed.
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Contamination was seven times more common in the nappy pad than the clean-catch samples, and was
identified more often by the NHS than research laboratories. Probability of contamination was not
increased by increased time taken for samples to arrive at laboratories, but being female, home sampling,
and increased frequency of nappy use did increase risk of contamination. Of note, contamination was no
more likely among children with a nappy rash.
A similar proportion of children who had culture results meeting criteria for UTI, contamination and no
growth/indeterminate results had improved symptomatically by 2 weeks, and the median number of days
to improvement was similar in all of these groups. Children who had a UTI were more likely to have
further urine samples in the subsequent 3 months. There was no difference in the proportion of children
prescribed antibiotics or in the median number of reconsultations in the subsequent 3 months between
the groups. Slightly more children who had UTI were seen in secondary care.
Strengths
This is the largest prospective study of UTI in individually recruited, acutely unwell young children
presenting to primary care. It was conducted in a large number of primary care sites supported locally by
four university-supported centres. We recruited ahead of schedule, and included additional patients to help
to account for fewer than expected numbers of children with UTI diagnosed in the research laboratory.
At some sites, we were able to record details of eligible children invited but declining to participate, and
although these data were incomplete, they suggest that, compared with the recruited sample, there were
no important differences in age or sex. We therefore consider that participating children are likely to be
representative of children presenting to primary care in the UK with an acute illness.
All index tests were measured according to routine clinical practice using standardised reporting forms and
equipment, and nearly all were completed within 24 hours of urine sample retrieval, minimising the impact
of disease progression bias. We obtained a urine sample from a high percentage of recruited children and
were able to describe certain demographic differences between those children for whom we were able
to obtain a urine sample and those for whom a urine sample was not obtained.
We asked clinicians to provide a working diagnosis and estimate the likelihood of a UTI based on their
clinical opinion alone, information which was crucial in demonstrating the added diagnostic value of the
diagnostic algorithm and technologies such as dipstick testing over and above ‘clinician diagnosis’.
Two members of staff carried out all urine analyses in the research laboratory, blind to all of the index tests
and clinical features apart from the children’s age. They performed the microbiological cultures and
interpreted results using standardised processes, which included spiral plating, a more accurate method of
quantifying bacterial counts and differentiating mixed cultures.126 We prospectively collected cost data,
allowing us to model cost-effectiveness. Our statistical techniques are well described, and the clinical rules
we produced have clinical face validity, and should be easy use in everyday general practice.114
Weaknesses
Design weaknesses
We were not able to obtain a sufficient volume of urine to send a large enough fraction to the research
laboratory for all children who submitted a urine sample, as we prioritised the NHS laboratory fraction in
order to ensure that clinicians were sent laboratory results for clinical purposes. There was no mechanism
to provide a result from a research laboratory to all the general practices that participated in DUTY.
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Although we knew which NHS laboratories routinely used boric acid containing specimen pots, we did not
record which individual NHS samples contained boric acid and so were unable to perform exploratory
analyses of how boric acid in urine containers may have influenced NHS laboratory culture results. All
samples were sent via routine transport (NHS laboratories) and post (research laboratory). This introduced
delays before research laboratory processing, but means that our results reflect those likely to be obtained
if such a system was introduced into routine clinical practice.
Although we piloted our CRF with, and invited comments from practising clinicians and parents, our CRF
did not ask about infectious contacts, and so we were unable to determine if infectious contacts were
protective or otherwise for UTI.
While participants were asked to provide clean-catch samples whenever possible, we received a large
number of nappy pad samples (our second-choice sampling method). Nappy pad and bag samples are
often the only feasible methods (outside hospital settings) for obtaining urine samples from young children
in the UK; there is usually insufficient space or time for parents and children to wait to provide clean-catch
specimens and most primary care clinicians (other than those with specialist paediatric or emergency
department training) are not trained in SPA or catheterisation techniques. SPA and catheterisation
sampling methods are invasive and are unlikely to be acceptable to parents and children in the context of
low risk for UTI. Nappy pads have been shown to be acceptable to parents63 and endorsed by NICE.2
Our reference standard defined uropathogens as members of the Enterobacteriaceae group at the UK
guidelines’2,82 threshold of a pure/predominant growth of ≥ 105 CFU/ml. We used a rigorous criterion
(minimum 3-log difference between the predominant and next most concentrated organism) for defining
predominance. This definition could have reduced estimated prevalence if some UTIs were incorrectly
classified as contamination; the only other UK primary care-based study of which we are aware estimated
prevalence to be 6% (based on NHS laboratory culture results).9 Collecting an uncontaminated urine
specimen is most difficult in the youngest children, and no study has yet reliably distinguished pathogen
from contaminant, especially when they coexist. Our definition of UTI excluded atypical bacteria which are
also thought to be more common in younger children.137,138
There is some evidence that false-positive samples taken from children can be identified by taking
sequential urine samples.81 We considered, however, that the increased burden on patients and the health
services associated with taking two separate samples from each child would lead to fewer children
being sampled. Thus, the advantages of sequential sampling in terms of reduced false positives would
probably be outweighed by more UTIs being identified at an early stage of the child’s illness through a
single-sample approach. Single samples are the norm in routine UK primary care.
Clinicians’ assessment of the likelihood of UTI may have been influenced by a Hawthorne effect from
participating in a study that they knew was about diagnosing UTI in young children.
Analytic weaknesses
A major limitation of our study is the relatively small number of UTI microbiological diagnoses, particularly
for nappy pad samples. It is plausible that contamination of urine specimens in these samples led to
underdiagnosis, limiting our ability to identify the symptoms, signs and dipstick results associated with UTI
in children aged < 2 years. Because of lower than expected urine samples positive for UTI on culture, and
the unanticipated differences between clean-catch and nappy pad samples in the reliability and accuracy of
the laboratory results that meant developing separate algorithms by urine collection method, we had
insufficient numbers of children with UTI to both derive and externally validate the algorithms. Although
bootstrap validation is an accepted technique to use in this situation, leading to reduced AUROC for our
models, even these estimates may be optimistic in relation to values that would have been achieved had
we externally validated.
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Our economic analyses did not attempt to capture possible impact on antibiotic resistance rates in the
population. Taking these into account is likely to increase the cost-effectiveness of more conservative
antibiotic treatment. Similarly, our analysis does not include benefits for false-negative UTI diagnosis where
an antibiotic serendipitously prescribed for a presumed infection might be effective in treating a true
underlying UTI. We focused on NHS rather than societal cost. Our Bayesian framework required the
specification of a prior distribution for each parameter. We used diffuse priors to ensure that the posterior
distribution was dominated by the likelihood; however, for parameters where the number of events was
small the prior might have had an effect.
Results in the context of research literature
Our clean-catch models include clinically intuitive items. Previous investigation of malodorous urine has
shown conflicting results,67,139 but our study strongly supports its diagnostic value. We investigated, but did
not find evidence for, a number of non-specific symptoms (including fever, vomiting, lethargy, irritability
and poor feeding) previously found to be diagnostic of UTI116 and recommended for clinical use by NICE.2
It remains possible that such symptoms are of use in the secondary care settings in which studies reporting
their utility were conducted, or in children with a different illness spectrum. We found that presence of
symptoms and signs suggestive of alternative diagnoses to UTI were associated with a reduced risk of UTI.
Such inverse associations are unlikely to reflect biological mechanisms, but to arise because both they and
UTI are causes of children attending primary health care. Such ‘conditioning on a common effect’ induces
inverse associations between factors that are independent in the source population of well and unwell
children.140 These associations are, nonetheless, of diagnostic utility.
Our nappy pad model, and to some extent the clean-catch model for children aged between 2 and 3 years, is
the first primary care study to identify parent-reported symptoms that can be used to select preverbal children
warranting urine sampling and presumptive antibiotic treatment. Female sex and parent-reported smelly or
darker urine all appear biologically plausible as contributing to the diagnosis of UTI. However, we believe that
the apparently substantial reduction in the risk of UTI associated with presence of a nappy rash should be
interpreted with caution. The inverse association may arise through conditioning on the common effect of
primary care attendance,140 but this is unlikely to produce such a substantial association. Alternative candidate
explanations are that rash may be a risk factor for contamination of urine and hence mask the presence of a
UTI, or that skin products used to treat nappy rash could render the urine sterile. However, we did not find
nappy rash to be associated with contamination in either the clean-catch or nappy pad samples, and
antimicrobial substances were not present for the vast majority of samples. An increased likelihood of
contamination of nappy pad samples might also explain the more modest associations of symptoms and
dipstick test results with UTI than were found in clean-catch samples. These differences could also arise from
differences in illness profiles between older and younger children.
As far as we are aware, this is the first study to evaluate the cost-effectiveness of prediction rules to
optimise the selection of children with suspected UTI for urine sampling. Previous work has assessed the
most cost-effective test or series of tests for diagnosing UTI, rather than evaluating which children should
be selected for urine sampling.
Clinical and research implications
Parent-reported symptoms and clinical signs can be used to identify preschool children presenting to
primary care in whom urine should be collected. The diagnostic utility is better for urine collected using
clean catch than nappy pads, but despite higher contamination rates in nappy pad samples they still
provide better diagnostic accuracy than current clinical practice for children < 2 years in whom the
diagnosis of UTI is most challenging. That said, clinicians should be cautious about using the nappy pad
collection method in children with a nappy rash, in whom they should try to collect urine via clean catch.
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The addition of dipstick testing can help to decide whether or not to prescribe an immediate antibiotic.
Dipsticks have been considered unhelpful in young children2 until now. We found that dipstick testing
compared with a strategy based on laboratory test results could increase the proportion of children with
UTI treated immediately and decrease the proportion of children without UTI treated with antibiotics.
By choosing a high specificity threshold for older children in whom clean catch is possible, primary care
clinicians would request a urine sample from fewer children with equivalent or higher sensitivity and
specificity, achieving marginally better costs and patient outcomes in the short and long term. However, in
younger children whose urine was collected using a nappy pad, the distinction in cost-effectiveness
between the DUTY risk score and clinical judgement was not clear-cut.
We believe that our results can be applied to other resource rich nations with similar ‘first point of contact’ health
service provision, but may not be applicable to the spectra of illness in preschool children presenting to primary
care in resource-poor settings or those referred to secondary care following an initial primary care assessment.
In adult medicine, results from urine microbiology can be interpreted in the clinical context of the patient’s
presentation. However, in young children the significant difficulties in obtaining uncontaminated samples,
together with the non-specific nature of the presenting symptoms, mean there is greater reliance on the
laboratory result. More detailed routine microbiological examination of paediatric urine samples would
have resource implications that could be better justified if urines were selected for testing through an
algorithm that increased the prior probability of positivity. Our results suggest that NHS laboratories should
distinguish primary care paediatric (aged < 5 years) samples from adult samples and consider reporting
these in more detail, and that national procedures should, correspondingly, be updated.
Even for samples processed in the research laboratory, the diagnostic utility of microbiology based on
nappy pad samples was less than for clean-catch samples. Therefore, primary care clinicians should try to
obtain clean-catch samples in even very young children in whom they suspect a UTI,127 for example by
providing the time and space to support urine collection. If an algorithm based on parent-reported
symptoms can provide earlier ID of the children at greatest risk of UTI, parents could be advised to obtain a
urine sample prior to attending primary care.
To reduce the risk of contamination, urine samples should ideally be clean catch, taken in the GP surgery
and not taken from children where there has been extensive nappy use within 24 hours of presenting at
surgery. These factors may be useful in addition to microbiological criteria in clinical decisions.
Further research is needed to (1) distinguish pathogens from contaminants when bacteria are found in
significant concentrations in urine; (2) improve our understanding of the reasons for the discrepancies
between research and NHS laboratories; (3) establish the cost-effectiveness of different sensitivity/specificity
cut-points for the clean-catch and nappy pad models for use in routine clinical practice, using routine
health service laboratories; and (4) to assess the impact on clinical behaviour and patient outcomes, the
third of the three steps in the development of a clinical algorithm,128 using a RCT.
The first of these may be achievable through the use of new diagnostic methods involving sequencing of
genetic material in urine samples and investigating the contribution of proteomics and the value of
immunological markers in the urine.
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Appendix 2 Systematic review (update) for the
DUTY study: accuracy of symptoms and signs
and dipstick tests for diagnosing UTI in children
< 5 years old in primary care and choice of urine
sampling method
Methods
A HTA-funded review that evaluated all tests for the diagnosis of UTI in children was published in 2006;
we updated the searches conducted for this review to inform a publication on diagnosing UTI in children
published in the British Medical Journal (BMJ) in 2011.56,116 In 2007, NICE published clinical guidelines on
the diagnosis, treatment and long-term management of UTI in children.2 We conducted a systematic
literature search to identify studies published since these reports.2,56,116 We searched MEDLINE from 2010
(the end date of the BMJ paper searches) to January 2013 using a sensitive search strategy combining
terms related to UTI with terms relating to ‘clinical signs and symptoms’, ‘dipstick testing’ or ‘urine
sampling’. We aimed to find evidence to address three questions on the diagnosis of UTI in children aged
less than 5 years in primary care:
1. What is the accuracy of clinical signs and symptoms?
2. What is the accuracy of the combination of nitrite and LE dipstick tests?
3. What is the evidence on nappy pad or nappy bag urine samples compared with SPA or
catheter samples?
We included primary studies or systematic reviews that addressed one of the above questions, used urine
culture as the reference standard, enrolled children aged 5 years or less, and were conducted in a primary
care or emergency department setting in the developed world. Full details of the inclusion criteria are
summarised in Table 83. We also included relevant studies from our previous reviews,56,116 and
recommendations from the NICE guidelines.2
TABLE 83 Inclusion criteria
Question Clinical signs and symptoms Dipstick tests Urine sampling
Population Children aged < 5 years
Index test Any clinical sign, symptom, or combination
of signs/symptoms/tests
Nitrite or LE dipstick test Nappy or bag sample
Reference standard Culture Culture CVU, catheter or SPA
sample
Target condition UTI UTI Contaminated sample
Study design Diagnostic cohort
Setting Primary care or ED
ED, emergency department.
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Results
The update literature searches identified 368 hits; of these 11 were identified as being potentially relevant
and full texts were obtained. Five studies and one systematic review fulfilled the inclusion criteria. The
systematic review evaluated dipstick testing in children with suspected UTI and examined the relationship
with age.64 Two studies were retrospective cohort studies that assessed dipstick testing in children aged
less than 2 years presenting to paediatric emergency departments,176 two were prospective diagnostic
cohort studies and assessed clinical features for the prediction of UTI.67 The final prospective cohort study
assessed a novel device which combined a dipstick test for nitrite and LE with a urine collection pad and
was designed to be inserted into the nappy.62 Combined with the studies identified by our previous
reviews56,116 this gives a total of six included studies for urine sampling, five primary studies and one
systematic review for clinical signs and symptoms, and eight primary studies and one systematic review for
dipstick testing (Figure 34).
BMJ paper
Search results: 368
Potentially relevant: 11
Included studies: 5 + 1 SR
LE and nitrite dipstick: 3 + 1 SRUrine sampling: 1 Clinical: 2
LE and nitrite dipstick: 0Urine sampling: 1 Clinical: 2 + 1 SR
Total LE and nitrite dipstick: 8 + 1Urine sampling: 6 Clinical: 5 + 1 SR
HTA LE and nitrite dipstick: 5Urine sampling: 4 Clinical: 1
FIGURE 34 Flow of studies through the review. SR, systematic review.
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Urine sampling (six primary studies)
We identified a total of six studies that assessed urine sampling methods: four from the HTA review,57–60
one from the BMJ paper61 and one from our update searches.62
Bag specimens
Two studies compared culture of urine bag specimens with culture of SPA samples.57,59 There were
considerable differences in the results from these studies with one reporting a sensitivity of 100% and the
other of 50%. Both studies found specificity to be around 90%. Two studies compared culture results
from urine samples obtained by bag specimens with those obtained by catheter.58,61 One reported
sensitivity of 81% and specificity of 87%;58 the other reported sensitivity of 88% and specificity of 80%.61
The appropriateness of a catheter specimen as the reference standard is questionable, and this, along with
the small number of data available, means that these results are of limited value.
Nappy pads
One study compared culture of a pad/nappy specimen with culture of SPA samples. This study reported a
sensitivity of 100% and specificity of 94% suggesting excellent agreement between the two sampling
methods.60 A further recently published study identified by our update searches assessed a device known
as the ‘U-test’ which is a nappy pad incorporating a urine dipstick.62 The accuracy results are therefore a
combination of the nappy pad and the dipstick but show good accuracy with a sensitivity of 100% and
specificity of 79%. However, these were compared with a reference standard consisting of a variety of
urine collection methods (clean catch, bag, catheter or SPA) and the study only had results available for
25 participants.
The NICE guidelines found ‘insufficient data to draw conclusions about urine collection bags and urine
collection pads’. There have only been two studies published since these guidelines and these do not
provide sufficiently strong data to change these conclusions although the very limited data suggest that
pad specimens may be a more accurate method of urine collection than bag specimens.
Clinical signs and symptoms (five primary studies and
one systematic review)
The update searches identified two new primary studies.9,67 This gave a total of five primary studies1,65–67
(n= 18 390) and one systematic review3 that included eight primary studies in children aged < 5 years
(n= 7892). Of these 13 studies, 10 were conducted in hospital emergency departments, and two in
paediatricians’ offices; only one was conducted in GP practices. Table 83 shows positive and negative LRs
for each clinical sign and symptom together with estimates of the post-test probability of disease for the
presence and absence of each symptom based on the prevalences (pre-test probabilities) of UTI of 2% and
5.9% seen in the DUTY research laboratory and O’Brien9 study, respectively.
These data show that no individual, or any combination of, symptom/s or sign/s were sufficient to rule in a
diagnosis of UTI, though some post-test probabilities (e.g. 25% for increased capillary refill time, no fluid
intake and supra-pubic tenderness) appear high enough to mandate urine testing and empirical treatment
while awaiting culture confirmation. A number of symptoms and signs did not appear to have diagnostic
value, including some recommended for the diagnosis of UTI by NICE2 (e.g. poor feeding and vomiting).
Some symptoms, signs (for example respiratory) and proposed clinical prediction rules did reduce the
probability of UTI to below 2% (given a pre-test probability of 6%) and these may be considered low
enough to rule out UTI and avoid the need to obtain urine. These are summarised in Table 84.
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The largest study, which included almost 16,000 children,1 derived a clinical prediction rule based on a
combination of 27 signs and symptoms. Results were not reported for specific thresholds, but the model
was found to have an AUROC of 0.80 (95% CI 0.78 to 0.82) leading the authors to conclude that a
computer-assisted diagnostic decision tool based on this model could improve decision-making in the
emergency department.
Leucocyte esterase and nitrite dipstick testing (eight primary
studies and one systematic review)
The systematic review included six primary studies; only three of these reported data separately for children
aged < 5 years. Two of these were also included in our review,177,178 and one was excluded179 as it was
based on secondary care. The review is therefore not considered further and this synthesis focuses instead
on the eight primary studies.
Six studies evaluated the combination of both LE and nitrite positive (Figure 35). These data showed
substantial heterogeneity in estimates of sensitivity which varied from 14% to 100%; specificity was more
homogeneous varying from 86% to 100%. Negative LRs were too heterogeneous to permit conclusions
regarding the utility of this combination for ruling out a diagnosis of UTI ranging from < 0.01 to 0.88 with
a pooled estimate of 0.46 (95% CI 0.18 to 1.13). Positive LRs ranged from 6 to 108 with a pooled
estimate of 22.8 (95% CI 11.1 to 46.5) suggesting that a dipstick positive for both LE and nitrite may be
useful for ruling in a diagnosis of UTI.
Data were also heterogeneous for the combination of either nitrite or LE positive (Figure 36). Specificity
ranged from 50% to 99% and sensitivity ranged from 70% to 91%. Positive LRs ranged from 1.8 to 73
with a pooled estimate of 10.5 (95% CI 3.4 to 32.2) making it difficult to draw conclusions regarding the
utility of this combination for ruling in a diagnosis of UTI. Negative LRs ranged from 0.16 to 0.32 with a
pooled estimate of 0.22 (95% CI 0.16 to 0.30) suggesting that a dipstick negative for both nitrite and LE
may be useful in ruling out a diagnosis of UTI.
Overall the data were too heterogeneous to draw firm conclusions regarding the accuracy of dipstick
testing, however, the data suggest that a dipstick positive for both nitrite and LE may be useful for ruling
in a diagnosis of UTI, while dipstick negative for both nitrite and LE may be useful for ruling out a UTI. The
NICE guidelines stated that ‘further investigation of leucocyte esterase and nitrite dipstick tests alone and
in combination, stratified by age and method of urine collection, is required to determine their accuracy in
diagnosing UTI.’2
Conclusions
There were insufficient data to draw firm conclusions about urine collection bags and urine collection pads
although limited data suggest that pad specimens may be a more accurate method of urine collection than
bag specimens.
Most previous studies on clinical signs and symptoms for diagnosing UTIs in children were conducted in
hospital EDs; none were conducted in primary care. No individual, or any combination of, symptoms or
signs were sufficient to rule in a diagnosis of UTI, though some post-test probabilities appear high enough
to mandate urine testing and empirical treatment while awaiting culture confirmation. A number of
symptoms and signs did not appear to have diagnostic value. Some symptoms, signs (for example
respiratory) and proposed clinical prediction rules reduced the probability of UTI to a threshold that may be
considered low enough to rule out UTI and avoid the need to obtain urine.
Heterogeneous data on dipstick testing suggest that a dipstick positive for both nitrite and LE may be useful for
ruling in a diagnosis of UTI, while a dipstick negative for both nitrite and LE may be useful for ruling out a UTI.
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FIGURE 35 Summary ROC plot showing estimates of sensitivity and specificity from studies assessing dipstick
positive for both nitrite and LE together with summary ROC curve, summary estimate and 95% confidence and
prediction regions. HSROC, hierarchical summary receiver operating characteristic.
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FIGURE 36 Summary ROC plot showing estimates of sensitivity and specificity from studies assessing dipstick
positive for either nitrite and LE together with summary ROC curve, summary estimate and 95% confidence and
prediction regions. HSROC, hierarchical summary receiver operating characteristic.
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Primary study data extraction tables
Urine sampling
Study
details
Study design
and setting Population Index test
Reference
standard Sensitivity Specificity
Cohen et al.
(1997)60
Study design:
prospective
Country: Israel
Setting: primary
care
Number (number girls):
38 (24)
Age: < 2 years
Urine sampling: catheter;
SPA; nappy
Patient spectrum: query UTI
Pad vs. SPA 100 94
Hardy et al.
(1976)57
Study design:
prospective
Country: UK
Setting:
secondary care
Number (number girls):
30 (10)
Age: < 5 years
Urine sampling: clean catch;
bag; SPA
Patient spectrum: query UTI
Bag vs. SPA 50 92
Benito
Fernandez
et al. (1996)59
Study design:
prospective
Country: Spain
Setting:
secondary care
Number (number girls):
61 [48 included in analysis (20)]
Age: < 2 years
Urine sampling: bag; SPA
Patient spectrum: query UTI
Bag vs. SPA 100 89
Braude et al.
(1967)58
Study design:
prospective
Country: UK
Setting:
secondary care
Number (number girls):
68 (49)
Age: 3.2 years (9 days to
11 years), results for subgroup
< 5 years
Urine sampling: bag; SPA
Patient spectrum:
symptomatic or query UTI
Bag Catheter 81 87
Etoubleau
et al. (2009)61
Study design:
prospective
Country: France
Setting:
emergency
department
Number (number girls): 192
(138)
Age: < 3 years (non-toilet
trained)
Urine sampling: bag and
catheter
Patient spectrum: positive
bag sample
Results also reported for
polybacterial samples: there
were 16 using catheter and
84 using bag; 14 of these were
polybacterial using both
samples
Bag catheter 88 80
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Study
details
Study design
and setting Population Index test
Reference
standard Sensitivity Specificity
Krahenbuhl
et al. (2012)62
Study design:
Prospective
Country:
Switzerland
Setting: children’s
hospital and
15 paediatricians’
offices
Reference
standard: culture
Number (number girls):
75 (45); only 25 had culture
and U-test results available
Age: 0.9 years (9 days to
3.2 years)
Urine sampling: mid-stream
clean catch, urine bag, catheter
or SPA for urine collection for
reference standard
Patient spectrum: suspected
UTI
Pad combined
with dipstick
Mid-stream
clean catch,
urine bag,
catheter or
SPA
100% 79%
Clinical signs and symptoms
Study details
Study
design and
setting Population Index test Sensitivity Specificity
Craig et al.
(2010)1
Study
design:
prospective
cohort
Country:
Australia
Setting:
emergency
department
Number of children
(number of girls):
15,781 (8814)
Age: < 5 years
Urine sampling: mixed
Patient spectrum:
query infection
The following were associated with a significant increase
in the odds of UTI: urinary symptoms, general appearance
(mild, moderately or very unwell), fluid intake (none but not
small or moderate decrease), highest temperature > 38 °C,
chronic disease, felt hot, unvaccinated by meningococcal
vaccine, crying, elevated heart rate
The following showed no significant association: capillary
refill time, chest crackles, pneumoccocal vaccine status,
difficult breathing, elevated respiratory rate, abnormal chest
sounds, bulging fontanelle, wheezing and stridor
The following were associated with a significant decrease
in the odds of UTI: infectious contacts, male, respiratory
symptoms, diarrhoea, abnormal ear, nose and throat signs,
cough, focal bacterial infection, rash, age > 3 months,
duration of illness
A multivariable model was constructed based on the above
signs and symptoms (final model not shown). This had
diagnostic discrimination with an AUROC of 0.80 (95% CI
0.78 to 0.82). Validation of the model in 5584 illnesses also
showed good performance (AUROC 0.78, 95% CI 0.74 to
0.81). The model performed significantly better than
clinician estimation
Gauthier et al.
(2012)67
Study
design:
prospective
diagnostic
cohort
Country:
Canada
Setting:
paediatric
emergency
department
Reference
standard:
culture
Number (number
girls): 331 (189)
Age: median 12
(range 1–36) months
Urine sampling: ‘usual
method’; bad specimens
excluded
Patient spectrum:
suspected UTI
Circumcision 0 71%
Presence of fever 100% 8%
Duration of fever (≥ 72 hours) 49% 44%
Parent report of:
Smelly urine 57% 68%
Vomiting 31% 62%
Diarrhoea 27% 76%
Abdominal pain 41% 55%
Dysuria 19% 78%
Painful urination 26% 86%
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Study details
Study
design and
setting Population Index test Sensitivity Specificity
Gorelick and
Shaw (2000)65
Study
design:
prospective
cohort
Country:
USA
Setting:
emergency
department
Number of children
(number of girls):
1469 (1469)
Age: < 2 years
Urine sampling:
catheter specimen
Patient spectrum:
query UTI
CPR: < 12 months, white race,
temperature ≥ 39 °C, absence
of source of fever, fever for
≥ 2 days
Presence of ≥ 2/5 variables
95 31
aGorelick et al.
(2003)66
Validation of
above
Study
design:
nested
case–control
Country:
unclear
Setting:
emergency
department
Number of children
(number of girls): 212
(212)
Age: < 2 years
Urine sampling: not
stated
Patient spectrum:
query UTI
CPR
≥ 3 risk factors
88 70
O’Brien et al.
(2013)9
Study
design:
prospective
cohort
Country:
Wales
Setting:
general
practice
Number of children
(number of girls): 597
(284)
Age: < 5 years
Urine sampling: clean
catch or nappy pad
Patient spectrum:
acute illness < 28 days’
duration
Increased urinary frequency 31 87
Wetting when previously dry 14 94
Pain/crying when passing
urine
14 95
Irritable/grouchy 80 37
Temperature ≥ 38 °C 43 71
Muscle aches or pains 0 90
Poor feeding/off food 69 45
a It is unclear what was meant by dipstick normal.
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Dipstick testing
Study details
Study design and
setting Population Threshold Sensitivity Specificity
Armengol et al.
(2001)180
Study design:
retrospective
Country: USA
Setting: outpatient
paediatric clinic or
emergency
department
Number (number girls):
260 (not reported)
Age: < 4 years
Urine sampling: catheter
specimen
Patient spectrum: query
UTI
Nitrite or LE 70 98
Dayan et al.
(2002)178
Study design:
prospective
Country: USA
Setting:
emergency
department
Number (number girls):
246 [232 (118)]
Age: ≤ 60 days
Urine sampling: catheter
or SPA
Patient spectrum: query
UTI
Nitrite or LE
Nitrite and LE
85
30
92
100
Krahenbuhl et al.
(2012)62
Study design:
prospective
diagnostic cohort
Country:
Switzerland
Setting: children’s
hospital and 15
paediatricians’
offices
Reference
standard: culture
Number (number girls):
75 (45); only 25 had
culture and U-test results
available
Age: 0.9 years (9 days to
3.2 years)
Urine sampling:
mid-stream clean catch,
urine bag, catheter or SPA
for urine collection for
reference standard
Patient spectrum:
suspected UTI
U-Test® device:
nappy pad
incorporating
dipstick tests for
nitrite and LE
Standard dipstick:
nitrite and LE
100%
100%
79%
86%
Lejeune et al.
(1991)181
Study design:
prospective
Country: France
Setting: unclear
Number (number girls):
243 (not reported)
Age: < 18 months
Urine sampling: not clear
Patient spectrum: query
UTI
Nitrite and LE 89 98
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Study details
Study design and
setting Population Threshold Sensitivity Specificity
Ramlakhan et al.
(2011)183
Study design:
retrospective
diagnostic cohort
Country: UK
Setting: paediatric
emergency
department
Reference
standard: culture
(> 105 CFU/ml of a
single pathogen for
clean void urines or
104 CFU/ml for
other specimens)
Number (number girls):
321 (202)
Age: mean 9.3 months
(range 2 days to 2 years)
Urine sampling: most
clean void urine; otherwise,
catheter or SPA
Patient spectrum: febrile
children who had urine
dipstick and quantitative
culture
Nitrite and LE
Nitrite or LE
37
91
95
50
Rodriguez et al.
(2011)176
Study design:
retrospective
diagnostic cohort
Country: Spain
Setting: paediatric
emergency
department
Reference
standard: culture
(> 10,000CFU/ml
of a single
pathogen)
Number (number girls):
980 (430)
Age: mean 6 months
(< 2 years)
Urine sampling: bladder
catheterisation
Patient spectrum:
possible UTI
LE and nitrite
LE or nitrite
26
80
99
83
Shaw et al.
(1998)71
Study design:
prospective
Country: USA
Setting:
emergency
department
Number (number girls):
3873 (2363)
Age: < 2 years
Urine sampling: clean
catch; catheter
Patient spectrum: query
UTI
Nitrite or LE: trace
LE
73 99
Shaw et al.
(1991)182
Study design:
prospective
Country: USA
Setting:
emergency
department
Number (number girls):
491 (309)
Age: < 18 years
Urine sampling: clean
catch; bag; catheter
Patient spectrum: query
UTI
< 2 years: nitrite or
LE
71 92
< 2 years: nitrite
and LE
14 98
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Appendix 3 DUTY study protocol
STUDY PROTOCOL Open Access
The diagnosis of urinary tract infections in young
children (DUTY): protocol for a diagnostic and
prospective observational study to derive and
validate a clinical algorithm for the diagnosis of
UTI in children presenting to primary care with an
acute illness
Harriet Downing1†, Emma Thomas-Jones2*†, Micaela Gal3, Cherry-Ann Waldron2, Jonathan Sterne4,
William Hollingworth4, Kerenza Hood2, Brendan Delaney5, Paul Little6, Robin Howe7, Mandy Wootton7,
Alastair Macgowan8, Christopher C Butler3 and Alastair D Hay1 DUTY study team
Abstract
Background: Urinary tract infection (UTI) is common in children, and may cause serious illness and recurrent
symptoms. However, obtaining a urine sample from young children in primary care is challenging and not feasible
for large numbers. Evidence regarding the predictive value of symptoms, signs and urinalysis for UTI in young
children is urgently needed to help primary care clinicians better identify children who should be investigated for
UTI. This paper describes the protocol for the Diagnosis of Urinary Tract infection in Young children (DUTY) study.
The overall study aim is to derive and validate a cost-effective clinical algorithm for the diagnosis of UTI in children
presenting to primary care acutely unwell.
Methods/design: DUTY is a multicentre, diagnostic and prospective observational study aiming to recruit at least
7,000 children aged before their fifth birthday, being assessed in primary care for any acute, non-traumatic, illness
of≤ 28 days duration. Urine samples will be obtained from eligible consented children, and data collected on
medical history and presenting symptoms and signs. Urine samples will be dipstick tested in general practice and
sent for microbiological analysis. All children with culture positive urines and a random sample of children with
urine culture results in other, non-positive categories will be followed up to record symptom duration and
healthcare resource use. A diagnostic algorithm will be constructed and validated and an economic
evaluation conducted.
The primary outcome will be a validated diagnostic algorithm using a reference standard of a pure/predominant
growth of at least >103, but usually >105 CFU/mL of one, but no more than two uropathogens.
We will use logistic regression to identify the clinical predictors (i.e. demographic, medical history, presenting signs
and symptoms and urine dipstick analysis results) most strongly associated with a positive urine culture result. We
will then use economic evaluation to compare the cost effectiveness of the candidate prediction rules.
(Continued on next page)
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Discussion: This study will provide novel, clinically important information on the diagnostic features of childhood
UTI and the cost effectiveness of a validated prediction rule, to help primary care clinicians improve the efficiency
of their diagnostic strategy for UTI in young children.
Keywords: Urinary Tract Infection, Children, Primary care, Point-of-care-test, Dipstick test, Near-patient testing,
Diagnosis, Economic models
Background
Acute illness in young children is one of the commonest
reasons for seeking health care worldwide. Reported
rates of urinary tract infection (UTI) in children consult-
ing for any acute condition vary widely (from 2% to 20%
depending on setting and inclusion criteria) and most of
this research has been hospital based [1,2]. Only one
study has systematically sampled urine from sequentially
presenting acutely unwell children in primary care, and
found UTI prevalence of 4% [3]. However, that study
was not adequately powered to estimate the predictive
value of symptoms and signs with adequate precision.
UTI may be missed in as many as 50% of young chil-
dren presenting to primary care [4,5]. The clinical diag-
nosis of UTI in young children is difficult because: (1)
pre-verbal (predominantly under 3 years) children can-
not articulate symptoms and present with the same non-
specific symptoms (e.g. fever, irritability, vomiting and
poor feeding) when suffering from a wide range of ill-
nesses [6]; (2) identifying dysuria and changes in urin-
ation frequency in children wearing nappies (diapers) is
difficult; (3) obtaining urine samples is often challenging
and time consuming for parents[1] and costly to the
health service [7,8]; and (4) the National Institute for
Health and Clinical Excellence (NICE) does not recom-
mend routine urine dipstick testing in children under
3 years because of a lack of research evidence as to its
diagnostic value [9]. UTI diagnosis is therefore often
delayed [6], missed [4] or symptoms attributed to other
causes (such as otitis media) [10].
UTIs in young children may cause acute morbidity
and recurrent symptoms that may indicate functional
and anatomical abnormalities. In some young children,
UTI may lead to renal scarring [11], leading to poor
renal growth, recurrent pyelonephritis, impaired glom-
erular function, early hypertension, end stage renal dis-
ease [12] and pre-eclampsia [13-15]. Some experts,
therefore, recommend aggressive, early antibiotic treat-
ment for symptoms suggestive of UTI in young children
to prevent renal scarring [16].
Dramatic reductions during the second half of the
1990s and early 2000s in antibiotic prescribing for chil-
dren with upper respiratory infections [17] may have
reduced serendipitous treatment of undiagnosed UTI
and the consequent prevention of renal scarring.
However, antibiotic prescribing in the UK may now be
on the increase [18]. NICE promotes early recognition
and treatment to prevent short-term suffering and pos-
sibly serious long-term complications [9]. However,
increased urine sampling will increase costs, consult-
ation length and frequency of consultations in primary
care. Clinicians will therefore only increase their sam-
pling rates if evidence shows this really does improve the
identification of UTI among the many acutely unwell
children consulting primary care.
To date there is a lack of evidence as to the clinical
predictors of UTI in young children. A meta-analysis [1]
including 8,837 mostly pre-verbal children from 12 stud-
ies, showed that fever, non black race, a history of a pre-
vious UTI, temperature higher than 40°C, and
suprapubic tenderness were the findings most useful for
identifying those with a UTI. Uncircumcised boys were
also more likely to have a UTI. While individual symp-
toms and signs were helpful in the diagnosis of a UTI,
they were not sufficiently accurate to definitely rule it in,
however a combination of findings could identify infants
with a low probability of UTI [1]. The applicability of
this review to UK general practice is limited because: (1)
included studies were set in the US private and emer-
gency care system where consultation and investigation
threshold differs from UK primary care and other health
care systems that are free at the point of delivery; (2)
children had to either already have symptoms of UTI or
fever ≥38°C, so many subtle symptoms and signs may
not have been considered; (3) urine sampling was by
catheter or suprapubic aspiration (which is not con-
ducted in most primary care settings world-wide and
from which any bacterial growth is regarded as signifi-
cant); (4) diagnostic criteria used were different (≥104
colony forming units per millilitre (CFU/mL)) to UK
practice (≥105 CFU/mL); (5) the relationship between
ethnicity and UTI could be confounded; and (6) none of
the studies included in the meta-analysis checked the ex-
ternal validity [19] of the findings, meaning that esti-
mates of association could be inflated [20].
A more recent review of primary care based paediatric
studies using urine culture as the reference standard
found that no individual symptom or sign, or any com-
bination of symptoms or signs, was sufficient to rule in a
diagnosis of UTI, although some (e.g. increased capillary
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refill time, no fluid intake, and supra-pubic tenderness)
appear to warrant urine testing and empirical treatment
while awaiting culture confirmation [2]. Furthermore, a
number of symptoms and signs did not appear to have
diagnostic value, including some of those included in the
NICE guidelines (e.g. poor feeding and vomiting). Some
symptoms, signs and proposed clinical prediction rules
were associated with a sufficiently low UTI probability
to rule out UTI, thereby removing the need to obtain a
urine sample [1-3].
We found only one clinical algorithm derived from
primary research for the diagnosis of UTI in young chil-
dren. The research included febrile girls aged under two
years in one US Emergency Department [21] and was
validated in a case–control study in a different Emer-
gency Department [22]. They found that more than
three findings of: aged less than 12 months; white race;
temperature of ≥39°C; absence of any other likely
source of fever; or fever for 2 or more days gave an area
under the curve of 0.72, a sensitivity of 88% (95% CI:
79% to 94%) with a false-positive rate of 70% (95% CI:
61% to 79%).
An additional issue for the diagnosis of UTI in chil-
dren is uncertainty as to the best criteria for microbio-
logical diagnosis of UTI in this age group. Historically
this has been based on a colony count of bacteria in the
urine with a cut-off of ≥105 colony forming units (cfu)/
mL of a uropathogen indicating infection. However this
was derived from studies in adult women [23] and its
applicability to children has been questioned by NICE
[9] and others. Current guidance for microbiological
diagnosis of UTI in children is at variance. The UK Na-
tional Standard Method suggests that colony counts of
≥103 cfu/mL of a single species may be diagnostic of
UTI in voided urine and that a pure growth of between
104–105 cfu/mL is indicative of UTI in a carefully taken
specimen [24]. For midstream specimens, the European
Association of Urology, suggests a cut-off of ≥104 cfu/
mL if associated with symptoms, but ≥105 cfu/mL if
symptoms are absent; lower cut-offs are suggested for
PSA and bladder catheterisation samples [25]. However
guidance from the American Academy of Pediatrics sug-
gests that both urinalysis suggesting infection (pyuria
and/or bacteriuria) plus the presence of ≥ 5x104cfu/mL
of a uropathogen are required for a diagnosis of UTI, al-
though these guidelines are for urine specimens
obtained through catheterization or an SPA, which
would not be routine in the UK [26].
Additional value of dipstick testing in young children
A 2006 Health Technology Assessment (HTA) review
found there was inadequate evidence on the diagnostic
performance of dipstick tests for protein or blood for
children aged under 5 years old. The combination of a
positive test for both nitrite and leucocyte esterase (LE)
was most accurate for ruling in UTI (pooled LR+ 28.2
(95% CI: 17.3 to 46.0)), and a negative test for both ni-
trite and LE was most accurate for ruling out UTI
(pooled LR- 0.20 (95% CI: 0.16 to 0.26)) [27]. The NICE
UTI guideline development group concluded that there
was insufficient evidence to recommend the use of dip-
stick urine tests for children under 3 years [9].
Economic impact of UTI
UTI is the fourth most common reason overall for pre-
scribing antibiotics in UK general practice, accounting
for approximately 8% of all antibacterial prescriptions .
However, UTI is currently infrequently diagnosed in
children [28]. Whilst the unit costs of laboratory testing
and antibiotic prescribing are relatively low [27], the eco-
nomic implications of new clinical algorithms for urine
sampling and testing may be substantial in young chil-
dren because of: (1) the large numbers of children who
present with non-specific symptoms who might be can-
didates for urine sampling and testing; (2) the cost, to
healthcare services and to patients, of subsequent diag-
nostic tests (e.g. ultrasound, Micturating Cystourethro-
gram (MCUG) and Dimercaptosuccinic Acid (DMSA)
scans) used to further evaluate children with recurrent/
atypical UTI [9]; (3) the substantial societal costs and
utility detriments of a missed diagnosis that leads to rare
but serious complications of UTI; and (4) the wider,
long-term population impact of diagnostic algorithms on
antibiotic prescribing and resistance [29].
The few economic evaluations of methods for diagnos-
ing UTI in young children [27,30] have primarily evalu-
ated ‘which tests to use?’ rather than ‘who to test?’ The
2006 HTA review [27] evaluated 79 permutations of dip-
stick, cultures, ultrasound, and MCUG, and identified
four testing strategies most likely to be cost-effective, al-
though the optimal strategy differed by gender and age
group. Current NICE guidance on testing strategies for
UTI in children under 3 years is not based on evidence
of cost-effectiveness [9].
Research objectives
In summary, rigorous evidence regarding the predictive
value of symptoms, signs and urinalysis for UTI in
young children is urgently needed to help primary care
clinicians better identify UTI. Furthermore, since obtain-
ing urine samples is especially challenging in children
aged before their fifth birthday, the resulting algorithm
will be constructed to answer two separate questions:
first, which children warrant urine sampling? And sec-
ond, can point of care dipstick urinalysis help clinicians
determine which samples should be sent for laboratory
culture? The algorithm will then be the subject of a val-
idation study. Furthermore, since changes in the
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frequency with which urine samples are requested has
implications for parents and for healthcare services, ana-
lyses will model the economic impact (from the NHS
and societal perspectives) of GP judgement versus diag-
nostic algorithm guided diagnosis and management with
respect to the cost per correctly identified UTI, cost per
symptomatic day avoided and the cost per quality
adjusted life year.
The Diagnosis of Urinary Tract Infection in Young
Children (DUTY) study protocol has the following re-
search objectives:
1. To develop candidate clinical prediction rules that
accurately identify children presenting in primary
care with an acute illness in whom a urine sample
should be obtained, based on socio-demographic
factors, medical history, symptoms and signs.
2. To assess whether dipstick urinalysis for nitrite,
leukocyte esterase, protein, blood and glucose gives
additional diagnostic information to objective (1) in
the identification of urine samples that should be
sent for laboratory analysis.
3. To model cost-effectiveness from NHS and societal
perspectives of the candidate clinical prediction rules.
4. To compare contamination rates for different urine
sampling methods.
Methods/Design
Ethical and governance approval
Multi-centre approval was granted by the South West
Southmead Research Ethics Committee (previously
Southmead Research Ethics Committee, then South
West 4 REC), Ref #09/H0102/64. Research and Develop-
ment (R&D) approval has been granted for all sites tak-
ing part in the study.
Design
DUTY is a 3-year, multicentre, diagnostic accuracy study
to derive and validate a cost effective algorithm for the
diagnosis of UTI in children under 5 presenting to pri-
mary care with an acute illness.
Children are eligible if they are aged before their fifth
birthday and present to primary care with a new acute
illness episode of less than or equal to 28 days duration.
A Case Report Form (CRF) will be completed for all eli-
gible, consented children and a urine sample obtained.
The prevalence of UTI will be determined on laboratory
culture. An algorithm will be derived and validated in
separate samples of children.
Setting
This UK study will be implemented from four research
centres at the Universities of Bristol, Cardiff, Southampton
and King’s College London. Each centre will recruit
children from primary care, defined as any NHS facility
providing first-point-of-contact face-to-face advice for
parents of unwell children (GP practices, Walk-in-Centres
(WIC), and Children’s Emergency Departments (CED)).
Study procedures
Primary care sites/GP practice recruitment
Primary care sites will be recruited by each study centre
covering both urban and rural areas across England and
Wales. Two models of recruitment will be offered: (1) Op-
tion 1, in which the majority of the recruitment proce-
dures will be undertaken by a dedicated Research Nurse
(RN) or Clinical Studies Officer (CSO) external to the site;
and (2) Option 2, in which recruitment will be undertaken
entirely ‘in house’ by the primary care site’s clinical team.
From now on, members of staff taking informed consent
for the DUTY study will be referred to as “recruiting clini-
cians”. Dedicated RNs/CSOs providing external support
for sites will be referred to as “DUTY recruiters”, while
members of practice staff involved in option 2 recruitment
will be referred to as “site-based recruiters”.
Recruiting staff
The study grant will provide full-time equivalent DUTY
recruiter posts across all four study centres, which will
be supplemented by additional DUTY recruiter posts
provided by local Primary Care Research Networks
(PCRNs) and Comprehensive Local Research Networks
(CLRNs) (in England) and by the National Institute for
Social Care and Health Research – Coordinating Re-
search Centre (NISCHR-CRC) (in Wales). These DUTY
recruiters will be available to provide Option 1 support
to primary care sites, and to support autonomously
recruiting Option 2 sites through the provision of expert
training, mentoring and problem-solving.
NHS microbiology laboratory recruitment
The participation of any primary care site in recruitment
to the study will depend on the support and participa-
tion of the local NHS microbiology laboratory to which
the site routinely sends urine samples. In each area of
recruitment, the local NHS laboratory will be
approached and service level agreements put in place
prior to involvement in the study.
Participant recruitment
The recruitment process is summarised in Figure 1.
Registration and consent
Parents and children may be invited to take part in the
study in a number of ways:
1. Where possible, primary care sites will mention the
study to parents of children under 5 when they
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Parents of children under 5 years of age who have approached 
the surgery and requested an appointment are identified by 
reception staff or nurse and given information about the study 
and asked to indicate if they would like to see the RN/CSO 
before they see the clinician
12-21  day follow-up by telephone 
(for those >105CFU ml and a sample <105 CFU ml using proportional 
selection rules in Table 2)
A second voucher is posted to the parent from the study centre as a 
‘Thank You’ token for taking part in the interview.
Parent & child see Doctor/Nurse who
• Answers questions about the study
• Assesses eligibility
• Records diagnostic & examination 
information
Parent & child see Doctor/Nurse who
• Records diagnostic & examination 
information
Urine sample provided to RN/CSO
(either during visit or done at home and returned to the surgery). 
Parent receives voucher from RN/CSO as a ‘Thank You’ token.
Urine sample tested with dipstick by RN/CSO, result passed to clinician and 
recorded on CRF/website.
Management due to local clinical practice
Indicates that the parents can choose  to  participate either before or after the child 
sees the doctor/nurse.
3 month medical notes review
(for those>105CFU ml and a sample>105CFU ml using proportional     
selection rules in Table 2) 
Parent & child  see RN/CSO who  
• Answers questions about the study
• Assesses eligibility
• Takes consent
• Collects basic information
• Explains to parents how to get urine 
sample
Parent & child see RN/CSO who
• Takes consent
• Collects basic information
• Explains to parents how to get a  urine 
sample
Figure 1 DUTY participant flow diagram.
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phone for an appointment, and ask them to come to
the surgery 15 minutes early to receive further
information.
2. Where the study was not raised at the time of
making the appointment, parents of children already
booked in may be phoned and told about the study
and invited to attend a little earlier.
3. If they cannot be contacted by telephone, they will
be approached on arrival at the site, given
information sheets and asked if they would be
happy to see a recruiting clinician to discuss
participation.
Once the parent has indicated they are happy to dis-
cuss the study, the recruiting clinician will explain study
participation answer any questions that the parent may
have, ensure that they fully understand the implications
of participation, and check the child’s eligibility. If the
child is eligible and the parent agrees to participate, writ-
ten informed consent will be obtained from the parent.
If the parent wishes to see the GP before consenting, the
recruiting clinician will arrange for this to happen, with
the parent and child returning to the recruiting clinician
afterwards to complete recruitment. Where possible the
recruiting clinician will recruit the participant while they
are waiting to see the GP, in order that the parent and
child are not delayed. However, if more practical or con-
venient, the recruiting clinician may offer, with the par-
ent’s permission, to visit the family later the same day at
their home to complete recruitment. If the parent is not
interested in hearing more about the study, no further
approach will be made.
Non-registration
A screening log of all children aged before their fifth
birthday, who are attending for care and whose parents
are approached by the recruiting clinician to invite par-
ticipation in the study, will be compiled. Details will be
recorded as to their eligibility, whether consent was
given or declined, and reason for declining to
participate.
Participant eligibility
Table 1 details the inclusion and exclusion criteria for
the study. Since ruling out UTI may be as important as
ruling it in, the study inclusion criteria were designed to
be as broad as possible. Therefore, children consulting
with other ‘obvious’ causes for their symptoms such as
otitis media or bronchiolitis, as well as those with a his-
tory of previous UTI and known abnormalities of the
urinary tract, learning difficulties, or re-consulting for an
existing illness are all included as long as none of the ex-
clusion criteria apply.
The study will include parents who speak other (non-
English) languages. Parent information sheets and con-
sent forms will be translated into other languages as
required by participating GP practices (e.g. Welsh, Polish
and Brazilian Portuguese). For languages less commonly
spoken in the UK, particularly for those in which oral
translation is more useful than written translation (e.g.
Somali), translational services will be accessed, where
possible, via interpreters employed by recruiting primary
care sites to support patient-clinician communications.
Where these services are not available, translational ser-
vices will be provided via Language Line.
Collecting urine samples and dipstick testing
The recruiting clinician will attempt to obtain a urine
sample from the children of consenting parents during
the recruitment visit. If this is not possible, the recruit-
ing clinician will ask the parent to collect the sample at
home, give them the appropriate equipment and explain
how to collect it. To minimise contamination, urine
samples will be obtained using the ‘clean catch’ where
this is possible. Where this is not possible, the ‘nappy
pad’ method (which involves cleaning the child’s peri-
neum and inserting a sterile pad into the nappy to soak
up urine, for a maximum period of 1 hour) will be used,
as described by Liaw et al. [31] and as recommended by
the recent NICE guidelines [9]. Urine sampling can be
underway whilst the recruiting clinician completes the
study CRF.
The recruiting clinician will retrieve the urine sample,
test it with a urine dipstick (Siemans/Bayer multistix
8SG) provided by the study and record the urine sam-
pling method and dipstick result on the CRF. The urine
sample will then be split, if sufficient quantity is avail-
able, with the priority fraction being sent to the local
NHS laboratory for routine diagnostic processing, and
the second ‘research’ fraction being sent to the SACU
(Specialist Antimicrobial Chemotherapy Unit, Public
Health Wales Microbiology Cardiff, University Hospital
of Wales) reference laboratory: for more in-depth ana-
lysis. As only small volumes of urine (minimum 1 mL)
are required for each laboratory, it is expected that for
most urine samples, it will be possible to split the urine
into the two fractions.
If a sample is not obtained during this visit the parent
will be asked if they could obtain one at home, refriger-
ate it and return it to the primary care site within 24
hours. Where possible, the DUTY recruiter will offer to
collect the urine sample from the patient’s home.
In a sub-sample of children recruited from a handful
of sites linked to the Bristol study centre, we will use
time-motion techniques to measure the additional time
(parent and healthcare professional) taken to collect the
urine sample and to perform dipstick testing during the
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primary care appointment. These data will be used to in-
form the economic analysis.
Maximising urine samples
Obtaining the urine samples will be challenging, and a
suboptimal return rate will diminish power and increase
risk of bias. Therefore: (1) we will monitor the location
of urine specimens using a web-based database. Clinical
data for recruited children will be logged onto the secure
study website. Dipstick urinalysis data may be added
after the clinical data and will provide a record of the
urine having been obtained. This will allow the research
team to identify children for whom urine samples have
not been provided, and to check with the relevant re-
cruiter as to whether this should be followed up. Both
the Research and NHS laboratories will also record the
arrival of, and results from, the specimens on the web-
site; and (2) each centre will provide dedicated DUTY
recruiter resource to assist Option 1 practices with
obtaining urines.
Laboratory processing of urine samples
The NHS ‘clinical’ fraction will be labelled with the
child’s unique DUTY study identification (ID) number
on DUTY specific labels as provided in patient packs.
Similar DUTY labels will be adhered to the DUTY study
specific microbiology form and the sample sent to the
local laboratories using the site’s normal method of
transport. Any samples not collected within 4 hours will
be refrigerated at the site and processed within 36 hours.
Clinicians will receive and act on reports from their local
laboratory as in the course of usual clinical care.
The remaining portion of urine will be decanted into a
sterile monovette container containing boric acid. This
will be labelled with the child’s study ID number and
sent by 1st Class Royal Mail using Post Office approved
SafeboxesTM to the central research laboratory.
Minimising effects of sample contamination and
assessment of asymptomatic bacteriuria
Contamination of urine (a cultured organism from a
source other than the urinary tract) can lead to false
positives: a potential false positive rate of 7.2% has been
identified in one study by comparing pairs of urines
from 203 children [32]. All nine (5.4%) children in this
study with a mixed culture ≥105 CFU/mL of uropatho-
gens (a heavy mixed growth) in their first sample had a
UTI excluded in the second [32]. In addition, bacteria at
≥106 CFU/mL (have also been found in the urine of ap-
proximately 1.5% of young, asymptomatic, children
when screened using the ‘gold standard method’, supra-
pubic aspiration [33], and most did not experience long
term sequelae [34]. Therefore, distinguishing UTI from
asymptomatic bacteriuria and bacterial contamination is
difficult, and could lead to spurious associations between
symptoms (e.g. diarrhoea) and apparent ‘UTI’ that is in
reality contamination or potential harmLess asymptom-
atic carriage.
Clinicians use the presence of UTI symptoms to help
interpret culture positive results but this leads to incorp-
oration bias. In DUTY, we could restrict recruitment to
those children with currently recognised symptoms of
UTI, but since the purpose of DUTY is to determine the
strength of association between currently recognised as
Table 1 DUTY eligibility criteria
Children will be included if: Children will be excluded if:
Aged before their fifth birthday. Aged 5 years and above.
Presenting at a participating NHS primary care site. Parents are unable or unwilling to assist with study.
Presenting with an acute (≤28 days) illness as the main reason for the
parent to have requested an appointment.
Illness longer than 28 days duration.
Presenting with trauma as a predominant concern.
Presenting with at least one ’constitutional’ symptom or sign identified by
NICE [9] as a potential marker for UTI – that is, fever, vomiting, lethargy/
malaise, irritability, poor feeding and failure to thrive and/or at least one
urinary symptom identified by NICE [9] as a potential marker of UTI – that
is, abdominal pain, jaundice (children <3 months only), haematuria,
offensive urine, cloudy urine, loin tenderness, frequency, apparent pain on
passing urine and changes to continence.
No urinary or constitutional symptoms as defined by NICE [9] and listed
in the left hand column.
Known neurogenic (e.g. spina bifida) or surgically reconstructed bladder
or urinary permanent or intermittent catheterisation (for whom different
bacterial concentration cut points are used).
Taking any antibiotics in the last 7 days.
Taking immunosuppressant medication (e.g. anti-rejection drugs, oral or
intramuscular steroids or chemotherapy).
Already recruited into the DUTY study.
Involved in current research or have recently (within 28 days) been
involved in any research prior to recruitment.
There will be no recruitment to the study after the last NHS laboratory
transport of the day has departed from that primary care site on Fridays.
For recruitment at A&E settings only: children will not be eligible if their
presentation at A&E is a direct result of GP referral.
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well as currently unrecognised symptoms/signs and UTI,
it is important that eligibility criteria are as ‘open’ as
possible (and that a prospective cohort, as opposed to
retrospective case–control, design is used), but without
including children in whom a positive culture is unlikely
to be clinically relevant (e.g. a well child with conjunctiv-
itis). Therefore, DUTY will recruit children with consti-
tutional and/or urinary symptoms and make the
assumption that the presence of no more than two
pathological bacteria of at least >103, but usually
>105 CFU/mL on culture of their urine is clinically sig-
nificant. This could result in more urine samples being
tested and more children receiving antibiotics than is
strictly necessary, but carries the benefit that more UTIs
would be identified and treated promptly.
Data collection
Unique study identification numbers will be sequen-
tially generated and used on pre-printed consent
forms, paper CRFs, urine sample labels and test re-
quest forms (for local NHS and central research
laboratories).
A CRF will be completed for all consented patients.
This will include a short medical history including re-
cent antibiotic use and other potential risk factors for
UTIs and resistance, and clinical examination findings.
An outline of the domains covered in the CRF can be
found below in the next section.
Case report form
The CRF will contain as many of the known and poten-
tial features associated with UTI as are feasible without
overly compromising the speed and simplicity of
completion.
Five sections will facilitate data entry by different
personnel (recruiter taking consent or responsible clin-
ician) so as to minimise the burden to healthcare profes-
sionals undertaking same day primary care:
1. Eligibility screening and consent (to be completed by
recruiting clinician within the recruitment interview
with the parent).
2. Registration (to be completed by recruiting clinician
as above): Socio-demographic data (to include: date
of consultation, name, address, contact telephone
number/s, ethnicity [21], date of birth and gender
[9]). We will also ask about parent’s highest
educational attainment level and their financial well-
being in order to assign a measure of socio-economic
deprivation.
3. Presenting Symptoms and Medical History (to be
completed by recruiting clinician as above): child’s
presenting symptoms will be recorded, along with
known previous medical history (e.g. previous UTI,
circumcision [5,35], child or family history of vesico-
ureteric reflux [36], other abnormalities of the
urinary tract, learning difficulties, details of prior
surgery, other co-morbidities, recent and previous
long-term use of medicines, including antibiotics).
4. Clinical Examination and Management (to be
completed by child’s responsible clinician within a
standard consultation): in addition to the
‘constitutional’ and ‘urinary’ study eligibility
symptoms defined by NICE [9], we will collect
information regarding the clinician’s global
assessment of illness severity [37], respiratory and
gastro-intestinal symptoms and signs, and the
symptoms and signs proposed by NICE to
distinguish ‘typical’ from ‘atypical’ UTI, such as poor
urinary flow and abdominal mass.
Clinicians will be asked to record the child’s
management, including antibiotic use and immediate
referral to secondary care. To assess the diagnostic
value of the urine dipstick test, we will ask clinicians
to record their working diagnosis before having seen
the dipstick results, and to record whether their
working diagnosis has changed after they have seen
them. Finally, for the economic analysis, we will ask
clinicians to state what their management would be
if the patient were not enrolled in the DUTY study
(e.g. no urine test/not treated for UTI or urine test/
treat for UTI). This will provide information on the
‘clinician judgement’ diagnostic strategy that will be a
comparator in the economic evaluation.
5. Urine collection and processing (to be completed by
recruiting clinician): Urine sampling method (clean
catch or nappy pad) and urinalysis results with date,
time of testing, with a prompt to inform the
responsible clinician of dipstick result and
confirmation that the sample has been sent to the
local NHS and central research laboratories.
In addition to the CRF, the study web-based data col-
lection platform will include additional sections to cover
data entry for the following: (1) NHS microbiology la-
boratory microscopy and culture; (2) SACU research la-
boratory microscopy and culture; (3) patient follow-up
at Day 14 following recruitment, and (4) patient notes
review at 3 months from recruitment. Further detail of
the content of these domains is provided below.
Processing of urine samples by NHS laboratories
NHS laboratories will be informed of the study and the
agreement of the lead consultant microbiologist, labora-
tory manager and the NHS hospital Research and Devel-
opment approval obtained before patient recruitment
begins. The laboratories will be asked to complete the
following tasks for DUTY study samples:
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1. Log the date and time of specimen arrival on the
secure DUTY web-based database.
2. Process the urine and report the result back to the
requestor using their own Standard Operating
Procedures (SOPs) and Laboratory Information
Management Systems (LIMS).
3. Enter the results of urine culture onto the DUTY
study web-based database. Since laboratories vary in
their SOPs, not all of the following will be available
however, microscopy for white and red cells;
quantification and purity of bacterial growth; and
speciation will be requested. Laboratories will be
asked to transcribe this information onto the DUTY
web-based database in order to activate laboratory
payment.
4. Store any isolates from urines with >105 CFU/mL in
pure/predominant ureopathogen growth for referral
onto the central research laboratory at the end of the
study. These should be stored, ideally on cryogenic
beads, at temperatures of -70 C, or on slopes at
-20 C if -70 C storage facilities are not available.
Processing of urine samples by the research laboratory
The central research laboratory has experience in sup-
porting other primary care UTI studies and performed a
similar role to that described below in the previous EUR-
ICA study (Epidemiology of urinary tract infection in
children with acute illness in primary care) [3].
1. Urines will be sent overnight by Royal Mail
SafeBoxesTM by the participating sites. Boric acid will
be used to stabilise bacterial counts.
2. On receipt at the central research laboratory, the
urine sample will be spiral-plated on blood agar and
UTI Chromogenic agar will be used to quantify
bacteria >2x101 CFU/mL and <1010 CFU/mL.
3. The bacteria will be identified to species level and
stored on cryogenic beads at −80°C. The urine will
be stored frozen.
4. Results will be recorded on a designated laboratory
worksheet and entered into the DUTY web-based
database.
Where the urine culture result produced by the central
research laboratory is positive and the local NHS
laboratory result is negative or not processed, and if this
discrepancy is considered by the lead SACU microbiolo-
gist to be clinically significant, we will inform the child’s
responsible clinician. This will enable the child’s respon-
sible clinician to consider the future management of the
child in the light of the additional information arising
from the study.
Patient follow-Up
Telephone follow-up at Day 14
Each centre will telephone parents of all children
selected for follow-up according to the proportional se-
lection rules in Table 2, to record symptom duration and
healthcare resource use (e.g. repeat primary care con-
tacts other community care, secondary care contacts,
prescribed and over-the-counter medications) during the
14 day period after recruitment. Parents will also be
asked to detail expenses and time off work due to
their child’s illness and rate the child’s quality of life
(including symptoms, sleeping, feeding, behaviour
and wellbeing) using a previously validated measure
(TAPQoL) [38].
3 Months note review
Each research centre will conduct a primary care notes
review for all children who were selected for follow-up.
Primary care contacts, medications and secondary care
utilisation during the 3 months after study recruitment
will be recorded during the review.
Withdrawal & loss to follow-Up
In the majority of cases the only active participation of
participants is at the initial consultation, and withdrawal
from the study in most cases is unlikely. Attrition in
those selected for 14 day follow-up due to the challenges
of making contact with busy parents will be minimised
by making several attempts to contact parents/guardians
by telephone and, if this is unsuccessful, a postal version
of the resource use questionnaire will be posted to parti-
cipants with a stamped addressed envelope for return.
Parents will be offered a £5 voucher, by post, on comple-
tion of follow-up either by telephone or post.
Table 2 Proportional selection rules for DUTY follow-up
Category Definition Location Proportion to be sampled at Day 14
> 105 CFU/ml Pure or 1 predominant species BOTH NHS lab and Central research lab 100% (All)
>103 and < 105 CFU/ml Pure or 1 predominant species Central research lab 20% in total (combination of both categories)
>105 CFU/ml 2 or more species BOTH NHS lab and Central research lab
< 103 CFU/ml and ‘No
Growth’
BOTH NHS lab and Central research lab 10%
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Electronic data entry
The DUTY data collection process is complex and
involves input from a number of different personnel
at different sites: (1) CRF data by a combination of
study DUTY recruiters, practice nurses, GPs and
dedicated staff at recruiting primary care sites; (2)
clinical and research urine culture results by labora-
tory technicians and managers; and (3) follow-up data
at Day 14 and 3 months by study centre administra-
tors and research nurses. To optimise the quality of
the data entry and to enable effective data collection
from multiple sites across England and Wales, we
decided to use a secure, web-based electronic data
collection platform.
We will use a secure web 2.0 clinical study manage-
ment system (The electronic Primary Care Research
Network (ePCRN)). Hosted by South London and
Maudsley (SLAM) NHS Foundation Trust, the ePCRN
implementation is of a separate domain and a Citrix
farm serving published applications, with a Structured
Query Language (SQL) server providing clinical based
study application databases. The system avoids poten-
tial data loss, duplication and security issues with lap-
tops and portable media and has been approved by
ethics and by the SLAM Caldicott and Executive
Committees.
Web-forms for data collection will be created in ASP.
net (a dynamic web application framework) on top of a
dedicated SQL data management server, with data vari-
ables forced to comply with entry and validation rules
defined in the data element definitions. The SQL data
management server will incorporate auditing, backup
and recovery facilities. The study workflow and algo-
rithms will be enforced using the same methods, and a
visual algorithm on the web pages will guide users. The
web-based system will be piloted for ease of use prior to
data entry go-live.
Electronic data protection and confidentiality
The ePCRN safeguards the legal and ethic rights of ser-
vice users through a fully integrated research security
management system consisting of two component parts:
(1) technical specifications built into the DUTY study
database during the development phase, and (2) proced-
ural standards governing the launch and day-to-day use
of the application by DUTY study researchers.
Access to users will be provided through study-specific
logon points in Citrix Access Gateway Advanced Access
Control. Citrix software establishes a secure, encrypted,
connection with the user’s PC, allowing access from
the Internet uniquely to the Citrix Access Gateway
and enabling access to identifiable study data for
authorized users.
Data entry in primary care sites
In order to maximise the acceptability and ease of use of
DUTY data collection tools, clinicians working in set-
tings without web access or whose working practice
made web data entry an unwelcome burden, will be able
to opt for paper-based data collection with the support
of the local study centre in entering data, or making al-
ternative arrangements for data entry, on their behalf.
The web-based data collection system will be pre-
sented as the preferred method of data collection, and
practice-based recruiting staff will be strongly encour-
aged and supported to enter CRF data onto the database
directly or, if using paper-based CRFs in the recruitment
interviews, to retrospectively enter the data in a timely
way (consent and registration within 24 hours, and full
eCRF data within 5 working days).
Data entry in the local NHS laboratory and central
research laboratory
Once in the local NHS and SACU research laboratories,
staff will be able to access an anonymised data collection
page, where only study numbers and the data collection
forms for the urine samples can be seen. Laboratory staff
will be asked to log the samples on receipt and enter the
results when available.
Follow-up data entry in research centres
At day 14 from recruitment, and at 3 months, research
staff will enter symptom duration, healthcare resource
utilisation and expenses data from telephone interviews
and practice records respectively onto web-based data
collection forms.
Analysis
The overall aim of the analyses is to derive a validated
clinical prediction rule for UTI among acutely ill chil-
dren presenting to primary care.
Sample size calculation
To estimate the required sample size we drew on our
experience with the EURICA study, which found a UTI
prevalence rate in children aged before their fifth birth-
day of 4% [3]. We considered first the strength of associ-
ation between candidate predictors (symptoms, signs or
dipstick results) and UTI as well as the precision of the
final algorithm’s sensitivity for the detection of UTI. Tak-
ing the most conservative assumptions, i.e. candidate
predictors present in 10% of children and an overall UTI
prevalence of 2%, 3,000 urine sample results are required
to detect an odds ratio of 2.4 with 80% power and a
two-sided alpha of 5%. With an overall prevalence of
UTI of 2%, an algorithm sensitivity of 80% and 3,100
urines, the 95% confidence interval (CI) will be no more
than +/−10%. We propose to recruit 4,000 children with
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a target of recovering urines from at least 77.5% for al-
gorithm derivation and a further 2,000 children for
validation.
Given the complexity of the statistical analyses, large
number of possible predictors and the need to account
for some missing data in predictor variables, we propose
to recruit at least 7000 children in total (two-thirds for
algorithm derivation; one-third for validation), in order
to maximise the statistical power of the sample).
Statistical analysis
Defining the primary outcome
The first stage of the analysis will investigate the best
combination of microbiology data from the local (NHS)
laboratories and the central research laboratory that can
be used to define urine samples as positive for UTI. We
will agree definitions of UTI positivity for data from
each laboratory (using culture results and white cell
counts) and will cross-tabulate these. Possible disagree-
ments will be examined, and samples classified after dis-
cussion as: (1) “Agree UTI negative”; (2) “Agree UTI
positive”; (3) “Disagree (CL positive, LL negative)”; (4)
“Disagree (CL negative, LL positive)”. If overall between-
laboratory reliability (classified on kappa statistics) is
good, the primary outcome will be defined as positive
for samples classified as (2) “Agree UTI positive”. If
overall agreement is moderate or poor, we will explore
reasons for this. We will stratify according to age of the
child and method of collection (clean catch or nappy
pad), and investigate whether reliability varies between
strata. We will also examine the inference of laboratory
methods (e.g. whether samples are process in boric acid)
and time from sample collection to laboratory
processing.
If the best definition of UTI positivity remains unclear,
then we will select a small number of signs and symp-
toms that the literature suggests are clearly associated
with presence of a UTI. We will examine associations of
UTI positivity with these symptoms, using different defi-
nitions of positivity (e.g. based on central or local labora-
tory, threshold for amount of growth, evidence of
growth of other species, method of sample collection.
We will select the best definition of microbiological
positivity based on the magnitude of associations with
the selected signs and symptoms.
Descriptive analyses
We will use methods appropriate for small proportions
[39] to estimate the prevalence (with 95% confidence
interval) of culture positive urines in acutely unwell chil-
dren aged before their fifth birthday presenting in pri-
mary care. This will be undertaken on the whole dataset.
The degree of variation in prevalence between practices
and geographical areas will be explored using two level
random-effects logistic regression models (with practice/
site as a random effect and area as a fixed effect). This
analysis will also explore difference by recruitment site
type (general practice, WICs and CEDs). Children in
whom urine samples are obtained will be compared to
those who are recruited, but no urine sample is obtained
in terms of clinical presentation and demographics.
We will compare the probability of contamination in
samples that are retrieved via a ‘clean catch’ method with
those using nappy pads, controlling for patient and prac-
tice factors in a two level random-effects logistic regres-
sion model (objective 4). We will examine the impact of
timing of sample in relation to the time between obtain-
ing the urine transportation (including day of the week)
and laboratory analysis on the rates of positive and con-
taminated urine samples (e.g. exploring if delayed sam-
ples such as those taken after daily laboratory collection
have an impact on contamination rates).
The sample will then be sub-divided into algorithm
derivation and validation datasets, compromising two-
thirds to one-third of the data set, respectively. This will
be done by randomly selecting practices: all of their
patients will then contribute to one of the two datasets.
Development of clinical prediction rules
We will develop a clinical prediction rule based on the
linear predictor in a logistic regression model in which
the outcome variable is a culture-positive urine result.
Candidate diagnostic variables will be categorised into
demographic background and medical history (for ex-
ample, gender, previous UTI); both specific and general
systemic presenting symptoms and signs (for example
overall illness severity, fever, vomiting); and results from
urine dipstick analysis (nitrite, leukocyte esterase, pro-
tein, blood and glucose). Because of concerns that some
aspects of medical history or demographics may be asso-
ciated with asymptomatic carriage rather than active in-
fection, we will also develop a ‘signs and symptoms’ only
prediction rule. Variables will be included in logistic re-
gression models based on an “inclusive” p value thresh-
old of 0.1. We will check for nonlinear effects of
continuous variables, and will examine candidate inter-
actions specified a priori. Any further candidate interac-
tions will be agreed before analyses commence. Such
effects will be included in the final models as necessary.
We will begin by examining the predictive value
(based on diagnostic odds ratios and C statistics) of the
best predictors from each of the three categories (socio-
demographic and previous medical history, clinical as-
sessment, and dipstick urinalysis) of variables. We will
then examine the additional diagnostic value of present-
ing signs and symptoms (compared with socio-
demographic and medical history alone) and of dipstick
results (compared with the other two categories). We
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will examine whether it is possible to identify subgroups
of children in whom dipstick testing is and is not
justified based on their signs and symptoms. The final
algorithm will be characterised based on its sensitivity
and specificity, and positive and negative likelihood
ratios.
Validation of clinical prediction rule
Diagnostic models that are developed using p-value-
based variable selection will inevitably suffer from statis-
tical over-optimism. Therefore, the final models will be
validated using the second dataset, and the published
rule will be based on the linear predictors from the
model re-estimated in this validation dataset. A compari-
son will be made between the results obtained from the
validation and the use of shrinkage based approaches ap-
plied to the original development dataset [40]. A com-
parison will be made between the results obtained from
the validation dataset and the use of shrinkage based
approaches applied to the original development dataset.
The magnitudes of regression coefficients, and overall
diagnostic value of the linear predictor, will be compared
between the primary outcome and other definitions of
culture positivity.
Analyses of follow up data
Children with positive urine cultures (‘contaminants’ and
‘UTIs’) who the clinician felt at recruitment had a sus-
pected UTI will be compared to those who the clinician
felt there was little probability of a UTI in terms of their
subsequent illness course and resource usage over the
next three months.
Risk stratification for clinical practice
In the final stages of analysis, we will examine the sensi-
tivity and specificity of the linear predictor, based on a
set of chosen thresholds for positivity. This will be used
to identify several candidate clinical prediction rules for
comparison in the economic evaluation. We will select
thresholds that provide a range of clinical prediction
rules from high sensitivity/low specificity to low sensitiv-
ity/high specificity.
Minimising Bias
The following design and analytic strategies will be
employed to minimise bias:
(1) Selection bias: where possible we will recruit
consecutive children. We will ask sites to keep a
screening log of patients approached but who did
not take part in the study and reasons for this;
(2) Index test technology: all tests (symptoms, signs,
nappy pads, dipstick tests) will be carried out using
standardised equipment and protocols;
(3) Incorporation bias: the reference standard will
consist of culture alone and will not incorporate any
of the index tests;
(4) Review bias: observers assessing the index tests will
differ from and be blind to those assessing the
reference standard (and vice versa);
(5) Verification bias: all children who contribute to the
study will have a urine sample sent to assess the
reference standard. Children in whom it is not
possible to obtain a sample will be excluded from
the analysis. It is unlikely that reasons for failure to
obtain urine samples will be related to the index
tests but we will compare children with and without
urine cultures;
(6) Disease progression bias: we expect the time
between clinical assessment and obtaining the urine
samples to be minimal (no more than 24 hours);
(7) Treatment paradox: for most children, antibiotic
treatment will be started after the urine sample has
been obtained, but we will record where this has
not been possible;
(8) Handling of indeterminate or uninterpretable results
or withdrawals: these parameters will be measured
and considered in the analysis, and;
(9) Appropriateness of the reference standard: use of
>103, but usually >105 CFU/mL of one, but no more
than two uropathogens is likely to detect the
majority of children with UTI, but the second
‘research’ urine result from the SACU laboratory
will allow for sensitivity analyses around different
bacterial concentrations. Where possible, we will
measure all threats to validity (e.g. time between
clinical assessment and obtaining and culturing the
urine sample) that could influence results.
Economic analysis
The aim of the economic analysis is to compare candi-
date clinical prediction rules (CPRs) on: (a) incremental
cost per correct diagnosis of bacteruria, b) incremental
cost per symptomatic day avoided, and c) incremental
lifetime cost per quality adjusted life year, including po-
tential long term complications of UTI from NHS and
societal perspectives.
The cost-effectiveness of each candidate prediction
rule will be compared to a ‘clinical judgement’ testing
strategy and two ‘boundary strategies’: 1) Performing a
urine test in every child meeting the DUTY eligibility
criteria, and 2) No testing, the diagnosis of UTI is made
clinically. The two boundary strategies are not intended
to reflect clinical reality, but provide a reference point
against which other diagnostic strategies can be com-
pared. The cost-effectiveness of each candidate CPR will
be assessed against these three strategies using a deci-
sion analytical model. The face validity of the model
Downing et al. BMC Infectious Diseases 2012, 12:158 Page 12 of 15
http://www.biomedcentral.com/1471-2334/12/158
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
228
structure will be reviewed by clinicians on the DUTY
study team before being finalised.
Cost per correct diagnosis of UTI (diagnostic model)
The diagnostic cost-effectiveness model requires infor-
mation on cost (cost of sample collection, cost of NHS
laboratory testing), probabilities (probability of sample
being obtained and probability of sample being contami-
nated) and diagnostic accuracy parameters (sensitivity
and specificity of the various diagnostic strategies). The
diagnostic accuracy parameters will be derived directly
from the DUTY CRF and the statistical analysis
described above. The probability of sample collection
and contamination will be observed in the DUTY study.
The cost of sample collection and laboratory testing will
be derived from a combination of surveys of NHS la-
boratories and GPs and a time motion study observing
primary care clinical staff as they collect and process
urine samples. The model will estimate the cost per pa-
tient correctly diagnosed. The model will also include
diagnostic strategies that incorporate dipstick testing (e.
g. in those children thought to be a moderate risk of
bacteriuria) with information on a small number of add-
itional parameters (i.e. cost, sensitivity and specificity of
dipstick testing).
Cost per symptomatic day avoided (short term model)
The model will then be extended to estimate cost per
symptomatic day avoided at day 14. A Markov model
will estimate the short-run cost-effectiveness of each
diagnostic strategy. This extension will require informa-
tion on additional parameters including the probabilities
of receiving antibiotics and hospital admission in chil-
dren diagnosed with and without UTI, the cost of anti-
biotics and hospital admission/testing, and the daily
recovery probability for children with bacteriuria treated
with antibiotics, children with bacteriuria not treated
with antibiotics and children without bacteriuria. The
probabilities of antibiotic treatment and hospital admis-
sion will be based on 14 day interviews and review of
patients’ primary care medical notes at 3 months. The
daily recovery probabilities will be based on 14 day inter-
views with parents of children selected for follow-up. As
all children in DUTY will receive a urine test, we will
not be able to observe the recovery of children with bac-
teriuria not treated with antibiotics (i.e. false negatives).
For this transition probability we will use literature esti-
mates of the effect of antibiotic therapy on symptom
duration.
Cost per quality adjusted life year (QALY -long
term model)
The structure of the long-run Markov model will be
based on the a previously developed model [27]. The
model will provide a link between the number of UTI
attacks that a child will experience, the proportion that
are pyelonephritic, the prevalence of vesicoureteral re-
flux, the probability of progressive renal scarring, the
risk of end stage renal disease (ESRD) and disease man-
agement. Outcome parameters such as probability of
UTI recurrence, renal scarring, ESRD, survival and util-
ity values of renal disease will be based estimates for the
sensitivity and specificity of imaging tests for VUR (e.g.
ultrasound, MCUG), costs of treatment (e.g. antibiotic
prophylaxis, cost of pyelonephritic treatment, dialysis,
transplant), recurrence of UTI, disutilities (pyeloneph-
ritic, dialysis, transplant) and survival [27].
All analyses will be probabilistic, as all parameters will
be entered into the model as distributions. Therefore the
results will be presented as cost-effectiveness acceptabil-
ity curves (CEACs). The CEAC demonstrates which of
several testing strategies is most likely to be cost-
effective at any fixed willingness to pay for a correct
diagnosis. Costs and outcomes occurring after the first
year will be discounted at 3.5%. We will use net monet-
ary benefits and cost-effectiveness acceptability curves,
at plausible willingness to pay thresholds (e.g. £0 to
£50,000 per QALY) to identify the most cost-effective
diagnostic strategies. Deterministic sensitivity analyses
will also be used to evaluate the impact of key para-
meters on results and the influence of various CFU/mL
thresholds on the choice of clinical prediction rule.
Discussion
This paper describes a diagnostic and prospective obser-
vational study in primary care, that aims to recruit at
least 7,000 children aged before their fifth birthday, who
are assessed for any acute, non traumatic, illness
of ≤ 28 days duration. Urine samples will be obtained
from eligible consented children and tested with a dip-
stick before being sent to a local NHS laboratory and a
central research laboratory for microbiological analysis.
This study will provide novel, clinically important in-
formation on the diagnostic features of childhood UTI
to help primary care clinicians improve their diagnostic
efficiency. New insight into the diagnostic value of dip-
stick urinalysis and urine sampling methods will also be
provided.
The observational design of the study will minimise
disruption to normal practice and reduce the research
burden on healthcare professionals, thereby maximising
the applicability and generalisability of findings. In
addition, this study will increase awareness of UTI as a
possible diagnosis in appropriate children under 5 years
old. We will collect full clinical information, including
presenting symptoms and signs, medical history and
clinical diagnosis; urine dipstick data and culture data
from both usual routine local NHS laboratories and
Downing et al. BMC Infectious Diseases 2012, 12:158 Page 13 of 15
http://www.biomedcentral.com/1471-2334/12/158
DOI: 10.3310/hta20510 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 51
229
© 2012 Downing et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
central research laboratory. All the above will be utilised
for derivation and validation of the diagnostic algorithm.
In addition the follow-up data at 14 days and 3 months
will allow for full health economic analysis, providing
cost effectiveness outcomes. Additional useful informa-
tion such as the best way of sampling urine from young
children in primary care, the species and sensitivities of
the infecting organisms, and contamination rates will
also inform care in the future.
The main challenge to the DUTY study is the large
number of participants and urine samples needed. A
substantial number of practices across each of the four
centres will need to be recruited, to provide a large
enough population of potential participants. In addition
to this, parental consent will be required at the same
general practice visit when they are invited to partici-
pate, meaning there is a reliance on parents being willing
and having the time to participate immediately. Despite
the dedicated DUTY recruiting staff on the ground, who
will provide support to practices, study buy-in is needed
from all primary care staff to ensure adequate resources
and infrastructure are in place to facilitate the conduct
of the study. This will require training of all staff
involved at each participating primary care site. A major
contribution from NHS microbiology laboratories will
also be necessary, for processing the increased number
of urine samples received from primary care sites.
This study will rely on sampling methods most com-
monly used currently in UK primary care, namely nappy
pad and clean catch. Suprapubic aspiration and catheter-
isation methods are neither feasible nor appropriate for
primary care. Nappy pad sampling may carry an
increased risk of contamination or un-interpretable
results. This may lead to the exclusion of some results
from the main analysis. However, this will be minimised
by obtaining clean catch samples where possible. Lastly,
the electronic data capture on the database has been
designed to allow for all parties to enter data separately.
A challenge will be to ensure all data is entered into the
database in a timely way, to allow for both the real time
monitoring of recruitment and urine sample location, as
well as the conduction of the follow-up interviews
within the tight timeframe.
In summary, this will be one of the largest studies of
its kind undertaken in primary care, involving obtaining
clinical samples from children, and will help guide man-
agement of the acutely unwell child, which is a common
and important aspect of primary health care delivery.
Improved assessment and diagnosis may lead to more
appropriate microbiological and point of care testing
and more timely treatment and investigation of those
children who are most likely to benefit, while reducing
unnecessary treatment and investigation among those
that are most unlikely to benefit. This is likely to
improve outcomes for individual patients and may help
prevent long-term sequelae. The overall outcome of the
study will be to achieve a more consistent approach in
the clinical care of a common condition, based on accur-
ate diagnosis and effective clinical management.
Endnotes
a This paper will use the term ‘parent’ to refer to the per-
son with legal responsibility for the child, therefore as ap-
plied in this paper the term also encompasses carers
(foster parents, legal guardians etc.).
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Appendix 6 Three-month follow-up data
collection form
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Appendix 7 Laboratory data entry forms
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Appendix 8 Laboratory methods
TABLE 86 Typical results recorded for a calibrated loop method
Number of CFU counted using inoculum of 0.3 µl 1 µl 2 µl 5 µl 10 µl
106 CFU/l or 103 CFU/ml – – – 5 10
107 CFU/l or 105 CFU/ml 3 10 20 50 100
108 CFU/l or 106 CFU/ml 30 100 200 500 1000
TABLE 87 Dilution of urine
Urine opacity Dilutions made Dilutions spiral plated
Clear 1:103
(10 µl into 10ml of water)
Neat urine+ 103
Cloudy 1:103+ 1:106
(103: 10 µl into 10ml of water
106: 10 µl of 103 into 10ml water)
103+ 106
Cloudy? (If unsure) 1:103+ 1:106
(103: 10 µl into 10ml of water
106: 10 µl of 103 into 10ml of water)
Neat urine+ 103+ 106
TABLE 88 Summary of research laboratory methods
Microscopy: Automated
Antimicrobial substance assay: Phenotypic
Culture method: Precise colony counts from spiral plater
Culture media: CBA Chromogenic media
Total count from: *
Species specific count from: *
Culture volume: 50µl
Culture plate: Whole
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TABLE 89 Identification of isolates at the research laboratory
Chromogenic agar Presumptive ID Further tests Confirmatory tests
Large PINK/RED colonys E. coli Indole (+) Phoenix™
Large DARK BLUE/PURPLE
colonys
KES (Klebsiella
spp/Enterobacter
spp/Serratia spp)
N/A Phoenix™ to differentiate
b/w species
Large BROWN/GREEN
colonys
Pseudomonas spp Oxidase (+) Phoenix™
Large cols with BROWN
HALO colonys
Proteus spp/Providencia
spp/Morganella spp
Indole (+)
Oxidase (–)
Swarming with Proteus
Phoenix™ to differentiate
b/w species
Large opaque colonys Coliform Indole (+/–)
Oxidase (+/–)
Phoenix™
Small BLUE/GREEN colonys Enterococci Catalase (–)
Group (D)
Phoenix™
Medium WHITE colonys Staph/yeast
(+ Cryptococcus
neoformans)
Check if yeast seen in
microscopy and growth
on Sabouraud
Gram (record result)
Catalase (record result)
Staphaurex (record result
Phoenix™ if GPC
Auxacolor kit for yeast
(Bio-Rad Laboratories Ltd,
Hertfordshire, UK)
Small PINK colonys S. saprophyticus Staphaurex (+/–)
Catalase (+)
Novobiocin (R)
Phoenix™
Small opaque colonys ? Gram (if GPC coagulase
and staphaurex)
Research laboratory quality control
Spiral plater
Daily checks on the instrument were carried out according to manufacturers’ guidelines. Internal quality
assurance was carried out weekly and monthly.
Bacteriology reagents
Control organisms (with known reliable target results) were tested alongside each ID and susceptibility test
performed. If incorrect test results were obtained for any control organism the test was repeated. Control
organism test results were recorded in the quality assurance folder.
Disc susceptibility testing
Control strains S. aureus NCTC 6571, E. faecalis ATCC 29212, E. coli ATCC 25922 and P. aeruginosa
ATCC 27853 were used on every occasion to quality check the media and disc susceptibility testing
conditions. Results were recorded in the DUTY disc-media spreadsheet.
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Urine analyser
Control runs were performed at the start, middle and end of each day to assure quality of testing.
Calibration was performed monthly. Results were recorded automatically in the instrument.
Incubator/freezers/fridges
All temperature-controlled equipment is monitored by an automated system (Comark Instruments Ltd,
Norwich, UK). Temperatures are recorded at 15-minute intervals and anomalies e-mailed to managers.
Internal DUTY quality assurance
An internal quality assurance system was set up for the DUTY study involving randomised urine samples.
After initial processing, urines were randomly chosen to be processed again. Urines would be processed as
per standard DUTY procedures and the microscopy and culture results compared with original results.
Any discrepancies were investigated by further testing.
Vertical audit of DUTY data entry
Each month a processed sample is chosen for vertical audit to assure quality in data entry to the web database.
All data from worksheets are compared with the web database entry and any discrepancies recorded.
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Appendix 9 Health economic analysis and
modelling of diagnostic strategies
0 UTI
0 PA
1 UTI
1 PA
1 UTI
0 PA
2 UTI
1 PA
2 UTI
0 PA
2 UTI
2 PA
3 UTI
1 PA
3 UTI
0 PA
3 UTI
2 PA
3 UTI
3 PA
4 UTI
1 PA
4 UTI
0 PA
4 UTI
2 PA
4 UTI
3 PA
4 UTI
4 PA
FIGURE 37 Medium-term model. Figure represents the movement of the patient within the medium-term model
for one of the four states corresponding to the VUR status and UTI history of the patient. Patients may move
between the untreated VUR and treated VUR if they receive a correct VUR diagnosis. Patients may move from the
‘no history of UTI’ state to the ‘history of UTI state’ if they suffer a UTI infection. PA, pyelonephritic attack.
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FIGURE 41 Long-term model. PA, pyelonephritic attack.
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FIGURE 42 Comparison of observed and modelled (using a Weibull model: shape= 1.497, scale= 0.091) symptom
resolution rates for patients with UTI treated immediately with antibiotics (n= 38).
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FIGURE 43 Comparison of observed and modelled (using a Weibull model: shape= 1.246, scale= 0.099) symptom
resolution rates for patients without UTI (n= 733).
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FIGURE 44 Symptom resolution in a selection of treatment states.
Time and motion methods
We observed two RNs collecting urine samples on six DUTY participants at four sites between February 2012
and April 2012. We collected data using a Samsung mobile device with Timer Pro software (Applied
Computer Services Inc., Engelwood, CO, USA), which allowed a range of pre-programmed tasks to be
selected and the time taken for each task to be recorded. Timing began when first contact was made with
the patient and ended when the urine sample was left for collection by the laboratory. As the study was
nested within the DUTY study many tasks, for example gaining informed consent, were undertaken by the
nurses, which would not form part of routine NHS care. We excluded these protocol driven tasks from our
cost analysis. We defined a usual care pathway for both clean catch and nappy pad collection (Table 90).
When activities which would normally be undertaken in usual practice were not performed by the nurses
(e.g. when completion of laboratory request was undertaken by the GP due to electronic laboratory
requesting in the general practice) we imputed the time using the mean other children where this activity
was undertaken. We included the cost of time taken for a nurse to give instructions on urine sampling to
the parent when a sample was attempted but not successful. We calculated costs by multiplying the number
of minutes taken by the cost per minute for a practice nurse (£0.65).158 The average time taken for sampling
was 9.08 minutes (cost: £6.78) for samples with no dipstick test and 12.04 minutes (cost: £7.81) when a
dipstick was required.
TABLE 90 Time for activities (minutes)
Activity
Patient number
Average time Cost, £1 2 3 4 5 6
Nurse gives instructions on urine sampling NO NO NO 0.83 2.23 3.47 2.18 1.41
Nurse administers dipstick testa 1.5 0.75 1.53 2.07 1.65 2.00 1.58 1.03
Nurse draws sample 1.00 0.50 0.83 0.88 0.80 1.18 0.87 0.56
Nurse fills in laboratory request form 4.00 4.75 3.90 NO 3.35 NO 4.00 2.60
Nurse prepares laboratory sample 1.67 2.00 1.42 1.60 2.13 3.35 2.03 1.32
Nurse leaves dipstick results for GPa 1.17 1.50 1.53 NO 1.91 0.78 1.38 0.89
Total sample obtained without dipstick 9.08 6.78
Total sample obtained with dipstick 12.04 7.81
Total sample not obtained 2.18 1.41
NO, not observed.
a Cost only included for diagnostic strategies that include dipstick testing.
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Acute illness costs
Data were collected on the number of clinical contacts, prescription medications, hospital tests, outpatient
appointments, inpatient stays and other personal costs in the 14 days following the index consultation.
When a record of a contact was made, but no detailed information was given allowing it to be costed a
clean catch separately, the average cost of all contacts within that resource group (e.g. hospital test,
outpatient appointment) was used. We mapped drug names, forms and dose to British National Formulary
(BNF)185 codes using the prescription cost analysis160 data set for England in 2011, which is in turn based
on BNF data from 2010. When dose was not provided, we mapped to the most commonly prescribed
dose for the given drug and formulation. If drug formulation was not provided, we mapped to the average
drug chemical cost where this was available, or used the most commonly prescribed formulation within the
drug type. We calculated the total number of prescriptions for each patient and used the average cost of a
prescription for the formulation or chemical to calculate the total cost of prescribed medication. In a small
number of cases, non-specific drug groups were reported (e.g. antibiotic, cough syrup); when this occurred
we used the code of the most commonly prescribed formulation within this drug group. When no drug
name was given (e.g. unsure) or the drug name could not be matched to any BNF formulation or chemical,
we used the mean cost of all prescriptions during the 14 days’ follow-up.
Our primary analysis includes only costs borne by the NHS; however, we also collected some personal cost
data to enable a secondary analysis taking a societal perspective and cost related to travel, parking,
over-the-counter medications and time off work. Personal costs were reported directly; however, for
non-prescribed medicines we supplemented this information using similar methods to those applied for
prescribed medicines when costs were omitted by parents. We used the Automobile Association’s estimate
of the average cost per mile186 to convert miles of travel to a cost. Costs for a pyelonephritic attack were
assumed to be 50% higher than a lower UTI.
We also used the costs derived from the 14-day interviews to estimate short-term costs of a UTI infection
(Table 91). We removed antibiotic and VUR scan costs to avoid double-counting as these are included
separately in the model. We calculated the mean cost for infections lasting < 2 days and assumed this to
be the fixed cost of a UTI infection, and then we calculated the excess daily cost of infection by dividing
the average cost of an infection lasting > 2 days, minus the fixed cost, by the average number of days an
infection lasted over 2 days (Table 92). A small number of infections had not resolved by the end of the
follow-up; when this occurred, we assumed that symptoms had resolved at 21 days.
Estimation of utility values
In the absence of preference-based measures of health-related quality of life (e.g. EQ-5D) that have been
developed and validated in infants, we used TAPQOL questionnaires,110 completed by parents at 14 days,
to evaluate the impact on quality of life. The TAPQOL questionnaire was specifically designed for use in
infants and comprises 43 items across eight domains, including sleeping, lung function and anxiety, which
aim to describe the health state of the patient. No mapping function187 has been developed for the
TAPQOL; therefore, we cannot use it to directly derive utility scores needed to calculate QALYs. However,
it does allow us to compare the health states of children with and without UTI to determine whether or
not quality of life is markedly different and, therefore, whether or not utility scores measured in other
infant diseases (e.g. rotavirus or respiratory syncytial virus) might provide suitable substitutes. On the basis
of these exploratory results we concluded that the impact of UTI on infant quality of life was similar to
other diseases commonly presenting in primary care (Table 93).
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TABLE 91 Fourteen-day resource use
Resource
Not UTI UTI
Mean cost
difference,
£ (95% CI)b p-valueNa Mean
Unit
cost, £
Average
cost, £ N
Mean,
£
Unit
cost, £
Average
cost, £
GP primary care
face to face
738 0.366 39.72 14.53 58 0.431 39.12 16.86 2.33
(–6.05 to 10.71)
0.586
GP primary care
telephone
738 0.157 27.07 4.25 58 0.362 24.67 8.93 4.68
(0.08 to 9.27)
0.046
Nurse primary
care face to face
738 0.098 17.43 1.70 58 0.138 15.53 2.14 0.44
(–1.94 to 2.82)
0.717
Nurse primary
care telephone
738 0.042 14.66 0.62 58 0.034 8.00 0.28 –0.34
(–0.79 to 0.11)
0.137
Community 738 0.136 23.62 3.20 58 0.086 25.45 2.19 –1.01
(–3.42 to 1.41)
0.415
A&E 740 0.058 103.88 6.04 58 0.069 107.00 7.38 1.34
(–8.25 to 10.94)
0.784
Inpatient days 740 0.032 425.00 13.78 58 0.103 425.00 43.97 30.18
(–25.04 to 85.41)
0.284
Outpatient 740 0.036 105.00 3.83 58 0.069 105.00 7.24 3.41
(–5.16 to 11.98)
0.435
Ambulance 738 0.008 226.06 1.84 58 0.000 –1.84
(–3.60 to -0.08)
0.041
Hospital tests 740 0.023 31.59 0.73 58 0.034 38.40 1.32 0.60
(–1.47 to 2.67)
0.571
Prescription
medicine
740 0.824 4.46 3.68 58 1.207 2.52 3.05 –0.63
(–1.93 to 0.67)
0.344
Non-prescription
medicine
740 0.936 3.39 3.17 58 0.776 3.24 2.51 –0.66
(–1.41 to 0.10)
0.088
Travel 740 0.331 4.66 1.54 58 0.397 9.64 3.82 2.28
(–1.75 to 6.31)
0.267
Lost earnings 735 0.118 105.84 12.53 58 0.172 138.74 23.92 11.38
(–10.59 to 33.34)
0.310
Other personal
costs
735 0.076 70.23 5.35 58 0.086 38.60 3.33 –2.02
(–6.00 to 1.96)
0.319
Total 76.79 126.95
a Different numbers of observations due to missing data.
b Bootstrapped CIs.
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TABLE 92 Fixed and variable costs of infection excluding antibiotic treatment or imaging scansa
Outcome Not UTI UTI
Average infection fixed costs (less than 2 days) 19.58 20.46
Average cost of infection given it lasts more than 2 days 58.71 112.22
Average variable cost of infection 39.14 91.77
Average length of infection 7.74 8.60
Average excess length of infection given it lasts for more than 2 days 5.74 6.60
Average cost per excess day 6.82 13.91
a Antibiotic treatment and imaging scan costs are included in the model directly.
TABLE 93 Comparison of mean TAPQOL domain scores across GP diagnosisa
Domain
UTI
(n= 58)
URTI
(n= 229)
Viral
illness
(n= 109)
Otitis
media
(n= 66)
Chest
infection
(n= 46)
Tonsillitis
(n= 29)
Gastroenteritis
(n= 26)
Other
(n= 112)
Sleeping 0.598 0.569 0.592 0.538 0.511 0.504 0.603 0.611
Appetite 0.603 0.654 0.667 0.667 0.607 0.526 0.564 0.683
Lungs 0.954 0.912 0.939 0.962 0.79 0.848 0.978 0.921
Stomach 0.803 0.870 0.818 0.889 0.855 0.802 0.638 0.804
Skin 0.909 0.875 0.896 0.876 0.909 0.888 0.933 0.878
Motor 0.948 0.939 0.952 0.950 0.924 0.881 0.910 0.942
Social 0.841 0.799 0.817 0.795 0.819 0.795 0.796 0.795
Problem 0.741 0.689 0.706 0.697 0.685 0.653 0.676 0.698
Communication 0.949 0.944 0.971 0.909 0.952 0.847 0.958 0.933
Anxiety 0.845 0.877 0.867 0.889 0.830 0.902 0.859 0.823
Positive 0.739 0.750 0.752 0.750 0.685 0.707 0.699 0.733
Liveliness 0.615 0.702 0.734 0.727 0.645 0.701 0.590 0.687
a Scores are given based on the working diagnosis of the consulting GP, except for UTI, where only those with
laboratory-confirmed UTI are included.
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Appendix 10 STROBE checklist
TABLE 94 STROBE statement: checklist of items that should be included in reports of observational studies
Item number Recommendation
Page of DUTY
report
Title and
abstract
1 (a) Indicate the study’s design with a commonly used term in the title
or the abstract
Title page
(b) Provide in the abstract an informative and balanced summary of
what was done and what was found
xviii
Introduction
Background/
rationale
2 Explain the scientific background and rationale for the investigation
being reported
1
Objectives 3 State specific objectives, including any prespecified hypotheses 15
Methods
Study design 4 Present key elements of study design early in the paper 18
Setting 5 Describe the setting, locations, and relevant dates, including periods
of recruitment, exposure, follow-up and data collection
20, 34
Participants 6 (a) Cohort study: give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods of
follow-up
Case–control study: give the eligibility criteria, and the sources and
methods of case ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study: give the eligibility criteria, and the sources and
methods of selection of participants
25, 35
(b) Cohort study: for matched studies, give matching criteria and
number of exposed and unexposed
Case–control study: for matched studies, give matching criteria and
the number of controls per case
N/A
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria, if
applicable
33, 103
Data sources/
measurement
8* For each variable of interest, give sources of data and details of
methods of assessment (measurement). Describe comparability of
assessment methods if there is more than one group
33
Bias 9 Describe any efforts to address potential sources of bias 51
Study size 10 Explain how the study size was arrived at 50
Quantitative
variables
11 Explain how quantitative variables were handled in the analyses.
If applicable, describe which groupings were chosen and why
N/A
continued
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TABLE 94 STROBE statement: checklist of items that should be included in reports of
observational studies (continued )
Item number Recommendation
Page of DUTY
report
Statistical
methods
12 (a) Describe all statistical methods, including those used to control for
confounding
48, 52, 63, 85,
106, 125
(b) Describe any methods used to examine subgroups and interactions N/A
(c) Explain how missing data were addressed 48, 52, 63, 85,
105, 135
(d) Cohort study: if applicable, explain how loss to follow-up was
addressed
Case–control study: if applicable, explain how matching of cases and
controls was addressed
Cross-sectional study: if applicable, describe analytical methods taking
account of sampling strategy
38
(e) Describe any sensitivity analyses 176, 192
N/A, not applicable.
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Appendix 11 STARD checklist
TABLE 95 STARD checklist for reporting of studies of diagnostic accuracy (version January 2003)
Section and topic Item # On page #
Title/abstract/
keywords
1 Identify the article as a study of diagnostic accuracy (recommend
MeSH heading ‘sensitivity and specificity’)
Title page
xvii
Introduction 2 State the research questions or study aims, such as estimating
diagnostic accuracy or comparing accuracy between tests or across
participant groups
15
Methods
Participants 3 The study population: the inclusion and exclusion criteria, setting and
locations where data were collected
21, 25, 26
4 Participant recruitment: was recruitment based on presenting
symptoms, results from previous tests, or the fact that the participants
had received the index tests or the reference standard?
26
5 Participant sampling: was the study population a consecutive series of
participants defined by the selection criteria in items 3 and 4? If not,
specify how participants were further selected
26, 104
6 Data collection: was data collection planned before the index test and
reference standard were performed (prospective study) or after
(retrospective study)?
16, 33
Test methods 7 The reference standard and its rationale xvii, xxii, 17, 52,
80, 103, 105,
146, 237
8 Technical specifications of material and methods involved including
how and when measurements were taken, and/or cite references for
index tests and reference standard
40, Appendix 8
9 Definition of and rationale for the units, cut-offs and/or categories of
the results of the index tests and the reference standard
34, 103
10 The number, training and expertise of the persons executing and
reading the index tests and the reference standard
41, 55, 105
11 Whether or not the readers of the index tests and reference standard
were blind (masked) to the results of the other test and describe any
other clinical information available to the readers
52, 80, 105,
145, 146
Statistical methods 12 Methods for calculating or comparing measures of diagnostic
accuracy, and the statistical methods used to quantify uncertainty
(e.g. 95% confidence intervals)
9, 59, 189, 191,
195, 205, 215
13 Methods for calculating test reproducibility, if done 102
Results
Participants 14 When study was performed, including beginning and end dates of
recruitment
20
15 Clinical and demographic characteristics of the study population (at
least information on age, gender, spectrum of presenting symptoms)
59, 68, 69
16 The number of participants satisfying the criteria for inclusion who did
or did not undergo the index tests and/or the reference standard;
describe why participants failed to undergo either test (a flow diagram
is strongly recommended)
57, 59
continued
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TABLE 95 STARD checklist for reporting of studies of diagnostic accuracy (version January 2003) (continued )
Section and topic Item # On page #
Test results 17 Time-interval between the index tests and the reference standard, and
any treatment administered in between
86, 88, 98, 99,
100, 113, 133,
205, 2113
18 Distribution of severity of disease (define criteria) in those with the
target condition; other diagnoses in participants without the target
condition
219
19 A cross tabulation of the results of the index tests (including
indeterminate and missing results) by the results of the reference
standard; for continuous results, the distribution of the test results by
the results of the reference standard
109
20 Any adverse events from performing the index tests or the reference
standard
38, 110
Estimates 21 Estimates of diagnostic accuracy and measures of statistical
uncertainty (e.g. 95% confidence intervals)
9, 51, 58, 59,
107, 124, 184,
189, 191, 195,
207, 208, 209
22 How indeterminate results, missing data and outliers of the index tests
were handled
48, 52, 63, 85,
105, 135
23 Estimates of variability of diagnostic accuracy between subgroups of
participants, readers or centres, if done
112, 117, 118,
120, 122, 123,
124, 126, 134,
135, 137, 138,
140
24 Estimates of test reproducibility, if done N/A
Discussion 25 Discuss the clinical applicability of the study findings 242
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